Any feedback?
Information on EC 3.4.25.1 - proteasome endopeptidase complex
for references in articles please use BRENDA:EC3.4.25.1Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
3.4.25.1 proteasome endopeptidase complexSpecify your search results
Word Map
- 3.4.25.1
- bortezomib
- myeloma
-
polyubiquitinated
- neurodegenerative
-
misfolded
- lysosomal
- histone
-
chymotrypsin-like
- ligases
- leukemia
-
relapsed
- nf-kappab
-
immunomodulatory
- parkinsonism
- lymphoma
- deacetylase
-
ubiquitin-dependent
- alzheimer
- cyclins
- hematologic
-
caspase
-
histocompatibility
-
proteostasis
-
ubiquitin-like
- dexamethasone
- hsp90
-
deubiquitinating
-
ubiquitin-conjugating
- calpains
-
autologous
- inclusions
-
incurable
-
cyclin-dependent
-
short-lived
-
mantle
-
trypsin-like
-
progression-free
- thalidomide
-
ubiquitin-mediated
-
polyglutamine
- ikappab
- mcl-1
-
multisubunit
- mdm2
- ikappabalpha
- parkin
- rituximab
- alpha-synuclein
-
single-agent
- p27kip1
- synthesis
- medicine
- degradation
- analysis
- drug development
- biotechnology
The enzyme appears in viruses and cellular organisms
Synonyms
proteasome, 26s proteasome, 20s proteasome, 26 s proteasome, multicatalytic proteinase, 20 s proteasome, multicatalytic protease, 26s proteasome complex, prosome, proteasome 20s, 
more
top
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
26S protease
-
-
-
-
27 kDa prosomal protein
-
-
-
-
30 kDa prosomal protein
-
-
-
-
Component Y8
-
-
-
-
GPRO-28
-
-
-
-
HsBPROS26
-
-
-
-
HSN3
-
-
-
-
ingensin
-
-
-
-
large multicatalytic protease
-
-
-
-
macropain
-
-
-
-
multicatalytic endopeptidase complex
-
-
-
-
Multicatalytic endopeptidase complex C7
-
-
-
-
multicatalytic protease
-
-
-
-
multicatalytic proteinase
-
-
-
-
p27K
-
-
-
-
PROS-27
-
-
-
-
PROS-30
-
-
-
-
PROS-Dm25
-
-
-
-
PROS-Dm28.1
-
-
-
-
PROS-Dm29
-
-
-
-
PROS-Dm35
-
-
-
-
prosome
-
-
-
-
proteasome
-
-
-
-
Proteasome component C13
-
-
-
-
Proteasome component C2
-
-
-
-
Proteasome component C3
-
-
-
-
Proteasome component C5
-
-
-
-
Proteasome component C8
-
-
-
-
Proteasome component C9
-
-
-
-
Proteasome component DD4
-
-
-
-
Proteasome component DD5
-
-
-
-
Proteasome component pts1
-
-
-
-
RING12 protein
-
-
-
-
RN3
-
-
-
-
SCL1 suppressor protein
-
-
-
-
TAS-F22/FAFP98
-
-
-
-
TAS-G64
-
-
-
-
TCPR29
-
-
-
-
tricorn protease
-
-
-
-
tricorn proteinase
-
-
-
-
XC3
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hydrolysis of peptide bond
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
140879-24-9
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abnormalities, Multiple
Role of the deubiquitylating enzyme DmUsp5 in coupling ubiquitin equilibrium to development and apoptosis in Drosophila melanogaster.
Abortion, Spontaneous
Proteomic analysis on the alteration of protein expression in the placental villous tissue of early pregnancy loss.
Acidosis
Acidosis and glucocorticoids concomitantly increase ubiquitin and proteasome subunit mRNAs in rat muscle.
Acidosis
Acidosis and glucocorticoids interact to provoke muscle protein and amino acid catabolism.
Acidosis
Inhibition of SNAT2 by metabolic acidosis enhances proteolysis in skeletal muscle.
Acidosis
Metabolic acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes.
Acidosis
Necessary but not sufficient: the role of glucocorticoids in the acidosis-induced increase in levels of mRNAs encoding proteins of the ATP-dependent proteolytic pathway in rat muscle.
Acidosis
TSS-Seq analysis of low pH-induced gene expression in intercalated cells in the renal collecting duct.
Acquired Immunodeficiency Syndrome
Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation.
Acquired Immunodeficiency Syndrome
Protection against experimental autoimmune encephalomyelitis by a proteasome modulator.
Acquired Immunodeficiency Syndrome
Protein degradation and apoptotic death in lymphocytes during Fiv infection: activation of the ubiquitin-proteasome proteolytic system.
Acquired Immunodeficiency Syndrome
The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes.
Acquired Immunodeficiency Syndrome
Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients.
Acute Kidney Injury
Nicotinic acetylcholine receptor agonists attenuate septic acute kidney injury in mice by suppressing inflammation and proteasome activity.
Acute Kidney Injury
Pathophysiological role of proteasome-dependent proteolytic pathway in endothelin-1-related cardiovascular diseases.
Acute Kidney Injury
Preventive effect of lactacystin, a selective proteasome inhibitor, on ischemic acute renal failure in rats.
Acute Kidney Injury
Proteasome inhibition attenuates renal endothelin-1 production and the development of ischemic acute renal failure in rats.
Acute Kidney Injury
Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity.
Acute Kidney Injury
Proteasome or immunoproteasome inhibitors cause apoptosis in human renal tubular epithelial cells under normoxic and hypoxic conditions.
Acute Kidney Injury
Proteasome participates in the pathogenesis of ischemic acute renal failure in rats.
Acute Kidney Injury
Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.
Acute Lung Injury
Age influences inflammatory responses, hemodynamics, and cardiac proteasome activation during acute lung injury.
Acute Lung Injury
Alveolar Extracellular 20S Proteasome in Patients with Acute Respiratory Distress Syndrome.
Acute Lung Injury
Proteolytic cleavage of elafin by 20S proteasome may contribute to inflammation in acute lung injury.
Adenocarcinoma
A Bowman-Birk inhibitor induces apoptosis in human breast adenocarcinoma through mitochondrial impairment and oxidative damage following proteasome 20S inhibition.
Adenocarcinoma
A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.
Adenocarcinoma
An Investigation Into the Prognostic Significance of High Proteasome PSB7 Protein Expression in Colorectal Cancer.
Adenocarcinoma
APEH Inhibition Affects Osteosarcoma Cell Viability via Downregulation of the Proteasome.
Adenocarcinoma
Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer.
Adenocarcinoma
Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib.
Adenocarcinoma
Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia.
Adenocarcinoma
Extracellular matrix-induced changes in expression of cell cycle-related proteins and proteasome components in endometrial adenocarcinoma cells.
Adenocarcinoma
Gel-based proteomics analysis of the heterogeneity of 20S proteasomes from four human pancreatic cancer cell lines.
Adenocarcinoma
Ghrelin induces apoptosis in colon adenocarcinoma cells via proteasome inhibition and autophagy induction.
Adenocarcinoma
Gold nanoparticle delivery-enhanced proteasome inhibitor effect in adenocarcinoma cells.
Adenocarcinoma
Potential roles for PA28beta in gastric adenocarcinoma development and diagnosis.
Adenocarcinoma
Prognostic Value and Molecular Mechanisms of Proteasome 26S Subunit, Non-ATPase Family Genes for Pancreatic Ductal Adenocarcinoma Patients after Pancreaticoduodenectomy.
Adenocarcinoma
Proteasome inhibitor MG-132 lowers gastric adenocarcinoma TMK1 cell proliferation via bone morphogenetic protein signaling.
Adenocarcinoma
Proteasome inhibitors and their combination with antiandrogens: effects on apoptosis, cellular proliferation and viability of prostatic adenocarcinoma cell cultures.
Adenocarcinoma
Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Adenocarcinoma of Lung
A new gold(I) complex-Au(PPh3)PT is a deubiquitinase inhibitor and inhibits tumor growth.
Adenocarcinoma of Lung
Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.
Adenocarcinoma of Lung
Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma.
Adenocarcinoma of Lung
Carfilzomib inhibits the growth of lung adenocarcinoma via upregulation of Gadd45a expression.
Adenocarcinoma of Lung
CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice.
Adenocarcinoma of Lung
Combination of photodynamic therapy with aspirin in human-derived lung adenocarcinoma cells affects proteasome activity and induces apoptosis.
Adenocarcinoma of Lung
Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor.
Adenocarcinoma of Lung
Inhibition of NF-kappa B with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro.
Adenocarcinoma of Lung
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma.
Adenocarcinoma of Lung
Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas.
Adenocarcinoma of Lung
Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line.
Adenocarcinoma of Lung
Response and resistance to NF-?B inhibitors in mouse models of lung adenocarcinoma.
Adenocarcinoma of Lung
Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.
Adenocarcinoma of Lung
The Silence of PSMC6 Inhibits Cell Growth and Metastasis in Lung Adenocarcinoma.
Adenoma
Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of Both Normal and Tumor Tissues In Vivo.
Adenoma
Changes in the Proteasome Pool during Malignant Transformation of Mouse Liver Cells.
Adenomatous Polyposis Coli
Retinol decreases beta-catenin protein levels in retinoic acid-resistant colon cancer cell lines.
Adenomatous Polyposis Coli
Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein.
Adenomatous Polyposis Coli
The COP9 signalosome mediates beta-catenin degradation by deneddylation and blocks adenomatous polyposis coli destruction via USP15.
Adenoviridae Infections
Rejection of adenovirus infection is independent of coxsackie and adenovirus receptor expression in cisplatin-resistant human lung cancer cells.
Adrenocortical Carcinoma
Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.
Adrenoleukodystrophy
Adrenoleukodystrophy: subcellular localization and degradation of adrenoleukodystrophy protein (ALDP/ABCD1) with naturally occurring missense mutations.
Airway Obstruction
Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation.
Alexander Disease
In vitro treatments with ceftriaxone promote elimination of mutant glial fibrillary acidic protein and transcription down-regulation.
Alexander Disease
Oligomers of mutant glial fibrillary acidic protein (GFAP) Inhibit the proteasome system in alexander disease astrocytes, and the small heat shock protein alphaB-crystallin reverses the inhibition.
Alexander Disease
Synergistic effects of the SAPK/JNK and the proteasome pathway on glial fibrillary acidic protein (GFAP) accumulation in Alexander disease.
Alzheimer Disease
18?-Glycyrrhetinic Acid Proteasome Activator Decelerates Aging and Alzheimer's Disease Progression in Caenorhabditis elegans and Neuronal Cultures.
Alzheimer Disease
20S proteasome activation promotes life span extension and resistance to proteotoxicity in Caenorhabditis elegans.
Alzheimer Disease
20S proteasome and glyoxalase 1 activities decrease in erythrocytes derived from Alzheimer's disease patients.
Alzheimer Disease
4-Hydroxynonenal-modified amyloid-beta peptide inhibits the proteasome: possible importance in Alzheimer's disease.
Alzheimer Disease
?-Secretase 1's Targeting Reduces Hyperphosphorilated Tau, Implying Autophagy Actors in 3xTg-AD Mice.
Alzheimer Disease
A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer's disease.
Alzheimer Disease
Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases.
Alzheimer Disease
Agouti Related Peptide Secreted Via Human Mesenchymal Stem Cells Upregulates Proteasome Activity in an Alzheimer's Disease Model.
Alzheimer Disease
Alzheimer's disease associated presenilin 1 interacts with HC5 and ZETA, subunits of the catalytic 20S proteasome.
Alzheimer Disease
Alzheimer's disease: correlation of the suppression of beta-amyloid peptide secretion from cultured cells with inhibition of the chymotrypsin-like activity of the proteasome.
Alzheimer Disease
Amyloid-? Secretion, Generation, and Lysosomal Sequestration in Response to Proteasome Inhibition: Involvement of Autophagy.
Alzheimer Disease
Analysis of gene expression in neural cells subject to chronic proteasome inhibition.
Alzheimer Disease
Apolipoprotein E Polymorphism and Oxidative Stress in Human Peripheral Blood Cells: Can Physical Activity Reactivate the Proteasome System through Epigenetic Mechanisms?
Alzheimer Disease
Archaeal proteasomes effectively degrade aggregation-prone proteins and reduce cellular toxicities in mammalian cells.
Alzheimer Disease
Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates.
Alzheimer Disease
Characterization of chronic low-level proteasome inhibition on neural homeostasis.
Alzheimer Disease
Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.
Alzheimer Disease
Computational identification of key genes that may regulate gene expression reprogramming in Alzheimer's patients.
Alzheimer Disease
Contribution of the proteasome to the alpha-secretase pathway in Alzheimer's disease.
Alzheimer Disease
Disrupted ubiquitin proteasome system underlying tau accumulation in Alzheimer's disease.
Alzheimer Disease
Divergent effect of proteasome inhibition on interleukin-1beta and tumor necrosis factor alpha signaling in human astroglial cells.
Alzheimer Disease
Does proteasome inhibition play a role in mediating neuropathology and neuron death in Alzheimer's disease?
Alzheimer Disease
Endoplasmic reticulum stress activates autophagy but not the proteasome in neuronal cells: implications for Alzheimer's disease.
Alzheimer Disease
Failures in Protein Clearance Partly Underlie Late Onset Neurodegenerative Diseases and Link Pathology to Genetic Risk.
Alzheimer Disease
Identification of Caspase-6-mediated processing of the valosin containing protein (p97) in Alzheimer's disease: a novel link to dysfunction in ubiquitin proteasome system-mediated protein degradation.
Alzheimer Disease
Immunohistochemical analysis of ubiquilin-1 in the human hippocampus: Association with neurofibrillary tangle pathology.
Alzheimer Disease
Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease.
Alzheimer Disease
Loss of TDP-43 Inhibits Amyotrophic Lateral Sclerosis-Linked Mutant SOD1 Aggresome Formation in an HDAC6-Dependent Manner.
Alzheimer Disease
Low Erythrocyte Levels of Proteasome and Acyl-Peptide Hydrolase (APEH) Activities in Alzheimer's Disease: A Sign of Defective Proteostasis?
Alzheimer Disease
Molecular Basis of Etiological Implications in Alzheimer's Disease: Focus on Neuroinflammation.
Alzheimer Disease
Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: relevance to Alzheimer's disease.
Alzheimer Disease
Optimization of in vitro measurement of proteasome activity in mammalian cells using fluorogenic substrates.
Alzheimer Disease
Pathological lesions of Alzheimer's disease and dementia with Lewy bodies brains exhibit immunoreactivity to an ATPase that is a regulatory subunit of the 26S proteasome.
Alzheimer Disease
Peptidase activities of the 20/26S proteasome and a novel protease in human brain.
Alzheimer Disease
Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease.
Alzheimer Disease
Phospho-beta-catenin accumulation in Alzheimer's disease and in aggresomes attributable to proteasome dysfunction.
Alzheimer Disease
Polyubiquitin linkage profiles in three models of proteolytic stress suggest the etiology of Alzheimer disease.
Alzheimer Disease
Production of active glycosylation-deficient ?-secretase complex for crystallization studies.
Alzheimer Disease
Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover.
Alzheimer Disease
Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease.
Alzheimer Disease
Proteasome inhibition increases tau accumulation independent of phosphorylation.
Alzheimer Disease
Proteasome inhibition induces stress kinase dependent transport deficits--implications for Alzheimer's disease.
Alzheimer Disease
Proteasome modulator 9 (PSMD9) gene rs14259 polymorphism in Alzheimer's disease.
Alzheimer Disease
Proteasome-mediated effects on amyloid precursor protein processing at the gamma-secretase site.
Alzheimer Disease
Protein quality control in Alzheimer's disease by the ubiquitin proteasome system.
Alzheimer Disease
Protein ubiquitination, degradation and the proteasome in neuro-degenerative disorders: no clear evidence for a significant pathogenetic role of proteasome failure in Alzheimer disease and related disorders.
Alzheimer Disease
Pyrazolones Activate the Proteasome by Gating Mechanisms and Protect Neuronal Cells from ?-Amyloid Toxicity.
Alzheimer Disease
Reactive glia show increased immunoproteasome activity in Alzheimer's disease.
Alzheimer Disease
Regulation of aberrant proteasome activity re-establishes plasticity and long-term memory in an animal model of Alzheimer's disease.
Alzheimer Disease
Review: Unchained maladie - a reassessment of the role of Ubb(+1) -capped polyubiquitin chains in Alzheimer's disease.
Alzheimer Disease
Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
Alzheimer Disease
Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6.
Alzheimer Disease
The 20S proteasome isolated from Alzheimer's disease brain shows post-translational modifications but unchanged proteolytic activity.
Alzheimer Disease
The Proteasome Function Reporter GFPu Accumulates in Young Brains of the APPswe/PS1dE9 Alzheimer's Disease Mouse Model.
Alzheimer Disease
The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1.
Alzheimer Disease
Transcriptome sequencing (RNA-seq) analysis of the effects of metal nanoparticle exposure on the transcriptome of Chlamydomonas reinhardtii.
Alzheimer Disease
Ubiquitin binds the amyloid ? peptide and interferes with its clearance pathways.
Alzheimer Disease
Unexpected beta-amyloid production by middle doses of resveratrol through stabilization of APP protein and AMPK-mediated inhibition of trypsin-like proteasome activity in a cell model of Alzheimer's disease.
Alzheimer Disease
Up-regulation of endoplasmic reticulum stress-related genes during the early phase of treatment of cultured cortical neurons by the proteasomal inhibitor lactacystin.
Amebiasis
The effect of peptidic and non-peptidic proteasome inhibitors on the biological properties of Acanthamoeba castellanii belonging to the T4 genotype.
aminopeptidase i deficiency
Sculpting MHC class II-restricted self and non-self peptidome by the class I Ag-processing machinery and its impact on Th-cell responses.
Amnesia, Retrograde
The ubiquitin-proteasome cascade is required for mammalian long-term memory formation.
Amyloidosis
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Amyloidosis
Bortezomib Subcutaneous Injection in Combination Regimens for Myeloma or Systemic Light-Chain Amyloidosis: A Retrospective Chart Review of Response Rates and Toxicity in Newly Diagnosed Patients.
Amyloidosis
Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.
Amyloidosis
Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis.
Amyloidosis
Functional proteasome complex is required for turnover of islet amyloid polypeptide in pancreatic ?-cells.
Amyloidosis
Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.
Amyloidosis
Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era.
Amyloidosis
Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
Amyloidosis
Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597-605.
Amyloidosis
Severe Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma: A Case Report and Review of the Literature.
Amyotrophic Lateral Sclerosis
Analysis of the cytosolic proteome in a cell culture model of familial amyotrophic lateral sclerosis reveals alterations to the proteasome, antioxidant defenses, and nitric oxide synthetic pathways.
Amyotrophic Lateral Sclerosis
Archaeal proteasomes effectively degrade aggregation-prone proteins and reduce cellular toxicities in mammalian cells.
Amyotrophic Lateral Sclerosis
Biological and Pathological Implications of an Alternative ATP-Powered Proteasomal Assembly With Cdc48 and the 20S Peptidase.
Amyotrophic Lateral Sclerosis
Effect of geranylgeranylaceton on cellular damage induced by proteasome inhibition in cultured spinal neurons.
Amyotrophic Lateral Sclerosis
Expression of ubiquitin and proteasome in motorneurons and astrocytes of spinal cords from patients with amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Focal dysfunction of the proteasome: a pathogenic factor in a mouse model of amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Impaired proteasome function in sporadic amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Novel autoantibodies against the proteasome subunit PSMA7 in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Proteasome Activation is a Mechanism for Pyrazolone Small Molecules Displaying Therapeutic Potential in Amyotrophic Lateral Sclerosis.
Amyotrophic Lateral Sclerosis
Proteasome inhibition enhances the stability of mouse Cu/Zn superoxide dismutase with mutations linked to familial amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS).
Amyotrophic Lateral Sclerosis
Tdp-25 Routing to Autophagy and Proteasome Ameliorates its Aggregation in Amyotrophic Lateral Sclerosis Target Cells.
Anemia
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).
Anemia
High dose carfilzomib proteasome inhibition induces anemia by oxidative hemolysis: A case series of 8 patients from a single centre.
Anemia
Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Anemia
PSMB8 encoding the ?5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome.
Anemia
Retroviruses have differing requirements for proteasome function in the budding process.
Anemia, Diamond-Blackfan
Study of the effects of proteasome inhibitors on ribosomal protein S19 (RPS19) mutants, identified in patients with Diamond-Blackfan anemia.
Anemia, Hemolytic
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Anemia, Sickle Cell
Proteasome Inhibition Induces Both Antioxidant and Hb F Responses in Sickle Cell Disease Via the Nrf2 Pathway.
Angelman Syndrome
Angelman syndrome-associated point mutations in the Zn-binding N-terminal (AZUL) domain of UBE3A ubiquitin ligase inhibit binding to the proteasome.
Angelman Syndrome
Angelman syndrome-associated ubiquitin ligase UBE3A/E6AP mutants interfere with the proteolytic activity of the proteasome.
Angiomyolipoma
Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress.
Anhedonia
[Signs of anhedonia and destructive changes in the ventral tegmental area of the midbrain in the model of the preclinical Parkinson's disease stage in experiment].
Anthrax
Anthrax lethal toxin-induced inflammasome formation and caspase-1 activation are late events dependent on ion fluxes and the proteasome.
Anthrax
Chemical genetic screening identifies critical pathways in anthrax lethal toxin-induced pathogenesis.
Anthrax
Heat shock inhibits caspase-1 activity while also preventing its inflammasome-mediated activation by anthrax lethal toxin.
Anthrax
Hyaline Fibromatosis Syndrome inducing mutations in the ectodomain of anthrax toxin receptor 2 can be rescued by proteasome inhibitors.
Anthrax
Proteasome inhibitors prevent caspase-1-mediated disease in rodents challenged with anthrax lethal toxin.
Anthrax
Role of the N-terminal amino acid of Bacillus anthracis lethal factor in lethal toxin cytotoxicity and its effect on the lethal toxin neutralization assay.
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Early Bortezomib Therapy for Refractory Anti-NMDA Receptor Encephalitis.
Aortic Aneurysm, Abdominal
Effect of Bortezomib on Angiotensin ?-induced Abdominal Aortic Aneurysm in ApoE
Aortic Aneurysm, Abdominal
Inhibition of Proteasome Activity by Low-dose Bortezomib Attenuates Angiotensin II-induced Abdominal Aortic Aneurysm in Apo E(-/-) Mice.
Appendicitis
Concentration of Proteasome in the Blood Plasma of Children with Acute Appendicitis, Before and After Surgery, and Its Correlation with CRP.
Appendicitis
Determination of the concentration of cathepsin B by SPRI biosensor in children with appendicitis, and its correlation with proteasomes.
Appendicitis
Immunoproteasome in the of children with acute appendicitis, and its correlation with proteasome and UCHL1 measured by SPR imaging biosensors.
Arrhythmias, Cardiac
MG132 proteasome inhibitor upregulates the expression of connexin 43 in rats with adriamycin-induced heart failure.
Arrhythmogenic Right Ventricular Dysplasia
Identification of differentially expressed genes and pathways crosstalk analysis in Rheumatoid and Osteoarthritis using next-generation sequencing and protein-protein networks.
Arthritis
Attenuation of pain and inflammation in adjuvant-induced arthritis by the proteasome inhibitor MG132.
Arthritis
Juvenile Idiopathic Arthritis Subtype- and Sex-specific Associations with Genetic Variants in the PSMA6/PSMC6/PSMA3 Gene Cluster.
Arthritis
Polymorphism in the LMP2 gene influences the relative risk for acute anterior uveitis in unselected patients with ankylosing spondylitis.
Arthritis
Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
Arthritis
Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis.
Arthritis
Serum amyloid A-luciferase transgenic mice: response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition.
Arthritis
The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats.
Arthritis
The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases.
Arthritis, Experimental
Proteasome inhibitor MG132 modulates inflammatory pain by central mechanisms in adjuvant arthritis.
Arthritis, Juvenile
Juvenile Idiopathic Arthritis Subtype- and Sex-specific Associations with Genetic Variants in the PSMA6/PSMC6/PSMA3 Gene Cluster.
Arthritis, Juvenile
Polymorphism in the LMP2 gene influences disease susceptibility and severity in HLA-B27 associated juvenile rheumatoid arthritis.
Arthritis, Psoriatic
Proteolytic activity and expression of the 20S proteasome are increased in psoriasis lesional skin.
Arthritis, Rheumatoid
Analysis of LMP and TAP polymorphisms by polymerase chain reaction-restriction fragment length polymorphism in rheumatoid arthritis.
Arthritis, Rheumatoid
Cardiac complications may be higher with use of proteasome inhibitors in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis.
Arthritis, Rheumatoid
Increased proteasome activator 28 gamma (PA28?) levels are unspecific but correlate with disease activity in rheumatoid arthritis.
Arthritis, Rheumatoid
Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences.
Arthritis, Rheumatoid
Proteasome inhibition as a novel therapy in treating rheumatoid arthritis.
Arthritis, Rheumatoid
Response to abatacept is associated with the inhibition of proteasome ?1i expression in T cells of patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Role of ADAM17, p38 MAPK, cathepsins, and proteasome pathway in the synthesis and shedding of fractalkine/CX3CL1 in rheumatoid arthritis.
Arthritis, Rheumatoid
The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients.
Arthritis, Rheumatoid
The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases.
Arthritis, Rheumatoid
[The ubiquitin system for intracellular protein degradation--involvement in human pathologies and therapeutic implications]
Asthenozoospermia
Proteomics-based study on asthenozoospermia: differential expression of proteasome alpha complex.
Asthma
Long-Term Bortezomib Treatment Reduces Allergen-Specific IgE but Fails to Ameliorate Chronic Asthma in Mice.
Asthma
Proteasomal inhibition upregulates the endogenous MAPK deactivator MKP-1 in human airway smooth muscle: mechanism of action and effect on cytokine secretion.
Asthma
Targeting PP2A and proteasome activity ameliorates features of allergic airway disease in mice.
Asthma
[The ubiquitin system for intracellular protein degradation--involvement in human pathologies and therapeutic implications]
Astrocytoma
Decreased proteasomal cleavage at nitrotyrosine sites in proteins and peptides.
Astrocytoma
Intermediate filament transcription in astrocytes is repressed by proteasome inhibition.
Astrocytoma
Proteasome inhibitor differentially regulates expression of the major immediate early genes of human cytomegalovirus in human central nervous system-derived cell lines.
Astrocytoma
Proteasome inhibitors potentiate etoposide-induced cell death in human astrocytoma cells bearing a mutated p53 isoform.
Astrocytoma
The ubiquitin proteasome system plays a role in venezuelan equine encephalitis virus infection.
Astrocytoma
WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?
Ataxia
RAN translation at CGG repeats induces ubiquitin proteasome system impairment in models of fragile X-associated tremor ataxia syndrome.
Ataxia
Ump1p is required for proper maturation of the 20S proteasome and becomes its substrate upon completion of the assembly.
Ataxia Telangiectasia
Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks.
Ataxia Telangiectasia
The Role of the Nuclear Factor ?B Pathway in the Cellular Response to Low and High Linear Energy Transfer Radiation.
Atherosclerosis
"Hidden targets of ubiquitin proteasome system: To prevent diabetic nephropathy".
Atherosclerosis
Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis.
Atherosclerosis
Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition.
Atherosclerosis
Changes in expression of proteasome in rats at different stages of atherosclerosis.
Atherosclerosis
Down-regulation of Flt-1 gene expression by the proteasome inhibitor MG262.
Atherosclerosis
Effects of ubiquitin-proteasome system deregulation on the vascular senescence and atherosclerosis process in elderly patients.
Atherosclerosis
Efficacy of Qingre Huayu Fang on atherosclerotic vulnerable plaque in apolipoprotein E knockout mice: proteasome pathway involvement.
Atherosclerosis
Integrated analysis of microarray data of atherosclerotic plaques: modulation of the ubiquitin-proteasome system.
Atherosclerosis
Physiological and pathological role of the ubiquitin-proteasome system in the vascular smooth muscle cell.
Atherosclerosis
Potential role of proteasome on c-jun related signaling in hypercholesterolemia induced atherosclerosis.
Atherosclerosis
Preventive effect of a proteasome inhibitor on the formation of accelerated atherosclerosis in rabbits with uremia.
Atherosclerosis
Protein oxidative modification in the aging organism and the role of the ubiquitin proteasomal system.
Atherosclerosis
Relationship of the 20S proteasome and the proteasome activator PA28 to atherosclerosis and intimal hyperplasia in the human vascular system.
Atherosclerosis
Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease.
Atherosclerosis
Targeting the Ubiquitin-Proteasome System in Atherosclerosis: Status Quo, Challenges, and Perspectives.
Atherosclerosis
The Effect of Low-Dose Proteasome Inhibition on Pre-Existing Atherosclerosis in LDL Receptor-Deficient Mice.
Atherosclerosis
The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes.
Atherosclerosis
The proteasome: a central regulator of inflammation and macrophage function.
Atherosclerosis
The Ubiquitin Proteasome System in Human Cardiomyopathies and Heart Failure.
Atherosclerosis
[Proteasome activity changes in the aorta, heart tissues, and blood leucocytes in modelling of cholesterol atherosclerosis]
Atrial Fibrillation
Genetic ablation and pharmacological inhibition of immunosubunit ?5i attenuates cardiac remodeling in deoxycorticosterone-acetate (DOCA)-salt hypertensive mice.
Autoimmune Diseases
A case-control study on association of proteasome subunit beta 8 (PSMB8) and transporter associated with antigen processing 1 (TAP1) polymorphisms and their transcript levels in vitiligo from Gujarat.
Autoimmune Diseases
A Minimal ?-Lactone Fragment for Selective ?5c or ?5i Proteasome Inhibitors.
Autoimmune Diseases
Activity-Based Near-Infrared Fluorescent Probe for LMP7: A Chemical Proteomics Tool for the Immunoproteasome in Living Cells.
Autoimmune Diseases
Anti-proteasome autoantibodies contribute to anti-nuclear antibody patterns on human larynx carcinoma cells.
Autoimmune Diseases
Autoantibodies in primary Sjögren's syndrome are directed against proteasomal subunits of the alpha and beta type.
Autoimmune Diseases
Bladder cancer detection using a peptide substrate of the 20S proteasome.
Autoimmune Diseases
Bortezomib-based antibody depletion for refractory autoimmune hematological diseases.
Autoimmune Diseases
Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases.
Autoimmune Diseases
Cellular Responses to Proteasome Inhibition: Molecular Mechanisms and Beyond.
Autoimmune Diseases
Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases.
Autoimmune Diseases
Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
Autoimmune Diseases
Development of proteasome inhibitors in oncology and autoimmune diseases.
Autoimmune Diseases
Drug discovery and assay development in the ubiquitin-proteasome system.
Autoimmune Diseases
Heightened levels of circulating 20S proteasome in critically ill patients.
Autoimmune Diseases
Opposing effects on immune function and skin barrier regulation by the proteasome inhibitor bortezomib in an allergen-induced eczema model.
Autoimmune Diseases
Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto's thyroiditis, but not for Graves' hyperthyroidism, in mice.
Autoimmune Diseases
Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus.
Autoimmune Diseases
Proteasome Immunosubunits Protect against the Development of CD8 T Cell-Mediated Autoimmune Diseases.
Autoimmune Diseases
Proteasome inhibition suppresses Th17 cell generation and ameliorates autoimmune development in experimental Sjögren's syndrome.
Autoimmune Diseases
Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis.
Autoimmune Diseases
Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors.
Autoimmune Diseases
Proteasome inhibitors as experimental therapeutics of autoimmune diseases.
Autoimmune Diseases
Proteasome inhibitors: a new perspective for treating autoimmune diseases.
Autoimmune Diseases
Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer.
Autoimmune Diseases
Protection against experimental autoimmune encephalomyelitis by a proteasome modulator.
Autoimmune Diseases
Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
Autoimmune Diseases
Selective inhibition of the immunoproteasome by ligand-induced crosslinking of the active site.
Autoimmune Diseases
Significance of increased circulating proteasome in autoimmune disease.
Autoimmune Diseases
Subunit specific inhibitors of proteasomes and their potential for immunomodulation.
Autoimmune Diseases
Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?
Autoimmune Diseases
The capture proteasome assay: A method to measure proteasome activity in vitro.
Autoimmune Diseases
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.
Autoimmune Diseases
Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519.
Azoospermia
Ehrlichia chaffeensis TRP32 interacts with host cell targets that influence intracellular survival.
Bacterial Infections
Pathogen-associated Molecular Pattern-triggered Immunity Involves Proteolytic Degradation of Core Nonsense-mediated mRNA Decay Factors During the Early Defense Response.
Bacterial Infections
Subunit-selective proteasome activity profiling uncovers uncoupled proteasome subunit activities during bacterial infections.
Bacterial Infections
The 11S Proteasome Subunit PSME3 Is a Positive Feedforward Regulator of NF-?B and Important for Host Defense against Bacterial Pathogens.
Biliary Tract Neoplasms
A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Biliary Tract Cancers.
Blepharitis
Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series.
Blindness
Temperature sensitive retinoid isomerase activity of RPE65 mutants associated with Leber congenital amaurosis.
Blister
Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation.
Bone Diseases
Cell cycle exit during bortezomib-induced osteogenic differentiation of mesenchymal stem cells was mediated by Xbp1s-upregulated p21Cip1 and p27Kip1.
Bone Diseases
Effects on bone metabolism of new therapeutic strategies with standard chemotherapy and biologic drugs.
Bone Diseases
Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease.
Bone Diseases
Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function.
Bone Diseases
Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1; A Potential Therapeutic Strategy for Myeloma Bone Disease.
Bone Diseases
Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
Bone Diseases
Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease.
Bone Diseases
The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats.
Bone Diseases
[The influence and clinical significance of proteasome inhibitor on serum bone metabolite markers in patients with myeloma bone disease].
Bone Resorption
Blocking of the Ubiquitin-Proteasome System Prevents Inflammation-Induced Bone Loss by Accelerating M-CSF Receptor c-Fms Degradation in Osteoclast Differentiation.
Bone Resorption
ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation.
Bone Resorption
HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk.
Bone Resorption
Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
Bone Resorption
Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
Bone Resorption
The effects of proteasome inhibitors on bone remodeling in multiple myeloma.
Bone Resorption
[Pathophysiological and therapeutic aspects of bone lesions in patients with multiple myelomas]
Brain Diseases
Differential hippocampal gene expression and pathway analysis in an etiology-based mouse model of major depressive disorder.
Brain Diseases
Report of the first patient with a homozygous OTUD7A variant responsible for epileptic encephalopathy and related proteasome dysfunction.
Brain Diseases
Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation.
Brain Edema
Relative Contribution of Prolyl Hydroxylase-Dependent and -Independent Degradation of HIF-1alpha by Proteasomal Pathways in Cerebral Ischemia.
Brain Edema
Systemic Proteasome Inhibition Induces Sustained Post-stroke Neurological Recovery and Neuroprotection via Mechanisms Involving Reversal of Peripheral Immunosuppression and Preservation of Blood-Brain-Barrier Integrity.
Brain Infarction
The role of the ubiquitin proteasome system in ischemia and ischemic tolerance.
Brain Injuries
Cellular prion protein promotes post-ischemic neuronal survival, angioneurogenesis and enhances neural progenitor cell homing via proteasome inhibition.
Brain Injuries
Delayed treatment with MLN519 reduces infarction and associated neurologic deficit caused by focal ischemic brain injury in rats via antiinflammatory mechanisms involving nuclear factor-kappaB activation, gliosis, and leukocyte infiltration.
Brain Injuries
Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the rat.
Brain Injuries
Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration.
Brain Injuries
Recovery from ischemic brain injury in the rat following a 10 h delayed injection with MLN519.
Brain Injuries
Spatiotemporal progression of ubiquitin-proteasome system inhibition after status epilepticus suggests protective adaptation against hippocampal injury.
Brain Injuries
Systemic Proteasome Inhibition Induces Sustained Post-stroke Neurological Recovery and Neuroprotection via Mechanisms Involving Reversal of Peripheral Immunosuppression and Preservation of Blood-Brain-Barrier Integrity.
Brain Injuries
Temporal Profiles of Stress Protein Inductions after Focal Transient Ischemia in Mice Brain.
Brain Injuries
The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases.
Brain Injuries
Voluntary exercise may engage proteasome function to benefit the brain after trauma.
Brain Injuries, Traumatic
Alterations of cerebral cortex and hippocampal proteasome subunit expression and function in a traumatic brain injury rat model.
Brain Injuries, Traumatic
Mutation of a Ubiquitin Carboxy Terminal Hydrolase L1 Lipid Binding Site Alleviates Cell Death, Axonal Injury, and Behavioral Deficits After Traumatic Brain Injury in Mice.
Brain Injuries, Traumatic
Nrf2-ARE signaling provides neuroprotection in traumatic brain injury via modulation of the ubiquitin proteasome system.
Brain Injuries, Traumatic
Proteasome and Autophagy-Mediated Impairment of Late Long-Term Potentiation (l-LTP) after Traumatic Brain Injury in the Somatosensory Cortex of Mice.
Brain Injuries, Traumatic
Voluntary exercise may engage proteasome function to benefit the brain after trauma.
Brain Ischemia
Associations between Huwe1 and autophagy in rat cerebral neuron oxygen?glucose deprivation and reperfusion injury.
Brain Ischemia
Excitotoxic stimulation downregulates the ubiquitin-proteasome system through activation of NMDA receptors in cultured hippocampal neurons.
Brain Ischemia
Ginsenoside Rd attenuates blood-brain barrier damage by suppressing proteasome-mediated signaling after transient forebrain ischemia.
Brain Ischemia
Inhibition of immunoproteasome promotes angiogenesis via enhancing hypoxia-inducible factor-1? abundance in rats following focal cerebral ischaemia.
Brain Ischemia
Life and death in the trash heap: The ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral Ischemia.
Brain Ischemia
Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-kappaB activation.
Brain Ischemia
Possible contribution of proteins of Bcl-2 family in neuronal death following transient global brain ischemia.
Brain Ischemia
Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia.
Brain Ischemia
Proteasomal activity in brain tissue following ischemic stroke in Wistar rats.
Brain Ischemia
Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia.
Brain Ischemia
Proteolysis of oxidized proteins after oxygen-glucose deprivation in rat cortical neurons is mediated by the proteasome.
Brain Ischemia
PSD-93 Interacts with SynGAP and Promotes SynGAP Ubiquitination and Ischemic Brain Injury in Mice.
Brain Ischemia
Short Chemical Ischemia Triggers Phosphorylation of eIF2? and Death of SH-SY5Y Cells but not Proteasome Stress and Heat Shock Protein Response in both SH-SY5Y and T98G Cells.
Brain Ischemia
Suppression of proteasome C2 contralateral to ischemic lesions in rat brain.
Brain Ischemia
The proteasome inhibitor VELCADE reduces infarction in rat models of focal cerebral ischemia.
Brain Ischemia
The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.
Brain Ischemia
Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator.
Brain Neoplasms
Elevated plasma 20S proteasome chymotrypsin-like activity is correlated with IL-8 levels and associated with an increased risk of death in glial brain tumor patients.
Brain Neoplasms
Enzymatic activity of extracellular circulating proteasome in the CSF of patients with malignant intrinsic and metastatic brain tumors: proof of concept.
Brain Neoplasms
Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.
Brain Neoplasms
Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
Brain Neoplasms
Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts.
Brain Neoplasms
The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities.
Breast Neoplasms
1,10-Phenanthroline promotes copper complexes into tumor cells and induces apoptosis by inhibiting the proteasome activity.
Breast Neoplasms
A bismuth diethyldithiocarbamate compound induced apoptosis via mitochondria-dependent pathway and suppressed invasion in MCF-7 breast cancer cells.
Breast Neoplasms
A Bowman-Birk inhibitor induces apoptosis in human breast adenocarcinoma through mitochondrial impairment and oxidative damage following proteasome 20S inhibition.
Breast Neoplasms
A new combination strategy to enhance apoptosis in cancer cells by using nanoparticles as biocompatible drug delivery carriers.
Breast Neoplasms
A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts.
Breast Neoplasms
A novel combination treatment for breast cancer cells involving BAPTA-AM and proteasome inhibitor bortezomib.
Breast Neoplasms
A novel dithiocarbamate analogue with potentially decreased ALDH inhibition has copper-dependent proteasome-inhibitory and apoptosis-inducing activity in human breast cancer cells.
Breast Neoplasms
A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent.
Breast Neoplasms
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Breast Neoplasms
A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer.
Breast Neoplasms
A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer.
Breast Neoplasms
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
Breast Neoplasms
A Second-Generation Proteasome Inhibitor and Doxorubicin Modulates IL-6, pSTAT-3 and NF-kB Activity in MDA-MB-231 Breast Cancer Cells.
Breast Neoplasms
Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells.
Breast Neoplasms
Advancing the Role of Gamma-Tocotrienol as Proteasomes Inhibitor: A Quantitative Proteomic Analysis of MDA-MB-231 Human Breast Cancer Cells.
Breast Neoplasms
An autophagy inhibitor enhances the inhibition of cell proliferation induced by a proteasome inhibitor in MCF-7 cells.
Breast Neoplasms
An integrated analysis of genes and pathways exhibiting metabolic differences between estrogen receptor positive breast cancer cells.
Breast Neoplasms
Anticancer activity and computational modeling of ternary copper (II) complexes with 3-indolecarboxylic acid and 1,10-phenanthroline.
Breast Neoplasms
Autophagy Blockade by Ai Du Qing Formula Promotes Chemosensitivity of Breast Cancer Stem Cells Via GRP78/?-Catenin/ABCG2 Axis.
Breast Neoplasms
Bioactivity-Guided Identification and Cell Signaling Technology to Delineate the Lactate Dehydrogenase A Inhibition Effects of Spatholobus suberectus on Breast Cancer.
Breast Neoplasms
Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells.
Breast Neoplasms
Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.
Breast Neoplasms
Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a pro-apoptotic unfolded protein response.
Breast Neoplasms
Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1.
Breast Neoplasms
Breast Cancer Anti-Estrogen Resistance-3 inhibits transforming growth factor-ß/Smad signaling and associates with favorable breast cancer disease outcomes.
Breast Neoplasms
Breast cancer cell line MCF7 escapes from G1/S arrest induced by proteasome inhibition through a GSK-3? dependent mechanism.
Breast Neoplasms
Breast cancer cells: Modulation by melatonin and the ubiquitin-proteasome system--a review.
Breast Neoplasms
Breast cancer genes PSMC3IP and EPSTI1 play a role in apoptosis regulation.
Breast Neoplasms
Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4.
Breast Neoplasms
Carnosol, a Natural Polyphenol, Inhibits Migration, Metastasis, and Tumor Growth of Breast Cancer via a ROS-Dependent Proteasome Degradation of STAT3.
Breast Neoplasms
Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132.
Breast Neoplasms
Catechol Polymers for pH-Responsive, Targeted Drug Delivery to Cancer Cells.
Breast Neoplasms
Cefepime, a fourth-generation cephalosporin, in complex with manganese, inhibits proteasome activity and induces the apoptosis of human breast cancer cells.
Breast Neoplasms
Circulating 20S proteasome in patients with non-metastasized breast cancer.
Breast Neoplasms
Cks1 proteasomal turnover is a predominant mode of regulation in breast cancer cells: role of key tyrosines and lysines.
Breast Neoplasms
Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells.
Breast Neoplasms
Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.
Breast Neoplasms
Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells.
Breast Neoplasms
Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer.
Breast Neoplasms
Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton.
Breast Neoplasms
Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells.
Breast Neoplasms
Competitive Metabolite Profiling of Natural Products Reveals Subunit Specific Inhibitors of the 20S Proteasome.
Breast Neoplasms
Crosstalk between estrogen receptor alpha and the aryl hydrocarbon receptor in breast cancer cells involves unidirectional activation of proteasomes.
Breast Neoplasms
Cytotoxicity and Proteasome Inhibition by Alkaloid Extract from Murraya koenigii Leaves in Breast Cancer Cells-Molecular Docking Studies.
Breast Neoplasms
Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin-induced apoptosis.
Breast Neoplasms
Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy.
Breast Neoplasms
Design, synthesis and biological evaluation of novel naphthoquinone-4-aminobenzensulfonamide/carboxamide derivatives as proteasome inhibitors.
Breast Neoplasms
Deubiquitinase ubiquitin-specific protease 9X regulates the stability and function of E3 ubiquitin ligase ring finger protein 115 in breast cancer cells.
Breast Neoplasms
Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway.
Breast Neoplasms
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells.
Breast Neoplasms
Differential proteomic profiling identifies novel molecular targets of paclitaxel and phytoagent deoxyelephantopin against mammary adenocarcinoma cells.
Breast Neoplasms
Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
Breast Neoplasms
Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells.
Breast Neoplasms
Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors.
Breast Neoplasms
Disulfiram promotes the conversion of carcinogenic cadmium to a proteasome inhibitor with pro-apoptotic activity in human cancer cells.
Breast Neoplasms
Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity.
Breast Neoplasms
Down-regulation of estrogen receptor-alpha in MCF-7 human breast cancer cells after proteasome inhibition.
Breast Neoplasms
Dyclonine and alverine citrate enhance the cytotoxic effects of proteasome inhibitor MG132 on breast cancer cells.
Breast Neoplasms
Dynamic interplay between breast cancer cells and normal endothelium mediates the expression of matrix macromolecules, proteasome activity and functional properties of endothelial cells.
Breast Neoplasms
Effects of an Anticarcinogenic Bowman-Birk Protease Inhibitor on Purified 20S Proteasome and MCF-7 Breast Cancer Cells.
Breast Neoplasms
Efficient induction of apoptosis by proteasome inhibitor: bortezomib in the human breast cancer cell line MDA-MB-231.
Breast Neoplasms
Engineering Single Pan-Specific Ubiquibodies for Targeted Degradation of All Forms of Endogenous ERK Protein Kinase.
Breast Neoplasms
Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor.
Breast Neoplasms
Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7.
Breast Neoplasms
Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
Breast Neoplasms
Estrogen-Dependent Gene Transcription in Human Breast Cancer Cells Relies upon Proteasome-Dependent Monoubiquitination of Histone H2B.
Breast Neoplasms
Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis.
Breast Neoplasms
Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role.
Breast Neoplasms
Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions.
Breast Neoplasms
Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome.
Breast Neoplasms
Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections.
Breast Neoplasms
Fhit Nuclear Import Following EGF Stimulation Sustains Proliferation of Breast Cancer Cells.
Breast Neoplasms
Flavopiridol Induces Cellular FLICE-Inhibitory Protein Degradation by the Proteasome and Promotes TRAIL-Induced Early Signaling and Apoptosis in Breast Tumor Cells.
Breast Neoplasms
Gel-based chemical cross-linking analysis of 20S proteasome subunit-subunit interactions in breast cancer.
Breast Neoplasms
Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer.
Breast Neoplasms
Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition.
Breast Neoplasms
Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells.
Breast Neoplasms
Gold(III)-dithiocarbamato peptidomimetics in the forefront of the targeted anticancer therapy: preclinical studies against human breast neoplasia.
Breast Neoplasms
GSK-3? signaling determines autophagy activation in the breast tumor cell line MCF7 and inclusion formation in the non-tumor cell line MCF10A in response to proteasome inhibition.
Breast Neoplasms
Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in ZR-75 breast cancer cells.
Breast Neoplasms
I-kappaBalpha depletion by transglutaminase 2 and mu-calpain occurs in parallel with the ubiquitin-proteasome pathway.
Breast Neoplasms
IKK? inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.
Breast Neoplasms
Imaging Reporters for Proteasome Activity Identify Tumor- and Metastasis-Initiating Cells.
Breast Neoplasms
In Vitro and In Vivo Antitumor Activities and DNA Binding Mode of Five Coordinated Cyclometalated Organoplatinum(II) Complexes Containing Biphosphine Ligands.
Breast Neoplasms
In Vivo Inhibition of Proteasome Activity and Tumour Growth by Murraya koenigii Leaf Extract in Breast Cancer Xenografts and by its active flavonoids in breast cancer cells.
Breast Neoplasms
Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells.
Breast Neoplasms
Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors.
Breast Neoplasms
Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue.
Breast Neoplasms
Increasing intratumor C/EBP-? LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Breast Neoplasms
Induction of tumor cell apoptosis by taurine Schiff base copper complex is associated with the inhibition of proteasomal activity.
Breast Neoplasms
Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation.
Breast Neoplasms
Inhibition of catechol-Omicron-methyltransferase activity in human breast cancer cells enhances the biological effect of the green tea polyphenol (-)-EGCG.
Breast Neoplasms
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Breast Neoplasms
Inhibition of HDAC3- and HDAC6-Promoted Survivin Expression Plays an Important Role in SAHA-Induced Autophagy and Viability Reduction in Breast Cancer Cells.
Breast Neoplasms
Inhibition of Paclitaxel-Induced Proteasome Activation Influences Paclitaxel Cytotoxicity in Breast Cancer Cells in a Sequence-Dependent Manner.
Breast Neoplasms
Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis.
Breast Neoplasms
Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts.
Breast Neoplasms
Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts.
Breast Neoplasms
Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein.
Breast Neoplasms
Inhibition of tumor proteasome activity by gold-dithiocarbamato complexes via both redox-dependent and -independent processes.
Breast Neoplasms
Interaction with Pyruvate Kinase M2 Destabilizes Tristetraprolin by Proteasome Degradation and Regulates Cell Proliferation in Breast Cancer.
Breast Neoplasms
Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma.
Breast Neoplasms
Investigation of the eIF2alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells.
Breast Neoplasms
Knockdown of PSMC3IP suppresses the proliferation and xenografted tumorigenesis of hepatocellular carcinoma cell.
Breast Neoplasms
L-Ornithine Schiff base-copper and -cadmium complexes as new proteasome inhibitors and apoptosis inducers in human cancer cells.
Breast Neoplasms
LXY6090 - a novel manassantin A derivative - limits breast cancer growth through hypoxia-inducible factor-1 inhibition.
Breast Neoplasms
Mangiferin blocks proliferation and induces apoptosis of breast cancer cells via suppression of the mevalonate pathway and by proteasome inhibition.
Breast Neoplasms
Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition.
Breast Neoplasms
miR-7-5p suppresses cell proliferation and induces apoptosis of breast cancer cells mainly by targeting REG?.
Breast Neoplasms
Murraya koenigii leaf extract inhibits proteasome activity and induces cell death in breast cancer cells.
Breast Neoplasms
New Peptidomimetic Boronates for Selective Inhibition of the Chymotrypsin-like Activity of the 26S Proteasome.
Breast Neoplasms
Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis.
Breast Neoplasms
Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells.
Breast Neoplasms
Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells.
Breast Neoplasms
Novel 8-hydroxylquinoline analogs induce copper-dependent proteasome inhibition and cell death in human breast cancer cells.
Breast Neoplasms
Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens.
Breast Neoplasms
Organic cadmium complexes as proteasome inhibitors and apoptosis inducers in human breast cancer cells.
Breast Neoplasms
Ouabain and Digoxin Activate the Proteasome and the Degradation of the ER? in Cells Modeling Primary and Metastatic Breast Cancer.
Breast Neoplasms
Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics.
Breast Neoplasms
Oxygen levels do not determine radiation survival of breast cancer stem cells.
Breast Neoplasms
P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
Breast Neoplasms
Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor.
Breast Neoplasms
Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents.
Breast Neoplasms
Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant.
Breast Neoplasms
PKC?-dependent activation of the ubiquitin proteasome system is responsible for high glucose-induced human breast cancer MCF-7 cell proliferation, migration and invasion.
Breast Neoplasms
Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
Breast Neoplasms
Prognoses and genomic analyses of proteasome 26S subunit, ATPase (PSMC) family genes in clinical breast cancer.
Breast Neoplasms
Protease Cargo in Circulating Exosomes of Breast Cancer and Ovarian Cancer Patients
Breast Neoplasms
Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
Breast Neoplasms
Proteasome 26S subunit PSMD1 regulates breast cancer cell growth through p53 protein degradation.
Breast Neoplasms
Proteasome 26S Subunit, non-ATPase 3 (PSMD3) Regulates Breast Cancer by Stabilizing HER2 from Degradation.
Breast Neoplasms
Proteasome affects the expression of aryl hydrocarbon receptor-regulated proteins.
Breast Neoplasms
Proteasome functioning in breast cancer: connection with clinical-pathological factors.
Breast Neoplasms
Proteasome inhibition creates a chromatin landscape favorable to RNA Pol II processivity.
Breast Neoplasms
Proteasome inhibition in human breast cancer cells with high catechol-O-methyltransferase activity by green tea polyphenol EGCG analogs.
Breast Neoplasms
Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy.
Breast Neoplasms
Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.
Breast Neoplasms
Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231 breast cancer cell migration.
Breast Neoplasms
Proteasome Inhibitor Carbobenzoxy-L-Leucyl-L-Leucyl-L-Leucinal (MG132) Enhances Therapeutic Effect of Paclitaxel on Breast Cancer by Inhibiting Nuclear Factor (NF)-?B Signaling.
Breast Neoplasms
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
Breast Neoplasms
Proteasome inhibitors induce AMPK activation via CaMKK? in human breast cancer cells.
Breast Neoplasms
Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells.
Breast Neoplasms
Proteasome Inhibitors Suppress ErbB Family Expression through HSP90-Mediated Lysosomal Degradation.
Breast Neoplasms
Proteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells.
Breast Neoplasms
Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi.
Breast Neoplasms
Proteasome-mediated degradation of BRCA1 protein in MCF-7 human breast cancer cells.
Breast Neoplasms
Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation.
Breast Neoplasms
Proteomic analysis of ubiquitinated proteins from human MCF-7 breast cancer cells by immunoaffinity purification and mass spectrometry.
Breast Neoplasms
PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.
Breast Neoplasms
PSMD12 promotes glioma progression by upregulating the expression of Nrf2.
Breast Neoplasms
PSME3 induces epithelial-mesenchymal transition with inducing the expression of CSC markers and immunosuppression in breast cancer.
Breast Neoplasms
RAC1B Induces SMAD7 via USP26 to Suppress TGF?1-Dependent Cell Migration in Mesenchymal-Subtype Carcinoma Cells.
Breast Neoplasms
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.
Breast Neoplasms
Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers: effects on replication, transcription, translation, and the cellular stress response.
Breast Neoplasms
Repression of breast cancer cell growth by proteasome inhibitors in vitro: impact of mitogen-activated protein kinase phosphatase 1.
Breast Neoplasms
Restoring E-cadherin-mediated cell-cell adhesion increases PTEN protein level and stability in human breast carcinoma cells.
Breast Neoplasms
Resveratrol fuels HER2 and ER?-positive breast cancer behaving as proteasome inhibitor.
Breast Neoplasms
Retinoic acid mediates degradation of IRS-1 by the ubiquitin-proteasome pathway, via a PKC-dependant mechanism.
Breast Neoplasms
Role of the proteasome in the regulation of estrogen receptor alpha turnover and function in MCF-7 breast carcinoma cells.
Breast Neoplasms
Sal-like 4 protein levels in breast cancer cells are post-translationally down-regulated by tripartite motif containing 21.
Breast Neoplasms
Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.
Breast Neoplasms
Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells.
Breast Neoplasms
Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.
Breast Neoplasms
Shotgun proteomics and network analysis of ubiquitin-related proteins from human breast carcinoma epithelial cells.
Breast Neoplasms
Signaling network analysis of ubiquitin-mediated proteins suggests correlations between the 26S proteasome and tumor progression.
Breast Neoplasms
Silencing Hsp25/Hsp27 gene expression augments proteasome activity and increases CD8+ T-cell-mediated tumor killing and memory responses.
Breast Neoplasms
Spiropyran-Based Nanocarrier: A New Zn2+ -Responsive Delivery System with Real-Time Intracellular Sensing Capabilities.
Breast Neoplasms
Stronger proteasomal inhibition and higher CHOP induction are responsible for more effective induction of paraptosis by dimethoxycurcumin than curcumin.
Breast Neoplasms
Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells.
Breast Neoplasms
Targeted elimination of breast cancer cells with low proteasome activity is sufficient for tumor regression.
Breast Neoplasms
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
Breast Neoplasms
Targeting bortezomib-induced aggresome formation using vinorelbine enhances the cytotoxic effect along with ER stress loading in breast cancer cell lines.
Breast Neoplasms
The CCAAT box-binding transcription factor NF-Y regulates basal expression of human proteasome genes.
Breast Neoplasms
The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition.
Breast Neoplasms
The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma.
Breast Neoplasms
The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib.
Breast Neoplasms
The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Breast Neoplasms
The proteasome inhibitor bortezomib induces an inhibitory chromatin environment at a distal enhancer of the estrogen receptor-? gene.
Breast Neoplasms
The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment.
Breast Neoplasms
The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
Breast Neoplasms
The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy.
Breast Neoplasms
Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib.
Breast Neoplasms
Transcription factor AP-2alpha is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor alpha-induced apoptosis in breast cancer cells.
Breast Neoplasms
Transcriptome Guided Drug Combination Suppresses Proliferation of Breast Cancer Cells.
Breast Neoplasms
Treating MCF7 breast cancer cell with proteasome inhibitor Bortezomib restores apoptotic factors and sensitizes cell to Docetaxel.
Breast Neoplasms
Treatment of breast cancer cells with proteasome inhibitor lactacystin increases the level of sensitivity to cell death induced by human immunodeficiency virus type 1.
Breast Neoplasms
Ubiquitin-Conjugating Enzyme UBE2C Is Highly Expressed in Breast Microcalcification Lesions.
Breast Neoplasms
Ubiquitin-immunoreactive degradation products of cytokeratin 8/18 correlate with aggressive breast cancer.
Breast Neoplasms
Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription.
Breast Neoplasms
[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].
Bronchiolitis Obliterans
Repetitive diacetyl vapor exposure promotes ubiquitin proteasome stress and precedes bronchiolitis obliterans pathology.
Bronchitis
Interplay of the ubiquitin proteasome system and the innate immune response is essential for the replication of infectious bronchitis virus.
Bulbo-Spinal Atrophy, X-Linked
Aggregation and proteasome: the case of elongated polyglutamine aggregation in spinal and bulbar muscular atrophy.
Bulbo-Spinal Atrophy, X-Linked
Archaeal proteasomes effectively degrade aggregation-prone proteins and reduce cellular toxicities in mammalian cells.
Bulbo-Spinal Atrophy, X-Linked
Enhanced Clearance of Neurotoxic Misfolded Proteins by the Natural Compound Berberine and Its Derivatives.
Bulbo-Spinal Atrophy, X-Linked
HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS.
Bulbo-Spinal Atrophy, X-Linked
Paeoniflorin eliminates a mutant AR via NF-YA-dependent proteolysis in spinal and bulbar muscular atrophy.
Bulbo-Spinal Atrophy, X-Linked
The unfolded protein response modulates toxicity of the expanded glutamine androgen receptor.
Burkitt Lymphoma
Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
Burkitt Lymphoma
Epstein-Barr virus lytic cycle activation alters proteasome subunit expression in Burkitt's lymphoma cells.
Burkitt Lymphoma
HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway.
Burkitt Lymphoma
Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
Burkitt Lymphoma
Novel N-amidinopiperidine-based proteasome inhibitor preserves dendritic cell functionality and rescues their Th1-polarizing capacity in Ramos-conditioned tumor environment.
Burkitt Lymphoma
Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.
Burkitt Lymphoma
Selective Cytotoxicity of Amidinopiperidine Based Compounds Towards Burkitt's Lymphoma Cells Involves Proteasome Inhibition.
Burkitt Lymphoma
Synergism of arsenic trioxide and MG132 in Raji cells attained by targeting BNIP3, autophagy, and mitochondria with low doses of valproic acid and vincristine.
Burkitt Lymphoma
The presence or absence of latent Epstein-Barr virus does not alter the sensitivity of Burkitt's lymphoma cell lines to proteasome inhibitors.
Burkitt Lymphoma
The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
Burkitt Lymphoma
Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor.
calpain-3 deficiency
Down-regulation of genes in the lysosomal and ubiquitin-proteasome proteolytic pathways in calpain-3-deficient muscle.
Carcinogenesis
Analyzing proteasomal subunit expression reveals Rpt4 as a prognostic marker in stage II colorectal cancer.
Carcinogenesis
Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
Carcinogenesis
Antitumor Effect of Inula viscosa Extracts on DMBA-Induced Skin Carcinoma Are Mediated by Proteasome Inhibition.
Carcinogenesis
Autophagy and Ubiquitination as Two Major Players in Colorectal Cancer: Recent Patents Review.
Carcinogenesis
CCR 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer.
Carcinogenesis
Changes in the Proteasome Pool during Malignant Transformation of Mouse Liver Cells.
Carcinogenesis
Colonic Lamina Propria Inflammatory Cells from Patients with IBD Induce the Nuclear Factor-E2 Related Factor-2 Thereby Leading to Greater Proteasome Activity and Apoptosis Protection in Human Colonocytes.
Carcinogenesis
Combining Genomics To Identify the Pathways of Post-Transcriptional Nongenotoxic Signaling and Energy Homeostasis in Livers of Rats Treated with the Pregnane X Receptor Agonist, Pregnenolone Carbonitrile.
Carcinogenesis
Complex formation between metabolic enzymes in tumor cells: Unfolding the MDR1-IDE paradigm.
Carcinogenesis
Differential regulation of the REG?-proteasome pathway by p53/TGF-? signalling and mutant p53 in cancer cells.
Carcinogenesis
Enhanced Efficacy against Cervical Carcinomas through Polymeric Micelles Physically Incorporating the Proteasome Inhibitor MG132.
Carcinogenesis
Expression of p28GANK and its correlation with RB in human hepatocellular carcinoma.
Carcinogenesis
Fascin protein stabilization by miR-146a implicated in the process of a chronic inflammation-related colon carcinogenesis model.
Carcinogenesis
Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin.
Carcinogenesis
GRP75 modulates oncogenic Dbl-driven endocytosis derailed via the CHIP-mediated ubiquitin degradation pathway.
Carcinogenesis
Homology modeling and virtual screening of ubiquitin conjugation enzyme E2A for designing a novel selective antagonist against cancer.
Carcinogenesis
Identifying reproducible cancer-associated highly expressed genes with important functional significances using multiple datasets.
Carcinogenesis
Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part II: targeting cell cycle events, caspases, NF-?B and the proteasome.
Carcinogenesis
Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2).
Carcinogenesis
Inflammatory macrophages induce Nrf2 transcription factor-dependent proteasome activity in colonic NCM460 cells and thereby confer anti-apoptotic protection.
Carcinogenesis
Inhibition of beta-TrCP function potentiates UVB-induced apoptosis in hTERT-immortalized normal human keratinocytes.
Carcinogenesis
Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy.
Carcinogenesis
Isolation of the Schizosaccharomyces pombe Proteasome Subunit Rpn7 and a Structure-Function Study of the Proteasome-COP9-Initiation Factor Domain.
Carcinogenesis
MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation.
Carcinogenesis
Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma.
Carcinogenesis
Mutant p53 (p53-R248Q) functions as an oncogene in promoting endometrial cancer by up-regulating REG?
Carcinogenesis
Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents.
Carcinogenesis
Negatively Charged Metal Oxide Nanoparticles Interact with the 20S Proteasome and Differentially Modulate Its Biologic Functional Effects.
Carcinogenesis
p28GANK overexpression is associated with chemotherapy resistance and poor prognosis in ovarian cancer.
Carcinogenesis
Peroxisome proliferator-activated receptor gamma and regulations by the ubiquitin-proteasome system in pancreatic cancer.
Carcinogenesis
Pharmacological Approaches in an Experimental Model of Non-Small Cell Lung Cancer: Effects on Tumor Biology.
Carcinogenesis
Potential roles for PA28beta in gastric adenocarcinoma development and diagnosis.
Carcinogenesis
Proteasome activity is required for the initiation of precancerous pancreatic lesions.
Carcinogenesis
Proteasome particle-rich structures are widely present in human epithelial neoplasms: correlative light, confocal and electron microscopy study.
Carcinogenesis
Proteasome-Rich PaCS as an Oncofetal UPS Structure Handling Cytosolic Polyubiquitinated Proteins. In Vivo Occurrence, in Vitro Induction, and Biological Role.
Carcinogenesis
PSMC2 is up-regulated in osteosarcoma and regulates osteosarcoma cell proliferation, apoptosis and migration.
Carcinogenesis
PSMC2 is Up-regulated in Pancreatic Cancer and Promotes Cancer Cell Proliferation and Inhibits Apoptosis.
Carcinogenesis
Regulation of FOXO protein stability via ubiquitination and proteasome degradation.
Carcinogenesis
Repression of breast cancer cell growth by proteasome inhibitors in vitro: impact of mitogen-activated protein kinase phosphatase 1.
Carcinogenesis
Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.
Carcinogenesis
Roles of the two distinct proteasome pathways in hepatitis C virus infection.
Carcinogenesis
Selective induction of the tumor marker glutathione S-transferase P1 by proteasome inhibitors.
Carcinogenesis
Sequential down-regulation of E-cadherin with squamous cell carcinoma progression: loss of E-cadherin via a prostaglandin E2-EP2 dependent posttranslational mechanism.
Carcinogenesis
Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.
Carcinogenesis
Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy.
Carcinogenesis
The possible role of EWS-Fli1 in evasion of senescence in Ewing family tumors.
Carcinogenesis
The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma.
Carcinogenesis
The Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis.
Carcinogenesis
The ubiquitin-proteasome pathway and enhanced activity of NF-kappaB in gastric carcinoma.
Carcinogenesis
TRIB2 desensitizes ferroptosis via ?TrCP-mediated TFRC ubiquitiantion in liver cancer cells.
Carcinogenesis
UBE2D3 gene overexpression increases radiosensitivity of EC109 esophageal cancer cells in vitro and in vivo.
Carcinogenesis
UBE2D3 is a positive prognostic factor and is negatively correlated with hTERT expression in esophageal cancer.
Carcinogenesis
Ubiquitin-specific protease 14 is a new therapeutic target for the treatment of diseases.
Carcinogenesis
Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18.
Carcinoid Tumor
Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours.
Carcinoma
15,16-Dihydrotanshinone I, a Compound of Salvia miltiorrhiza Bunge, Induces Apoptosis through Inducing Endoplasmic Reticular Stress in Human Prostate Carcinoma Cells.
Carcinoma
A novel component of the ubiquitin pathway, ubiquitin carboxyl extension protein 1 is overexpressed in prostate cancer.
Carcinoma
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: A trial of the eastern cooperative oncology group (E1303).
Carcinoma
A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
Carcinoma
Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6.
Carcinoma
Antitumor Effect of Inula viscosa Extracts on DMBA-Induced Skin Carcinoma Are Mediated by Proteasome Inhibition.
Carcinoma
Autophagic Inhibition of Caveolin-1 by Compound Phyllanthus urinaria L. Activates Ubiquitination and Proteasome Degradation of ?-catenin to Suppress Metastasis of Hepatitis B-Associated Hepatocellular Carcinoma.
Carcinoma
Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation.
Carcinoma
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
Carcinoma
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Carcinoma
Can tumor growth be further inhibited by combining drugs such as bortezomib with image-guided interventional oncologic procedures?
Carcinoma
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Carcinoma
Caveolin-1 down-regulates inducible nitric oxide synthase via the proteasome pathway in human colon carcinoma cells.
Carcinoma
Changes in immunocytochemical detectability of proteasome epitopes depending on cell growth and fixation conditions of lung cancer cell lines.
Carcinoma
Changes in proteasome chymotrypsin-like activity during the development of human mammary and thyroid carcinomas.
Carcinoma
Changes in the Proteasome Pool during Malignant Transformation of Mouse Liver Cells.
Carcinoma
Circulating Proteasomes in the Pathogenesis of Head and Neck Squamous Cell Carcinoma.
Carcinoma
Combination of photodynamic therapy with aspirin in human-derived lung adenocarcinoma cells affects proteasome activity and induces apoptosis.
Carcinoma
Correction for Ye et al., Nrf2- and ATF4-Dependent Upregulation of xCT Modulates the Sensitivity of T24 Bladder Carcinoma Cells to Proteasome Inhibition.
Carcinoma
Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma.
Carcinoma
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
Carcinoma
Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
Carcinoma
Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.
Carcinoma
Direct inhibition of the ubiquitin-proteasome pathway by ester bond-containing green tea polyphenols is associated with increased expression of sterol regulatory element-binding protein 2 and LDL receptor.
Carcinoma
Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors.
Carcinoma
Downregulation of 26S proteasome catalytic activity promotes epithelial-mesenchymal transition.
Carcinoma
Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.
Carcinoma
Effect of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells.
Carcinoma
Enhanced Efficacy against Cervical Carcinomas through Polymeric Micelles Physically Incorporating the Proteasome Inhibitor MG132.
Carcinoma
Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor.
Carcinoma
Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.
Carcinoma
Establishment and some characteristics of epoxomicin (a proteasome inhibitor) resistant variants of the human squamous cell carcinoma cell line, A431.
Carcinoma
Experimental and computational studies indicate specific binding of pVHL protein to Aurora-A kinase.
Carcinoma
Expression of Proteasome Activator REG? in Human Laryngeal Carcinoma and Associations with Tumor Suppressor Proteins.
Carcinoma
Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities.
Carcinoma
Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN.
Carcinoma
HCMV-Mediated Interference of Bortezomib-Induced Apoptosis in Colon Carcinoma Cell Line Caco-2.
Carcinoma
Heparan sulfate degradation products can associate with oxidized proteins and proteasomes.
Carcinoma
Identification of an EGCG oxidation derivative with proteasome modulatory activity.
Carcinoma
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
Carcinoma
Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression.
Carcinoma
Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib.
Carcinoma
Inhibition of autophagy promotes cell apoptosis induced by the proteasome inhibitor MG-132 in human esophageal squamous cell carcinoma EC9706 cells.
Carcinoma
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
Carcinoma
Inhibition of proteasome activity in Gleditsia sinensis fruit extract-mediated apoptosis on human carcinoma cells.
Carcinoma
Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity.
Carcinoma
Isolation, Structure, and Biological Activities of Fellutamides C and D from an Undescribed Metulocladosporiella (Chaetothyriales) Using the Genome-Wide Candida albicans Fitness Test.
Carcinoma
Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
Carcinoma
Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
Carcinoma
Matrine inhibits prostate cancer via activation of the unfolded protein response/endoplasmic reticulum stress signaling and reversal of epithelial to mesenchymal transition.
Carcinoma
Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
Carcinoma
MHC class I-related antigen-processing machinery component defects in feline mammary carcinoma.
Carcinoma
N-acetyl-L-cysteine inhibits 26S proteasome function: implications for effects on NF-kappaB activation.
Carcinoma
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
Carcinoma
Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.
Carcinoma
Nuclear factor-KappaB as a common target and activator of oncogenes in head and neck squamous cell carcinoma.
Carcinoma
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Carcinoma
p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells.
Carcinoma
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group.
Carcinoma
Potential Role of Targeting KDR and Proteasome Inhibitors in the Therapy of Esophageal Squamous Cell Carcinoma.
Carcinoma
Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity.
Carcinoma
Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors.
Carcinoma
Prognostic Role of the Ubiquitin Proteasome System in Clear Cell Renal Cell Carcinoma: A Bioinformatic Perspective.
Carcinoma
Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53.
Carcinoma
Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
Carcinoma
Proteasomal degradation of the papillomavirus E2 protein is inhibited by overexpression of bromodomain-containing protein 4.
Carcinoma
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Carcinoma
Proteasome Inhibition Contributed to the Cytotoxicity of Arenobufagin after Its Binding with Na, K-ATPase in Human Cervical Carcinoma HeLa Cells.
Carcinoma
Proteasome inhibition leads to altered signaling in the proteome of cisplatin-resistant human ovarian carcinoma cell line.
Carcinoma
Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARgamma ligand troglitazone.
Carcinoma
Proteasome inhibitor bortezomi-induced the apoptosis of laryngeal squamous cell carcinoma Hep-2 cell line via disrupting redox equilibrium.
Carcinoma
Proteasome inhibitor MG-132 modifies coxsackie and adenovirus receptor expression in colon cancer cell line lovo.
Carcinoma
Proteasome Inhibitor MG132 Enhances Sensitivity to Cisplatin on Ovarian Carcinoma Cells In Vitro and In Vivo.
Carcinoma
Proteasome inhibitor MG132 inhibits the proliferation and promotes the cisplatin-induced apoptosis of human esophageal squamous cell carcinoma cells.
Carcinoma
Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway.
Carcinoma
Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa.
Carcinoma
Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
Carcinoma
Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis.
Carcinoma
Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent Mcl-1 protein cleavage.
Carcinoma
Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells.
Carcinoma
Proteasome inhibitors modulate chemokine production in lung epithelial and monocytic cells.
Carcinoma
Proteasome Inhibitors Sensitize Colon Carcinoma Cells to TRAIL-Induced Apoptosis via Enhanced Release of Smac/DIABLO from the Mitochondria.
Carcinoma
Proteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells.
Carcinoma
Proteasome Subunit Alpha Type 7 Promotes Proliferation and Metastasis of Gastric Cancer Through MAPK Signaling Pathway.
Carcinoma
Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib.
Carcinoma
RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage.
Carcinoma
Radix Tetrastigma Hemsleyani Flavone Suppresses Cutaneous Squamous Cell Carcinoma A431 Cells via Proteasome Inhibition.
Carcinoma
Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.
Carcinoma
Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis.
Carcinoma
Silencing of the proteasome and oxidative stress impair endoplasmic reticulum targeting and signal cleavage of a prostate carcinoma antigen.
Carcinoma
Spiropyran-Based Nanocarrier: A New Zn2+ -Responsive Delivery System with Real-Time Intracellular Sensing Capabilities.
Carcinoma
Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties.
Carcinoma
Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
Carcinoma
Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice.
Carcinoma
Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Carcinoma
Synergistic induction of apoptosis in HeLa cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitor SAHA.
Carcinoma
Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Carcinoma
Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
Carcinoma
Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery.
Carcinoma
Targeting transcription factor NFB: comparative analysis of proteasome and IKK inhibitors.
Carcinoma
The molecular mechanisms of XBP-1 gene silencing on IRE1?-TRAF2-ASK1-JNK pathways in oral squamous cell carcinoma under endoplasmic reticulum stress.
Carcinoma
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
Carcinoma
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Carcinoma
The proteasome inhibitor MG-132 protects hypoxic SiHa cervical carcinoma cells after cyclic hypoxia/reoxygenation from ionizing radiation.
Carcinoma
The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism.
Carcinoma
The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
Carcinoma
The ubiquitin-proteasome pathway and enhanced activity of NF-kappaB in gastric carcinoma.
Carcinoma
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
Carcinoma
Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients.
Carcinoma
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
Carcinoma
Ubiquitination and the ubiquitin - proteasome system in the pathogenesis and treatment of squamous head and neck carcinoma.
Carcinoma
[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].
Carcinoma
[Effect of EGF on ubiquitination and proteasome-dependent degradation of phospholipase C gamma1 in A431 cells]
Carcinoma
[Proteasome inhibitor bortezomib sensitizes Hep-2 human laryngeal squamous cell carcinoma cells to ionizing radiation in vitro and in vivo]
Carcinoma, Adenoid Cystic
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: A trial of the eastern cooperative oncology group (E1303).
Carcinoma, Basal Cell
Dual degradation signals control Gli protein stability and tumor formation.
Carcinoma, Ductal
Gel-based proteomics analysis of the heterogeneity of 20S proteasomes from four human pancreatic cancer cell lines.
Carcinoma, Hepatocellular
A new TRAIL to therapy of hepatocellular carcinoma: blocking the proteasome.
Carcinoma, Hepatocellular
Anticancer activity of an antisense oligonucleotide targeting TRADD combined with proteasome inhibitors in chemoresistant hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Apoptosis induced in hepatoblastoma HepG2 cells by the proteasome inhibitor MG132 is associated with hydrogen peroxide production, expression of Bcl-XS and activation of caspase-3.
Carcinoma, Hepatocellular
ATP-based cell viability assay is superior to trypan blue exclusion and XTT assay in measuring cytotoxicity of anticancer drugs Taxol and Imatinib, and proteasome inhibitor MG-132 on human hepatoma cell line HepG2.
Carcinoma, Hepatocellular
Autophagic Inhibition of Caveolin-1 by Compound Phyllanthus urinaria L. Activates Ubiquitination and Proteasome Degradation of ?-catenin to Suppress Metastasis of Hepatitis B-Associated Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.
Carcinoma, Hepatocellular
Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines.
Carcinoma, Hepatocellular
Bortezomib induces in HepG2 cells IkappaBalpha degradation mediated by caspase-8.
Carcinoma, Hepatocellular
Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome.
Carcinoma, Hepatocellular
cDNA cloning of rat proteasome subunit RC7-I, a homologue of yeast PRE1 essential for chymotrypsin-like activity.
Carcinoma, Hepatocellular
Direct inhibition of the ubiquitin-proteasome pathway by ester bond-containing green tea polyphenols is associated with increased expression of sterol regulatory element-binding protein 2 and LDL receptor.
Carcinoma, Hepatocellular
Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-gamma.
Carcinoma, Hepatocellular
Effects of the beta2 agonist formoterol on atrophy signaling, autophagy, and muscle phenotype in respiratory and limb muscles of rats with cancer-induced cachexia.
Carcinoma, Hepatocellular
Endoplasmic Reticulum Stress Induced Synthesis of a Novel Viral Factor Mediates Efficient Replication of Genotype-1 Hepatitis E Virus.
Carcinoma, Hepatocellular
Expression of p28GANK and its correlation with RB in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1.
Carcinoma, Hepatocellular
HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
Carcinoma, Hepatocellular
Hepatitis B virus X protein stimulates cell growth by downregulating p16 levels via PA28?-mediated proteasomal degradation.
Carcinoma, Hepatocellular
Hepatitis C virus core protein activates proteasomal activator 28 gamma to downregulate p16 levels via ubiquitin-independent proteasomal degradation.
Carcinoma, Hepatocellular
Hsp72 controls bortezomib-induced HepG2 cell death via interaction with pro-apoptotic factors.
Carcinoma, Hepatocellular
Identification of proteasome subunit alpha type-1 as a novel biomarker in HBV-associated hepatocellular carcinoma tissue interstitial fluid by proteomic analysis.
Carcinoma, Hepatocellular
Impaired methylation as a novel mechanism for proteasome suppression in liver cells.
Carcinoma, Hepatocellular
Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib.
Carcinoma, Hepatocellular
Inhibition of proteasome function leads to NF-kappaB-independent IL-8 expression in human hepatocytes.
Carcinoma, Hepatocellular
Involvement of the proteasome and antizyme in ornithine decarboxylase degradation by a reticulocyte lysate.
Carcinoma, Hepatocellular
Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2.
Carcinoma, Hepatocellular
MG132 inhibits the expression of PBX3 through miRNAs by targeting Argonaute2 in hepatoma cells.
Carcinoma, Hepatocellular
mTORC1-dependent protein synthesis and autophagy uncouple in the regulation of Apolipoprotein A-I expression.
Carcinoma, Hepatocellular
Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma.
Carcinoma, Hepatocellular
Notch1 signaling sensitizes TRAIL-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression.
Carcinoma, Hepatocellular
Novel CADD-based peptidyl vinyl ester derivatives as potential proteasome inhibitors.
Carcinoma, Hepatocellular
Oligosaccharide modification in the early secretory pathway directs the selection of a misfolded glycoprotein for degradation by the proteasome.
Carcinoma, Hepatocellular
Oxidative stress and activation of proteasome protease during serum deprivation-induced apoptosis in rat hepatoma cells; inhibition of cell death by melatonin.
Carcinoma, Hepatocellular
Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-?B activity in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Pattern RT1A and proteasome expression in cellular fractions of Zajdela ascitic hepatoma.
Carcinoma, Hepatocellular
Pharmacological or TRIB3-Mediated Suppression of ATF4 Transcriptional Activity Promotes Hepatoma Cell Resistance to Proteasome Inhibitor Bortezomib.
Carcinoma, Hepatocellular
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.
Carcinoma, Hepatocellular
Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis.
Carcinoma, Hepatocellular
Possible role of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat hepatocellular carcinoma.
Carcinoma, Hepatocellular
Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Proteasome inhibition induces differential heat shock protein response but not unfolded protein response in HepG2 cells.
Carcinoma, Hepatocellular
Proteasome inhibition induces inclusion bodies associated with intermediate filaments and fragmentation of the Golgi apparatus.
Carcinoma, Hepatocellular
Proteasome inhibition protects against diet-induced gallstone formation through modulation of cholesterol and bile acid homeostasis.
Carcinoma, Hepatocellular
Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway.
Carcinoma, Hepatocellular
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
Carcinoma, Hepatocellular
Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Proteasome pathway operates for the degradation of ornithine decarboxylase in intact cells.
Carcinoma, Hepatocellular
Proteomic analysis of hepatitis C virus (HCV) core protein transfection and host regulator PA28? knockout in HCV pathogenesis: a network-based study.
Carcinoma, Hepatocellular
Proteomic identification of down-regulation of oncoprotein DJ-1 and proteasome activator subunit 1 in hepatitis B virus-infected well-differentiated hepatocellular carcinoma.
Carcinoma, Hepatocellular
Quercetin suppresses the chymotrypsin-like activity of proteasome via inhibition of MEK1/ERK1/2 signaling pathway in hepatocellular carcinoma HepG2 cells.
Carcinoma, Hepatocellular
Reciprocal REG?-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Research progress on proteasome subunits in regulating occurrence and development of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Rock2 regulates Cdc25A through ubiquitin proteasome system in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.
Carcinoma, Hepatocellular
Secretomic profiling of cells from hollow fiber bioreactor reveals PSMA3 as a potential cholangiocarcinoma biomarker.
Carcinoma, Hepatocellular
Selective induction of the tumor marker glutathione S-transferase P1 by proteasome inhibitors.
Carcinoma, Hepatocellular
Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo.
Carcinoma, Hepatocellular
Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
Carcinoma, Hepatocellular
Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinoma.
Carcinoma, Hepatocellular
The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo.
Carcinoma, Hepatocellular
The intracellular stability of DLC1 is regulated by the 26S proteasome in human hepatocellular carcinoma cell line Hep3B.
Carcinoma, Hepatocellular
The oncoprotein gankyrin negatively regulates both p53 and RB by enhancing proteasomal degradation.
Carcinoma, Hepatocellular
The proteasome participates in degradation of mutant alpha 1-antitrypsin Z in the endoplasmic reticulum of hepatoma-derived hepatocytes.
Carcinoma, Hepatocellular
The up-regulation of proteasome subunits and lysosomal proteases in hepatocellular carcinomas of the HBx gene knockin transgenic mice.
Carcinoma, Hepatocellular
Tumor suppressor DCAF15 inhibits epithelial-mesenchymal transition by targeting ZEB1 for proteasomal degradation in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Turnover of hepatitis B virus X protein is facilitated by Hdj1, a human Hsp40/DnaJ protein.
Carcinoma, Hepatocellular
Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
Carcinoma, Hepatocellular
[Features of the immune proteasome expression in ascite Zajdela hepatoma after implantation into Brattleboro rats with the hereditary defect of arginine-vasopressin synthesis].
Carcinoma, Intraductal, Noninfiltrating
Gel-based proteomics analysis of the heterogeneity of 20S proteasomes from four human pancreatic cancer cell lines.
Carcinoma, Medullary
Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition.
Carcinoma, Neuroendocrine
Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours.
Carcinoma, Non-Small-Cell Lung
Association between TGM5, PPAP2B and PSMA4 polymorphisms and NSCLC in never-smoking Chinese population.
Carcinoma, Non-Small-Cell Lung
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Carcinoma, Non-Small-Cell Lung
c-Myc down-regulation is involved in proteasome inhibitor-mediated enhancement of radiotherapeutic efficacy in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
Carcinoma, Non-Small-Cell Lung
Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.
Carcinoma, Non-Small-Cell Lung
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Carcinoma, Non-Small-Cell Lung
KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
Carcinoma, Non-Small-Cell Lung
Lovastatin overcomes gefitinib resistance through TNF-? signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
Carcinoma, Non-Small-Cell Lung
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
Carcinoma, Non-Small-Cell Lung
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade((R))) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
Carcinoma, Non-Small-Cell Lung
Pre-cachexia in patients with stages I-III non-small cell lung cancer: Systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system.
Carcinoma, Non-Small-Cell Lung
Proteasome inhibition improves fractionated radiation treatment against non-small cell lung cancer: an antioxidant connection.
Carcinoma, Non-Small-Cell Lung
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Carcinoma, Non-Small-Cell Lung
Proteasome inhibitor MG132 enhances the antigrowth and antimetastasis effects of radiation in human nonsmall cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling.
Carcinoma, Non-Small-Cell Lung
Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Proteasome inhibitors diminish c-Met expression and induce cell death in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent Mcl-1 protein cleavage.
Carcinoma, Non-Small-Cell Lung
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Silencing Core Spliceosome Sm Gene Expression Induces a Cytotoxic Splicing Switch in the Proteasome Subunit Beta 3 mRNA in Non-Small Cell Lung Cancer Cells.
Carcinoma, Non-Small-Cell Lung
Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity.
Carcinoma, Non-Small-Cell Lung
SPOP promotes FADD degradation and inhibits NF-?B activity in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Sulforaphane Induced Apoptosis via Promotion of Mitochondrial Fusion and ERK1/2-Mediated 26S Proteasome Degradation of Novel Pro-survival Bim and Upregulation of Bax in Human Non-Small Cell Lung Cancer Cells.
Carcinoma, Non-Small-Cell Lung
Sulforaphane metabolites reduce resistance to paclitaxel via microtubule disruption.
Carcinoma, Non-Small-Cell Lung
Systemic inflammation in chronic obstructive pulmonary disease and lung cancer: common driver of pulmonary cachexia?
Carcinoma, Non-Small-Cell Lung
The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.
Carcinoma, Non-Small-Cell Lung
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Carcinoma, Non-Small-Cell Lung
The role of proteasome inhibition in nonsmall cell lung cancer.
Carcinoma, Non-Small-Cell Lung
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
Carcinoma, Non-Small-Cell Lung
Updated review and perspective on 20S proteasome inhibitors in the treatment of Lung Cancer.
Carcinoma, Ovarian Epithelial
Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic.
Carcinoma, Ovarian Epithelial
The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Ubiquitin Proteasome Pathway Transcriptome in Epithelial Ovarian Cancer.
Carcinoma, Renal Cell
A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production.
Carcinoma, Renal Cell
Basic science and research in renal cell carcinoma: from workbench to bedside.
Carcinoma, Renal Cell
Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.
Carcinoma, Renal Cell
Experimental and computational studies indicate specific binding of pVHL protein to Aurora-A kinase.
Carcinoma, Renal Cell
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
Carcinoma, Renal Cell
Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
Carcinoma, Renal Cell
Insulin-induced gene 1 (INSIG1) inhibits HIV-1 production by degrading Gag via activity of the ubiquitin ligase TRC8.
Carcinoma, Renal Cell
Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
Carcinoma, Renal Cell
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
Carcinoma, Renal Cell
Prognostic Role of the Ubiquitin Proteasome System in Clear Cell Renal Cell Carcinoma: A Bioinformatic Perspective.
Carcinoma, Renal Cell
Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model.
Carcinoma, Renal Cell
Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARgamma ligand troglitazone.
Carcinoma, Renal Cell
Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis.
Carcinoma, Renal Cell
Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery.
Carcinoma, Renal Cell
The interaction of superoxide with nitric oxide destabilizes hypoxia-inducible factor-1alpha.
Carcinoma, Renal Cell
[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].
Carcinoma, Squamous Cell
A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
Carcinoma, Squamous Cell
Antitumor activity of CTFB, a novel anticancer agent, is associated with the down-regulation of nuclear factor-kappaB expression and proteasome activation in head and neck squamous carcinoma cell lines.
Carcinoma, Squamous Cell
Apoptotic effect of MG-132 on human tongue squamous cell carcinoma.
Carcinoma, Squamous Cell
Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation.
Carcinoma, Squamous Cell
Can tumor growth be further inhibited by combining drugs such as bortezomib with image-guided interventional oncologic procedures?
Carcinoma, Squamous Cell
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Carcinoma, Squamous Cell
Circulating Proteasomes in the Pathogenesis of Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
Carcinoma, Squamous Cell
Establishment and some characteristics of epoxomicin (a proteasome inhibitor) resistant variants of the human squamous cell carcinoma cell line, A431.
Carcinoma, Squamous Cell
Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities.
Carcinoma, Squamous Cell
Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN.
Carcinoma, Squamous Cell
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
Carcinoma, Squamous Cell
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
Carcinoma, Squamous Cell
Nuclear factor-KappaB as a common target and activator of oncogenes in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Carcinoma, Squamous Cell
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group.
Carcinoma, Squamous Cell
Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity.
Carcinoma, Squamous Cell
Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa.
Carcinoma, Squamous Cell
Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
Carcinoma, Squamous Cell
Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib.
Carcinoma, Squamous Cell
RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage.
Carcinoma, Squamous Cell
Radix Tetrastigma Hemsleyani Flavone Suppresses Cutaneous Squamous Cell Carcinoma A431 Cells via Proteasome Inhibition.
Carcinoma, Squamous Cell
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
Carcinoma, Squamous Cell
The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
Carcinoma, Squamous Cell
Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients.
Carcinoma, Squamous Cell
[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].
Cardiomegaly
Activation of the cardiac proteasome promotes angiotension II-induced hypertrophy by down-regulation of ATRAP.
Cardiomegaly
Aerobic exercise training improves oxidative stress and ubiquitin proteasome system activity in heart of spontaneously hypertensive rats.
Cardiomegaly
Back to your heart: Ubiquitin proteasome system-regulated signal transduction.
Cardiomegaly
Deubiquitinase Inhibitor Auranofin Attenuated Cardiac Hypertrophy by Blocking NF-?B Activation.
Cardiomegaly
Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy.
Cardiomegaly
Genetically induced moderate inhibition of 20S proteasomes in cardiomyocytes facilitates heart failure in mice during systolic overload.
Cardiomegaly
MG132, a proteasome inhibitor, attenuates pressure-overload-induced cardiac hypertrophy in rats by modulation of mitogen-activated protein kinase signals.
Cardiomegaly
Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors.
Cardiomegaly
Proteasome activation during cardiac hypertrophy by the chaperone H11 Kinase/Hsp22.
Cardiomegaly
Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts.
Cardiomegaly
Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload.
Cardiomegaly
Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy.
Cardiomegaly
Proteasome inhibitors attenuated cholesterol-induced cardiac hypertrophy in H9c2 cells.
Cardiomegaly
Quercetin Prevents In Vivo and In Vitro Myocardial Hypertrophy Through the Proteasome-GSK-3 Pathway.
Cardiomegaly
Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease.
Cardiomegaly
Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system.
Cardiomegaly
The mammalian target of rapamycin modulates the immunoproteasome system in the heart.
Cardiomegaly
The proteasome activator REG? accelerates cardiac hypertrophy by declining PP2Ac?-SOD2 pathway.
Cardiomegaly
Ubiquitin proteasome system (UPS) activation in the cardiac hypertrophy of hyperthyroidism.
Cardiomegaly
Ubiquitin-Specific Protease 4 Is an Endogenous Negative Regulator of Pathological Cardiac Hypertrophy.
Cardiomyopathies
A substitution mutation in cardiac ubiquitin ligase, FBXO32, is associated with an autosomal recessive form of dilated cardiomyopathy.
Cardiomyopathies
Cardiac proteasome functional insufficiency plays a pathogenic role in diabetic cardiomyopathy.
Cardiomyopathies
Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice.
Cardiomyopathies
Enhancement of proteasome function by PA28α overexpression protects against oxidative stress.
Cardiomyopathies
Identification of differentially expressed genes and pathways crosstalk analysis in Rheumatoid and Osteoarthritis using next-generation sequencing and protein-protein networks.
Cardiomyopathies
Inadequate ubiquitination-proteasome coupling contributes to myocardial ischemia-reperfusion injury.
Cardiomyopathies
p62 Stages an Interplay Between the Ubiquitin-Proteasome System and Autophagy in the Heart of Defense Against Proteotoxic Stress.
Cardiomyopathies
Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts.
Cardiomyopathies
Proteasome inhibition promotes regression of left ventricular hypertrophy.
Cardiomyopathies
Regulation of cardiac proteasomes by ubiquitination, SUMOylation, and beyond.
Cardiomyopathies
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
Cardiomyopathies
Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies.
Cardiomyopathies
The Ubiquitin Proteasome System in Human Cardiomyopathies and Heart Failure.
Cardiomyopathies
The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective.
Cardiomyopathies
Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies.
Cardiomyopathy, Dilated
Cardiomyocyte degeneration with calpain deficiency reveals a critical role in protein homeostasis.
Cardiomyopathy, Dilated
Detecting the genetic link between Alzheimer's disease and obesity using bioinformatics analysis of GWAS data.
Cardiomyopathy, Dilated
Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice.
Cardiomyopathy, Dilated
Identification of six cardiovascular risk biomarkers in the young population: A promising tool for early prevention.
Cardiomyopathy, Dilated
Lack of evidence for a pathogenic role of proteasome-directed autoimmunity in dilated cardiomyopathy.
Cardiomyopathy, Dilated
The Ubiquitin Proteasome System in Ischemic and Dilated Cardiomyopathy.
Cardiomyopathy, Dilated
TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy.
Cardiomyopathy, Dilated
Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies.
Cardiomyopathy, Hypertrophic
Corrigendum: Emergence of Members of TRAF and DUB of Ubiquitin Proteasome System in the Regulation of Hypertrophic Cardiomyopathy.
Cardiomyopathy, Hypertrophic
Detecting the genetic link between Alzheimer's disease and obesity using bioinformatics analysis of GWAS data.
Cardiomyopathy, Hypertrophic
Effects of a Proteasome Inhibitor on Cardiomyocytes in a Pressure-Overload Hypertrophy Rat Model: An Animal Study.
Cardiomyopathy, Hypertrophic
Emergence of Members of TRAF and DUB of Ubiquitin Proteasome System in the Regulation of Hypertrophic Cardiomyopathy.
Cardiomyopathy, Hypertrophic
Identification of differentially expressed genes and pathways crosstalk analysis in Rheumatoid and Osteoarthritis using next-generation sequencing and protein-protein networks.
Cardiomyopathy, Hypertrophic
Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy.
Cardiomyopathy, Hypertrophic
Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies.
Cardiomyopathy, Restrictive
Repeated intermittent administration of a ubiquitous proteasome inhibitor leads to restrictive cardiomyopathy.
Cardiotoxicity
A BAG3 chaperone complex maintains cardiomyocyte function during proteotoxic stress.
Cardiotoxicity
A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Cardiotoxicity
Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib.
Cardiotoxicity
Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats.
Cardiotoxicity
Diclofenac induces proteasome and mitochondrial dysfunction in murine cardiomyocytes and hearts.
Cardiotoxicity
Different effects of the nonsteroidal anti-inflammatory drugs meclofenamate sodium and naproxen sodium on proteasome activity in cardiac cells.
Cardiotoxicity
Doxorubicin induces protein ubiquitination and inhibits proteasome activity during cardiotoxicity.
Cardiotoxicity
Genetically induced moderate inhibition of 20S proteasomes in cardiomyocytes facilitates heart failure in mice during systolic overload.
Cardiotoxicity
In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline.
Cardiotoxicity
Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis.
Cardiotoxicity
Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin.
Cardiotoxicity
Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
Cardiotoxicity
Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy.
Cardiotoxicity
Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
Cardiotoxicity
Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management.
Cardiotoxicity
Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
Cardiotoxicity
Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF-?B, Hypertrophic Gene Expression and Oxidative Stress.
Cardiotoxicity
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Cardiotoxicity
Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies.
Cardiotoxicity
The Calcineurin-TFEB-p62 Pathway Mediates the Activation of Cardiac Macroautophagy by Proteasomal Malfunction.
Cardiotoxicity
Ubiquitin-based anticancer therapy: Carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors.
Cardiovascular Diseases
Basic mechanisms in endoplasmic reticulum stress and relation to cardiovascular diseases.
Cardiovascular Diseases
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).
Cardiovascular Diseases
Deficiency of the Immunoproteasome LMP10 Subunit Attenuates Angiotensin II-Induced Cardiac Hypertrophic Remodeling via Autophagic Degradation of gp130 and IGF1R.
Cardiovascular Diseases
Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives.
Cardiovascular Diseases
Exercise Modulates Oxidative Stress and Inflammation in Aging and Cardiovascular Diseases.
Cardiovascular Diseases
Metabolomic Quantitative Trait Loci (mQTL) Mapping Implicates the Ubiquitin Proteasome System in Cardiovascular Disease Pathogenesis.
Cardiovascular Diseases
Muscarinic 2 receptors modulate cardiac proteasome function in a protein kinase G-dependent manner.
Cardiovascular Diseases
Nutritional Supplement-5 with a Combination of Proteasome Inhibitors (Resveratrol, Quercetin, ?-Tocotrienol) Modulate Age-Associated Biomarkers and Cardiovascular Lipid Parameters in Human Subjects.
Cardiovascular Diseases
Pathophysiological role of proteasome-dependent proteolytic pathway in endothelin-1-related cardiovascular diseases.
Cardiovascular Diseases
Preliminary comments on proteasome inhibition and cardiovascular disease.
Cardiovascular Diseases
Protein kinase g positively regulates proteasome-mediated degradation of misfolded proteins.
Cardiovascular Diseases
Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease.
Cardiovascular Diseases
The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended.
Cardiovascular Diseases
The ubiquitin-proteasome system--micro target for macro intervention?
Cardiovascular Diseases
Ubiquitin proteasome system (UPS) activation in the cardiac hypertrophy of hyperthyroidism.
Carpal Tunnel Syndrome
Proteasome Modulator 9 SNPs are linked to Hypertension in Type 2 Diabetes Families.
Cataract
Age-dependent protein modifications and declining proteasome activity in the human lens.
Cataract
Comprehensive Profiling of Proteome and Ubiquitome Changes in Human Lens Epithelial Cell Line after Ultraviolet-B Irradiation.
Cataract
Differential gene expression in male and female rat lenses undergoing cataract induction by transforming growth factor-beta (TGF-beta).
Cataract
H2O2-induced cataract as a model of age-related cataract: Lessons learned from overexpressing the proteasome activator PA28?? in mouse eye lens.
Cataract
Increased O-GlcNAc causes disrupted lens fiber cell differentiation and cataracts.
Cataract
N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: Glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population.
Cataract
Peptidases play an important role in cataractogenesis: an immunohistochemical study on lenses derived from Shumiya cataract rats.
Cataract
Proteasome activity in human lens nuclei and correlation with age, gender and severity of cataract.
Cataract
Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6.
Cataract
Proteasome subunit PSMC3 variants cause neurosensory syndrome combining deafness and cataract due to proteotoxic stress.
Cataract
Protein oxidative modification in the aging organism and the role of the ubiquitin proteasomal system.
Cataract
Proteolytic cleavage of N-Succ-Leu-Leu-Val-Tyr-AMC by the proteasome in lens epithelium from clear and cataractous human lenses.
Cataract
Sustained oxidative stress inhibits NF-kappaB activation partially via inactivating the proteasome.
Cataract
The apoptosis of bovine lens epithelial cells induced by proteasome inhibitor MG132.
Cataract
[Compare the proteasome activity in the epithelium of human age-related cataract and normal lens]
Cell Transformation, Neoplastic
PSMD5 Inactivation Promotes 26S Proteasome Assembly during Colorectal Tumor Progression.
Central Nervous System Diseases
Immunoproteasome in cancer and neuropathologies: a new therapeutic target?
Central Nervous System Diseases
Is PROTAC technology really a game changer for central nervous system drug discovery?
Central Nervous System Diseases
The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases.
Cerebral Hemorrhage
Morphological Changes within the Rat Lateral Ventricle after the Administration of Proteasome Inhibitors.
Cerebral Hemorrhage
Over-Activated Proteasome Mediates Neuroinflammation on Acute Intracerebral Hemorrhage in Rats.
Cerebral Hemorrhage
Proteasome Inhibitor Reduces Astrocytic iNOS Expression and Functional Deficit after Experimental Intracerebral Hemorrhage in Rats.
Cerebral Small Vessel Diseases
Cerebral Small Vessel Disease Is Associated with Dysregulation in the Ubiquitin Proteasome System and Other Major Cellular Pathways in Specific Brain Regions.
Cerebrovascular Disorders
The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.
Chagas Disease
Anti-Trypanosomal Proteasome Inhibitors Cure Hemolymphatic and Meningoencephalic Murine Infection Models of African Trypanosomiasis.
Chagas Disease
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.
Chagas Disease
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness.
Chalazion
Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series.
Charcot-Marie-Tooth Disease
Elevated Peripheral Myelin Protein 22, Reduced Mitotic Potential, and Proteasome Impairment in Dermal Fibroblasts from Charcot-Marie-Tooth Disease Type 1A Patients.
Charcot-Marie-Tooth Disease
Inducible HSP70 is critical in preventing the aggregation and enhancing the processing of PMP22.
Charcot-Marie-Tooth Disease
Mutations associated with Charcot-Marie-Tooth disease cause SIMPLE protein mislocalization and degradation by the proteasome and aggresome-autophagy pathways.
Chickenpox
Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease.
Cholangiocarcinoma
Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.
Cholangiocarcinoma
Proteasome inhibition-induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells.
Cholangiocarcinoma
PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma.
Cholangiocarcinoma
RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing NF-KB-Mediated Cell Apoptosis.
Cholangiocarcinoma
Secretomic profiling of cells from hollow fiber bioreactor reveals PSMA3 as a potential cholangiocarcinoma biomarker.
Cholelithiasis
Proteasome Activity and C-Reactive Protein Concentration in the Course of Inflammatory Reaction in Relation to the Type of Abdominal Operation and the Surgical Technique Used.
Cholelithiasis
Proteasome inhibition protects against diet-induced gallstone formation through modulation of cholesterol and bile acid homeostasis.
Chondrosarcoma
The Proteasome Inhibitor Bortezomib Affects Chondrosarcoma Cells via the Mitochondria-Caspase Dependent Pathway and Enhances Death Receptor Expression and Autophagy.
Choroidal Neovascularization
Small molecule anti-angiogenic probes of the ubiquitin proteasome pathway: potential application to choroidal neovascularization.
Chronic Urticaria
High plasma proteasome levels are detected in patients with metastatic malignant melanoma.
Ciliopathies
Dishevelled stabilization by the ciliopathy protein Rpgrip1l is essential for planar cell polarity.
Ciliopathies
The cilia-regulated proteasome and its role in the development of ciliopathies and cancer.
Classical Swine Fever
MG132 Attenuates the Replication of Classical Swine Fever Virus in vitro.
Coinfection
Comparative analysis of transcriptomic and hormonal responses to compatible and incompatible plant-virus interactions that lead to cell death.
Coinfection
HIV-1 burden influences host response to co-infection with Neisseria gonorrhoeae in vitro.
Coinfection
The proteasome acts as a hub for plant immunity and is targeted by Pseudomonas type-III effectors.
Colitis
Ameliorating effects of bortezomib, a proteasome inhibitor, on development of dextran sulfate sodium-induced murine colitis.
Colitis
Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome.
Colitis
Colonic Lamina Propria Inflammatory Cells from Patients with IBD Induce the Nuclear Factor-E2 Related Factor-2 Thereby Leading to Greater Proteasome Activity and Apoptosis Protection in Human Colonocytes.
Colitis
Enhanced inflammatory potential of CD4+ T-cells that lack proteasome immunosubunit expression, in a T-cell transfer-based colitis model.
Colitis
Glutamine enema regulates colonic ubiquitinated-proteins but not proteasome activities during TNBS-induced colitis leading to increased mitochondrial activity.
Colitis
Proteasome activator REG? promotes inflammation in Leydig cells via IkB? signaling.
Colitis
Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis.
Colitis
Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.
Colitis
The application and relevance of ex vivo culture systems for assessment of IBD treatment in murine models of colitis.
Colitis, Ulcerative
Increased Levels of Survivin, via Association With Heat Shock Protein 90, in Mucosal T Cells From Patients With Crohn's Disease.
Colitis-Associated Neoplasms
The REG?-proteasome forms a regulatory circuit with I?B? and NF?B in experimental colitis.
Colonic Neoplasms
A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells.
Colonic Neoplasms
Antineoplastic therapy in colorectal cancer through proteasome inhibition.
Colonic Neoplasms
ANXA1?derived peptides suppress gastric and colon cancer cell growth by targeting EphA2 degradation.
Colonic Neoplasms
Bax?2 sensitizes colorectal cancer cells to proteasome inhibitor-induced cell death.
Colonic Neoplasms
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Colonic Neoplasms
Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells.
Colonic Neoplasms
Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.
Colonic Neoplasms
Changes in spatio-temporal localization of tripeptidyl peptidase II (TPPII) in murine colon adenocarcinoma cells during aggresome formation: a microscopy study based on a novel fluorescent proteasome inhibitor.
Colonic Neoplasms
Ciglitazone-induced p27 gene transcriptional activity is mediated through Sp1 and is negatively regulated by the MAPK signaling pathway.
Colonic Neoplasms
Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant RAS/RAF via ER stress.
Colonic Neoplasms
Coronaridine, an iboga type alkaloid from Tabernaemontana divaricata, inhibits the Wnt signaling pathway by decreasing ?-catenin mRNA expression.
Colonic Neoplasms
Correction: Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant
Colonic Neoplasms
Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo.
Colonic Neoplasms
Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carfilzomib.
Colonic Neoplasms
Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
Colonic Neoplasms
Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines.
Colonic Neoplasms
Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line.
Colonic Neoplasms
Enhanced Protein Damage Clearance Induces Broad Drug Resistance in Multitype of Cancers Revealed by an Evolution Drug-Resistant Model and Genome-Wide siRNA Screening.
Colonic Neoplasms
Fascin protein stabilization by miR-146a implicated in the process of a chronic inflammation-related colon carcinogenesis model.
Colonic Neoplasms
Fem1b, a proapoptotic protein, mediates proteasome inhibitor-induced apoptosis of human colon cancer cells.
Colonic Neoplasms
Ghrelin induces apoptosis in colon adenocarcinoma cells via proteasome inhibition and autophagy induction.
Colonic Neoplasms
Glucose starvation and hypoxia induce nuclear accumulation of proteasome in cancer cells.
Colonic Neoplasms
HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha.
Colonic Neoplasms
Impaired expression of proteasome subunits and human leukocyte antigens class I in human colon cancer cells.
Colonic Neoplasms
Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2).
Colonic Neoplasms
Indirect participation of Hsp90 in the regulation of the cyclin E turnover.
Colonic Neoplasms
Induction of autophagy by proteasome inhibitor is associated with proliferative arrest in colon cancer cells.
Colonic Neoplasms
Inhibition of metalloproteinase and proteasome activities in colon cancer cells by citrus peel extracts.
Colonic Neoplasms
NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model.
Colonic Neoplasms
Oxaliplatin down-regulates survivin by p38 MAP kinase and proteasome in human colon cancer cells.
Colonic Neoplasms
Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers.
Colonic Neoplasms
Proteasome inhibition potentiates the cytotoxic effects of hyperthermia in HT-29 colon cancer cells through inhibition of heat shock protein 27.
Colonic Neoplasms
Proteasome inhibitor MG-132 modifies coxsackie and adenovirus receptor expression in colon cancer cell line lovo.
Colonic Neoplasms
Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Colonic Neoplasms
Proteasome Inhibitors-Mediated TRAIL Resensitization and Bik Accumulation.
Colonic Neoplasms
Repression of protein translation and mTOR signaling by proteasome inhibitor in colon cancer cells.
Colonic Neoplasms
Responses of Porcupine and Wntless proteins to oxidative, hypoxic and endoplasmic reticulum stresses.
Colonic Neoplasms
Role of AMP-activated protein kinase in cross-talk between apoptosis and autophagy in human colon cancer.
Colonic Neoplasms
Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors.
Colonic Neoplasms
Single-cell imaging of the heat-shock response in colon cancer cells suggests that magnitude and length rather than time of onset determines resistance to apoptosis.
Colonic Neoplasms
Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase.
Colonic Neoplasms
Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity.
Colonic Neoplasms
Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
Colonic Neoplasms
Synthesis and Inhibitory Activities against Colon Cancer Cell Growth and Proteasome of Alkylresorcinols.
Colonic Neoplasms
The calpain system is involved in the constitutive regulation of beta-catenin signaling functions.
Colonic Neoplasms
The deubiquitinase inhibitor b-AP15 induces strong proteotoxic stress and mitochondrial damage.
Colonic Neoplasms
The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
Colonic Neoplasms
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
Colonic Neoplasms
[Proteasome and calpain activities in colon cancer: the relation with metastasis and prognosis].
Colorectal Neoplasms
A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer.
Colorectal Neoplasms
Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib.
Colorectal Neoplasms
An Investigation Into the Prognostic Significance of High Proteasome PSB7 Protein Expression in Colorectal Cancer.
Colorectal Neoplasms
Antineoplastic therapy in colorectal cancer through proteasome inhibition.
Colorectal Neoplasms
Autophagy and Ubiquitination as Two Major Players in Colorectal Cancer: Recent Patents Review.
Colorectal Neoplasms
Bax?2 sensitizes colorectal cancer cells to proteasome inhibitor-induced cell death.
Colorectal Neoplasms
BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibition.
Colorectal Neoplasms
BRD8 is a potential chemosensitizing target for spindle poisons in colorectal cancer therapy.
Colorectal Neoplasms
Cancer stem cells don't waste their time cleaning-low proteasome activity, a marker for cancer stem cell function.
Colorectal Neoplasms
Cancer stem-like properties in colorectal cancer cells with low proteasome activity.
Colorectal Neoplasms
Clinical application of a systems model of apoptosis execution for the prediction of colorectal cancer therapy responses and personalisation of therapy.
Colorectal Neoplasms
Colonic Lamina Propria Inflammatory Cells from Patients with IBD Induce the Nuclear Factor-E2 Related Factor-2 Thereby Leading to Greater Proteasome Activity and Apoptosis Protection in Human Colonocytes.
Colorectal Neoplasms
Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack.
Colorectal Neoplasms
Depletion of the proteasome subunit PSMA7 inhibits colorectal cancer cell tumorigenicity and migration.
Colorectal Neoplasms
Downregulation of Siah1 promotes colorectal cancer cell proliferation and migration by regulating AKT and YAP ubiquitylation and proteasome degradation.
Colorectal Neoplasms
Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-?B in vitro and in vivo.
Colorectal Neoplasms
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
Colorectal Neoplasms
Expression of TMEM207 in Colorectal Cancer: Relation between TMEM207 and Intelectin-1.
Colorectal Neoplasms
Hypoxia Promotes Synergy between Mitomycin C and Bortezomib through a Coordinated Process of Bcl-xL Phosphorylation and Mitochondrial Translocation of p53.
Colorectal Neoplasms
Identification of differential proteins in colorectal cancer cells treated with caffeic acid phenethyl ester.
Colorectal Neoplasms
Identification of the anticancer effects of a novel proteasome inhibitor, ixazomib, on colorectal cancer using a combined method of microarray and bioinformatics analysis.
Colorectal Neoplasms
Impact of Losing hRpn13 Pru or UCHL5 on Proteasome Clearance of Ubiquitinated Proteins and RA190 Cytotoxicity.
Colorectal Neoplasms
Influence of p53 and p21Waf1 expression on G2/M phase arrest of colorectal carcinoma HCT116 cells to proteasome inhibitors.
Colorectal Neoplasms
Knockdown of the novel proteasome subunit Adrm1 located on the 20q13 amplicon inhibits colorectal cancer cell migration, survival and tumorigenicity.
Colorectal Neoplasms
Liposomes Loaded with the Proteasome Inhibitor Z-Leucinyl-Leucinyl-Norleucinal are Effective in Inducing Apoptosis in Colorectal Cancer Cell Lines.
Colorectal Neoplasms
NRF3-POMP-20S proteasome assembly axis promotes cancer development via ubiquitin-independent proteolysis of p53 and Rb.
Colorectal Neoplasms
Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor.
Colorectal Neoplasms
O-GlcNAcylation Signal Mediates Proteasome Inhibitor Resistance in Cancer Cells by Stabilizing NRF1.
Colorectal Neoplasms
Peroxisome proliferator activated receptor-? and the ubiquitin-proteasome system in colorectal cancer.
Colorectal Neoplasms
Proteasome versus Thioredoxin Reductase Competition as Possible Biological Targets in Antitumor Mixed Thiolate-Dithiocarbamate Gold(III) Complexes.
Colorectal Neoplasms
Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
Colorectal Neoplasms
PSMD5 Inactivation Promotes 26S Proteasome Assembly during Colorectal Tumor Progression.
Colorectal Neoplasms
Silencing of Proteasome 26S Subunit ATPase 2 Regulates Colorectal Cancer Cell Proliferation, Apoptosis, and Migration.
Colorectal Neoplasms
Superior antimitogenic and chemosensitization activities of the combination treatment of the histone deacetylase inhibitor apicidin and proteasome inhibitors on human colorectal cancer cells.
Colorectal Neoplasms
Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action.
Colorectal Neoplasms
Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib.
Colorectal Neoplasms
The COP9 signalosome mediates beta-catenin degradation by deneddylation and blocks adenomatous polyposis coli destruction via USP15.
Colorectal Neoplasms
The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer.
Colorectal Neoplasms
The proteasome inhibitor lactacystin enhances GSH synthesis capacity by increased expression of antioxidant components in an Nrf2-independent, but p38 MAPK-dependent manner in rat colorectal carcinoma cells.
Colorectal Neoplasms
The proteasome subunit PSMA7 located on the 20q13 amplicon is overexpressed and associated with liver metastasis in colorectal cancer.
Colorectal Neoplasms
The ubiquitination ligase SMURF2 reduces aerobic glycolysis and colorectal cancer cell proliferation by promoting ChREBP ubiquitination and degradation.
Colorectal Neoplasms
Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, in combination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: underlying molecular mechanisms.
Colorectal Neoplasms
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
Colorectal Neoplasms
[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].
Colorectal Neoplasms
[High expression of proteasome subunit PSMA7 in colorectal cancer is significantly correlated with liver metastasis]
Colorectal Neoplasms
[Silencing of Adrm1 by RNA interference suppresses proliferation of colorectal cancer cells]
Communicable Diseases
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective-immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine 1-phosphate receptor modulators and proteasome inhibitors.
Communicable Diseases
Impairment of immunoproteasome function by ?5i/LMP7 subunit deficiency results in severe enterovirus myocarditis.
Communicable Diseases
Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer.
Connective Tissue Diseases
Autoimmune response to proteasome activator 28alpha in patients with connective tissue diseases.
Contracture
Proteasome inhibition preserves longitudinal growth of denervated muscle and prevents neonatal neuromuscular contractures.
Contracture
PSMB8 encoding the ?5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome.
Contracture
Timing of proteasome inhibition as a pharmacologic strategy for prevention of muscle contractures in neonatal brachial plexus injury.
Corneal Dystrophies, Hereditary
A novel proteotoxic stress associated mechanism for macular corneal dystrophy.
Coronary Artery Disease
Chronic proteasome inhibition contributes to coronary atherosclerosis.
Coronary Artery Disease
Quantitative assessment of the influence of PSMA6 variant (rs1048990) on coronary artery disease risk.
Coronary Occlusion
Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury.
Coronary Vasospasm
Proteasome inhibitor-induced coronary vasospasm in multiple myeloma: a case report.
Coronavirus Infections
Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome.
Coronavirus Infections
Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention.
Corticobasal Degeneration
Clinicopathological correlations in behavioural variant frontotemporal dementia.
COVID-19
Cell Clearing Systems as Targets of Polyphenols in Viral Infections: Potential Implications for COVID-19 Pathogenesis.
COVID-19
Inferring SARS-CoV-2 functional genomics from viral transcriptome with identification of potential antiviral drugs and therapeutic targets.
COVID-19
Proteasome activator PA28?-dependent degradation of coronavirus disease (COVID-19) nucleocapsid protein.
Coxsackievirus Infections
Tripeptidyl peptidase II serves as an alternative to impaired proteasome to maintain viral growth in the host cells.
Craniocerebral Trauma
Circulating proteasome activity following mild head injury in children.
Craniocerebral Trauma
Glucocorticoids do not regulate the expression of proteolytic genes in skeletal muscle from Cushing's syndrome patients.
Craniocerebral Trauma
The comparison of C-proteasome activity in the plasma of children after burn injury, mild head injury and blunt abdominal trauma.
Crohn Disease
Expression of catalytic proteasome subunits in the gut of patients with Crohn's disease.
Crohn Disease
Increased Levels of Survivin, via Association With Heat Shock Protein 90, in Mucosal T Cells From Patients With Crohn's Disease.
Crohn Disease
Increased proteasome-mediated degradation of occludin in irritable bowel syndrome.
Crohn Disease
Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis.
Cryopyrin-Associated Periodic Syndromes
Monogenic autoinflammatory diseases: concept and clinical manifestations.
cystathionine beta-synthase deficiency
Correction of cystathionine ?-synthase deficiency in mice by treatment with proteasome inhibitors.
Cystic Fibrosis
A principal role for the proteasome in endoplasmic reticulum-associated degradation of misfolded intracellular cystic fibrosis transmembrane conductance regulator.
Cystic Fibrosis
BAG-2 acts as an inhibitor of the chaperone-associated ubiquitin ligase CHIP.
Cystic Fibrosis
Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia.
Cystic Fibrosis
Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway.
Cystic Fibrosis
Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622.
Cystic Fibrosis
Redundancy of mammalian proteasome beta subunit function during endoplasmic reticulum associated degradation.
Cystic Fibrosis
Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications.
Cystic Fibrosis
The forced aggresome formation of a bovine anion exchanger 1 (AE1) mutant through association with deltaF508-cystic fibrosis transmembrane conductance regulator upon proteasome inhibition in HEK293 cells.
Cystic Fibrosis
The mechanism underlying cystic fibrosis transmembrane conductance regulator transport from the endoplasmic reticulum to the proteasome includes Sec61beta and a cytosolic, deglycosylated intermediary.
Cystic Fibrosis
What shall we do with the damaged proteins in lung disease? Ask the proteasome!
Cysts
A reduced VWA domain-containing proteasomal ubiquitin receptor of Giardia lamblia localizes to the flagellar pore regions in microtubule-dependent manner.
Cysts
Acanthamoeba castellanii: Gene profile of encystation by ESTs analysis and KOG assignment.
Cysts
Proteasome-dependent cyst formation and stage-specific ubiquitin mRNA accumulation in Entamoeba invadens.
Cysts
The effect of peptidic and non-peptidic proteasome inhibitors on the biological properties of Acanthamoeba castellanii belonging to the T4 genotype.
Cytomegalovirus Infections
Nucleolar aggresomes as counterparts of cytoplasmic aggresomes in proteotoxic stress: Proteasome inhibitors induce nuclear ribonucleoprotein inclusions that accumulate several key factors of neurodegenerative diseases and cancer.
Cytomegalovirus Infections
Proteasome subunits relocalize during human cytomegalovirus infection, and proteasome activity is necessary for efficient viral gene transcription.
Deafness
De Novo Disruption of the Proteasome Regulatory Subunit PSMD12 Causes a Syndromic Neurodevelopmental Disorder.
Deafness
Proteasome subunit PSMC3 variants cause neurosensory syndrome combining deafness and cataract due to proteotoxic stress.
Dehydration
Gene expression changes governing extreme dehydration tolerance in an Antarctic insect.
Dementia
Immunohistochemical analysis of ubiquilin-1 in the human hippocampus: Association with neurofibrillary tangle pathology.
Dementia
Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation.
Dementia
Pathological lesions of Alzheimer's disease and dementia with Lewy bodies brains exhibit immunoreactivity to an ATPase that is a regulatory subunit of the 26S proteasome.
Dementia
Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems.
Dementia
Proteasome blockers inhibit TNF-alpha release by lipopolysaccharide stimulated macrophages and microglia: implications for HIV-1 dementia.
Dementia
Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture.
Dementia
Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia.
Dementia
T-Type Ca2+ Enhancer SAK3 Activates CaMKII and Proteasome Activities in Lewy Body Dementia Mice Model.
Dementia
TDP-43 cytoplasmic inclusion formation is disrupted in C9orf72-associated amyotrophic lateral sclerosis/frontotemporal lobar degeneration.
Demyelinating Diseases
Decreased levels of constitutive proteasomes in experimental autoimmune encephalomyelitis may be caused by a combination of subunit displacement and reduced Nfe2l1 expression.
Demyelinating Diseases
Partial inhibition of proteasome activity enhances remyelination after cuprizone-induced demyelination.
Dengue
Host gene expression profiling of dengue virus infection in cell lines and patients.
Dengue
K48-linked polyubiquitination of dengue virus NS1 protein inhibits its interaction with the viral partner NS4B.
Dengue
Platelet proteome reveals novel pathways of platelet activation and platelet-mediated immunoregulation in dengue.
Dengue
Production of Infectious Dengue Virus in Aedes aegypti Is Dependent on the Ubiquitin Proteasome Pathway.
Dengue
Proteasome Inhibition Suppresses Dengue Virus Egress in Antibody Dependent Infection.
Dengue
West nile virus and Dengue virus capsid protein negates the antiviral activity of human Sec3 protein Through The Proteasome Pathway.
Dental Pulp Calcification
Choniomyzon inflatus n. sp. (Crustacea: Copepoda: Nicothoidae) associated with Ibacus novemdentatus (Crustacea: Decapoda: Scyllaridae) from Japanese waters.
Dermatitis
Inhibition of NF-kappaB Signaling Retards Eosinophilic Dermatitis in SHARPIN-Deficient Mice.
Dermatitis, Atopic
Bortezomib, a proteasome inhibitor, alleviates atopic dermatitis by increasing claudin 1 protein expression.
Dermatitis, Atopic
The Role of Proteasome Inhibitor MG132 in 2,4-Dinitrofluorobenzene-Induced Atopic Dermatitis in NC/Nga Mice.
Dermatitis, Contact
Serum amyloid A-luciferase transgenic mice: response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition.
Diabetes Complications
High glucose and diabetes modulate cellular proteasome function: Implications in the pathogenesis of diabetes complications.
Diabetes Insipidus, Nephrogenic
The proteasome is involved in the degradation of different aquaporin-2 mutants causing nephrogenic diabetes insipidus.
Diabetes Mellitus
Alteration of 20S proteasome-subtypes and proteasome activator PA28 in skeletal muscle of rat after induction of diabetes mellitus.
Diabetes Mellitus
Downregulation of type II diabetes mellitus and maturity onset diabetes of young pathways in human pancreatic islets from hyperglycemic donors.
Diabetes Mellitus
Enhancement of 26S Proteasome Functionality Connects Oxidative Stress and Vascular Endothelial Inflammatory Response in Diabetes Mellitus.
Diabetes Mellitus
Implications of Sortilin in Lipid Metabolism and Lipid Disorder Diseases.
Diabetes Mellitus
Increased 4-hydroxy-2-nonenal-induced proteasome dysfunction is correlated with cardiac damage in streptozotocin-injected rats with isoproterenol infusion.
Diabetes Mellitus
Prevalence of 20S proteasome, anti-nuclear and thyroid antibodies in young patients at onset of type 1 diabetes mellitus and the risk of autoimmune thyroiditis.
Diabetes Mellitus
Relationship of large multifunctional proteasome 7 gene polymorphism with susceptibility to type 1 diabetes mellitus and DR3 gene.
Diabetes Mellitus
The GID ubiquitin ligase complex is a regulator of AMPK activity and organismal lifespan.
Diabetes Mellitus, Type 1
Increased 4-hydroxy-2-nonenal-induced proteasome dysfunction is correlated with cardiac damage in streptozotocin-injected rats with isoproterenol infusion.
Diabetes Mellitus, Type 1
Insulin inhibition of the proteasome is dependent on degradation of insulin by insulin-degrading enzyme.
Diabetes Mellitus, Type 1
Involvement of the proteasome in IL-1beta induced suppression of islets of Langerhans in the rat.
Diabetes Mellitus, Type 1
Prevalence of 20S proteasome, anti-nuclear and thyroid antibodies in young patients at onset of type 1 diabetes mellitus and the risk of autoimmune thyroiditis.
Diabetes Mellitus, Type 1
Proteasome subunits, low-molecular-mass polypeptides 2 and 7 are hyperexpressed by target cells in autoimmune thyroid disease but not in insulin-dependent diabetes mellitus: implications for autoimmunity.
Diabetes Mellitus, Type 1
Relationship of large multifunctional proteasome 7 gene polymorphism with susceptibility to type 1 diabetes mellitus and DR3 gene.
Diabetes Mellitus, Type 1
The balance between glucocorticoids and insulin regulates muscle proteolysis via the ubiquitin-proteasome pathway.
Diabetes Mellitus, Type 1
The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes.
Diabetes Mellitus, Type 2
An Extract of Artemisia dracunculus L. Inhibits Ubiquitin-Proteasome Activity and Preserves Skeletal Muscle Mass in a Murine Model of Diabetes.
Diabetes Mellitus, Type 2
Downregulation of type II diabetes mellitus and maturity onset diabetes of young pathways in human pancreatic islets from hyperglycemic donors.
Diabetes Mellitus, Type 2
Implications of Sortilin in Lipid Metabolism and Lipid Disorder Diseases.
Diabetes Mellitus, Type 2
Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes.
Diabetes Mellitus, Type 2
Proteasome Modulator 9 SNPs are linked to Hypertension in Type 2 Diabetes Families.
Diabetes Mellitus, Type 2
Significant improvement of stress and aging biomarkers using a novel stress management program with the cognitive restructuring method "Pythagorean Self-Awareness Intervention" in patients with type 2 diabetes mellitus and healthy adults.
Diabetes Mellitus, Type 2
The GID ubiquitin ligase complex is a regulator of AMPK activity and organismal lifespan.
Diabetes Mellitus, Type 2
The inducible ?5i proteasome subunit contributes to proinsulin degradation in GRP94-deficient ?-cells and is overexpressed in type 2 diabetes pancreatic islets.
Diabetes Mellitus, Type 2
The ubiquitin proteasome system regulates the stability and activity of the glucose sensor glucokinase in pancreatic beta cells.
Diabetic Cardiomyopathies
Cardiac proteasome functional insufficiency plays a pathogenic role in diabetic cardiomyopathy.
Diabetic Cardiomyopathies
Targeting the ubiquitin proteasome system in diabetic cardiomyopathy.
Diabetic Nephropathies
Apelin promotes diabetic nephropathy by inducing podocyte dysfunction via inhibiting proteasome activities.
Diabetic Nephropathies
Correction: Proteasome subunit-? type-6 protein is post-transcriptionally repressed by the microRNA-4490 in diabetic nephropathy.
Diabetic Nephropathies
MG132 ameliorates kidney lesions by inhibiting the degradation of Smad7 in streptozotocin-induced diabetic nephropathy.
Diabetic Nephropathies
Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome.
Diabetic Nephropathies
Proteasome Activators, PA28? and PA28?, Govern Development of Microvascular Injury in Diabetic Nephropathy and Retinopathy.
Diabetic Nephropathies
Proteasome subunit alpha type-6 protein is posttranscriptionally repressed by the microRNA-4490 in diabetic nephropathy.
Diabetic Nephropathies
The proteasome inhibitor, MG132, attenuates diabetic nephropathy by inhibiting SnoN degradation in vivo and in vitro.
Diabetic Retinopathy
Atorvastatin-mediated protection of the retina in a model of diabetes with hyperlipidemia.
Diabetic Retinopathy
Proteasome Modulator 9 gene is linked to diabetic and non-diabetic retinopathy in T2D.
Disorders of Excessive Somnolence
TNF-NF-kappaB signaling mediates excessive somnolence in hemiparkinsonian rats.
DNA Virus Infections
USP44 positively regulates innate immune response to DNA viruses through deubiquitinating MITA.
Down Syndrome
Decreased expression of thymus-specific proteasome subunit ?5t in Down syndrome patients.
Down Syndrome
Oxidized SOD1 alters proteasome activities in vitro and in the cortex of SOD1 overexpressing mice.
Down Syndrome
Selective upregulation of the ubiquitin-proteasome proteolytic pathway proteins, proteasome zeta chain and isopeptidase T in fetal Down syndrome.
Drug-Related Side Effects and Adverse Reactions
Non-proteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
Drug-Related Side Effects and Adverse Reactions
The Importance of CYP2E1 in the Pathogenesis of Alcoholic Liver Disease and Drug Toxicity and the Role of the Proteasome.
Dysautonomia, Familial
Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia.
Dyslipidemias
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).
Dyslipidemias
Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors.
Dyslipidemias
Lovastatin upregulates microRNA-29b to reduce oxidative stress in rats with multiple cardiovascular risk factors.
Dyslipidemias
Tyrosine nitration of PA700 links proteasome activation to endothelial dysfunction in mouse models with cardiovascular risk factors.
Dystonia
Dystonia-associated mutations cause premature degradation of torsinA protein and cell-type-specific mislocalization to the nuclear envelope.
Eczema
Opposing effects on immune function and skin barrier regulation by the proteasome inhibitor bortezomib in an allergen-induced eczema model.
Edema, Cardiac
Prolongation of myocardial viability by proteasome inhibition during hypothermic organ preservation.
Embolism
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Encephalitis
Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis.
Encephalitis
Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis.
Encephalitis
Brain aging in acquired immunodeficiency syndrome: increased ubiquitin-protein conjugate is correlated with decreased synaptic protein but not amyloid plaque accumulation.
Encephalitis
Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis.
Encephalitis
Systemic Proteasome Inhibition Induces Sustained Post-stroke Neurological Recovery and Neuroprotection via Mechanisms Involving Reversal of Peripheral Immunosuppression and Preservation of Blood-Brain-Barrier Integrity.
Encephalomyelitis
Decreased levels of constitutive proteasomes in experimental autoimmune encephalomyelitis may be caused by a combination of subunit displacement and reduced Nfe2l1 expression.
Encephalomyelitis
Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.
Encephalomyelitis
Protection against experimental autoimmune encephalomyelitis by a proteasome modulator.
Encephalomyelitis
REG? controls Th17 cell differentiation and autoimmune inflammation by regulating dendritic cells.
Encephalomyelitis
The Role of Calpain and Proteasomes in the Degradation of Carbonylated Neuronal Cytoskeletal Proteins in Acute Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis
Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519.
Encephalomyelitis, Autoimmune, Experimental
Decreased levels of constitutive proteasomes in experimental autoimmune encephalomyelitis may be caused by a combination of subunit displacement and reduced Nfe2l1 expression.
Encephalomyelitis, Autoimmune, Experimental
Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.
Encephalomyelitis, Autoimmune, Experimental
Protection against experimental autoimmune encephalomyelitis by a proteasome modulator.
Encephalomyelitis, Autoimmune, Experimental
REG? controls Th17 cell differentiation and autoimmune inflammation by regulating dendritic cells.
Encephalomyelitis, Autoimmune, Experimental
The Role of Calpain and Proteasomes in the Degradation of Carbonylated Neuronal Cytoskeletal Proteins in Acute Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519.
Encephalomyelitis, Venezuelan Equine
The ubiquitin proteasome system plays a role in venezuelan equine encephalitis virus infection.
Encephalomyelitis, Venezuelan Equine
West Nile virus genome amplification requires the functional activities of the proteasome.
Endocrine Gland Neoplasms
Synergistic effect of trichostatin A and 5-aza-2'-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study.
Endometrial Neoplasms
Antioxidants block proteasome inhibitor function in endometrial carcinoma cells.
Endometrial Neoplasms
Carfilzomib induces G2/M cell cycle arrest in human endometrial cancer cells via upregulation of p21(Waf1/Cip1) and p27(Kip1).
Endometrial Neoplasms
Mutant p53 (p53-R248Q) functions as an oncogene in promoting endometrial cancer by up-regulating REG?
Endometrial Neoplasms
Proteasome activity and their subunit composition in endometrial cancer tissue: correlations with clinical morphological parameters.
Endometrial Neoplasms
Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants.
Endometriosis
Bufalin suppresses endometriosis progression by inducing pyroptosis and apoptosis.
Endometriosis
Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways.
Endometriosis
Combating endometriosis by blocking proteasome and nuclear factor-{kappa}B pathways.
Endometriosis
Disulfiram, as a candidate NF-?B and proteasome inhibitor, prevents endometriotic implant growing in a rat model of endometriosis.
Endotoxemia
Protein metabolism in leg muscle following an endotoxin injection in healthy volunteers.
Endotoxemia
The dose-dependent effects of endotoxin on protein metabolism in two types of rat skeletal muscle.
Epilepsy
Dysregulation of the (immuno)proteasome pathway in malformations of cortical development.
Epilepsy
Increased expression of (immuno)proteasome subunits during epileptogenesis is attenuated by inhibition of the mammalian target of rapamycin pathway.
Epilepsy
Long-noncoding RNA Peg13 alleviates epilepsy progression in mice via the miR-490-3p/Psmd11 axis to inactivate the Wnt/?-catenin pathway.
Epilepsy
Spatiotemporal progression of ubiquitin-proteasome system inhibition after status epilepticus suggests protective adaptation against hippocampal injury.
Epilepsy
Ubiquitination and E3 Ubiquitin Ligases in Rare Neurological Diseases with Comorbid Epilepsy.
Epilepsy, Post-Traumatic
[The quantitative analysis of Ub and UbE1 in focus of traumatic epilepsy]
Equine Infectious Anemia
Budding of equine infectious anemia virus is insensitive to proteasome inhibitors.
Equine Infectious Anemia
Late domain-dependent inhibition of equine infectious anemia virus budding.
Equine Infectious Anemia
Retroviruses have differing requirements for proteasome function in the budding process.
Esophageal Neoplasms
Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
Esophageal Squamous Cell Carcinoma
Inhibition of autophagy promotes cell apoptosis induced by the proteasome inhibitor MG-132 in human esophageal squamous cell carcinoma EC9706 cells.
Esophageal Squamous Cell Carcinoma
Potential Role of Targeting KDR and Proteasome Inhibitors in the Therapy of Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
Proteasome inhibitor MG132 inhibits the proliferation and promotes the cisplatin-induced apoptosis of human esophageal squamous cell carcinoma cells.
Exanthema
Successful treatment of a novel type I interferonopathy due to a de novo PSMB9 gene mutation with a Janus kinase inhibitor.
Exfoliation Syndrome
Altered unfolded protein response and proteasome impairment in pseudoexfoliation pathogenesis.
Eye Diseases
Synthesis, Bioactivity, Docking and Molecular Dynamics Studies of Furan-Based Peptides as 20S Proteasome Inhibitors.
Familial Mediterranean Fever
Monogenic autoinflammatory diseases: concept and clinical manifestations.
Fanconi Anemia
Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
Fatty Liver
Nuclear factor-erythroid 2-related factor 1 regulates expression of proteasome genes in hepatocytes and protects against endoplasmic reticulum stress and steatosis in mice.
Fatty Liver
Nutrigenomics of high fat diet induced obesity in mice suggests relationships between susceptibility to fatty liver disease and the proteasome.
Fatty Liver
Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis.
Fatty Liver
Proteasome inhibitors protect the steatotic and non-steatotic liver graft against cold ischemia reperfusion injury.
Fatty Liver
Relevance of proteolysis and proteasome activation in fatty liver graft preservation: An Institut Georges Lopez-1 vs University of Wisconsin appraisal.
Fatty Liver
The REG? Proteasome Regulates Hepatic Lipid Metabolism through Inhibition of Autophagy.
Feline Infectious Peritonitis
The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle.
Fetal Growth Retardation
Altered expression of p97/Valosin containing protein and impaired autophagy in preeclamptic human placenta.
Fibroma
Hyaline Fibromatosis Syndrome inducing mutations in the ectodomain of anthrax toxin receptor 2 can be rescued by proteasome inhibitors.
Fibrosarcoma
Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells.
Fibrosarcoma
Peripheral Endoplasmic Reticulum Localization of Gp78 Ubiquitin Ligase Activity.
Fibrosarcoma
Systemic analysis of heat shock response induced by heat shock and a proteasome inhibitor MG132.
Food Hypersensitivity
Bortezomib treatment diminishes hazelnut-induced intestinal anaphylaxis in mice.
Foot-and-Mouth Disease
Poliovirus induces autophagic signaling independent of the ULK1 complex.
Frontotemporal Dementia
Clinicopathological correlations in behavioural variant frontotemporal dementia.
Frontotemporal Dementia
Contribution of genetic factors to the pathogenesis of Paget's disease of bone and related disorders.
Frontotemporal Dementia
Reduced protein turnover mediates functional deficits in transgenic mice expressing the 25 kDa C-terminal fragment of TDP-43.
Frontotemporal Dementia
The DNA repair-ubiquitin-associated HR23 proteins are constituents of neuronal inclusions in specific neurodegenerative disorders without hampering DNA repair.
Frontotemporal Lobar Degeneration
Clinicopathological correlations in behavioural variant frontotemporal dementia.
Frontotemporal Lobar Degeneration
Loss of TDP-43 Inhibits Amyotrophic Lateral Sclerosis-Linked Mutant SOD1 Aggresome Formation in an HDAC6-Dependent Manner.
Gallbladder Neoplasms
PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer.
Gallstones
Proteasome inhibition protects against diet-induced gallstone formation through modulation of cholesterol and bile acid homeostasis.
Gastritis
Ubiquitin/proteasome-rich particulate cytoplasmic structures (PaCSs) in the platelets and megakaryocytes of ANKRD26-related thrombo-cytopenia.
Gastrointestinal Neoplasms
Ubiquitin proteasome system research in gastrointestinal cancer.
Gastrointestinal Stromal Tumors
Proteasome Inhibition Suppresses KIT-Independent Gastrointestinal Stromal Tumors Via Targeting Hippo/YAP/Cyclin D1 Signaling.
Gastrointestinal Stromal Tumors
Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Genetic Diseases, Inborn
Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70.
Genetic Diseases, Inborn
Compounds that correct F508del-CFTR trafficking can also correct other protein trafficking diseases: an in vitro study using cell lines.
Genetic Diseases, Inborn
Proteasome protease mediated regulation of cytokine induction and inflammation.
Genetic Diseases, Inborn
Ubiquitin/proteasome-rich particulate cytoplasmic structures (PaCSs) in the platelets and megakaryocytes of ANKRD26-related thrombo-cytopenia.
Gingival Overgrowth
Therapeutic potential of proteasome inhibitors for dihydropyridine-induced gingival overgrowth.
Glaucoma
Effects of donor age on proteasome activity and senescence in trabecular meshwork cells.
Glaucoma
Increased plasma levels of 20S proteasome alpha-subunit in glaucoma patients: an observational pilot study.
Glaucoma
Proteasome inhibition by chronic oxidative stress in human trabecular meshwork cells.
Glioblastoma
A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy.
Glioblastoma
Anticancer drugs exert differential apoptotic and cytotoxic effects on glioblastoma primary cultures with various EGFR and bcl-2 profiles.
Glioblastoma
Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
Glioblastoma
Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474).
Glioblastoma
Epidermal Growth Factor Receptor vIII Expression in U87 Glioblastoma Cells Alters Their Proteasome Composition, Function, and Response to Irradiation.
Glioblastoma
Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.
Glioblastoma
HDAC8 affects MGMT levels in glioblastoma cell lines via interaction with the proteasome receptor ADRM1.
Glioblastoma
Imaging Reporters for Proteasome Activity Identify Tumor- and Metastasis-Initiating Cells.
Glioblastoma
Immunotherapy gone viral: Bortezomib and oHSV enhance antitumor NK cell activity.
Glioblastoma
Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.
Glioblastoma
Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells.
Glioblastoma
Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib.
Glioblastoma
Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
Glioblastoma
Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist.
Glioblastoma
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
Glioblastoma
NF-kappaB-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition.
Glioblastoma
Paeoniflorin inhibits glioblastoma growth in vivo and in vitro: a role for the Triad3A-dependent ubiquitin proteasome pathway in TLR4 degradation.
Glioblastoma
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.
Glioblastoma
Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival.
Glioblastoma
Proteasome inhibitor MG132 induces NAG-1/GDF15 expression through the p38 MAPK pathway in glioblastoma cells.
Glioblastoma
Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling.
Glioblastoma
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).
Glioblastoma
Proteasome Stress Triggers Death of SH-SY5Y and T98G Cells via Different Cellular Mechanisms.
Glioblastoma
Proteolysis of MOB1 by the ubiquitin ligase praja2 attenuates Hippo signalling and supports glioblastoma growth.
Glioblastoma
PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma.
Glioblastoma
Short Chemical Ischemia Triggers Phosphorylation of eIF2? and Death of SH-SY5Y Cells but not Proteasome Stress and Heat Shock Protein Response in both SH-SY5Y and T98G Cells.
Glioblastoma
Synthetic chenodeoxycholic acid derivatives inhibit glioblastoma multiform tumor growth in vitro and in vivo.
Glioblastoma
The degradation (by distinct pathways) of human D-amino acid oxidase and its interacting partner pLG72--two key proteins in D-serine catabolism in the brain.
Glioblastoma
The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme.
Glioblastoma
Ursodeoxycholic Acid Inhibits Glioblastoma Progression via Endoplasmic Reticulum Stress Related Apoptosis and Synergizes with the Proteasome Inhibitor Bortezomib.
Glioblastoma
Valosin-containing protein regulates the proteasome-mediated degradation of DNA-PKcs in glioma cells.
Glioblastoma
z-Leucinyl-Leucinyl-Norleucinal Induces Apoptosis of Human Glioblastoma Tumor-Initiating Cells by Proteasome Inhibition and Mitotic Arrest Response.
Glioma
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.
Glioma
Arginylated Calreticulin Increases Apoptotic Response Induced by Bortezomib in Glioma Cells.
Glioma
Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner.
Glioma
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Glioma
Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
Glioma
Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Glioma
Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
Glioma
Corilagin induces human glioblastoma U251 cell apoptosis by impeding activity of (immuno)proteasome.
Glioma
Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo.
Glioma
Enzymatic activity of extracellular circulating proteasome in the CSF of patients with malignant intrinsic and metastatic brain tumors: proof of concept.
Glioma
Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy.
Glioma
Hydrogen Peroxide-Induced Oxidative Stress Activates Proteasomal Trypsin-Like Activity in Human U373 Glioma Cells.
Glioma
Identification of ubiquitination-related genes in human glioma as indicators of patient prognosis.
Glioma
Implication of 14-3-3? and 14-3-3?/? in proteasome inhibition-induced apoptosis of glioma cells.
Glioma
Inhibition of autophagy induced by proteasome inhibition increases cell death in human SHG-44 glioma cells.
Glioma
Innervation-dependent phosphorylation and accumulation of alphaB-crystallin and Hsp27 as insoluble complexes in disused muscle.
Glioma
Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
Glioma
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
Glioma
MicroRNA-326 functions as a tumor suppressor in glioma by targeting the Nin one binding protein (NOB1).
Glioma
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
Glioma
Morphine induces ubiquitin-proteasome activity and glutamate transporter degradation.
Glioma
Oncogenic dependence of glioma cells on kish/TMEM167A regulation of vesicular trafficking.
Glioma
Overexpression of immunoproteasome low-molecular-mass polypeptide 7 and inhibiting role of next-generation proteasome inhibitor ONX 0912 on cell growth in glioma.
Glioma
p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.
Glioma
Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors.
Glioma
Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts.
Glioma
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Glioma
Proteasome inhibitor differentially regulates expression of the major immediate early genes of human cytomegalovirus in human central nervous system-derived cell lines.
Glioma
Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release.
Glioma
Proteasome inhibitors induce Fas-mediated apoptosis by c-Myc accumulation and subsequent induction of FasL message in human glioma cells.
Glioma
Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells.
Glioma
Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKC?-dependent downregulation of AKT and XIAP expressions.
Glioma
Proteasome mediated degradation of CDC25C and Cyclin B1 in Demethoxycurcumin treated human glioma U87 MG cells to trigger G2/M cell cycle arrest.
Glioma
PTEN increases autophagy and inhibits the ubiquitin-proteasome pathway in glioma cells independently of its lipid phosphatase activity.
Glioma
Reduced expression of the transporter associated with antigen processing 1 molecule in malignant glioma cells, and its restoration by interferon-gamma and -beta.
Glioma
Retinoid receptor turnover mediated by sumoylation, ubiquitination and the valosin-containing protein is disrupted in glioblastoma.
Glioma
SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: An in vitro and vivo study.
Glioma
SC68896, a Novel Small Molecule Proteasome Inhibitor, Exerts Antiglioma Activity In vitro and In vivo.
Glioma
SUMO-1 is associated with a subset of lysosomes in glial protein aggregate diseases.
Glioma
Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma.
Glioma
Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance.
Glioma
The Bmi-1/NF-?B/VEGF story: another hint for proteasome involvement in glioma angiogenesis?
Glioma
The proteasome inhibitor lactacystin exerts its therapeutic effects on glioma via apoptosis: an in vitro and in vivo study.
Glioma
The Proteasome Inhibitor MG-132 Induces AIF Nuclear Translocation Through Down-Regulation of ERK and Akt/mTOR Pathway.
Glioma
The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme.
Glioma
Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts.
Glioma
Transient nuclear factor kappaB (NF-kappaB) activation stimulated by interleukin-1beta may be partly dependent on proteasome activity, but not phosphorylation and ubiquitination of the IkappaBalpha molecule, in C6 glioma cells. Regulation of NF-kappaB linked to chemokine production.
Glioma
Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.
Glioma
Visualization of stem cell features in human hepatocellular carcinoma enlightened in vivo significance of tumor-host interaction and clinical implication.
Glioma
[The intracellular mechanism of NF-kappa B activation involved in iNOS and chemokine induction in C6 glioma cells]
Glomerulonephritis
Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis.
Glomerulonephritis
Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.
Glomerulonephritis, IGA
The ubiquitin-proteasome pathway and IgA nephropathy: a novel link?
Glomerulonephritis, Membranous
Bortezomib as a Novel Approach to Early Recurrent Membranous Glomerulonephritis After Kidney Transplant Refractory to Combined Conventional Rituximab Therapy.
Glomerulosclerosis, Focal Segmental
A case of nephrotic syndrome, showing evidence of response to saquinavir.
Glycogen Storage Disease Type II
Proteasome Inhibitor Bortezomib Enhances the Activity of Multiple Mutant Forms of Lysosomal ?-Glucosidase in Pompe Disease.
Glycogen Storage Disease Type II
Proteasome inhibitors improve the function of mutant lysosomal ?-glucosidase in fibroblasts from Pompe disease patient carrying c.546G>T mutation.
Graft vs Host Disease
Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
Graft vs Host Disease
Development of novel compounds to treat autoimmune and inflammatory diseases and graft versus host reactions.
Graft vs Host Disease
Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity.
Graft vs Host Disease
IL-1? and TLR4 signaling are involved in the aggravated murine acute graft-versus-host disease caused by delayed bortezomib administration.
Graft vs Host Disease
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.
Graft vs Host Disease
Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib.
Graft vs Host Disease
Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation.
Graft vs Host Disease
Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review.
Graft vs Host Disease
Proteasome inhibition in transplantation-focusing on the experience with bortezomib.
Graft vs Host Disease
Proteasome inhibitor clioquinol as a candidate drug in prophylaxis and treatment of acute graft-versus-host disease.
Graft vs Host Disease
Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience.
Graft vs Host Disease
Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels.
Graft vs Host Disease
Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population.
Granulosa Cell Tumor
Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
Graves Disease
Association of the large multifunctional proteasome (LMP2) gene with Graves' disease is a result of linkage disequilibrium with the HLA haplotype DRB1*0304-DQB1*02-DQA1*0501.
Head and Neck Neoplasms
An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro.
Head and Neck Neoplasms
Antitumor activity of CTFB, a novel anticancer agent, is associated with the down-regulation of nuclear factor-kappaB expression and proteasome activation in head and neck squamous carcinoma cell lines.
Head and Neck Neoplasms
CCR 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer.
Head and Neck Neoplasms
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
Head and Neck Neoplasms
Induction of synergistic non-apoptotic cell death by simultaneously targeting proteasomes with bortezomib and histone deacetylase 6 with ricolinostat in head and neck tumor cells.
Head and Neck Neoplasms
Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
Head and Neck Neoplasms
Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients.
Hearing Loss
A small molecule mitigates hearing loss in a mouse model of Usher syndrome III.
Hearing Loss
Proteasome inhibitors induce auditory hair cell death through peroxisome dysfunction.
Hearing Loss
The effect and mechanism of 19S proteasome PSMD11/Rpn6 subunit in D-Galactose induced mimetic aging models.
Hearing Loss, Bilateral
Proteasome inhibitors induce auditory hair cell death through peroxisome dysfunction.
Heart Arrest
Proteasome Biology Is Compromised in White Matter After Asphyxic Cardiac Arrest in Neonatal Piglets.
Heart Diseases
Activation of the cardiac proteasome promotes angiotension II-induced hypertrophy by down-regulation of ATRAP.
Heart Diseases
Appetite for destruction: E3 ubiquitin-ligase protection in cardiac disease.
Heart Diseases
Back to your heart: Ubiquitin proteasome system-regulated signal transduction.
Heart Diseases
Crosstalk between cardiomyocytes and noncardiomyocytes is essential to prevent cardiomyocyte apoptosis induced by proteasome inhibition.
Heart Diseases
Inhibition of NF-kappa B activation in vitro and in vivo: role of 26S proteasome.
Heart Diseases
p62 Stages an Interplay Between the Ubiquitin-Proteasome System and Autophagy in the Heart of Defense Against Proteotoxic Stress.
Heart Diseases
Regulation of the Proteasome: Evaluating the Lung Proteasome as a New Therapeutic Target.
Heart Diseases
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
Heart Diseases
Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies.
Heart Diseases
The Ubiquitin Proteasome System in Human Cardiomyopathies and Heart Failure.
Heart Failure
Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib.
Heart Failure
Aerobic exercise training improves oxidative stress and ubiquitin proteasome system activity in heart of spontaneously hypertensive rats.
Heart Failure
Back to your heart: Ubiquitin proteasome system-regulated signal transduction.
Heart Failure
Chronic aspirin via dose-dependent and selective inhibition of cardiac proteasome possibly contributed a potential risk to the ischemic heart.
Heart Failure
Crosstalk between cardiomyocytes and noncardiomyocytes is essential to prevent cardiomyocyte apoptosis induced by proteasome inhibition.
Heart Failure
Cytokine-induced oxidative stress in cardiac inflammation and heart failure-how the ubiquitin proteasome system targets this vicious cycle.
Heart Failure
Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure.
Heart Failure
Emergence of Members of TRAF and DUB of Ubiquitin Proteasome System in the Regulation of Hypertrophic Cardiomyopathy.
Heart Failure
Enhancement of proteasome function by PA28α overexpression protects against oxidative stress.
Heart Failure
Impaired Assembly and Post-Translational Regulation of 26S Proteasome in Human End Stage Heart Failure.
Heart Failure
In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline.
Heart Failure
Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis.
Heart Failure
MG132 proteasome inhibitor upregulates the expression of connexin 43 in rats with adriamycin-induced heart failure.
Heart Failure
Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition.
Heart Failure
Pathophysiology and pathological remodelling associated with dilated cardiomyopathy in broiler chickens predisposed to heart pump failure.
Heart Failure
Priming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafil.
Heart Failure
Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts.
Heart Failure
Proteasome inhibition attenuates heart failure during the late stages of pressure overload through alterations in collagen expression.
Heart Failure
Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload.
Heart Failure
Proteasome inhibition improves diaphragm function in congestive heart failure rats.
Heart Failure
Proteasome inhibitors attenuated cholesterol-induced cardiac hypertrophy in H9c2 cells.
Heart Failure
Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies.
Hematologic Diseases
Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas.
Hematologic Diseases
Proteasome inhibition therapy: assessing the clinical implications in hematologic diseases.
Hematologic Diseases
Proteasome inhibition: a new approach to the treatment of hematologic diseases.
Hematologic Neoplasms
A new class of ?-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.
Hematologic Neoplasms
A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.
Hematologic Neoplasms
A Phase I Study of the Metal Ionophore Clioquinol in Patients With Advanced Hematologic Malignancies.
Hematologic Neoplasms
A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities.
Hematologic Neoplasms
Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia.
Hematologic Neoplasms
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
Hematologic Neoplasms
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
Hematologic Neoplasms
Anticancer drug bortezomib increases interleukin-8 expression in human monocytes.
Hematologic Neoplasms
Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
Hematologic Neoplasms
Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
Hematologic Neoplasms
Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas.
Hematologic Neoplasms
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Hematologic Neoplasms
Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway.
Hematologic Neoplasms
Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
Hematologic Neoplasms
Bortezomib as a probable cause of the syndrome of inappropriate antidiuretic hormone secretion: A case report and review of the literature.
Hematologic Neoplasms
Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1.
Hematologic Neoplasms
Bortezomib represses HIF-1? protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells.
Hematologic Neoplasms
Bortezomib therapy-related lung disease in a patient with light chain amyloidosis: A case report.
Hematologic Neoplasms
Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
Hematologic Neoplasms
Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.
Hematologic Neoplasms
Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
Hematologic Neoplasms
Carfilzomib induces G2/M cell cycle arrest in human endometrial cancer cells via upregulation of p21(Waf1/Cip1) and p27(Kip1).
Hematologic Neoplasms
Carfilzomib inhibits the growth of lung adenocarcinoma via upregulation of Gadd45a expression.
Hematologic Neoplasms
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
Hematologic Neoplasms
Chemotherapy-induced peripheral neuropathies in hematological malignancies.
Hematologic Neoplasms
Chromatin immunoprecipitation analysis of bortezomib-mediated inhibition of NF?B recruitment to IL-1? and TNF? gene promoters in human macrophages.
Hematologic Neoplasms
CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
Hematologic Neoplasms
Clinical development of novel proteasome inhibitors for cancer treatment.
Hematologic Neoplasms
Clinical trials with anti-angiogenic agents in hematological malignancies.
Hematologic Neoplasms
Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection.
Hematologic Neoplasms
Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.
Hematologic Neoplasms
Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy.
Hematologic Neoplasms
Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Hematologic Neoplasms
Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies.
Hematologic Neoplasms
Different induction of GRP78 and CHOP as a predictor of sensitivity to proteasome inhibitors in thyroid cancer cells.
Hematologic Neoplasms
Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation.
Hematologic Neoplasms
Discovery of PI-1840, a novel non-covalent and rapidly reversible proteasome inhibitor with anti-tumor activity.
Hematologic Neoplasms
Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
Hematologic Neoplasms
Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
Hematologic Neoplasms
Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies.
Hematologic Neoplasms
Erucylphospho-N,N,N-trimethylpropylammonium shows substantial cytotoxicity in multiple myeloma cells.
Hematologic Neoplasms
HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer.
Hematologic Neoplasms
Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies.
Hematologic Neoplasms
Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence.
Hematologic Neoplasms
Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib.
Hematologic Neoplasms
Histone deacetylase inhibitors: clinical implications for hematological malignancies.
Hematologic Neoplasms
Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors.
Hematologic Neoplasms
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
Hematologic Neoplasms
Impaired bortezomib binding to mutant ?5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Hematologic Neoplasms
Implication of 14-3-3? and 14-3-3?/? in proteasome inhibition-induced apoptosis of glioma cells.
Hematologic Neoplasms
In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s.
Hematologic Neoplasms
Inducible nitric oxide synthase mediates MG132 lethality in leukemic cells through mitochondrial depolarization.
Hematologic Neoplasms
Inhibitors of the Immunoproteasome: Current Status and Future Directions.
Hematologic Neoplasms
Interferon-?-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Hematologic Neoplasms
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Hematologic Neoplasms
Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
Hematologic Neoplasms
Mcl-1 downregulation sensitizes glioma to bortezomib-induced apoptosis.
Hematologic Neoplasms
Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
Hematologic Neoplasms
Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent.
Hematologic Neoplasms
Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Hematologic Neoplasms
Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma.
Hematologic Neoplasms
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.
Hematologic Neoplasms
Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome.
Hematologic Neoplasms
Oxidative stress by targeted agents promotes cytotoxicity in hematological malignancies.
Hematologic Neoplasms
P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
Hematologic Neoplasms
Peripheral neuropathy in hematologic malignancies - Past, present and future.
Hematologic Neoplasms
Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma.
Hematologic Neoplasms
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
Hematologic Neoplasms
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
Hematologic Neoplasms
Positioning of proteasome inhibitors in therapy of solid malignancies.
Hematologic Neoplasms
Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia.
Hematologic Neoplasms
Proteasome Complexes and Their Heterogeneity in Colorectal, Breast and Pancreatic Cancers.
Hematologic Neoplasms
Proteasome inhibition as a new therapeutic principle in hematological malignancies.
Hematologic Neoplasms
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Hematologic Neoplasms
Proteasome inhibition in hematologic malignancies: clinical update and practical applications.
Hematologic Neoplasms
Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy.
Hematologic Neoplasms
Proteasome inhibition: a new approach for the treatment of malignancies.
Hematologic Neoplasms
Proteasome inhibition: a new therapeutic strategy to cancer treatment.
Hematologic Neoplasms
Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma.
Hematologic Neoplasms
Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a.
Hematologic Neoplasms
Proteasome inhibitors as experimental therapeutics of autoimmune diseases.
Hematologic Neoplasms
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
Hematologic Neoplasms
Proteasome inhibitors: a new perspective for treating autoimmune diseases.
Hematologic Neoplasms
Quantitative analysis of bortezomib-induced IL-8 gene expression in ovarian cancer cells.
Hematologic Neoplasms
Rapid fatal pulmonary complications in a Chinese patient after bortezomib treatment for ALK-negative anaplastic large-cell lymphoma.
Hematologic Neoplasms
Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
Hematologic Neoplasms
Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors.
Hematologic Neoplasms
Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance.
Hematologic Neoplasms
Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias.
Hematologic Neoplasms
Suppression of MG132-mediated cell death by peroxiredoxin 1 through influence on ASK1 activation in human thyroid cancer cells.
Hematologic Neoplasms
Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib.
Hematologic Neoplasms
Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy.
Hematologic Neoplasms
The aggresome pathway as a target for therapy in hematologic malignancies.
Hematologic Neoplasms
The combined effects of proteasome inhibitor bortezomib with topoisomerase I and II inhibitors on topoisomerase enzymes.
Hematologic Neoplasms
The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
Hematologic Neoplasms
The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells.
Hematologic Neoplasms
The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
Hematologic Neoplasms
The Ubiquitin Proteasome System in Hematological Malignancies: New Insight into Its Functional Role and Therapeutic Options.
Hematologic Neoplasms
The ubiquitin+proteasome protein degradation pathway as a therapeutic strategy in the treatment of solid tumor malignancies.
Hematologic Neoplasms
The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer.
Hematologic Neoplasms
The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities.
Hematologic Neoplasms
The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib.
Hematologic Neoplasms
The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias.
Hematologic Neoplasms
The vital link between the ubiquitin-proteasome pathway and DNA repair: Impact on cancer therapy.
Hematologic Neoplasms
Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.
Hematologic Neoplasms
TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.
Hematologic Neoplasms
Toward Understanding Induction of Oxidative Stress and Apoptosis by Proteasome Inhibitors.
Hematologic Neoplasms
Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Hematologic Neoplasms
Ubiquitin-based anticancer therapy: Carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors.
Hematologic Neoplasms
Update on the proteasome inhibitor bortezomib in hematologic malignancies.
Hematologic Neoplasms
Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib.
Hematologic Neoplasms
[CAR Technology and Its Application in Treatment of Multiple Myeloma].
Hemophilia A
Proteasome Inhibitors Enhance Gene Delivery by AAV Virus Vectors Expressing Large Genomes in Hemophilia Mouse and Dog Models: A Strategy for Broad Clinical Application.
Hepatitis
Autophagic Inhibition of Caveolin-1 by Compound Phyllanthus urinaria L. Activates Ubiquitination and Proteasome Degradation of ?-catenin to Suppress Metastasis of Hepatitis B-Associated Hepatocellular Carcinoma.
Hepatitis
Hepatic expression of proteasome subunit alpha type-6 is upregulated during viral hepatitis and putatively regulates the expression of ISG15 ubiquitin-like modifier, a proviral host gene in hepatitis C virus infection.
Hepatitis
Proteasome activity deregulation in LEC rat hepatitis: following the insights of transcriptomic analysis.
Hepatitis
Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome.
Hepatitis
Studies on immunoproteasome in human liver. Part I: absence in fetuses, presence in normal subjects, and increased levels in chronic active hepatitis and cirrhosis.
Hepatitis
The proteasome inhibitor Velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice.
Hepatitis
The ubiquitin-proteasome system facilitates the transfer of murine coronavirus from endosome to cytoplasm during virus entry.
Hepatitis
The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle.
Hepatitis
X-deficient woodchuck hepatitis virus mutants behave like attenuated viruses and induce protective immunity in vivo.
Hepatitis A
Degradation of the encephalomyocarditis virus and hepatitis A virus 3C proteases by the ubiquitin/26S proteasome system in vivo.
Hepatitis B
Chromatin remodelling factor BAF155 protects hepatitis B virus X protein (HBx) from ubiquitin-independent proteasomal degradation.
Hepatitis B
Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome.
Hepatitis B
Does rapid oligomerization of hepatitis B envelope proteins play a role in resistance to proteasome degradation and enhance chronicity?
Hepatitis B
Effect of a conserved peptide derived from Kunitz domain of hepatitis B virus x protein on the cell cycle and apoptosis of HepG2 cells via the proteasome pathway.
Hepatitis B
Engineered Human Ferritin Nanoparticles for Direct Delivery of Tumor Antigens to Lymph Node and Cancer Immunotherapy.
Hepatitis B
HBx protein of hepatitis B virus interacts with the C-terminal portion of a novel human proteasome alpha-subunit.
Hepatitis B
Hepatitis B virus HBx peptide 116-138 and proteasome activator PA28 compete for binding to the proteasome alpha4/MC6 subunit.
Hepatitis B
Hepatitis B virus HBx protein interactions with the ubiquitin proteasome system.
Hepatitis B
Hepatitis B virus large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme.
Hepatitis B
Hepatitis B virus X protein differentially affects the ubiquitin-mediated proteasomal degradation of beta-catenin depending on the status of cellular p53.
Hepatitis B
Hepatitis B virus X protein in the proteasome of mammalian cells: defining the targeting domain.
Hepatitis B
Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex.
Hepatitis B
Inhibition of cellular proteasome activities mediates HBX-independent hepatitis B virus replication in vivo.
Hepatitis B
Inhibition of Hepatitis B Virus Production In Vitro by Proteasome Inhibitor MG132.
Hepatitis B
Inhibition of hepatitis B virus replication by interferon requires proteasome activity.
Hepatitis B
Proteasome complex as a potential cellular target of hepatitis B virus X protein.
Hepatitis B
Proteomic identification of down-regulation of oncoprotein DJ-1 and proteasome activator subunit 1 in hepatitis B virus-infected well-differentiated hepatocellular carcinoma.
Hepatitis B
Sequential cleavage by metallopeptidases and proteasomes is involved in processing HIV-1 ENV epitope for endogenous MHC class I antigen presentation.
Hepatitis B
Structural and functional characterization of interaction between hepatitis B virus X protein and the proteasome complex.
Hepatitis B
The interaction of hepatitis B virus with the ubiquitin proteasome system in viral replication and associated pathogenesis.
Hepatitis B
The X-Linked Tumor Suppressor TSPX Interacts and Promotes Degradation of the Hepatitis B Viral Protein HBx via the Proteasome Pathway.
Hepatitis C
?-Tocotrienol feeding modulates gene expression of EIF2, mTOR, protein ubiquitination through multiple-signaling pathways in chronic hepatitis C patients.
Hepatitis C
Activity-based profiling of the proteasome pathway during hepatitis C virus infection.
Hepatitis C
Combination therapy for hepatitis C virus with heat-shock protein 90 inhibitor 17-AAG and proteasome inhibitor MG132.
Hepatitis C
Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
Hepatitis C
Escape mutations alter proteasome processing of major histocompatibility complex class I-restricted epitopes in persistent hepatitis C virus infection.
Hepatitis C
Ethanol and Hepatitis C Virus Suppress Peptide-MHC Class I Presentation in Hepatocytes by Altering Proteasome Function.
Hepatitis C
Hepatic expression of proteasome subunit alpha type-6 is upregulated during viral hepatitis and putatively regulates the expression of ISG15 ubiquitin-like modifier, a proviral host gene in hepatitis C virus infection.
Hepatitis C
Hepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activity.
Hepatitis C
Hepatitis C virus NS2 protein is phosphorylated by the protein kinase CK2 and targeted for degradation to the proteasome.
Hepatitis C
High-throughput RNA interference screens integrative analysis: Towards a comprehensive understanding of the virus-host interplay.
Hepatitis C
Involvement of proteasome alpha-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation.
Hepatitis C
Proteasome activation by hepatitis C core protein is reversed by ethanol-induced oxidative stress.
Hepatitis C
Proteasome activator and antigen-processing aminopeptidases are regulated by virus-induced type I interferon in the hepatitis C virus-infected liver.
Hepatitis C
Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein.
Hepatitis C
Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs.
Hepatitis C
Upregulation of nuclear PA28? expression in cirrhosis and hepatocellular carcinoma.
Hepatitis C, Chronic
Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
Hepatitis E
Inhibition of hepatitis E virus replication by proteasome inhibitor is nonspecific.
Hepatitis, Chronic
Studies on immunoproteasome in human liver. Part I: absence in fetuses, presence in normal subjects, and increased levels in chronic active hepatitis and cirrhosis.
Hepatitis, Chronic
The role of innate immunity in the pathogenesis of preneoplasia in drug-induced chronic hepatitis based on a mouse model.
Hepatoblastoma
Apoptosis induced in hepatoblastoma HepG2 cells by the proteasome inhibitor MG132 is associated with hydrogen peroxide production, expression of Bcl-XS and activation of caspase-3.
Hepatoblastoma
cDNA cloning of a new putative ATPase subunit p45 of the human 26S proteasome, a homolog of yeast transcriptional factor Sug1p.
Hepatoblastoma
cDNA cloning of p40, a regulatory subunit of the human 26S proteasome, and a homolog of the Mov-34 gene product.
Hepatoblastoma
Molecular cloning and sequence analysis of cDNAs for five major subunits of human proteasomes (multi-catalytic proteinase complexes).
Hepatoblastoma
Proteasome inhibition overcomes TRAIL resistance in human hepatoblastoma cells.
Herpes Simplex
Ability of the human cytomegalovirus IE1 protein to modulate sumoylation of PML correlates with its functional activities in transcriptional regulation and infectivity in cultured fibroblast cells.
Herpes Simplex
Antiviral activity of proteasome inhibitors in herpes simplex virus-1 infection: role of nuclear factor-kappaB.
Herpes Simplex
Bortezomib treatment sensitizes oncolytic HSV-1 treated tumors to NK cell immunotherapy.
Herpes Simplex
Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.
Herpes Simplex
Cellular proteasome activity facilitates herpes simplex virus entry at a postpenetration step.
Herpes Simplex
Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
Herpes Simplex
Enhanced Over-Representation Analysis for the Differential Regulation of Birc5a and HIF2?-Knockdown Approaches.
Herpes Simplex
Herpes simplex virus type 1 induces CD83 degradation in mature dendritic cells with immediate-early kinetics via the cellular proteasome.
Herpes Simplex
Hsc70 Focus Formation at the Periphery of HSV-1 Transcription Sites Requires ICP27.
Herpes Simplex
Zinc ionophores pyrithione inhibits herpes simplex virus replication through interfering with proteasome function and NF-?B activation.
Herpes Zoster
Comparative analysis of proteomes between diabetic and normal human sperm: Insights into the effects of diabetes on male reproduction based on the regulation of mitochondria-related proteins.
Herpes Zoster
Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease.
Herpes Zoster
Involvement of multimeric protein complexes in mediating the capacitation-dependent binding of human spermatozoa to homologous zonae pellucidae.
Herpes Zoster
Proteasomal interference prevents zona pellucida penetration and fertilization in mammals.
Herpes Zoster
Role of the sperm proteasome during fertilization and gamete interaction in the mouse.
Herpes Zoster
Sperm Proteasomes Degrade Sperm Receptor on the Egg Zona Pellucida during Mammalian Fertilization.
Herpes Zoster
Targeted salmon gene array (SalArray): a toxicogenomic tool for gene expression profiling of interactions between estrogen and aryl hydrocarbon receptor signalling pathways.
Herpes Zoster
Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors.
Herpes Zoster
[Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy]
Herpesviridae Infections
A surprising role for the proteasome in the regulation of herpesvirus infection.
HIV Infections
Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1.
HIV Infections
Identifying potential survival strategies of HIV-1 through virus-host protein interaction networks.
HIV Infections
Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection.
HIV Infections
The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes.
Hodgkin Disease
Bortezomib down-modulates the survival factor IRF4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-Associated Fibroblasts.
Hodgkin Disease
Development and evaluation of a sandwich ELISA for quantification of the 20S proteasome in human plasma.
Hodgkin Disease
Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
Hodgkin Disease
Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies.
Hodgkin Disease
Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC Dependent Cell Death in T-Cell and Hodgkin Lymphoma.
Hodgkin Disease
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
Hodgkin Disease
TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.
Homocystinuria
Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70.
Homocystinuria
Correction of cystathionine ?-synthase deficiency in mice by treatment with proteasome inhibitors.
Huntington Disease
20S proteasome activation promotes life span extension and resistance to proteotoxicity in Caenorhabditis elegans.
Huntington Disease
A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers.
Huntington Disease
Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases.
Huntington Disease
Aged monkey brains reveal the role of ubiquitin-conjugating enzyme UBE2N in the synaptosomal accumulation of mutant huntingtin.
Huntington Disease
Co-expression network-based analysis of hippocampal expression data associated with Alzheimer's disease using a novel algorithm.
Huntington Disease
Computational identification of key genes that may regulate gene expression reprogramming in Alzheimer's patients.
Huntington Disease
Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies.
Huntington Disease
Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease.
Huntington Disease
Enhanced induction of the immunoproteasome by interferon gamma in neurons expressing mutant Huntingtin.
Huntington Disease
Enhanced proteasome degradation extends Caenorhabditis elegans lifespan and alleviates aggregation-related pathologies.
Huntington Disease
FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington's disease and their derived neural cells.
Huntington Disease
Gene therapy by proteasome activator, PA28?, improves motor coordination and proteasome function in Huntington's disease YAC128 mice.
Huntington Disease
Generalized brain and skin proteasome inhibition in Huntington's disease.
Huntington Disease
Impaired degradation of PKCalpha by proteasome in a cellular model of Huntington's disease.
Huntington Disease
Indirect inhibition of 26S proteasome activity in a cellular model of Huntington's disease.
Huntington Disease
Induction of chemokines, MCP-1, and KC in the mutant huntingtin expressing neuronal cells because of proteasomal dysfunction.
Huntington Disease
Juvenile Huntington's Disease Skin Fibroblasts Respond with Elevated Parkin Level and Increased Proteasome Activity as a Potential Mechanism to Counterbalance the Pathological Consequences of Mutant Huntingtin Protein.
Huntington Disease
Micro RNA-214 contributes to proteasome independent downregulation of beta catenin in Huntington's disease knock-in striatal cell model STHdhQ111/Q111.
Huntington Disease
Misfolding of proteins with a polyglutamine expansion is facilitated by proteasomal chaperones.
Huntington Disease
Modest proteasomal inhibition by aberrant ubiquitin exacerbates aggregate formation in a Huntington disease mouse model.
Huntington Disease
Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation.
Huntington Disease
Neuroprotection by histone deacetylase-7 (HDAC7) occurs by inhibition of c-jun expression through a deacetylase-independent mechanism.
Huntington Disease
Phosphorylation of the 19S regulatory particle ATPase subunit, Rpt6, modifies susceptibility to proteotoxic stress and protein aggregation.
Huntington Disease
Proteasome activator enhances survival of huntington's disease neuronal model cells.
Huntington Disease
Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target.
Huntington Disease
Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease.
Huntington Disease
Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease.
Huntington Disease
Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
Huntington Disease
Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington's disease.
Huntington Disease
The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias.
Huntington Disease
The Ubiquitin-Proteasome System in Huntington's Disease: Are Proteasomes Impaired, Initiators of Disease, or Coming to the Rescue?
Huntington Disease
Widespread remodeling of proteome solubility in response to different protein homeostasis stresses.
Hyalinosis, Systemic
Hyaline Fibromatosis Syndrome inducing mutations in the ectodomain of anthrax toxin receptor 2 can be rescued by proteasome inhibitors.
Hydatidiform Mole
Low molecular mass polypeptide-2 in human trophoblast: over-expression in hydatidiform moles and possible role in trophoblast cell invasion.
Hyperalgesia
Control of chronic pain by the ubiquitin proteasome system in the spinal cord.
Hyperalgesia
The active second-generation proteasome inhibitor oprozomib reverts the oxaliplatin-induced neuropathy symptoms.
Hypercalcemia
Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma.
Hypercholesterolemia
Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia.
Hypercholesterolemia
Global gene expression changes in the prefrontal cortex of rabbits with hypercholesterolemia and/or hypertension.
Hypercholesterolemia
Potential role of proteasome on c-jun related signaling in hypercholesterolemia induced atherosclerosis.
Hypercholesterolemia
Proteasome Modulator 9 SNPs are linked to Hypertension in Type 2 Diabetes Families.
Hyperglycemia
Effect of Dietary Silk Peptide on Obesity, Hyperglycemia, and Skeletal Muscle Regeneration in High-Fat Diet-Fed Mice.
Hyperglycemia
Evidence for a role of immunoproteasomes in regulating cardiac muscle mass in diabetic mice.
Hyperglycemia
Functional proteasome complex is required for turnover of islet amyloid polypeptide in pancreatic ?-cells.
Hyperglycemia
Lovastatin upregulates microRNA-29b to reduce oxidative stress in rats with multiple cardiovascular risk factors.
Hyperglycemia
Mechanism and Consequences of The Impaired Hif-1? Response to Hypoxia in Human Proximal Tubular HK-2 Cells Exposed to High Glucose.
Hyperglycemia
Partial inhibition of the ubiquitin-proteasome system ameliorates cardiac dysfunction following ischemia-reperfusion in the presence of high glucose.
Hyperglycemia
Proteasome Activators, PA28? and PA28?, Govern Development of Microvascular Injury in Diabetic Nephropathy and Retinopathy.
Hyperglycemia
Proteasome inhibitors, including curcumin, improve pancreatic ?-cell function and insulin sensitivity in diabetic mice.
Hyperglycemia
Upregulation of myocardial 11S-activated proteasome in experimental hyperglycemia.
Hyperhomocysteinemia
Hyperhomocysteinemia-induced oxidative stress differentially alters proteasome composition and activities in heart and aorta.
Hyperhomocysteinemia
Lovastatin upregulates microRNA-29b to reduce oxidative stress in rats with multiple cardiovascular risk factors.
Hyperhomocysteinemia
Plasma asymmetric and symmetric dimethylarginine in a rat model of endothelial dysfunction induced by acute hyperhomocysteinemia.
Hyperlipidemias
HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia.
Hyperlipidemias
Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia.
Hyperlipidemias
LDL suppresses angiogenesis through disruption of the HIF pathway via NF-?B inhibition which is reversed by the proteasome inhibitor BSc2118.
Hypersensitivity
Drug screens of NGLY1 deficiency in worm and fly models reveal catecholamine, NRF2 and anti-inflammatory-pathway activation as potential clinical approaches.
Hypersensitivity
Isolation, Structure, and Biological Activities of Fellutamides C and D from an Undescribed Metulocladosporiella (Chaetothyriales) Using the Genome-Wide Candida albicans Fitness Test.
Hypersensitivity
Multiubiquitin chain binding and protein degradation are mediated by distinct domains within the 26 S proteasome subunit Mcb1.
Hypersensitivity
p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin.
Hypersensitivity
Proteasomal Control of Cytokinin Synthesis Protects Mycobacterium tuberculosis against Nitric Oxide.
Hypersensitivity
Proteasome nuclear import mediated by Arc3 can influence efficient DNA damage repair and mitosis in Schizosaccharomyces pombe.
Hypersensitivity
The Mycobacterium tuberculosis proteasome active site threonine is essential for persistence yet dispensable for replication and resistance to nitric oxide.
Hypersensitivity
The RPT2 subunit of the 26S proteasome directs complex assembly, histone dynamics, and gametophyte and sporophyte development in Arabidopsis.
Hypertension
Aerobic exercise training improves oxidative stress and ubiquitin proteasome system activity in heart of spontaneously hypertensive rats.
Hypertension
Antihypertensive effect of a proteasome inhibitor in DOCA-salt hypertensive rats.
Hypertension
Arterial hypertension and multiple myeloma: physiopathology and cardiovascular risk and 'practical' indications in patients receiving carfilzomib.
Hypertension
Arterial hypertension in patients under antineoplastic therapy: a systematic review.
Hypertension
Bortezomib, a proteasome inhibitor, attenuates Angiotensin II-induced hypertension and aortic remodeling in rats.
Hypertension
Digoxin-Mediated Upregulation of RGS2 Protein Protects against Cardiac Injury.
Hypertension
Forkhead box M1 transcription factor: a novel target for pulmonary arterial hypertension therapy.
Hypertension
Global gene expression changes in the prefrontal cortex of rabbits with hypercholesterolemia and/or hypertension.
Hypertension
Inhibition of ubiquitin proteasome function prevents monocrotaline-induced pulmonary arterial remodeling.
Hypertension
MG132 treatment attenuates cardiac remodeling and dysfunction following aortic banding in rats via the NF-?B/TGF?1 pathway.
Hypertension
Pathophysiological role of proteasome-dependent proteolytic pathway in endothelin-1-related cardiovascular diseases.
Hypertension
Plasma Cell Depletion Attenuates Hypertension in an Experimental Model of Autoimmune Disease.
Hypertension
Proteasome inhibitor PS-341 attenuates flow-induced pulmonary arterial hypertension.
Hypertension
Proteasome Modulator 9 SNPs are linked to Hypertension in Type 2 Diabetes Families.
Hypertension
Tyrosine hydroxylase is short-term regulated by the ubiquitin-proteasome system in PC12 cells and hypothalamic and brainstem neurons from spontaneously hypertensive rats: possible implications in hypertension.
Hypertension
Tyrosine nitration of PA700 activates the 26S proteasome to induce endothelial dysfunction in mice with angiotensin II-induced hypertension.
Hypertension
Tyrosine nitration of PA700 links proteasome activation to endothelial dysfunction in mouse models with cardiovascular risk factors.
Hypertension
[Allele polymorphism of genes coding proteasome subunits is associated with an enhanced risk for arterial hypertension in adolescents]
Hypertension
[Effect of quercetin on proteasome activity in the aorta and heart tissues of spontaneously hypertensive rats].
Hypertension, Pulmonary
Hypoxia-induced alterations in the lung ubiquitin proteasome system during pulmonary hypertension pathogenesis.
Hypertension, Pulmonary
Inhibition of ubiquitin proteasome function suppresses proliferation of pulmonary artery smooth muscle cells.
Hypertension, Pulmonary
Successful treatment of a novel type I interferonopathy due to a de novo PSMB9 gene mutation with a Janus kinase inhibitor.
Hypertension, Renovascular
Changes in proteasome activity in the ischemic kidney of rat with experimental renovascular hypertension.
Hypertensive Retinopathy
Proteasome Modulator 9 gene is linked to diabetic and non-diabetic retinopathy in T2D.
Hyperthyroidism
Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles.
Hyperthyroidism
Ubiquitin proteasome system (UPS) activation in the cardiac hypertrophy of hyperthyroidism.
Hypertrophy, Left Ventricular
Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy.
Hypertrophy, Left Ventricular
Activation of the cardiac proteasome promotes angiotension II-induced hypertrophy by down-regulation of ATRAP.
Hypertrophy, Left Ventricular
Proteasome inhibition promotes regression of left ventricular hypertrophy.
Hypertrophy, Right Ventricular
Altered proteasome function in right ventricular hypertrophy.
Hypertrophy, Right Ventricular
Gambogic acid moderates cardiac responses to chronic hypoxia likely by acting on the proteasome and NF-?B pathway.
Hypopharyngeal Neoplasms
MG132 reverse the malignant characteristics of hypopharyngeal cancer.
Hypophosphatasia
Molecular Genetics of Hypophosphatasia and Phenotype-Genotype Correlations.
Hypoxia-Ischemia, Brain
Oleuropein Activates Neonatal Neocortical Proteasomes, but Proteasome Gene Targeting by AAV9 Is Variable in a Clinically Relevant Piglet Model of Brain Hypoxia-Ischemia and Hypothermia.
Ichthyosis
129-Derived Mouse Strains Express an Unstable but Catalytically Active DNA Polymerase Iota Variant.
Ichthyosis, Lamellar
siRNA silencing of proteasome maturation protein (POMP) activates the unfolded protein response and constitutes a model for KLICK genodermatosis.
Immune System Diseases
Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations.
Immune System Diseases
Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents.
Immune System Diseases
Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience.
Immune System Diseases
Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.
Immune System Diseases
The proteasome and its inhibitors in immune regulation and immune disorders.
Immunoglobulin Light-chain Amyloidosis
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Immunoglobulin Light-chain Amyloidosis
Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis.
Immunoglobulin Light-chain Amyloidosis
Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases.
Immunoglobulin Light-chain Amyloidosis
Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.
Immunoglobulin Light-chain Amyloidosis
Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
Immunoglobulin Light-chain Amyloidosis
Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Immunoglobulin Light-chain Amyloidosis
Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen.
Immunoglobulin Light-chain Amyloidosis
Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity.
Immunoglobulin Light-chain Amyloidosis
Recurrent Syncope and Cardiac Arrest in a Patient with Systemic Light Chain Amyloidosis Treated with Bortezomib.
Immunoglobulin Light-chain Amyloidosis
Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597-605.
Immunoglobulin Light-chain Amyloidosis
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.
Infarction, Middle Cerebral Artery
Celecoxib-Dependent Neuroprotection in a Rat Model of Transient Middle Cerebral Artery Occlusion (tMCAO) Involves Modifications in Unfolded Protein Response (UPR) and Proteasome.
Infarction, Middle Cerebral Artery
Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the rat.
Infarction, Middle Cerebral Artery
Systemic Proteasome Inhibition Induces Sustained Post-stroke Neurological Recovery and Neuroprotection via Mechanisms Involving Reversal of Peripheral Immunosuppression and Preservation of Blood-Brain-Barrier Integrity.
Infections
A bacterial virulence protein suppresses host innate immunity to cause plant disease.
Infections
A luminescence assay for natural product inhibitors of the Mycobacterium tuberculosis proteasome.
Infections
A Pathogen and a Non-pathogen Spotted Fever Group Rickettsia Trigger Differential Proteome Signatures in Macrophages.
Infections
Age-Dependent Effects of Immunoproteasome Deficiency on Mouse Adenovirus Type 1 Pathogenesis.
Infections
Alteration of copper-zinc superoxide dismutase 1 expression by influenza A virus is correlated with virus replication.
Infections
Amniotic Fluid Proteasome and Immunoproteasome in the Setting of Intra-Amniotic Infection, Inflammation, and Preterm Birth.
Infections
An adenosine triphosphate-independent proteasome activator contributes to the virulence of Mycobacterium tuberculosis.
Infections
Analysis of cotton (Gossypium hirsutum) root proteomes during a compatible interaction with the black root rot fungus Thielaviopsis basicola.
Infections
Anti-Trypanosomal Proteasome Inhibitors Cure Hemolymphatic and Meningoencephalic Murine Infection Models of African Trypanosomiasis.
Infections
Antiviral activity of proteasome inhibitors in herpes simplex virus-1 infection: role of nuclear factor-kappaB.
Infections
Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1.
Infections
Appraising the roles of CBLL1 and the ubiquitin/proteasome system for flavivirus entry and replication.
Infections
Bacteria exploit autophagy for proteasome degradation and enhanced virulence in plants.
Infections
Biotyping of IRE/CTVM19 tick cell line infected by tick-borne encephalitis virus.
Infections
Bortezomib inhibits chikungunya virus replication by interfering with viral protein synthesis.
Infections
Brain-derived neurotrophic factor and the course of experimental cerebral malaria.
Infections
Cell Clearing Systems as Targets of Polyphenols in Viral Infections: Potential Implications for COVID-19 Pathogenesis.
Infections
Cellular localization of the herpes simplex virus ICP0 protein dictates its ability to block IRF3-mediated innate immune responses.
Infections
CHYR1 ubiquitinates the phosphorylated WRKY70 for degradation to balance immunity in Arabidopsis thaliana.
Infections
Comparative transcriptome analysis reveals distinct gene expression profiles in Brachypodium distachyon infected by two fungal pathogens.
Infections
Critical contribution of immunoproteasomes in the induction of protective immunity against Trypanosoma cruzi in mice vaccinated with a plasmid encoding a CTL epitope fused to green fluorescence protein.
Infections
Critical role for the immunoproteasome subunit LMP7 in the resistance of mice to Toxoplasma gondii infection.
Infections
Cyclophilin A potentiates TRIM5? inhibition of HIV-1 nuclear import without promoting TRIM5? binding to the viral capsid.
Infections
Cytoplasmic trafficking of minute virus of mice: low-pH requirement, routing to late endosomes, and proteasome interaction.
Infections
Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study.
Infections
Detecting the genetic link between Alzheimer's disease and obesity using bioinformatics analysis of GWAS data.
Infections
Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway.
Infections
Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
Infections
Early responses given distinct tactics to infection of Peronophythora litchii in susceptible and resistant litchi cultivar.
Infections
Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
Infections
Effector-triggered immunity blocks pathogen degradation of an immunity-associated vesicle traffic regulator in Arabidopsis.
Infections
Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus.
Infections
Enhanced Efficacy against Cervical Carcinomas through Polymeric Micelles Physically Incorporating the Proteasome Inhibitor MG132.
Infections
Enhanced Over-Representation Analysis for the Differential Regulation of Birc5a and HIF2?-Knockdown Approaches.
Infections
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective-immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine 1-phosphate receptor modulators and proteasome inhibitors.
Infections
Evidence against a direct antiviral activity of the proteasome during the early steps of HIV-1 replication.
Infections
Expression of herpes simplex virus ICP0 inhibits the induction of interferon-stimulated genes by viral infection.
Infections
Functional analysis of a DNA-shuffled movement protein reveals that microtubules are dispensable for the cell-to-cell movement of tobacco mosaic virus.
Infections
Functional genomic studies of tick cells in response to infection with the cattle pathogen, Anaplasma marginale.
Infections
Grass carp reovirus capsid protein interacts with cellular proteasome subunit beta-type 7: Evidence for the involvement of host proteasome during aquareovirus infection.
Infections
HCMV-Mediated Interference of Bortezomib-Induced Apoptosis in Colon Carcinoma Cell Line Caco-2.
Infections
HcPro, a multifunctional protein encoded by a plant RNA virus, targets the 20S proteasome and affects its enzymic activities.
Infections
Heat shock perturbs TRIM5alpha restriction of human immunodeficiency virus type 1.
Infections
Hepatitis C virus infection suppresses GLUT2 gene expression via downregulation of hepatocyte nuclear factor 1?.
Infections
Herpes simplex virus type 1 induces CD83 degradation in mature dendritic cells with immediate-early kinetics via the cellular proteasome.
Infections
Herpes simplex virus type I disrupts the ATR-dependent DNA-damage response during lytic infection.
Infections
High-Definition Analysis of Host Protein Stability during Human Cytomegalovirus Infection Reveals Antiviral Factors and Viral Evasion Mechanisms.
Infections
HopZ4 from Pseudomonas syringae, a member of the HopZ type III effector family from the YopJ superfamily, inhibits the proteasome in plants.
Infections
Host gene expression profiling of dengue virus infection in cell lines and patients.
Infections
Host Interaction Analysis of PA-N155 and PA-N182 in Chicken Cells Reveals an Essential Role of UBA52 for Replication of H5N1 Avian Influenza Virus.
Infections
Human Antiviral Protein IFIX Suppresses Viral Gene Expression during Herpes Simplex Virus 1 (HSV-1) Infection and Is Counteracted by Virus-induced Proteasomal Degradation.
Infections
Human Cytomegalovirus Tegument Protein pp65 (pUL83) Dampens Type I Interferon Production by Inactivating the DNA Sensor cGAS without Affecting STING.
Infections
Human immunodeficiency virus type 1 Vpr modulates cellular expression of UNG2 via a negative transcriptional effect.
Infections
Identification of New Mycobacterium tuberculosis Proteasome Inhibitors Using a Knowledge-Based Computational Screening Approach.
Infections
IFN-beta mediates coordinate expression of antigen-processing genes in RSV-infected pulmonary epithelial cells.
Infections
Immunomodulation of lambs following treatment with a proteasome preparation from infective larvae of Trichostrongylus colubriformis.
Infections
Immunoproteasome Activity and Content Determine Hematopoietic Cell Sensitivity to ONX-0914 and to the Infection of Cells with Lentiviruses.
Infections
Immunoproteasome Upregulation Is Not Required to Control Protein Homeostasis during Viral Infection.
Infections
Impact of Time-Varying Treatment Exposures on the Risk of Venous Thromboembolism in Multiple Myeloma.
Infections
In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice.
Infections
Infection of cells with human cytomegalovirus during S phase results in a blockade to immediate-early gene expression that can be overcome by inhibition of the proteasome.
Infections
Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.
Infections
Infection with Salmonella typhimurium has no effect on the composition and cleavage specificity of the 20S proteasome in human lymphoid cells.
Infections
Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection.
Infections
Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor.
Infections
Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes.
Infections
Innate Multigene Family Memories Are Implicated in the Viral-Survivor Zebrafish Phenotype.
Infections
Internal deletions of IE2 86 and loss of the late IE2 60 and IE2 40 proteins encoded by human cytomegalovirus affect the levels of UL84 protein but not the amount of UL84 mRNA or the loading and distribution of the mRNA on polysomes.
Infections
Investigating proteasome inhibitors as potential adjunct therapies for experimental cerebral malaria.
Infections
Involvement of JNK and NF-?B pathways in lipopolysaccharide (LPS)-induced BAG3 expression in human monocytic cells.
Infections
iTRAQ-based quantitative proteomic analysis of peripheral blood serum in piglets infected with Actinobacillus pleuropneumoniae.
Infections
Lentiviral vector gene transfer is limited by the proteasome at postentry steps in various types of stem cells.
Infections
Linkage of bacterial protein synthesis and presentation of MHC class I-restricted Listeria monocytogenes-derived antigenic peptides.
Infections
Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Infections
Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations.
Infections
Medicago Plants Control Nodulation by Regulating Proteolysis of the Receptor-Like Kinase DMI2.
Infections
MG-132 interferes with iron cellular homeostasis and alters virulence of bovine herpesvirus 1.
Infections
MG132 exerts anti-viral activity against HSV-1 by overcoming virus-mediated suppression of the ERK signaling pathway.
Infections
MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells.
Infections
Mitochondrial cell death suppressors carried by human and murine cytomegalovirus confer resistance to proteasome inhibitor-induced apoptosis.
Infections
Modification of cytoskeleton and prosome networks in relation to protein synthesis in influenza A virus-infected LLC-MK2 cells.
Infections
Multiple pathways involved in porcine parvovirus cellular entry and trafficking toward the nucleus.
Infections
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling.
Infections
Mycobacterium tuberculosis proteasomal ATPase Mpa has a ?-grasp domain that hinders docking with the proteasome core protease.
Infections
Myxoma virus M-T5 protects infected cells from the stress of cell cycle arrest through its interaction with host cell cullin-1.
Infections
Nanoluciferase-Based Method for Detecting Gene Expression in Caenorhabditis elegans.
Infections
New insights into host-parasite ubiquitin proteome dynamics in P. falciparum infected red blood cells using a TUBEs-MS approach.
Infections
Oligomerization of ICP4 and rearrangement of heat shock proteins may be important for herpes simplex virus type 1 prereplicative site formation.
Infections
Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps.
Infections
Persistent gammaherpesvirus replication and dynamic interaction with the host in vivo.
Infections
Plant Virus Infection and the Ubiquitin Proteasome Machinery: Arms Race along the Endoplasmic Reticulum.
Infections
Platelet Proteasome Activity and Metabolism Is Upregulated during Bacterial Sepsis.
Infections
Platelet proteome reveals novel pathways of platelet activation and platelet-mediated immunoregulation in dengue.
Infections
Postentry processing of recombinant adeno-associated virus type 1 and transduction of the ferret lung are altered by a factor in airway secretions.
Infections
Presentation of a new H-2D(k)-restricted epitope in the Tax protein of human T-lymphotropic virus type I is enhanced by the proteasome inhibitor lactacystin.
Infections
Promyelocytic Leukemia Restricts Enterovirus 71 Replication by Inhibiting Autophagy.
Infections
Proteasome activator REGgamma enhances coxsackieviral infection by facilitating p53 degradation.
Infections
Proteasome activity in a naïve mosquito cell line infected with Wolbachia pipientis wAlbB.
Infections
Proteasome inhibition attenuates coxsackievirus-induced myocardial damage in mice.
Infections
Proteasome inhibition enhances AAV-mediated transgene expression in human synoviocytes in vitro and in vivo.
Infections
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness.
Infections
Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins.
Infections
Proteasome Inhibition Suppresses Dengue Virus Egress in Antibody Dependent Infection.
Infections
Proteasome Inhibitor PS-341 Effectively Blocks Infection by the Severe Fever with Thrombocytopenia Syndrome Virus.
Infections
Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.
Infections
Proteasome inhibitors enhance bacteriophage lambda (lambda) mediated gene transfer in mammalian cells.
Infections
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
Infections
Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells.
Infections
Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection.
Infections
Proteasome serves as pivotal regulator in Angiostrongylus cantonensis-induced eosinophilic meningoencephalitis.
Infections
Proteasome subunit beta type-8 from sevenband grouper negatively regulates cytokine responses by interfering NF-?B signaling upon nervous necrosis viral infection.
Infections
Proteasome subunits relocalize during human cytomegalovirus infection, and proteasome activity is necessary for efficient viral gene transcription.
Infections
Proteasome-independent degradation of HIV-1 in naturally non-permissive human placental trophoblast cells.
Infections
Proteolytic enzymes involved in MHC class I antigen processing: A guerrilla army that partners with the proteasome.
Infections
Proteomic analysis of papaya (Carica papaya L.) displaying typical sticky disease symptoms.
Infections
Proteomics of the 26S proteasome in Spodoptera frugiperda cells infected with the nucleopolyhedrovirus, AcMNPV.
Infections
Proteotoxic stress induced by Autographa californica nucleopolyhedrovirus infection of Spodoptera frugiperda Sf9 cells.
Infections
Pulmonary Pseudomonas aeruginosa infection induces autophagy and proteasome proteolytic pathways in skeletal muscles: effects of a pressurized whey protein-based diet in mice.
Infections
Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway.
Infections
Recruitment and Dynamics of Proteasome Association with rhTRIM5? Cytoplasmic Complexes During HIV-1 Infection.
Infections
Reduced immunoproteasome formation and accumulation of immunoproteasomal precursors in the brains of lymphocytic choriomeningitis virus-infected mice.
Infections
Regulation of immunoproteasome subunit expression in vivo following pathogenic fungal infection.
Infections
Reovirus-induced apoptosis requires activation of transcription factor NF-kappaB.
Infections
Respiratory syncytial virus induces ?2-adrenergic receptor dysfunction in human airway smooth muscle cells.
Infections
Respiratory syncytial virus infection alters surfactant protein A expression in human pulmonary epithelial cells by reducing translation efficiency.
Infections
Rice stripe Tenuivirus nonstructural protein 3 hijacks the 26S proteasome of the small brown planthopper, via direct interaction with regulatory-particle non-ATPase subunit 3.
Infections
Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy.
Infections
Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus.
Infections
Roles for APIS and the 20S proteasome in adenovirus E1A-dependent transcription.
Infections
Second-strand genome conversion of adeno-associated virus type 2 (AAV-2) and AAV-5 is not rate limiting following apical infection of polarized human airway epithelia.
Infections
Selective autophagy controls the stability of transcription factor IRF3 to balance type I interferon production and immune suppression.
Infections
Selective restriction of Nef-defective human immunodeficiency virus type 1 by a proteasome-dependent mechanism.
Infections
Simultaneous neutralization and innate immune detection of a replicating virus by TRIM21.
Infections
Structural analysis of the dodecameric proteasome activator PafE in Mycobacterium tuberculosis.
Infections
Subunit-selective proteasome activity profiling uncovers uncoupled proteasome subunit activities during bacterial infections.
Infections
SUMO-1 modification of the major immediate-early (IE) 1 and 2 proteins of human cytomegalovirus is regulated by different mechanisms and modulates the intracellular localization of the IE1, but not IE2, protein.
Infections
The 19S proteasome activator promotes human cytomegalovirus immediate early gene expression through proteolytic and nonproteolytic mechanisms.
Infections
The existence of two types of proteasome, the constitutive proteasome and the immunoproteasome, may serve as another layer of protection against autoimmunity.
Infections
The major component of IkappaBalpha proteolysis occurs independently of the proteasome pathway in respiratory syncytial virus-infected pulmonary epithelial cells.
Infections
The Major Immediate-Early Protein IE2 of Human Cytomegalovirus Is Sufficient to Induce Proteasomal Degradation of CD83 on Mature Dendritic Cells.
Infections
The Mycobacterium tuberculosis proteasome active site threonine is essential for persistence yet dispensable for replication and resistance to nitric oxide.
Infections
The pathogenic potential of Campylobacter concisus strains associated with chronic intestinal diseases.
Infections
The proteasome immunosubunit multicatalytic endopeptidase complex-like 1 is a T-cell-intrinsic factor influencing homeostatic expansion.
Infections
The proteasome inhibitor Velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice.
Infections
The proteasome system in infection: impact of ?5 and LMP7 on composition, maturation and quantity of active proteasome complexes.
Infections
The role of Src protein in the process formation of PC12 cells induced by the proteasome inhibitor MG-132.
Infections
The Tomato yellow leaf curl virus V2 protein forms aggregates depending on the cytoskeleton integrity and binds viral genomic DNA.
Infections
The ubiquitin-proteasome machinery is essential for nuclear translocation of incoming minute virus of mice.
Infections
The ubiquitin-proteasome system is necessary for the replication of duck Tembusu virus.
Infections
The ubiquitin-proteasome system is required for the early stages of porcine circovirus type 2 replication.
Infections
The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle.
Infections
The ubiquitin/proteasome system mediates entry and endosomal trafficking of Kaposi's sarcoma-associated herpesvirus in endothelial cells.
Infections
Toxoplasma gondii infection of activated J774-A1 macrophages causes inducible nitric oxide synthase degradation by the proteasome pathway.
Infections
Transcriptional regulation of endothelial cell tissue factor expression during Rickettsia rickettsii infection: involvement of the transcription factor NF-kappaB.
Infections
TRIM41-Mediated Ubiquitination of Nucleoprotein Limits Vesicular Stomatitis Virus Infection.
Infections
Trypanosoma cruzi: effect of the infection on the 20S proteasome in non-immune cells.
Infections
Ubiquitin-Independent Proteasomal Degradation of Tumor Suppressors by Human Cytomegalovirus pp71 Requires the 19S Regulatory Particle.
Infections
Ubiquitin-Like protein 5 interacts with the silencing suppressor p3 of rice stripe virus and mediates its degradation through the 26S proteasome pathway.
Infections
Ubiquitin-Proteasome System Is Required for Efficient Replication of Singapore Grouper Iridovirus.
Infections
Ubiquitination and degradation of the ORF34 gene product of equine herpesvirus type 1 (EHV-1) at late times of infection.
Infections
Ubiquitylation and autophagy in the control of bacterial infections and related inflammatory responses.
Infections
Up-regulation of the ubiquitin-conjugating and proteolytic systems in murine acquired immunodeficiency syndrome.
Infections
VacA promotes CagA accumulation in gastric epithelial cells during Helicobacter pylori infection.
Infections
West Nile virus genome amplification requires the functional activities of the proteasome.
Infections
[Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy]
Infections
[Systemic varicella-zoster infection during ixazomib-containing multiagent chemotherapy for multiple myeloma].
Infections
[Transcriptome Analysis of Rabbit Spleen with Hog Cholera Lapinized Virus Infection Based on High-throughput Sequencing Technology].
Infertility
Proteasome localization and ultrastructure of spermatozoa from patients with varicocele--immunoelectron microscopic study.
Infertility, Male
FBXO7 sensitivity of phenotypic traits elucidated by a hypomorphic allele.
Infertility, Male
The REG?-Proteasome Regulates Spermatogenesis Partially by P53-PLZF Signaling.
Inflammatory Bowel Diseases
Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome.
Inflammatory Bowel Diseases
Enhanced intestinal expression of the proteasome subunit low molecular mass polypeptide 2 in patients with inflammatory bowel disease.
Inflammatory Bowel Diseases
Evaluation of ubiquitinated proteins by proteomics reveals the role of the ubiquitin proteasome system in the regulation of Grp75 and Grp78 chaperone proteins during intestinal inflammation.
Inflammatory Bowel Diseases
Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease.
Inflammatory Bowel Diseases
Monogenic autoinflammatory diseases: concept and clinical manifestations.
Inflammatory Bowel Diseases
Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease.
Inflammatory Bowel Diseases
Proteasome inhibitors: a new perspective for treating autoimmune diseases.
Inflammatory Bowel Diseases
Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
Inflammatory Bowel Diseases
Skeletal muscle catabolism in trinitrobenzene sulfonic acid-induced murine colitis.
Inflammatory Bowel Diseases
The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease.
Influenza, Human
Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.
Influenza, Human
Apolipoprotein E in macrophages and hepatocytes is eegraded via the proteasomal pathway.
Influenza, Human
CHD6, a Cellular Repressor of Influenza Virus Replication, Is Degraded in Human Alveolar Epithelial Cells and Mice Lungs during Infection.
Influenza, Human
Comparative Profiling of Ubiquitin Proteasome System Interplay with Influenza A Virus PB2 Polymerase Protein Recapitulating Virus Evolution in Humans.
Influenza, Human
Comparative transcriptome analysis of Ethiopian indigenous chickens from low and high altitudes under heat stress condition reveals differential immune response.
Influenza, Human
Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides.
Influenza, Human
Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein.
Influenza, Human
Identification of a membrane targeting and degradation signal in the p42 protein of influenza C virus.
Influenza, Human
Influenza A virus (H1N1) triggers a hypoxic response by stabilizing hypoxia-inducible factor-1? via inhibition of proteasome.
Influenza, Human
Modification of cytoskeleton and prosome networks in relation to protein synthesis in influenza A virus-infected LLC-MK2 cells.
Influenza, Human
Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation.
Influenza, Human
Proteasomes raise the microtubule dynamics in influenza A (H1N1) virus-infected LLC-MK2 cells.
Influenza, Human
Re-evaluating the generation of a "proteasome-independent" MHC class I-restricted CD8 T cell epitope.
Influenza, Human
The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state.
Influenza, Human
The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells.
Influenza, Human
The requirement for proteasome activity class I major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen.
Influenza, Human
Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States.
Insulin Resistance
"Hidden targets of ubiquitin proteasome system: To prevent diabetic nephropathy".
Insulin Resistance
Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity.
Insulin Resistance
Curcumin Improves Palmitate-Induced Insulin Resistance in Human Umbilical Vein Endothelial Cells by Maintaining Proteostasis in Endoplasmic Reticulum.
Insulin Resistance
Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells.
Insulin Resistance
Glycogen synthase kinase 3 beta mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1.
Insulin Resistance
Icariin Ameliorates Palmitate-Induced Insulin Resistance Through Reducing Thioredoxin-Interacting Protein (TXNIP) and Suppressing ER Stress in C2C12 Myotubes.
Insulin Resistance
Identification of intracellular peptides in rat adipose tissue: Insights into insulin resistance.
Insulin Resistance
Implications of Sortilin in Lipid Metabolism and Lipid Disorder Diseases.
Insulin Resistance
Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling.
Insulin Resistance
Nutrigenomics of high fat diet induced obesity in mice suggests relationships between susceptibility to fatty liver disease and the proteasome.
Insulin Resistance
Palmitate induces insulin resistance in human HepG2 hepatocytes by enhancing ubiquitination and proteasomal degradation of key insulin signaling molecules.
Insulin Resistance
PDE5A Suppresses Proteasome Activity Leading to Insulin Resistance in C2C12 Myotubes.
Insulin Resistance
PROTEASOME DYSFUNCTION ASSOCIATED TO OXIDATIVE STRESS AND PROTEOTOXICITY IN ADIPOCYTES COMPROMISE INSULIN SENSITIVITY IN HUMAN OBESITY.
Insulin Resistance
Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver.
Insulin Resistance
Proteasome dysfunction under compromised redox metabolism dictates liver injury in NASH through ASK1/PPAR? binodal complementary modules.
Insulin Resistance
Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes.
Insulin Resistance
Proteasome inhibitors, including curcumin, improve pancreatic ?-cell function and insulin sensitivity in diabetic mice.
Insulin Resistance
[The metabolic syndrome and type-2 diabetes mellitus as conditions predisposing for malignant tumors]
Insulinoma
Nuclear factor kappaB protects pancreatic beta-cells from tumor necrosis factor-alpha-mediated apoptosis.
Intellectual Disability
A mental retardation-linked nonsense mutation in cereblon is rescued by proteasome inhibition.
Intellectual Disability
Biallelic variants in PSMB1 encoding the proteasome subunit ?6 cause impairment of proteasome function, microcephaly, intellectual disability, developmental delay and short stature.
Intellectual Disability
Cowden syndrome-related mutations in PTEN associate with enhanced proteosome activity.
Intellectual Disability
De Novo Disruption of the Proteasome Regulatory Subunit PSMD12 Causes a Syndromic Neurodevelopmental Disorder.
Intellectual Disability
Postnatal proteasome inhibition induces neurodegeneration and cognitive deficiencies in adult mice: a new model of neurodevelopment syndrome.
Intellectual Disability
PSMD12 haploinsufficiency in a neurodevelopmental disorder with autistic features.
Intestinal Pseudo-Obstruction
Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.
Intracranial Aneurysm
Nocardia intracranial mycotic aneurysm associated with proteasome inhibitor.
Iritis
Polymorphism in an HLA linked proteasome gene influences phenotypic expression of disease in HLA-B27 positive individuals.
Iron Deficiencies
Iron-independent phosphorylation of iron regulatory protein 2 regulates ferritin during the cell cycle.
Iron Deficiencies
Phosphorylation and Proteasome Recognition of the mRNA-Binding Protein Cth2 Facilitates Yeast Adaptation to Iron Deficiency.
Iron Deficiencies
Processes underlying the nutritional programming of embryonic development by iron deficiency in the rat.
Irritable Bowel Syndrome
Evaluation of ubiquitinated proteins by proteomics reveals the role of the ubiquitin proteasome system in the regulation of Grp75 and Grp78 chaperone proteins during intestinal inflammation.
Isaacs Syndrome
Inhibition of ubiquitin proteasome system rescues the defective sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA1) protein causing Chianina cattle pseudomyotonia.
Ischemic Attack, Transient
Altered expression levels of SEF-2 and p112 in the rat hippocampus after transient cerebral ischemia: identification by mRNA differential display.
Ischemic Attack, Transient
Protein aggregation and proteasome dysfunction after brain ischemia.
Ischemic Stroke
Genetic association between inflammatory genes (IL-1?, CD14, LGALS2, PSMA6) and risk of ischemic stroke: A meta-analysis.
Ischemic Stroke
Ginsenoside Rd attenuates blood-brain barrier damage by suppressing proteasome-mediated signaling after transient forebrain ischemia.
Ischemic Stroke
Ginsenoside Rd Is Efficacious Against Acute Ischemic Stroke by Suppressing Microglial Proteasome-Mediated Inflammation.
Ischemic Stroke
Immunologic aspects of protein degradation by the ubiquitin-proteasome system.
Ischemic Stroke
The proteasome system and proteasome inhibitors in stroke: controlling the inflammatory response.
Ischemic Stroke
The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.
Ischemic Stroke
[Frequency of allele polymorphism of immune proteasome catalytic subunits in patients with ischemic stroke].
Keratosis
siRNA silencing of proteasome maturation protein (POMP) activates the unfolded protein response and constitutes a model for KLICK genodermatosis.
Kidney Diseases
Monoclonal gammopathy-associated pauci-immune extracapillary-proliferative glomerulonephritis successfully treated with bortezomib.
Kidney Failure, Chronic
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
Kidney Failure, Chronic
Oxidized LDL Modulates Apoptosis of Regulatory T Cells in Patients with ESRD.
Kidney Failure, Chronic
Renal cytoplasmic proteasome proteinase activities are altered in chronic renal failure.
Kidney Neoplasms
Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells.
Kidney Neoplasms
Delanzomib Interacts with Ritonavir Synergistically to Cause Endoplasmic Reticulum Stress in Renal Cancer Cells.
Kidney Neoplasms
Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma.
Kidney Neoplasms
Emetine promotes VHL-independent degradation of hypoxia inducible factor-2{alpha} in clear cell renal carcinoma.
Kidney Neoplasms
Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells.
Kidney Neoplasms
Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
Kidney Neoplasms
Inhibition of the JNK signalling pathway enhances proteasome inhibitor-induced apoptosis of kidney cancer cells by suppression of BAG3 expression.
Kidney Neoplasms
Ritonavir Interacts With Bortezomib to Enhance Protein Ubiquitination and Histone Acetylation Synergistically in Renal Cancer Cells.
Kidney Neoplasms
Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
Kidney Neoplasms
The transcription levels and prognostic values of seven proteasome alpha subunits in human cancers.
Kidney Neoplasms
Thymoquinone Selectively Kills Hypoxic Renal Cancer Cells by Suppressing HIF-1?-Mediated Glycolysis.
Lafora Disease
Lafora disease fibroblasts exemplify the molecular interdependence between thioredoxin 1 and the proteasome in mammalian cells.
Lambert-Eaton Myasthenic Syndrome
Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome.
Laryngeal Neoplasms
[Proteasome inhibitor bortezomib sensitizes Hep-2 human laryngeal squamous cell carcinoma cells to ionizing radiation in vitro and in vivo]
Leber Congenital Amaurosis
Temperature sensitive retinoid isomerase activity of RPE65 mutants associated with Leber congenital amaurosis.
Leiomyoma
Accumulation of retinoid X receptor-alpha in uterine leiomyomas is associated with a delayed ligand-dependent proteasome-mediated degradation and an alteration of its transcriptional activity.
Leiomyoma
Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.
Leiomyosarcoma
Characterization of Leiomyomatoid Angiomatous Neuroendocrine Tumour (LANT)-like Tumour in the Myometrium with Histopathological Examination.
Leiomyosarcoma
High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas.
Leishmaniasis
An Overview on the Therapeutics of Neglected Infectious Diseases-Leishmaniasis and Chagas Diseases.
Leishmaniasis
Anti-Trypanosomal Proteasome Inhibitors Cure Hemolymphatic and Meningoencephalic Murine Infection Models of African Trypanosomiasis.
Leishmaniasis
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.
Leishmaniasis
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness.
Leishmaniasis, Visceral
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.
Leishmaniasis, Visceral
Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis.
Leprosy
The proteasome function is required for Mycobacterium leprae-induced apoptosis and cytokine secretion.
Leukemia
A combination of retinoic acid and proteasome inhibitors for the treatment of leukemias is potentially dangerous.
Leukemia
A natural musaceas plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells.
Leukemia
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.
Leukemia
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Leukemia
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
Leukemia
A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Leukemia
Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
Leukemia
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
Leukemia
Analysis of changes in the proteome of HL-60 promyeloid leukemia cells induced by the proteasome inhibitor PSI.
Leukemia
Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
Leukemia
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Leukemia
Antiproliferative Properties of a Few Auranofin-Related Gold(I) and Silver(I) Complexes in Leukemia Cells and their Interferences with the Ubiquitin Proteasome System.
Leukemia
Apoptosis induction through proteasome inhibitory activity of cucurbitacin D in human T-Cell leukemia.
Leukemia
Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl?dependent mechanisms.
Leukemia
Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
Leukemia
Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase.
Leukemia
ASB2 is an Elongin BC-interacting protein that can assemble with Cullin 5 and Rbx1 to reconstitute an E3 ubiquitin ligase complex.
Leukemia
Assessment of circulating proteasome chymotrypsin-like activity in plasma of patients with acute and chronic leukemias.
Leukemia
Bcl-2 antibodies induce hemoglobin release by red blood cells loaded with in vitro translated Bcl-2 and its cleaved fragment.
Leukemia
BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
Leukemia
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Leukemia
Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.
Leukemia
Bortezomib Targets the Caspase-Like Proteasome Activity in Cervical Cancer Cells, Triggering Apoptosis That Can be Enhanced by Nelfinavir.
Leukemia
Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.
Leukemia
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
Leukemia
Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma.
Leukemia
Converting redox signaling to apoptotic activities by stress-responsive regulators HSF1 and NRF2 in fenretinide treated cancer cells.
Leukemia
Dasmahapatra G, Rahmani M, Dent P, Grant S. The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. Blood. 2006;107(1):232-240.
Leukemia
Detection of O-propargyl-puromycin with SUMO and ubiquitin by click chemistry at PML-nuclear bodies during abortive proteasome activities.
Leukemia
Deubiquitinating enzyme inhibitor alleviates cyclin A1-mediated proteasome inhibitor tolerance in mixed-lineage leukemia.
Leukemia
Development of novel compounds to treat autoimmune and inflammatory diseases and graft versus host reactions.
Leukemia
Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells.
Leukemia
Disruption of the menin-MLL interaction triggers menin protein degradation via ubiquitin-proteasome pathway.
Leukemia
Down-modulation of poly(ADP-ribose) polymerase-1 (PARP-1) in human TUR leukemia cells restores transcriptional responsiveness for differentiation and cell cycle arrest.
Leukemia
Effect of ajoene, a natural antitumor small molecule, on human 20S proteasome activity in vitro and in human leukemic HL60 cells.
Leukemia
Establishment of a human cell line stably overexpressing mouse Nip45 and characterization of Nip45 subcellular localization.
Leukemia
Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Leukemia
Exosomes mediate intercellular transfer of non-autonomous tolerance to proteasome inhibitors in mixed-lineage leukemia.
Leukemia
Extracellular polyphosphate signals through Ras and Akt to prime Dictyostelium discoideum cells for development.
Leukemia
Genistein induces topoisomerase IIbeta- and proteasome-mediated DNA sequence rearrangements: Implications in infant leukemia.
Leukemia
Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition.
Leukemia
Hemidesmus indicus induces apoptosis via proteasome inhibition and generation of reactive oxygen species.
Leukemia
Higher ratio immune vs. constitutive proteasome level as novelindicator of sensitivity of pediatric acute leukemia cells to proteasomeinhibitors.
Leukemia
Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
Leukemia
Human THP-1 monocytic leukemic cells induced to undergo monocytic differentiation by bryostatin 1 are refractory to proteasome inhibitor-induced apoptosis.
Leukemia
Impaired bortezomib binding to mutant ?5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Leukemia
Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors.
Leukemia
Induction of tumor cell apoptosis by taurine Schiff base copper complex is associated with the inhibition of proteasomal activity.
Leukemia
Inhibition of 20 S and 26 S proteasome activity by lithium chloride: impact on the differentiation of leukemia cells by all-trans retinoic acid.
Leukemia
Inhibition of all-Trans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells.
Leukemia
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Leukemia
Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts.
Leukemia
Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts.
Leukemia
Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.
Leukemia
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Leukemia
MDM2 and promyelocytic leukemia antagonize each other through their direct interaction with p53.
Leukemia
Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
Leukemia
Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
Leukemia
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.
Leukemia
Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells.
Leukemia
p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
Leukemia
Pentoxifylline and the proteasome inhibitor MG132 induce apoptosis in human leukemia U937 cells through a decrease in the expression of Bcl-2 and Bcl-XL and phosphorylation of p65.
Leukemia
Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients.
Leukemia
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
Leukemia
Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies.
Leukemia
Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy.
Leukemia
Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma.
Leukemia
Poly-ADP ribose polymerase activates nuclear proteasome to degrade oxidatively damaged histones.
Leukemia
Positive feedback between NF-?B and TNF-? promotes leukemia-initiating cell capacity.
Leukemia
Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
Leukemia
Prevention of etoposide-induced apoptosis by proteasome inhibitors in a human leukemic cell line but not in fresh acute leukemia blasts. A differential role of NF-kappab activation.
Leukemia
Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
Leukemia
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Leukemia
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.
Leukemia
Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins.
Leukemia
Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation.
Leukemia
Proteasome inhibitor-induced cleavage of HSP90 is mediated by ROS generation and caspase 10-activation in human leukemic cells.
Leukemia
Proteasome inhibitors abolish cell death downstream of caspase activation during anti-microtubule drug-induced apoptosis in leukemia cells.
Leukemia
Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.
Leukemia
Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion.
Leukemia
Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells.
Leukemia
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Leukemia
Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.
Leukemia
Regulation of the nuclear proteasome activity in myelomonocytic human leukemia cells after adriamycin treatment.
Leukemia
Relationship between the methylation status of dietary flavonoids and their growth-inhibitory and apoptosis-inducing activities in human cancer cells.
Leukemia
Retroviruses have differing requirements for proteasome function in the budding process.
Leukemia
Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.
Leukemia
Sensitization of U937 leukemia cells to doxorubicin by the MG132 proteasome inhibitor induces an increase in apoptosis by suppressing NF-kappa B and mitochondrial membrane potential loss.
Leukemia
Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance.
Leukemia
Silencing c-Myc translation as a therapeutic strategy through targeting PI3K? and CK1? in hematological malignancies.
Leukemia
Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias.
Leukemia
Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs.
Leukemia
SPR imaging biosensor for the 20S proteasome: sensor development and application to measurement of proteasomes in human blood plasma.
Leukemia
Substrate-guided optimization of the syringolins yields potent proteasome inhibitors with activity against leukemia cell lines.
Leukemia
SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome.
Leukemia
Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade.
Leukemia
Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib.
Leukemia
The coiled-coil domain is the structural determinant for mammalian homologues of Drosophila Sina-mediated degradation of promyelocytic leukemia protein and other tripartite motif proteins by the proteasome.
Leukemia
The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.
Leukemia
The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.
Leukemia
The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.
Leukemia
The PML nuclear bodies-associated protein TTRAP regulates ribosome biogenesis in nucleolar cavities upon proteasome inhibition.
Leukemia
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Leukemia
The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
Leukemia
The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism.
Leukemia
TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.
Leukemia
TP-110, a new proteasome inhibitor, down-regulates IAPs in human multiple myeloma cells.
Leukemia
Ubash3b promotes TPA-mediated suppression of leukemogenesis through accelerated downregulation of PKC? protein.
Leukemia
Ubiquitylation and destruction of endogenous c-mycS by the proteasome: are myc boxes dispensable?
Leukemia
Uncovering the SUMOylation and ubiquitylation crosstalk in human cells using sequential peptide immunopurification.
Leukemia
Vincristine and bortezomib cause axon outgrowth and behavioral defects in larval zebrafish.
Leukemia
VLX1570 induces apoptosis through the generation of ROS and induction of ER stress on leukemia cell lines.
Leukemia
WITHDRAWN: Evidence for the critical roles of NF-?B p65 and specificity proteins in the apoptosis-inducing activity of proteasome inhibitors in leukemia cells.
Leukemia
[Effect of Velcade on the gene expression profiles of K562 cells: study of its molecular mechanism.]
Leukemia
[Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia].
Leukemia
[Effects of proteasome inhibitor bortezomib on NF-kappaB activity and icam-1 mRNA expression of k562 cells.]
Leukemia
[Mechanism of G2/M cell cycle arrest before apoptosis in leukemia cell line HL-60 induced by proteasome inhibitor MG132]
Leukemia
[Rabdocoetsin B, a diterpenoid isolated from Isodon coetsa, is a potential proteasome inhibitor and induced apoptosis of t(8;21) leukemia cells]
Leukemia
[Role of MG132, a proteasome inhibitor, in inducing expression of costimulatory molecules CD86 in leukemic cells and its effect on allogeneic mixed lymphocyte reaction]
Leukemia
[Successful disease control of plasma cell leukemia by the treatment comprising proteasome inhibitors, followed by daratumumab, lenalidomide, and dexamethasone therapy].
Leukemia L1210
Lactacystin, a proteasome inhibitor, potentiates the apoptotic effect of parthenolide, an inhibitor of NFkappaB activation, on drug-resistant mouse leukemia L1210 cells.
Leukemia P388
Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo.
Leukemia, Erythroblastic, Acute
26S multicatalytic proteinase complexes decrease during the differentiation of murine erythroleukemia cells.
Leukemia, Erythroblastic, Acute
A novel ATP-requiring protease from skeletal muscle that hydrolyzes non-ubiquitinated proteins.
Leukemia, Erythroblastic, Acute
EKLF/KLF1 is ubiquitinated in vivo and its stability is regulated by activation domain sequences through the 26S proteasome.
Leukemia, Erythroblastic, Acute
Inducible p27(Kip1) expression inhibits proliferation of K562 cells and protects against apoptosis induction by proteasome inhibitors.
Leukemia, Erythroblastic, Acute
Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail.
Leukemia, Erythroblastic, Acute
[Induction of apoptosis by proteasome inhibitor MG-132 in human erythroleukemia cell line K562.]
Leukemia, Large Granular Lymphocytic
Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias.
Leukemia, Large Granular Lymphocytic
TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
?-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation.
Leukemia, Lymphocytic, Chronic, B-Cell
Development of the proteasome inhibitor Velcade (Bortezomib).
Leukemia, Lymphocytic, Chronic, B-Cell
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
Leukemia, Lymphocytic, Chronic, B-Cell
Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2.
Leukemia, Lymphocytic, Chronic, B-Cell
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.
Leukemia, Lymphocytic, Chronic, B-Cell
Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
The Proteasome Inhibitor Carfilzomib Functions Independently of p53 To Induce Cytotoxicity and an Atypical NF-?B Response in Chronic Lymphocytic Leukemia Cells.
Leukemia, Lymphocytic, Chronic, B-Cell
The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.
Leukemia, Lymphocytic, Chronic, B-Cell
ZGDHu-1 and fludarabine have a synergistic effect on apoptosis of chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
[Effect of nuclear transcription factor RelB on the proteasome inhibitor-sensitivity of chronic lymphocytic leukemia cells].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Development of novel compounds to treat autoimmune and inflammatory diseases and graft versus host reactions.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Proteasome inhibitor MG-132 enhances histone deacetylase inhibitor SAHA-induced cell death of chronic myeloid leukemia cells by an ROS-mediated mechanism and downregulation of the Bcr-Abl fusion protein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukemia and multiple myeloma.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Proteasome proteolytic profile is linked to Bcr-Abl expression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Effect of Bortezomib on Reverse Multidrug Resistance and XIAP Expression in Imatinib-resistant Primary Cells of Chronic Myeloid Leukemia in Blastic Crisis].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Effects of proteasome inhibitors on leukemias]
Leukemia, Myeloid
Inhibition of all-Trans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells.
Leukemia, Myeloid
Poly-ADP ribose polymerase activates nuclear proteasome to degrade oxidatively damaged histones.
Leukemia, Myeloid
Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.
Leukemia, Myeloid
Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukemia and multiple myeloma.
Leukemia, Myeloid
Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I.
Leukemia, Myeloid
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
Leukemia, Myeloid
The nanoparticulate Quillaja saponin KGI exerts anti-proliferative effects by down-regulation of cell cycle molecules in U937 and HL-60 human leukemia cells.
Leukemia, Myeloid
[Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor]
Leukemia, Myeloid
[Knockdown of proteasome subunit ?7 with small interfering RNA inhibits cell proliferation of K562 cell line].
Leukemia, Myeloid, Acute
A new gold(I) complex-Au(PPh3)PT is a deubiquitinase inhibitor and inhibits tumor growth.
Leukemia, Myeloid, Acute
A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.
Leukemia, Myeloid, Acute
Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
Leukemia, Myeloid, Acute
Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-?B and the accumulation of MCL-1.
Leukemia, Myeloid, Acute
CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia.
Leukemia, Myeloid, Acute
CDK2 destabilizes tumor suppressor C/EBP? expression through ubiquitin-mediated proteasome degradation in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth.
Leukemia, Myeloid, Acute
High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.
Leukemia, Myeloid, Acute
Higher ratio immune vs. constitutive proteasome level as novelindicator of sensitivity of pediatric acute leukemia cells to proteasomeinhibitors.
Leukemia, Myeloid, Acute
Human Telomerase Reverse Transcriptase (hTERT) Positively Regulates 26S Proteasome Activity.
Leukemia, Myeloid, Acute
Inhibition of all-Trans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3-ITD-driven acute myeloid leukemia.
Leukemia, Myeloid, Acute
Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
Leukemia, Myeloid, Acute
Proteasome chymotrypsin-like activity in plasma as a useful marker for children with acute lymphoblastic leukemia.
Leukemia, Myeloid, Acute
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.
Leukemia, Myeloid, Acute
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Leukemia, Myeloid, Acute
Proteasome Inhibition Specifically Sensitizes Leukemic Cells to Anthracyclin-Induced Apoptosis through the Accumulation of Bim and Bax Pro-Apoptotic Proteins.
Leukemia, Myeloid, Acute
Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: A correlation with the proteasome status.
Leukemia, Myeloid, Acute
Regulation of the nuclear proteasome activity in myelomonocytic human leukemia cells after adriamycin treatment.
Leukemia, Myeloid, Acute
Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.
Leukemia, Myeloid, Acute
Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.
Leukemia, Myeloid, Acute
Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I.
Leukemia, Myeloid, Acute
Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1.
Leukemia, Myeloid, Acute
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Leukemia, Myeloid, Acute
The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism.
Leukemia, Myeloid, Acute
The ubiquitin-proteasome pathway plays essential roles in ATRA-induced leukemia cells G(0)/G(1) phase arrest and transition into granulocytic differentiation.
Leukemia, Myeloid, Acute
TRIB3 destabilizes tumor suppressor PPAR? expression through ubiquitin-mediated proteasome degradation in acute myeloid leukemia.
Leukemia, Myeloid, Acute
[Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism].
Leukemia, Plasma Cell
Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion.
Leukemia, Plasma Cell
[Successful disease control of plasma cell leukemia by the treatment comprising proteasome inhibitors, followed by daratumumab, lenalidomide, and dexamethasone therapy].
Leukemia, Promyelocytic, Acute
Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
Leukemia, Promyelocytic, Acute
Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl?dependent mechanisms.
Leukemia, Promyelocytic, Acute
Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
Leukemia, Promyelocytic, Acute
Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase.
Leukemia, Promyelocytic, Acute
Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.
Leukemia, T-Cell
Apoptosis induction through proteasome inhibitory activity of cucurbitacin D in human T-Cell leukemia.
Leukemia, T-Cell
Apoptosis induction through proteasome inhibitory activity of cucurbitacin D in human T-cell leukemia.
Leukemia, T-Cell
Outfoxing FoxO transcription factors: HTLV-1 Tax oncoprotein inactivates FoxO4 via the ubiquitin-proteasome pathway.
Leukemia, T-Cell
PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells.
Leukemia, T-Cell
Stable ubiquitination of human T-cell leukemia virus type 1 tax is required for proteasome binding.
Leukemia, T-Cell
The human T-cell leukemia virus type 1 oncoprotein tax controls forkhead box O4 activity through degradation by the proteasome.
Leukemia, T-Cell
Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.
Leukemia-Lymphoma, Adult T-Cell
A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells.
Leukemia-Lymphoma, Adult T-Cell
Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.
Leukemia-Lymphoma, Adult T-Cell
Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
Leukemia-Lymphoma, Adult T-Cell
[Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells]
Leukocytosis
Proteasome chymotrypsin-like activity in plasma as a useful marker for children with acute lymphoblastic leukemia.
Leukocytosis
Systemic Proteasome Inhibition Induces Sustained Post-stroke Neurological Recovery and Neuroprotection via Mechanisms Involving Reversal of Peripheral Immunosuppression and Preservation of Blood-Brain-Barrier Integrity.
Lewy Body Disease
Multicatalytic proteinase is present in Lewy bodies and neurofibrillary tangles in diffuse Lewy body disease brains.
Lewy Body Disease
Polyubiquitin linkage profiles in three models of proteolytic stress suggest the etiology of Alzheimer disease.
Lewy Body Disease
Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture.
Lewy Body Disease
Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia.
Lewy Body Disease
T-Type Ca2+ Enhancer SAK3 Activates CaMKII and Proteasome Activities in Lewy Body Dementia Mice Model.
Lipodystrophy
Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production.
Lipodystrophy
Heterozygous Truncating Variants in POMP Escape Nonsense-Mediated Decay and Cause a Unique Immune Dysregulatory Syndrome.
Lipodystrophy
Mutations in proteasome subunit ? type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity.
Lipodystrophy
PSMB8 encoding the ?5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome.
Lipodystrophy
The human immunodeficiency virus (HIV1) protease inhibitor sanquinavir activates autophagy and removes lipids deposited in lipid droplets.
Liposarcoma
Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Liposarcoma
Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas.
Liposarcoma
Preferential cytotoxicity of bortezomib toward highly malignant human liposarcoma cells via suppression of MDR1 expression and function.
Liver Cirrhosis
Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
Liver Cirrhosis
Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis.
Liver Cirrhosis
Role of CYP2E1 activity in endoplasmic reticulum ubiquitination, proteasome association, and the unfolded protein response.
Liver Cirrhosis, Biliary
Proteasome is required for class I-restricted presentation by Fcgamma receptor-mediated endocytosis in primary biliary cirrhosis.
Liver Diseases
A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation.
Liver Diseases
Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis.
Liver Diseases
Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity.
Liver Diseases
Nutrigenomics of high fat diet induced obesity in mice suggests relationships between susceptibility to fatty liver disease and the proteasome.
Liver Diseases
Regulation of stathmin phosphorylation in mouse liver progenitor-29 cells during proteasome inhibition.
Liver Diseases
Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance.
Liver Diseases, Alcoholic
Decreased proteasome activity is associated with increased severity of liver pathology and oxidative stress in experimental alcoholic liver disease.
Liver Diseases, Alcoholic
Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease.
Liver Diseases, Alcoholic
Epigenetics of proteasome inhibition in the liver of rats fed ethanol chronically.
Liver Diseases, Alcoholic
Implication of altered proteasome function in alcoholic liver injury.
Liver Diseases, Alcoholic
Inhibition of proteasome function leads to NF-kappaB-independent IL-8 expression in human hepatocytes.
Liver Diseases, Alcoholic
Modifications in P62 occur due to proteasome inhibition in alcoholic liver disease.
Liver Diseases, Alcoholic
Proteasome inhibitor up regulates liver antioxidative enzymesin rat model of alcoholic liver disease.
Liver Diseases, Alcoholic
The effect of CYP2E1-dependent oxidant stress on activity of proteasomes in HepG2 cells.
Liver Diseases, Alcoholic
The Importance of CYP2E1 in the Pathogenesis of Alcoholic Liver Disease and Drug Toxicity and the Role of the Proteasome.
Liver Diseases, Alcoholic
[An experimental study on the relationship between proteasome LMP7 subunit and alcoholic liver disease]
Liver Failure, Acute
Caspase-cleaved cytokeratin 18 and 20 S proteasome in liver degeneration.
Liver Neoplasms
A tumor-suppressive circular RNA mediates uncanonical integrin degradation by the proteasome in liver cancer.
Liver Neoplasms
Activation of the ubiquitin proteasome pathway by silk fibroin modified chitosan nanoparticles in hepatic cancer cells.
Liver Neoplasms
Combination treatment with bortezomib and thiostrepton is effective against tumor formation in mouse models of DEN/PB-induced liver carcinogenesis.
Liver Neoplasms
Core and specific network markers of carcinogenesis from multiple cancer samples.
Liver Neoplasms
Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein.
Liver Neoplasms
ONX0912, a selective oral proteasome inhibitor, triggering mitochondrial apoptosis and mitophagy in liver cancer.
Liver Neoplasms
Reciprocal REG?-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma.
Liver Neoplasms
Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.
Liver Neoplasms
The ubiquitin-proteasome 26s pathway in liver cell protein turnover: effect of ethanol and drugs.
Liver Neoplasms
TRIB2 modulates proteasome function to reduce ubiquitin stability and protect liver cancer cells against oxidative stress.
Lung Diseases
Proteasome inhibition promotes autophagy and protects from endoplasmic reticulum stress in rat alveolar macrophages exposed to hypoxia-reoxygenation injury.
Lung Diseases
Proteasomes in lungs from organ donors and patients with end-stage pulmonary diseases.
Lung Diseases
Regulation of the Proteasome: Evaluating the Lung Proteasome as a New Therapeutic Target.
Lung Diseases
The emerging role of the ubiquitin proteasome in pulmonary biology and disease.
Lung Diseases
Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis.
Lung Diseases
What shall we do with the damaged proteins in lung disease? Ask the proteasome!
Lung Diseases, Interstitial
Proteasome dysfunction inhibits surfactant protein gene expression in lung epithelial cells: mechanism of inhibition of SP-B gene expression.
Lung Injury
IFN-beta mediates coordinate expression of antigen-processing genes in RSV-infected pulmonary epithelial cells.
Lung Injury
Proteasome inhibition attenuates lung injury induced by intestinal ischemia reperfusion in rats.
Lung Injury
Proteasome inhibitor ameliorates severe acute pancreatitis and associated lung injury of rats.
Lung Injury
[Effect of the proteasome inhibitor MG-132 on hyperoxic lung injury and its mechanism in rats]
Lung Injury
[Protective effect of proteasome inhibitor MG-132 in rats with severe acute pancreatitis and lung injury]
Lung Neoplasms
26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro.
Lung Neoplasms
4-Nitroquinoline-1-oxide effects human lung adenocarcinoma A549 cells by regulating the expression of POLD4.
Lung Neoplasms
A Bowman-Birk type chymotrypsin inhibitor peptide from the amphibian, Hylarana erythraea.
Lung Neoplasms
A new gold(I) complex-Au(PPh3)PT is a deubiquitinase inhibitor and inhibits tumor growth.
Lung Neoplasms
A Trib2-p38 axis controls myeloid leukaemia cell cycle and stress response signalling.
Lung Neoplasms
An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro.
Lung Neoplasms
Assessment of Apoptosis-Inducing Effects of Docetaxel Combined with the Proteasome Inhibitor PS-341 in Human Lung Cancer Cells.
Lung Neoplasms
Association between TGM5, PPAP2B and PSMA4 polymorphisms and NSCLC in never-smoking Chinese population.
Lung Neoplasms
Association of PSMA4 polymorphisms with lung cancer susceptibility and response to cisplatin-based chemotherapy in a Chinese Han population.
Lung Neoplasms
Autophagy Regulated by Gain of Function Mutant p53 Enhances Proteasomal Inhibitor-Mediated Cell Death through Induction of ROS and ERK in Lung Cancer Cells.
Lung Neoplasms
Bcl-2 Family Proteins Contribute to Apoptotic Resistance in Lung Cancer Multicellular Spheroids.
Lung Neoplasms
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Lung Neoplasms
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
Lung Neoplasms
Bufalin derivative BF211 inhibits proteasome activity in human lung cancer cells in vitro by inhibiting ?1 subunit expression and disrupting proteasome assembly.
Lung Neoplasms
c-Myc down-regulation is involved in proteasome inhibitor-mediated enhancement of radiotherapeutic efficacy in non-small cell lung cancer.
Lung Neoplasms
cAMP signaling increases histone deacetylase 8 expression by inhibiting JNK-dependent degradation via autophagy and the proteasome system in H1299 lung cancer cells.
Lung Neoplasms
Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
Lung Neoplasms
Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
Lung Neoplasms
Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132.
Lung Neoplasms
Cell-line-specific high background in the Proteasome-Glo assay of proteasome trypsin-like activity.
Lung Neoplasms
CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice.
Lung Neoplasms
Changes in immunocytochemical detectability of proteasome epitopes depending on cell growth and fixation conditions of lung cancer cell lines.
Lung Neoplasms
Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Lung Neoplasms
Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.
Lung Neoplasms
Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
Lung Neoplasms
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
Lung Neoplasms
Curcumin suppresses the stemness of non-small cell lung cancer cells via promoting the nuclear-cytoplasm translocation of TAZ.
Lung Neoplasms
Cytochalasin E increased the sensitivity of human lung cancer A549?cells to bortezomib via inhibition of autophagy.
Lung Neoplasms
Deubiquitinase inhibition of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-?B inhibition and p53 reactivation in human lung cancer cells.
Lung Neoplasms
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Lung Neoplasms
Enhancing the efficiency of bortezomib conjugated to pegylated gold nanoparticles: an in vitro study on human pancreatic cancer cells and adenocarcinoma human lung alveolar basal epithelial cells.
Lung Neoplasms
ER stress suppresses DNA double-strand break repair and sensitizes tumor cells to ionizing radiation by stimulating proteasomal degradation of Rad51.
Lung Neoplasms
Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer.
Lung Neoplasms
Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers.
Lung Neoplasms
Expression and purification of a rapidly degraded protein, TMEM8B-a, in mammalian cell line.
Lung Neoplasms
Fucoidan inhibition of lung cancer in vivo and in vitro : role of the Smurf2-dependent ubiquitin proteasome pathway in TGF? receptor degradation.
Lung Neoplasms
Functioning of Proteasomes in Lymphogenic Metastasizing of Non-Small-Cell Lung Cancer.
Lung Neoplasms
Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?
Lung Neoplasms
Histone deacetylase, proteasome, and heat shock protein inhibitors for the treatment of lung cancer.
Lung Neoplasms
Identification of differentially expressed genes and pathways crosstalk analysis in Rheumatoid and Osteoarthritis using next-generation sequencing and protein-protein networks.
Lung Neoplasms
Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer.
Lung Neoplasms
Impairment of the Ubiquitin-Proteasome Pathway by Methyl N-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells: A NOVEL ANTIPROLIFERATIVE AGENT WITH A POTENTIAL THERAPEUTIC IMPLICATION.
Lung Neoplasms
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Lung Neoplasms
Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.
Lung Neoplasms
KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
Lung Neoplasms
LC-MS/MS-Based Quantitative Proteomics Analysis of Different Stages of Non-Small-Cell Lung Cancer.
Lung Neoplasms
Ligand independent aryl hydrocarbon receptor inhibits lung cancer cell invasion by degradation of Smad4.
Lung Neoplasms
Lovastatin overcomes gefitinib resistance through TNF-? signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
Lung Neoplasms
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
Lung Neoplasms
MG132 as a proteasome inhibitor induces cell growth inhibition and cell death in A549 lung cancer cells via influencing reactive oxygen species and GSH level.
Lung Neoplasms
MG132, a proteasome inhibitor decreased the growth of Calu-6 lung cancer cells via apoptosis and GSH depletion.
Lung Neoplasms
MG132, a proteasome inhibitor, induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion.
Lung Neoplasms
Mitogen-activated protein kinase inhibitors differently affect the growth inhibition and death of a proteasome inhibitor, carbobenzoxy-Leu-Leu-leucinal-treated human pulmonary fibroblast cells.
Lung Neoplasms
Nitric oxide confers cisplatin resistance in human lung cancer cells through upregulation of aldo-keto reductase 1B10 and proteasome.
Lung Neoplasms
Pharmacological Strategies in Lung Cancer-Induced Cachexia: Effects on Muscle Proteolysis, Autophagy, Structure, and Weakness.
Lung Neoplasms
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
Lung Neoplasms
Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553).
Lung Neoplasms
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
Lung Neoplasms
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade((R))) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
Lung Neoplasms
Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
Lung Neoplasms
Pre-cachexia in patients with stages I-III non-small cell lung cancer: Systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system.
Lung Neoplasms
Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas.
Lung Neoplasms
Proteasome inhibition boosts autophagic degradation of ubiquitinated-AGR2 and enhances the antitumor efficiency of bevacizumab.
Lung Neoplasms
Proteasome inhibition by MG132 induces growth inhibition and death of human pulmonary fibroblast cells in a caspase-independent manner.
Lung Neoplasms
Proteasome inhibition improves fractionated radiation treatment against non-small cell lung cancer: an antioxidant connection.
Lung Neoplasms
Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.
Lung Neoplasms
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Lung Neoplasms
Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Lung Neoplasms
Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer.
Lung Neoplasms
Proteasome inhibitor MG132 enhances the antigrowth and antimetastasis effects of radiation in human nonsmall cell lung cancer cells.
Lung Neoplasms
Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling.
Lung Neoplasms
Proteasome Inhibitor YSY01A Abrogates Constitutive STAT3 Signaling via Down-regulation of Gp130 and JAK2 in Human A549 Lung Cancer Cells.
Lung Neoplasms
Proteasome Inhibitor-Induced I?B/NF-?B Activation is Mediated by Nrf2-Dependent Light Chain 3B Induction in Lung Cancer Cells.
Lung Neoplasms
Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer.
Lung Neoplasms
Proteasome inhibitors diminish c-Met expression and induce cell death in non-small cell lung cancer cells.
Lung Neoplasms
Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation.
Lung Neoplasms
Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent Mcl-1 protein cleavage.
Lung Neoplasms
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
Lung Neoplasms
Proteasome-dependent degradation of Smad7 is critical for lung cancer metastasis.
Lung Neoplasms
Proteasome-Independent Protein Knockdown by Small-Molecule Inhibitor for the Undruggable Lung Adenocarcinoma.
Lung Neoplasms
Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Lung Neoplasms
Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.
Lung Neoplasms
Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy.
Lung Neoplasms
Silencing Core Spliceosome Sm Gene Expression Induces a Cytotoxic Splicing Switch in the Proteasome Subunit Beta 3 mRNA in Non-Small Cell Lung Cancer Cells.
Lung Neoplasms
Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity.
Lung Neoplasms
Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy.
Lung Neoplasms
SPOP promotes FADD degradation and inhibits NF-?B activity in non-small cell lung cancer.
Lung Neoplasms
Sulforaphane Induced Apoptosis via Promotion of Mitochondrial Fusion and ERK1/2-Mediated 26S Proteasome Degradation of Novel Pro-survival Bim and Upregulation of Bax in Human Non-Small Cell Lung Cancer Cells.
Lung Neoplasms
Sulforaphane metabolites reduce resistance to paclitaxel via microtubule disruption.
Lung Neoplasms
Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.
Lung Neoplasms
Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia.
Lung Neoplasms
Systemic inflammation in chronic obstructive pulmonary disease and lung cancer: common driver of pulmonary cachexia?
Lung Neoplasms
The attenuation of MG132, a proteasome inhibitor, induced A549 lung cancer cell death by p38 inhibitor in ROS-independent manner.
Lung Neoplasms
The effects of N-acetyl cysteine on the MG132 proteasome inhibitor-treated lung cancer cells in relation to cell growth, reactive oxygen species and glutathione.
Lung Neoplasms
The potential role of proteasome inhibitors in the treatment of lung cancer.
Lung Neoplasms
The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.
Lung Neoplasms
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Lung Neoplasms
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Lung Neoplasms
The ubiquitin-interacting motif of 26S proteasome subunit S5a induces A549 lung cancer cell death.
Lung Neoplasms
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
Lung Neoplasms
Treatment with p38 inhibitor partially prevents Calu-6 lung cancer cell death by a proteasome inhibitor, MG132.
Lung Neoplasms
Updated review and perspective on 20S proteasome inhibitors in the treatment of Lung Cancer.
Lung Neoplasms
What shall we do with the damaged proteins in lung disease? Ask the proteasome!
Lupus Erythematosus, Systemic
Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis.
Lupus Erythematosus, Systemic
Autoantibodies against the multicatalytic proteinase in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Autoantibodies in primary Sjögren's syndrome are directed against proteasomal subunits of the alpha and beta type.
Lupus Erythematosus, Systemic
Bioinformatics analysis of the CDK2 functions in neuroblastoma.
Lupus Erythematosus, Systemic
Circulating 20S proteasome levels in patients with mixed connective tissue disease and systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
Lupus Erythematosus, Systemic
New evidence for the role of proteasome inhibitors in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases.
Lupus Erythematosus, Systemic
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.
Lupus Nephritis
The Proteasome Inhibitor Bortezomib Prevents Lupus Nephritis in the NZB/W F1 Mouse Model by Preservation of Glomerular and Tubulointerstitial Architecture.
Lupus Nephritis
[Depletion of plasma cells - a novel strategy in the therapy of systemic lupus erythematosus in mice and man.]
Lymphocytic Choriomeningitis
CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting.
Lymphocytic Choriomeningitis
Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus.
Lymphocytic Choriomeningitis
Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver.
Lymphocytic Choriomeningitis
Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope.
Lymphocytic Choriomeningitis
Reduced immunoproteasome formation and accumulation of immunoproteasomal precursors in the brains of lymphocytic choriomeningitis virus-infected mice.
Lymphocytic Choriomeningitis
The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader-derived T cell epitope.
Lymphohistiocytosis, Hemophagocytic
A Novel Model for IFN-?-Mediated Autoinflammatory Syndromes.
Lymphoma
2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma.
Lymphoma
3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma.
Lymphoma
A combination regimen of low-dose bortezomib and rapamycin prolonged the graft survival in a murine allogeneic islet transplantation model.
Lymphoma
A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.
Lymphoma
A Multi-target Drug Designing for BTK, MMP9, Proteasome and TAK1 for the Clinical Treatment of Mantle Cell Lymphoma.
Lymphoma
A new large proteolytic complex distinct from the proteasome is present in the cytosol of fission yeast.
Lymphoma
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.
Lymphoma
A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
Lymphoma
A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma.
Lymphoma
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.
Lymphoma
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
Lymphoma
A Translational Physiologically Based Pharmacokinetics/Pharmacodynamics Framework of Target-Mediated Disposition, Target Inhibition and Drug-Drug Interactions of Bortezomib.
Lymphoma
Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.
Lymphoma
Amino- and chloro-8-hydroxyquinolines and their copper complexes as proteasome inhibitors and antiproliferative agents.
Lymphoma
Anti-Inflammatory and Immunomodulatory Effects of Bortezomib in Various in vivo Models.
Lymphoma
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Lymphoma
Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma.
Lymphoma
Blocking Autophagy Prevents Bortezomib-Induced NF-?B Activation by Reducing I-?B? Degradation in Lymphoma Cells.
Lymphoma
Bortezomib alleviates experimental pulmonary hypertension by regulating intracellular calcium homeostasis in PASMCs.
Lymphoma
Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and I?B? kinase downregulation.
Lymphoma
Bortezomib as a probable cause of the syndrome of inappropriate antidiuretic hormone secretion: A case report and review of the literature.
Lymphoma
Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.
Lymphoma
Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of epstein-barr virus infection.
Lymphoma
Bortezomib Induces the Formation of Nuclear poly(A) RNA Granules Enriched in Sam68 and PABPN1 in Sensory Ganglia Neurons.
Lymphoma
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
Lymphoma
Bortezomib prevents the expression of MMP-13 and the degradation of collagen type 2 in human chondrocytes.
Lymphoma
Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.
Lymphoma
Bortezomib therapy-related lung disease in a patient with light chain amyloidosis: A case report.
Lymphoma
Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.
Lymphoma
Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity.
Lymphoma
Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics.
Lymphoma
Bortezomib-loaded solid lipid nanoparticles: preparation, characterization, and intestinal permeability investigation.
Lymphoma
Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma.
Lymphoma
Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation.
Lymphoma
Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.
Lymphoma
Carfilzomib Interacts Synergistically With Histone Deacetylase Inhibitors In Mantle Cell Lymphoma Cells In Vitro And In Vivo.
Lymphoma
Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132.
Lymphoma
Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes.
Lymphoma
Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-?B signaling.
Lymphoma
Cloning and expression of a human pro(tea)some beta-subunit cDNA: a homologue of the yeast PRE4-subunit essential for peptidylglutamyl-peptide hydrolase activity.
Lymphoma
Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
Lymphoma
Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells.
Lymphoma
Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma.
Lymphoma
Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.
Lymphoma
Corrigendum to <'The ?-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis'> [Cellular Signalling 59 (2019) 76-84].
Lymphoma
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Lymphoma
DANFIN functions as an inhibitor of transcription factor NF-?B and potentiates the antitumor effect of bortezomib in multiple myeloma.
Lymphoma
Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
Lymphoma
Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
Lymphoma
Dissecting bortezomib: development, application, adverse effects and future direction.
Lymphoma
Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Lymphoma
Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Lymphoma
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Lymphoma
Effects of the proteasome inhibitor bortezomib in combination with chemotherapy for the treatment of mantle cell lymphoma: a meta-analysis
Lymphoma
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells.
Lymphoma
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Lymphoma
Function-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropica.
Lymphoma
Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition.
Lymphoma
Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib.
Lymphoma
Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.
Lymphoma
Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma (ENKTL).
Lymphoma
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.
Lymphoma
Identification of proteasome inhibitors using analysis of gene expression profiles.
Lymphoma
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
Lymphoma
Improved SILAC Quantification with Data-Independent Acquisition to Investigate Bortezomib-Induced Protein Degradation.
Lymphoma
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Lymphoma
Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.
Lymphoma
Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Lymphoma
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity.
Lymphoma
Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells.
Lymphoma
Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.
Lymphoma
Investigating Intestinal Permeability of Bortezomib Using a Validated HPLC-UV Method.
Lymphoma
Lercanidipine Synergistically Enhances Bortezomib Cytotoxicity in Cancer Cells via Enhanced Endoplasmic Reticulum Stress and Mitochondrial Ca2+ Overload.
Lymphoma
Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects.
Lymphoma
Light Chain Amyloidosis (AL) Associated With B Cell Lymphoma a Single Center Experience.
Lymphoma
Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy.
Lymphoma
M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (?5i) Delivering Efficacy in Multiple Myeloma Models.
Lymphoma
Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas.
Lymphoma
MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NF?B Activation in Breast Cancer.
Lymphoma
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
Lymphoma
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Lymphoma
Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
Lymphoma
MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.
Lymphoma
Mechanistic Rationale and Clinical Evidence for the Efficacy of Proteasome Inhibitors against Indolent and Mantle Cell Lymphomas.
Lymphoma
Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib.
Lymphoma
MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.
Lymphoma
Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
Lymphoma
Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice.
Lymphoma
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.
Lymphoma
Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor.
Lymphoma
Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Lymphoma
p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors.
Lymphoma
Peptidyl aldehyde inhibitors of proteasome induce apoptosis rapidly in mouse lymphoma RVC cells.
Lymphoma
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Lymphoma
Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.
Lymphoma
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
Lymphoma
Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.
Lymphoma
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Lymphoma
Polypropyleneimine and polyamidoamine dendrimer mediated enhanced solubilization of bortezomib: Comparison and evaluation of mechanistic aspects by thermodynamics and molecular simulations.
Lymphoma
Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
Lymphoma
Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
Lymphoma
Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
Lymphoma
Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
Lymphoma
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.
Lymphoma
Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus.
Lymphoma
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Lymphoma
Proteasome inhibition as a new therapeutic principle in hematological malignancies.
Lymphoma
Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation.
Lymphoma
Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells.
Lymphoma
Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem.
Lymphoma
Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells.
Lymphoma
Proteasome inhibitors induce auditory hair cell death through peroxisome dysfunction.
Lymphoma
Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.
Lymphoma
Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Lymphoma
Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas.
Lymphoma
Regulated Cell Death of Lymphoma Cells after Graded Mitochondrial Damage is Differentially Affected by Drugs Targeting Cell Stress Responses.
Lymphoma
Reply to the letter to the editor 'Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma' by Tan et al.
Lymphoma
Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for fas-mediated apoptosis in human leukemic cells.
Lymphoma
Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
Lymphoma
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas.
Lymphoma
Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs).
Lymphoma
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Lymphoma
Silencing c-Myc translation as a therapeutic strategy through targeting PI3K? and CK1? in hematological malignancies.
Lymphoma
Structure-based design of ?1i or ?5i specific inhibitors of human immunoproteasomes.
Lymphoma
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
Lymphoma
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Lymphoma
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Lymphoma
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Lymphoma
Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity And Induces Tumor Cell Death.
Lymphoma
Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.
Lymphoma
Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib.
Lymphoma
The ?-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis.
Lymphoma
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
Lymphoma
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Lymphoma
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
Lymphoma
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
Lymphoma
The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells.
Lymphoma
The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
Lymphoma
The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib.
Lymphoma
The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients with Advanced Solid Tumors or Lymphoma.
Lymphoma
The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group.
Lymphoma
The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.
Lymphoma
The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.
Lymphoma
The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
Lymphoma
The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development.
Lymphoma
The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma.
Lymphoma
The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
Lymphoma
The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells.
Lymphoma
The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
Lymphoma
The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis.
Lymphoma
The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma.
Lymphoma
The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
Lymphoma
Thiasyrbactins Induce Cell Death via Proteasome Inhibition in Multiple Myeloma Cells.
Lymphoma
TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.
Lymphoma
Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Lymphoma
Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model.
Lymphoma
Vincristine and bortezomib cause axon outgrowth and behavioral defects in larval zebrafish.
Lymphoma
Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment.
Lymphoma
[Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma]
Lymphoma
[Synergistic effects of proteasome inhibitor and histone deacetylase inhibitor on apoptosis and aggresome formation in T lymphoma cells.]
Lymphoma
[The modulating effect of proapoptotic protein Bax on the resistance of malignant lymphoma cells to tumor necrosis factor related apoptosis inducing ligand-induced apoptosis]
Lymphoma
[The proteasome?-?structural aspects and inhibitors: a second life for a validated drug target].
Lymphoma, B-Cell
BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells.
Lymphoma, B-Cell
Blocking Autophagy Prevents Bortezomib-Induced NF-?B Activation by Reducing I-?B? Degradation in Lymphoma Cells.
Lymphoma, B-Cell
Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
Lymphoma, B-Cell
Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
Lymphoma, B-Cell
Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.
Lymphoma, B-Cell
Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition.
Lymphoma, B-Cell
Heat stress triggers apoptosis by impairing NF-kappaB survival signaling in malignant B cells.
Lymphoma, B-Cell
Identification of collaborative activities with oxidative phosphorylation in bipolar disorder.
Lymphoma, B-Cell
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Lymphoma, B-Cell
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Lymphoma, B-Cell
MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.
Lymphoma, B-Cell
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells.
Lymphoma, B-Cell
Proteasomal inhibition triggers viral oncoprotein degradation via autophagy-lysosomal pathway.
Lymphoma, B-Cell
Proteasome Inhibitor MG132 is Toxic and Inhibits the Proliferation of Rat Neural Stem Cells but Increases BDNF Expression to Protect Neurons.
Lymphoma, B-Cell
Proteasome inhibitors and Smac mimetics cooperate to induce cell death in Diffuse Large B-cell Lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis.
Lymphoma, B-Cell
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.
Lymphoma, B-Cell
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
Lymphoma, B-Cell
The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.
Lymphoma, B-Cell
The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
Lymphoma, B-Cell
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Lymphoma, B-Cell
The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis.
Lymphoma, Follicular
Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma.
Lymphoma, Follicular
Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib.
Lymphoma, Large B-Cell, Diffuse
Blocking Autophagy Prevents Bortezomib-Induced NF-?B Activation by Reducing I-?B? Degradation in Lymphoma Cells.
Lymphoma, Large B-Cell, Diffuse
Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition.
Lymphoma, Large B-Cell, Diffuse
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Lymphoma, Large B-Cell, Diffuse
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Lymphoma, Large B-Cell, Diffuse
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Proteasome inhibitors and Smac mimetics cooperate to induce cell death in Diffuse Large B-cell Lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis.
Lymphoma, Large B-Cell, Diffuse
Proteasome inhibitors in the treatment of B-cell malignancies.
Lymphoma, Large B-Cell, Diffuse
The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis.
Lymphoma, Large B-Cell, Diffuse
[Dynamics of the Functional Activity and Expression of Proteasome Subunits during Cellular Adaptation to Heat Shock].
Lymphoma, Large-Cell, Anaplastic
Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma.
Lymphoma, Large-Cell, Anaplastic
Corrigendum to <'The ?-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis'> [Cellular Signalling 59 (2019) 76-84].
Lymphoma, Large-Cell, Anaplastic
The ?-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis.
Lymphoma, Mantle-Cell
2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma.
Lymphoma, Mantle-Cell
3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma.
Lymphoma, Mantle-Cell
A Multi-target Drug Designing for BTK, MMP9, Proteasome and TAK1 for the Clinical Treatment of Mantle Cell Lymphoma.
Lymphoma, Mantle-Cell
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.
Lymphoma, Mantle-Cell
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
Lymphoma, Mantle-Cell
A Translational Physiologically Based Pharmacokinetics/Pharmacodynamics Framework of Target-Mediated Disposition, Target Inhibition and Drug-Drug Interactions of Bortezomib.
Lymphoma, Mantle-Cell
Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.
Lymphoma, Mantle-Cell
Advances in the understanding of mechanisms and therapeutic use of bortezomib.
Lymphoma, Mantle-Cell
Anti-Inflammatory and Immunomodulatory Effects of Bortezomib in Various in vivo Models.
Lymphoma, Mantle-Cell
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Lymphoma, Mantle-Cell
Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Bortezomib alleviates experimental pulmonary hypertension by regulating intracellular calcium homeostasis in PASMCs.
Lymphoma, Mantle-Cell
Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and I?B? kinase downregulation.
Lymphoma, Mantle-Cell
Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.
Lymphoma, Mantle-Cell
Bortezomib therapy-related lung disease in a patient with light chain amyloidosis: A case report.
Lymphoma, Mantle-Cell
Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.
Lymphoma, Mantle-Cell
Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity.
Lymphoma, Mantle-Cell
Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics.
Lymphoma, Mantle-Cell
Bortezomib-loaded solid lipid nanoparticles: preparation, characterization, and intestinal permeability investigation.
Lymphoma, Mantle-Cell
Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.
Lymphoma, Mantle-Cell
Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation.
Lymphoma, Mantle-Cell
Carfilzomib Interacts Synergistically With Histone Deacetylase Inhibitors In Mantle Cell Lymphoma Cells In Vitro And In Vivo.
Lymphoma, Mantle-Cell
Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells.
Lymphoma, Mantle-Cell
Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes.
Lymphoma, Mantle-Cell
Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-?B signaling.
Lymphoma, Mantle-Cell
Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
Lymphoma, Mantle-Cell
Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells.
Lymphoma, Mantle-Cell
Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.
Lymphoma, Mantle-Cell
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Lymphoma, Mantle-Cell
DANFIN functions as an inhibitor of transcription factor NF-?B and potentiates the antitumor effect of bortezomib in multiple myeloma.
Lymphoma, Mantle-Cell
Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells.
Lymphoma, Mantle-Cell
Dissecting bortezomib: development, application, adverse effects and future direction.
Lymphoma, Mantle-Cell
Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
Lymphoma, Mantle-Cell
Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Lymphoma, Mantle-Cell
Effects of the proteasome inhibitor bortezomib in combination with chemotherapy for the treatment of mantle cell lymphoma: a meta-analysis
Lymphoma, Mantle-Cell
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells.
Lymphoma, Mantle-Cell
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Lymphoma, Mantle-Cell
Function-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropica.
Lymphoma, Mantle-Cell
Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib.
Lymphoma, Mantle-Cell
Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.
Lymphoma, Mantle-Cell
Identification of proteasome inhibitors using analysis of gene expression profiles.
Lymphoma, Mantle-Cell
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
Lymphoma, Mantle-Cell
Improved SILAC Quantification with Data-Independent Acquisition to Investigate Bortezomib-Induced Protein Degradation.
Lymphoma, Mantle-Cell
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Lymphoma, Mantle-Cell
Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Inhibition of autophagy enhances apoptosis induced by bortezomib in AML cells.
Lymphoma, Mantle-Cell
Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Lymphoma, Mantle-Cell
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity.
Lymphoma, Mantle-Cell
Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells.
Lymphoma, Mantle-Cell
Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.
Lymphoma, Mantle-Cell
Investigating Intestinal Permeability of Bortezomib Using a Validated HPLC-UV Method.
Lymphoma, Mantle-Cell
Lercanidipine Synergistically Enhances Bortezomib Cytotoxicity in Cancer Cells via Enhanced Endoplasmic Reticulum Stress and Mitochondrial Ca2+ Overload.
Lymphoma, Mantle-Cell
Long term remission in a case of Plasmablastic lymphoma treated with COMP (Cyclophosphamide, Liposomal Doxorubicin, Vincristine, Prednisone) and Bortezomib.
Lymphoma, Mantle-Cell
M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (?5i) Delivering Efficacy in Multiple Myeloma Models.
Lymphoma, Mantle-Cell
MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NF?B Activation in Breast Cancer.
Lymphoma, Mantle-Cell
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Lymphoma, Mantle-Cell
Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
Lymphoma, Mantle-Cell
MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.
Lymphoma, Mantle-Cell
Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib.
Lymphoma, Mantle-Cell
Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
Lymphoma, Mantle-Cell
Molecular pathways: targeting proteasomal protein degradation in cancer.
Lymphoma, Mantle-Cell
Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice.
Lymphoma, Mantle-Cell
Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.
Lymphoma, Mantle-Cell
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.
Lymphoma, Mantle-Cell
Patented small molecule inhibitors in the ubiquitin proteasome system.
Lymphoma, Mantle-Cell
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Lymphoma, Mantle-Cell
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Lymphoma, Mantle-Cell
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.
Lymphoma, Mantle-Cell
Polypropyleneimine and polyamidoamine dendrimer mediated enhanced solubilization of bortezomib: Comparison and evaluation of mechanistic aspects by thermodynamics and molecular simulations.
Lymphoma, Mantle-Cell
Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
Lymphoma, Mantle-Cell
Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
Lymphoma, Mantle-Cell
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.
Lymphoma, Mantle-Cell
Proteasome inhibition as a new therapeutic principle in hematological malignancies.
Lymphoma, Mantle-Cell
Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem.
Lymphoma, Mantle-Cell
Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.
Lymphoma, Mantle-Cell
Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.
Lymphoma, Mantle-Cell
Rational approaches to design of therapeutics targeting molecular markers.
Lymphoma, Mantle-Cell
Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Lymphoma, Mantle-Cell
Recent Advancements of Bortezomib in Acute Lymphocytic Leukemia Treatment.
Lymphoma, Mantle-Cell
Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for fas-mediated apoptosis in human leukemic cells.
Lymphoma, Mantle-Cell
Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
Lymphoma, Mantle-Cell
Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs).
Lymphoma, Mantle-Cell
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Structure-based design of ?1i or ?5i specific inhibitors of human immunoproteasomes.
Lymphoma, Mantle-Cell
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
Lymphoma, Mantle-Cell
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Lymphoma, Mantle-Cell
Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity And Induces Tumor Cell Death.
Lymphoma, Mantle-Cell
Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.
Lymphoma, Mantle-Cell
Targeting the ubiquitin proteasome system in haematological malignancies.
Lymphoma, Mantle-Cell
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Lymphoma, Mantle-Cell
The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells.
Lymphoma, Mantle-Cell
The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
Lymphoma, Mantle-Cell
The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib.
Lymphoma, Mantle-Cell
The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group.
Lymphoma, Mantle-Cell
The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.
Lymphoma, Mantle-Cell
The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
Lymphoma, Mantle-Cell
The molecular mechanisms of acquired proteasome inhibitor resistance.
Lymphoma, Mantle-Cell
The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma.
Lymphoma, Mantle-Cell
The proteasome and its inhibitors in immune regulation and immune disorders.
Lymphoma, Mantle-Cell
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.
Lymphoma, Mantle-Cell
The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
Lymphoma, Mantle-Cell
The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib.
Lymphoma, Mantle-Cell
The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
Lymphoma, Mantle-Cell
Thiasyrbactins Induce Cell Death via Proteasome Inhibition in Multiple Myeloma Cells.
Lymphoma, Mantle-Cell
Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Lymphoma, Mantle-Cell
Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model.
Lymphoma, Mantle-Cell
Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Lymphoma, Mantle-Cell
Vincristine and bortezomib cause axon outgrowth and behavioral defects in larval zebrafish.
Lymphoma, Mantle-Cell
Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment.
Lymphoma, Non-Hodgkin
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib.
Lymphoma, Non-Hodgkin
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
Lymphoma, Non-Hodgkin
Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
Lymphoma, Non-Hodgkin
Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.
Lymphoma, Non-Hodgkin
Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
Lymphoma, Non-Hodgkin
Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
Lymphoma, Non-Hodgkin
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
Lymphoma, Non-Hodgkin
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Lymphoma, Non-Hodgkin
Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.
Lymphoma, Non-Hodgkin
Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation.
Lymphoma, Non-Hodgkin
Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
Lymphoma, Non-Hodgkin
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Lymphoma, Non-Hodgkin
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies.
Lymphoma, Non-Hodgkin
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.
Lymphoma, Non-Hodgkin
Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside.
Lymphoma, Non-Hodgkin
Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
Retraction: In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells.
Lymphoma, Non-Hodgkin
Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance.
Lymphoma, Non-Hodgkin
Severe Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma: A Case Report and Review of the Literature.
Lymphoma, Non-Hodgkin
Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells.
Lymphoma, Non-Hodgkin
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Lymphoma, Non-Hodgkin
The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
Lymphoma, Non-Hodgkin
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.
Lymphoma, Primary Effusion
Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells.
Lymphoma, Primary Effusion
Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells.
Lymphoma, Primary Effusion
The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells.
Lymphoma, T-Cell
A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.
Lymphoma, T-Cell
Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma.
Lymphoma, T-Cell
Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.
Lymphoma, T-Cell
PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.
Lymphoma, T-Cell
Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC Dependent Cell Death in T-Cell and Hodgkin Lymphoma.
Lymphoma, T-Cell, Cutaneous
cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas.
Lymphoma, T-Cell, Cutaneous
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Proteasome inhibition as a novel mechanism of the proapoptotic activity of ?-secretase inhibitor I in cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Lymphoma, T-Cell, Peripheral
CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia.
Lymphoma, T-Cell, Peripheral
Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial.
Lymphoma, T-Cell, Peripheral
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
Lymphopenia
Differential expression of genes associated with T lymphocytes function in septic patients with hypoxemia challenge.
Lymphopenia
Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors.
Lymphoproliferative Disorders
Immunotherapeutic and immunoregulatory drugs in haematologic malignancies.
Machado-Joseph Disease
Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions.
Machado-Joseph Disease
Targeting Ubiquitin Proteasome Pathway with Traditional Chinese Medicine for Treatment of Spinocerebellar Ataxia Type 3.
Machado-Joseph Disease
Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3.
Macular Degeneration
Increased 26S proteasome non-ATPase regulatory subunit 1 in the aqueous humor of patients with age-related macular degeneration.
Macular Degeneration
Inhibition of Proteasome Activity Upregulates IL-6 Expression in RPE Cells through the Activation of P38 MAPKs.
Macular Degeneration
Transformation of the proteasome with age-related macular degeneration.
Malaria
A Proteasome Mutation Sensitizes P. falciparum Cam3.II K13C580Y Parasites to DHA and OZ439.
Malaria
Analysis of the Plasmodium falciparum proteasome using Blue Native PAGE and label-free quantitative mass spectrometry.
Malaria
Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome.
Malaria
Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents.
Malaria
Genetic differentiation at the 3'UTR of PROS-Ag25: a cDNA homologue of Drosophila melanogaster proteasome subunit PROS-Dm25 in the malaria vector Anopheles gambiae.
Malaria
Identification of Small Molecules Disrupting the Ubiquitin Proteasome System in Malaria.
Malaria
Improvement of Asparagine Ethylenediamines as Anti-malarial Plasmodium-Selective Proteasome Inhibitors.
Malaria
Investigating proteasome inhibitors as potential adjunct therapies for experimental cerebral malaria.
Malaria
Malaria parasites regulate intra-erythrocytic development duration via serpentine receptor 10 to coordinate with host rhythms.
Malaria
Mammalian Deubiquitinating Enzyme Inhibitors Display in Vitro and in Vivo Activity against Malaria Parasites and Potentiate Artemisinin Action.
Malaria
Multi-output Model with Box-Jenkins Operators of Quadratic Indices for Prediction of Malaria and Cancer Inhibitors Targeting Ubiquitin- Proteasome Pathway (UPP) Proteins.
Malaria
Polymorphisms of transporter associated with antigen processing type 1 (TAP1), proteasome subunit beta type 9 (PSMB9) and their common promoter in African children with different manifestations of malaria.
Malaria
Role of the Ubiquitin-Proteasome Systems in the Biology and Virulence of Protozoan Parasites.
Malaria
Structure- and function-based design of Plasmodium-selective proteasome inhibitors.
Malaria
The cryo-EM structure of the Plasmodium falciparum 20S proteasome and its use in the fight against malaria.
Malaria
The prokaryotic ClpQ protease plays a key role in growth and development of mitochondria in Plasmodium falciparum.
Malaria
The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target.
Malaria
The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium parasites.
Malaria
The proteasome of malaria parasites: A multi-stage drug target for chemotherapeutic intervention?
Malaria
Thiostrepton and derivatives exhibit antimalarial and gametocytocidal activity by dually targeting parasite proteasome and apicoplast.
Malaria
Transcriptional analysis identifies potential biomarkers and molecular regulators in acute malaria infection.
Malaria, Cerebral
Investigating proteasome inhibitors as potential adjunct therapies for experimental cerebral malaria.
Malnutrition
Processes underlying the nutritional programming of embryonic development by iron deficiency in the rat.
Malnutrition
Proteasome production in human muscle during nutritional inhibition of myofibrillar protein degradation.
Mania
Investigation of manic and euthymic episodes identifies state- and trait-specific gene expression and STAB1 as a new candidate gene for bipolar disorder.
Marek Disease
Marek's disease virus Meq oncoprotein interacts with chicken HDAC 1 and 2 and mediates their degradation via proteasome dependent pathway.
Mastocytoma
Genistein-induced apoptosis of p815 mastocytoma cells is mediated by Bax and augmented by a proteasome inhibitor, lactacystin.
Mastocytoma
Proteasome-driven turnover of tryptophan hydroxylase is triggered by phosphorylation in RBL2H3 cells, a serotonin producing mast cell line.
Medulloblastoma
Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-?B signaling, and synergizes with an ERK inhibitor.
Medulloblastoma
Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma.
Medulloblastoma
Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma.
Medulloblastoma
Cytogenetic and molecular biological characterization of an adult medulloblastoma.
Medulloblastoma
Exploring the role and clinical implications of proteasome inhibition in medulloblastoma.
Medulloblastoma
The role of the ubiquitin proteasome system in cerebellar development and medulloblastoma.
Melanoma
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
Melanoma
A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
Melanoma
Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells.
Melanoma
Adjuvant interferon alfa treatment for patients with malignant melanoma stimulates transporter proteins associated with antigen processing and proteasome activator 28.
Melanoma
Alpha-lipoic acid alters the antitumor effect of bortezomib in melanoma cells in vitro.
Melanoma
An inhibitor of the chymotrypsin-like activity of the proteasome (PSI) induces similar morphological changes in various cell lines.
Melanoma
Analysis of the proteasome activity and the turnover of the serotonin receptor 2B (HTR2B) in human uveal melanoma.
Melanoma
APEH Inhibition Affects Osteosarcoma Cell Viability via Downregulation of the Proteasome.
Melanoma
Apoptosis-inducing levels of UV radiation and proteasome inhibitors produce opposite effects on p21(WAF1) in human melanoma cells.
Melanoma
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
Melanoma
BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
Melanoma
Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model.
Melanoma
Bortezomib enhances the antitumor effects of interferon-? gene transfer on melanoma cells.
Melanoma
Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.
Melanoma
Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells.
Melanoma
Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death.
Melanoma
Clinical use of p-proteasome in discriminating metastatic melanoma patients: Comparative study with LDH, MIA and S100B protein.
Melanoma
Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells.
Melanoma
Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line.
Melanoma
Depigmentation of ?-melanocyte-stimulating hormone-treated melanoma cells by ?-mangostin is mediated by selective autophagy.
Melanoma
Diagnostic value and prognostic significance of plasmatic proteasome level in patients with melanoma.
Melanoma
Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
Melanoma
Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
Melanoma
Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression.
Melanoma
Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines.
Melanoma
Elevated constitutive IkappaB kinase activity and IkappaB-alpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription.
Melanoma
ER-aminopeptidase 1 determines the processing and presentation of an immunotherapy-relevant melanoma epitope.
Melanoma
Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells.
Melanoma
High plasma proteasome levels are detected in patients with metastatic malignant melanoma.
Melanoma
Hypoxia negatively regulates antimetastatic PEDF in melanoma cells by a hypoxia inducible factor-independent, autophagy dependent mechanism.
Melanoma
IFN-alpha mediates the up-regulation of HLA class I on melanoma cells without switching proteasome to immunoproteasome.
Melanoma
IFN-gamma exposes a cryptic cytotoxic T lymphocyte epitope in HIV-1 reverse transcriptase.
Melanoma
Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.
Melanoma
Increased level of p27 subunit of proteasomes and its co-localization with tyrosinase in amelanotic melanoma cells indicate its direct role in the regulation of melanin biosynthesis.
Melanoma
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications.
Melanoma
Investigation of the eIF2alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells.
Melanoma
MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.
Melanoma
Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex.
Melanoma
Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals.
Melanoma
Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line.
Melanoma
MYC-induced sensitivity of human malignant melanoma to proteasome inhibitors - a KaMYCaze effect.
Melanoma
N-glycosylation enhances presentation of a MHC class I-restricted epitope from tyrosinase.
Melanoma
Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2.
Melanoma
New aldehyde and vinylsulfone proteasome inhibitors for targeted melanoma therapy.
Melanoma
NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Melanoma
Nuclear beta-catenin displays GSK-3beta- and APC-independent proteasome sensitivity in melanoma cells.
Melanoma
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
Melanoma
Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
Melanoma
Preliminary studies of new proteasome inhibitors in the tumor targeting approach: synthesis and in vitro cytotoxicity.
Melanoma
Proper folding and endoplasmic reticulum to golgi transport of tyrosinase are induced by its substrates, DOPA and tyrosine.
Melanoma
Proteasome beta-4 subunit contributes to the development of melanoma and is regulated by miR-148b.
Melanoma
Proteasome inhibition and ROS generation by 4-nerolidylcatechol induces melanoma cell death.
Melanoma
Proteasome inhibition blocks NF-?B and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.
Melanoma
Proteasome inhibitors remarkably prevent translesion replication in cancer cells but not normal cells.
Melanoma
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
Melanoma
RedOx status, proteasome and APEH: insights into anticancer mechanisms of t10,c12-conjugated linoleic acid isomer on A375 melanoma cells.
Melanoma
Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.
Melanoma
Retraction: Proteasome Inhibition Blocks NF-?B and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs.
Melanoma
Selective growth inhibition of human malignant melanoma cells by syringic acid-derived proteasome inhibitors.
Melanoma
The N-terminal flanking region of the TRP2360-368 melanoma antigen determines proteasome activator PA28 requirement for epitope liberation.
Melanoma
The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma.
Melanoma
The prognostic value of the proteasome activator subunit gene family in skin cutaneous melanoma.
Melanoma
The proteasome immunosubunits, PA28 and ER-aminopeptidase 1 protect melanoma cells from efficient MART-126-35 -specific T-cell recognition.
Melanoma
The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells.
Melanoma
The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo.
Melanoma
The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack.
Melanoma
The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells.
Melanoma
The Zinc-finger AN1-type Domain 2a Gene Acts as a Regulator of Cell Survival in Human Melanoma: Role of E3-Ligase cIAP2.
Melanoma
Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins.
Melanoma
Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
Melanoma
West Nile Virus NS1 Antagonizes Interferon Beta Production by Targeting RIG-I and MDA5.
Melanoma, Amelanotic
Increased level of p27 subunit of proteasomes and its co-localization with tyrosinase in amelanotic melanoma cells indicate its direct role in the regulation of melanin biosynthesis.
Melanoma, Amelanotic
Regulation of tyrosinase processing and trafficking by organellar pH and by proteasome activity.
Melanoma, Experimental
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells.
Melanoma, Experimental
CtBP2 downregulation during neural crest specification induces expression of Mitf and REST, resulting in melanocyte differentiation and sympathoadrenal lineage suppression.
Melanoma, Experimental
Immunosensitization of Tumor Cells to Dendritic Cell-Activated Immune Responses with the Proteasome Inhibitor Bortezomib (PS-341, Velcade).
Memory Disorders
Age-related memory deficits are associated with changes in protein degradation in brain regions critical for trace fear conditioning.
Meningioma
Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex.
Meningitis
Proteasome serves as pivotal regulator in Angiostrongylus cantonensis-induced eosinophilic meningoencephalitis.
Meningoencephalitis
Proteasome serves as pivotal regulator in Angiostrongylus cantonensis-induced eosinophilic meningoencephalitis.
Mental Retardation, X-Linked
UBE2A, which encodes a ubiquitin-conjugating enzyme, is mutated in a novel X-linked mental retardation syndrome.
Mesothelioma
BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.
Mesothelioma
Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.
Mesothelioma
Correction: Withaferin A Inhibits the Proteasome Activity in Mesothelioma In Vitro and In Vivo.
Mesothelioma
Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids.
Mesothelioma
Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors.
Mesothelioma
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Mesothelioma
Proteasome Inhibitor MG132 Induces Apoptosis and Inhibits Invasion of Human Malignant Pleural Mesothelioma Cells.
Mesothelioma
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis.
Mesothelioma
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
Mesothelioma
The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance.
Mesothelioma
TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages.
Mesothelioma
Withaferin a inhibits the proteasome activity in mesothelioma in vitro and in vivo.
Mesothelioma, Malignant
BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.
Mesothelioma, Malignant
Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.
Mesothelioma, Malignant
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Mesothelioma, Malignant
Proteasome Inhibitor MG132 Induces Apoptosis and Inhibits Invasion of Human Malignant Pleural Mesothelioma Cells.
Mesothelioma, Malignant
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis.
Mesothelioma, Malignant
TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages.
Metabolic Diseases
Proteasome Composition and Activity Changes in Cultured Fibroblasts Derived From Mucopolysaccharidoses Patients and Their Modulation by Genistein.
Metabolic Diseases
Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes.
Metabolic Syndrome
Effect of pioglitazone on the expression of ubiquitin proteasome system and autophagic proteins in rat pancreas with metabolic syndrome.
Metabolic Syndrome
Exercise training prevents the perivascular adipose tissue-induced aortic dysfunction with metabolic syndrome.
Metabolic Syndrome
Involvement of proteasome and macrophages M2 in the protection afforded by telmisartan against the acute myocardial infarction in Zucker diabetic fatty rats with metabolic syndrome.
methylenetetrahydrofolate dehydrogenase (nad+) deficiency
The 1316T>C missenses mutation in MTHFR contributes to MTHFR deficiency by targeting MTHFR to proteasome degradation.
Microcephaly
Biallelic variants in PSMB1 encoding the proteasome subunit ?6 cause impairment of proteasome function, microcephaly, intellectual disability, developmental delay and short stature.
Microscopic Polyangiitis
Serum 20S proteasome levels are associated with disease activity in MPO-ANCA-associated microscopic polyangiitis.
Mitochondrial Diseases
The ubiquitin-proteasome system and its crosstalk with mitochondria as therapeutic targets in medicine.
Mixed Connective Tissue Disease
Circulating 20S proteasome levels in patients with mixed connective tissue disease and systemic lupus erythematosus.
Monoclonal Gammopathy of Undetermined Significance
Bortezomib Treatment Modulates Autophagy in Multiple Myeloma.
Motor Neuron Disease
Accumulation of human SOD1 and ubiquitinated deposits in the spinal cord of SOD1G93A mice during motor neuron disease progression correlates with a decrease of proteasome.
Motor Neuron Disease
Clinicopathological correlations in behavioural variant frontotemporal dementia.
Motor Neuron Disease
The proteasome-associated deubiquitinating enzyme Usp14 is essential for the maintenance of synaptic ubiquitin levels and the development of neuromuscular junctions.
Motor Neuron Disease
The Ubiquitin Proteasome System Is a Key Regulator of Pluripotent Stem Cell Survival and Motor Neuron Differentiation.
Mouth Neoplasms
A novel transcript variant of proteasome activator 28?: Identification and function in oral cancer cells.
Mouth Neoplasms
Optimized combinations of bortezomib, camptothecin, and doxorubicin show increased efficacy and reduced toxicity in treating oral cancer.
Movement Disorders
Neuronal inclusions in degenerative disorders Do they represent static features or a key to understand the dynamics of the disease?
Mucopolysaccharidoses
Enhanced degradation of synaptophysin by the proteasome in mucopolysaccharidosis type IIIB.
Mucopolysaccharidoses
Proteasome Composition and Activity Changes in Cultured Fibroblasts Derived From Mucopolysaccharidoses Patients and Their Modulation by Genistein.
Mucopolysaccharidosis III
Enhanced degradation of synaptophysin by the proteasome in mucopolysaccharidosis type IIIB.
Multiple Myeloma
'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
Multiple Myeloma
(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.
Multiple Myeloma
?-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.
Multiple Myeloma
A case of bortezomib (Velcade)-induced Stevens-Johnson syndrome confirmed by patch test.
Multiple Myeloma
A Case of Disseminated and Fulminant Plasmacytomas That Developed during Bortezomib Treatment.
Multiple Myeloma
A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma.
Multiple Myeloma
A combination regimen of low-dose bortezomib and rapamycin prolonged the graft survival in a murine allogeneic islet transplantation model.
Multiple Myeloma
A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Multiple Myeloma
A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, ?-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice.
Multiple Myeloma
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.
Multiple Myeloma
A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma.
Multiple Myeloma
A High-Content Screening Assay for the Discovery of Novel Proteasome Inhibitors from Formosan Soft Corals.
Multiple Myeloma
A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement.
Multiple Myeloma
A metabolic switch in proteasome inhibitor resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis.
Multiple Myeloma
A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma.
Multiple Myeloma
A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
Multiple Myeloma
A novel combination treatment for breast cancer cells involving BAPTA-AM and proteasome inhibitor bortezomib.
Multiple Myeloma
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Multiple Myeloma
A novel orally active proteasome inhibitor ONX 0912 trigger in vitro and in vivo cytotoxicity in multiple myeloma.
Multiple Myeloma
A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.
Multiple Myeloma
A novel RP2 missense mutation Q158P identified in an X-linked retinitis pigmentosa family impaired RP2 protein stability.
Multiple Myeloma
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
Multiple Myeloma
A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity.
Multiple Myeloma
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.
Multiple Myeloma
A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
Multiple Myeloma
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
Multiple Myeloma
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
Multiple Myeloma
A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma.
Multiple Myeloma
A Phase II Study of Single Agent Bortezomib in Patients with Metastatic Breast Cancer: A Single Institution Experience.
Multiple Myeloma
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
Multiple Myeloma
A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
Multiple Myeloma
A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
Multiple Myeloma
A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Multiple Myeloma
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
Multiple Myeloma
A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma.
Multiple Myeloma
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Multiple Myeloma
A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cells.
Multiple Myeloma
A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
Multiple Myeloma
A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
Multiple Myeloma
A Translational Physiologically Based Pharmacokinetics/Pharmacodynamics Framework of Target-Mediated Disposition, Target Inhibition and Drug-Drug Interactions of Bortezomib.
Multiple Myeloma
A6 Peptide-Tagged Core-Disulfide-Cross-Linked Micelles for Targeted Delivery of Proteasome Inhibitor Carfilzomib to Multiple Myeloma In Vivo.
Multiple Myeloma
Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.
Multiple Myeloma
Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma.
Multiple Myeloma
Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib.
Multiple Myeloma
Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-?B Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells.
Multiple Myeloma
Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.
Multiple Myeloma
Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor ?B pathways.
Multiple Myeloma
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
Multiple Myeloma
Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition.
Multiple Myeloma
Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient.
Multiple Myeloma
Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA.
Multiple Myeloma
Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.
Multiple Myeloma
Advances in the understanding of mechanisms and therapeutic use of bortezomib.
Multiple Myeloma
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Multiple Myeloma
Alpha-lipoic acid alters the antitumor effect of bortezomib in melanoma cells in vitro.
Multiple Myeloma
Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathy.
Multiple Myeloma
Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma.
Multiple Myeloma
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib.
Multiple Myeloma
An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.
Multiple Myeloma
An in vitro and in vivo investigation of the cytotoxic effects of caffeic acid (3,4-dihydroxycinnamic acid) phenethyl ester and bortezomib in multiple myeloma cells.
Multiple Myeloma
An inhibitor of proteasome ?2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
Multiple Myeloma
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
Multiple Myeloma
An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro.
Multiple Myeloma
An update in treatment options for multiple myeloma in nontransplant eligible patients.
Multiple Myeloma
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.
Multiple Myeloma
Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ?3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.
Multiple Myeloma
Analyzing proteasomal subunit expression reveals Rpt4 as a prognostic marker in stage II colorectal cancer.
Multiple Myeloma
Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
Multiple Myeloma
Anti-Inflammatory and Immunomodulatory Effects of Bortezomib in Various in vivo Models.
Multiple Myeloma
Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib.
Multiple Myeloma
Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
Multiple Myeloma
Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Multiple Myeloma
Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B.
Multiple Myeloma
Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.
Multiple Myeloma
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Multiple Myeloma
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
Multiple Myeloma
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Multiple Myeloma
Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors.
Multiple Myeloma
APEX (Assessment of Proteasome inhibition for Extending remissions) trial: phase III randomized, multicenter, placebo-controlled trial to evaluate the efficacy and safety of bortezomib versus dexamethasone in patients with recurrent or treatment-resistant multiple myeloma.
Multiple Myeloma
Apigenin, Chrysin, and Luteolin Selectively Inhibit Chymotrypsin-Like and Trypsin-Like Proteasome Catalytic Activities in Tumor Cells.
Multiple Myeloma
Apremilast ameliorates carfilzomib-induced pulmonary inflammation and vascular injuries.
Multiple Myeloma
Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-?B and MAPK signaling in rats.
Multiple Myeloma
Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl?dependent mechanisms.
Multiple Myeloma
Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
Multiple Myeloma
Assessment of proteasome concentration and chymotrypsin-like activity in plasma of patients with newly diagnosed multiple myeloma.
Multiple Myeloma
Association of response endpoints with survival outcomes in multiple myeloma.
Multiple Myeloma
Bacterial self-resistance to the natural proteasome inhibitor salinosporamide a.
Multiple Myeloma
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Multiple Myeloma
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma.
Multiple Myeloma
Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers.
Multiple Myeloma
BET Inhibitors Synergize with Carfilzomib to Induce Cell Death in Cancer Cells via Impairing Nrf1 Transcriptional Activity and Exacerbating the Unfolded Protein Response.
Multiple Myeloma
Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
Multiple Myeloma
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Multiple Myeloma
Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.
Multiple Myeloma
Biotinylated HPMA centered polymeric nanoparticles for Bortezomib delivery.
Multiple Myeloma
Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-?B signaling.
Multiple Myeloma
Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Multiple Myeloma
Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma.
Multiple Myeloma
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.
Multiple Myeloma
Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.
Multiple Myeloma
Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study.
Multiple Myeloma
Bortezomib alleviates experimental pulmonary hypertension by regulating intracellular calcium homeostasis in PASMCs.
Multiple Myeloma
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
Multiple Myeloma
Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure.
Multiple Myeloma
Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.
Multiple Myeloma
Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment.
Multiple Myeloma
Bortezomib as a probable cause of the syndrome of inappropriate antidiuretic hormone secretion: A case report and review of the literature.
Multiple Myeloma
Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
Multiple Myeloma
Bortezomib at therapeutic doses poorly passes the blood-brain barrier and does not impair cognition.
Multiple Myeloma
Bortezomib Causes ER Stress-related Death of Acute Promyelocytic Leukemia Cells Through Excessive Accumulation of PML-RARA.
Multiple Myeloma
Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.
Multiple Myeloma
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
Multiple Myeloma
Bortezomib Improved the Joint Manifestations of Rheumatoid Arthritis in Three Patients.
Multiple Myeloma
Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial.
Multiple Myeloma
Bortezomib in combination with other therapies for the treatment of multiple myeloma.
Multiple Myeloma
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Multiple Myeloma
Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells.
Multiple Myeloma
Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
Multiple Myeloma
Bortezomib induces autophagic death in proliferating human endothelial cells.
Multiple Myeloma
Bortezomib induces canonical NF-{kappa}B activation in multiple myeloma cells.
Multiple Myeloma
Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1.
Multiple Myeloma
Bortezomib Induces the Formation of Nuclear poly(A) RNA Granules Enriched in Sam68 and PABPN1 in Sensory Ganglia Neurons.
Multiple Myeloma
Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes.
Multiple Myeloma
Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.
Multiple Myeloma
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Multiple Myeloma
Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1.
Multiple Myeloma
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
Multiple Myeloma
Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells.
Multiple Myeloma
Bortezomib Partially Improves Laminin ?2 Chain-Deficient Muscular Dystrophy.
Multiple Myeloma
Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition.
Multiple Myeloma
Bortezomib prevents the expression of MMP-13 and the degradation of collagen type 2 in human chondrocytes.
Multiple Myeloma
Bortezomib protects against dextran sulfate sodium?induced ulcerative colitis in mice.
Multiple Myeloma
Bortezomib resistance in a myeloma cell line is associated to PSM?5 overexpression and polyploidy.
Multiple Myeloma
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.
Multiple Myeloma
Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma.
Multiple Myeloma
Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data.
Multiple Myeloma
Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RAR?/STAT1 axis.
Multiple Myeloma
Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5.
Multiple Myeloma
Bortezomib Subcutaneous Injection in Combination Regimens for Myeloma or Systemic Light-Chain Amyloidosis: A Retrospective Chart Review of Response Rates and Toxicity in Newly Diagnosed Patients.
Multiple Myeloma
Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma.
Multiple Myeloma
Bortezomib therapy-related lung disease in a patient with light chain amyloidosis: A case report.
Multiple Myeloma
Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.
Multiple Myeloma
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Multiple Myeloma
Bortezomib-associated demyelinating neuropathy--clinical and pathologic features.
Multiple Myeloma
Bortezomib-based Chemotherapy for Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No Cardiotoxicity.
Multiple Myeloma
Bortezomib-induced acute pancreatitis: Case report and review of the literature.
Multiple Myeloma
Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.
Multiple Myeloma
Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity.
Multiple Myeloma
Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation.
Multiple Myeloma
Bortezomib-induced neuropathy: Axonal membrane depolarization precedes development of neuropathy.
Multiple Myeloma
Bortezomib-induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats.
Multiple Myeloma
Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse.
Multiple Myeloma
Bortezomib-induced peripheral neurotoxicity in human multiple myeloma-bearing mice.
Multiple Myeloma
Bortezomib-induced pneumonitis during bortezomib retreatment in multiple myeloma.
Multiple Myeloma
Bortezomib-Induced Pulmonary Toxicity: A Case Report and Review of Literature.
Multiple Myeloma
Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review.
Multiple Myeloma
Bortezomib-induced syndrome of inappropriate antidiuresis in a patient with multiple myeloma: A case report and literature review?.
Multiple Myeloma
Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b.
Multiple Myeloma
Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics.
Multiple Myeloma
Bortezomib-loaded solid lipid nanoparticles: preparation, characterization, and intestinal permeability investigation.
Multiple Myeloma
Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
Multiple Myeloma
Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.
Multiple Myeloma
Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases.
Multiple Myeloma
Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
Multiple Myeloma
Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation.
Multiple Myeloma
Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
Multiple Myeloma
Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
Multiple Myeloma
Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
Multiple Myeloma
BSc2118 is a Novel Proteasome Inhibitor with Activity against Multiple Myeloma.
Multiple Myeloma
Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
Multiple Myeloma
Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase.
Multiple Myeloma
Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells.
Multiple Myeloma
Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration.
Multiple Myeloma
Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11.
Multiple Myeloma
CAR-T cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.
Multiple Myeloma
Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma.
Multiple Myeloma
Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis.
Multiple Myeloma
Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
Multiple Myeloma
Cardiotoxicity with carfilzomib at doses greater than 27?mg/m(2): A case series.
Multiple Myeloma
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).
Multiple Myeloma
Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention.
Multiple Myeloma
Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma.
Multiple Myeloma
Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy.
Multiple Myeloma
Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma.
Multiple Myeloma
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma.
Multiple Myeloma
Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Multiple Myeloma
Carfilzomib as a potential inhibitor of NADH-dependent enoyl-acyl carrier protein reductases of Klebsiella pneumoniae and Mycobacterium tuberculosis as a drug target enzyme: insights from molecular docking and molecular dynamics.
Multiple Myeloma
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.
Multiple Myeloma
Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model.
Multiple Myeloma
Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
Multiple Myeloma
Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience
Multiple Myeloma
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.
Multiple Myeloma
Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes.
Multiple Myeloma
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Multiple Myeloma
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Multiple Myeloma
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.
Multiple Myeloma
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study.
Multiple Myeloma
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Multiple Myeloma
Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia.
Multiple Myeloma
Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and therapeutic success.
Multiple Myeloma
Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats.
Multiple Myeloma
Carfilzomib-induced pulmonary hypertension with associated right ventricular dysfunction: A case report.
Multiple Myeloma
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
Multiple Myeloma
Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine.
Multiple Myeloma
Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Multiple Myeloma
Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
Multiple Myeloma
Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma.
Multiple Myeloma
Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma.
Multiple Myeloma
Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Multiple Myeloma
Carfilzomib: a Tale of a Heartbreaking Moment. Case Report and Concise Review of the Literature.
Multiple Myeloma
Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring.
Multiple Myeloma
Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells.
Multiple Myeloma
Caspase-dependent cleavage of BAG3 in proteasome inhibitors-induced apoptosis in thyroid cancer cells.
Multiple Myeloma
Catechol Containing Polyelectrolyte Complex Nanoparticles as Local Drug Delivery System for Bortezomib at Bone Substitute Materials.
Multiple Myeloma
Celastrol induce apoptosis of human multiple myeloma cells involving inhibition of proteasome activity.
Multiple Myeloma
Cell cycle exit during bortezomib-induced osteogenic differentiation of mesenchymal stem cells was mediated by Xbp1s-upregulated p21Cip1 and p27Kip1.
Multiple Myeloma
Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells.
Multiple Myeloma
Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes.
Multiple Myeloma
Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters.
Multiple Myeloma
Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.
Multiple Myeloma
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
Multiple Myeloma
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.
Multiple Myeloma
Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors.
Multiple Myeloma
Chemokine receptor CXCR4: An important player affecting the molecular-targeted drugs commonly used in hematological malignancies.
Multiple Myeloma
Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner.
Multiple Myeloma
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.
Multiple Myeloma
Chromatin immunoprecipitation analysis of bortezomib-mediated inhibition of NF?B recruitment to IL-1? and TNF? gene promoters in human macrophages.
Multiple Myeloma
Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-?B signaling.
Multiple Myeloma
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Multiple Myeloma
Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation - a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients.
Multiple Myeloma
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma.
Multiple Myeloma
Clarifying the molecular mechanism associated with carfilzomib resistance in human multiple myeloma using microarray gene expression profile and genetic interaction network.
Multiple Myeloma
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.
Multiple Myeloma
Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.
Multiple Myeloma
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
Multiple Myeloma
Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors.
Multiple Myeloma
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
Multiple Myeloma
Clinical significance of cancer-related fatigue in multiple myeloma patients.
Multiple Myeloma
Clinical use of proteasome inhibitors in the treatment of multiple myeloma.
Multiple Myeloma
Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection.
Multiple Myeloma
Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy.
Multiple Myeloma
Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
Multiple Myeloma
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.
Multiple Myeloma
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
Multiple Myeloma
Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells.
Multiple Myeloma
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.
Multiple Myeloma
Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells.
Multiple Myeloma
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Multiple Myeloma
Combined therapeutic effects of bortezomib and anacardic acid on multiple myeloma cells via activation of the endoplasmic reticulum stress response.
Multiple Myeloma
Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes.
Multiple Myeloma
Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
Multiple Myeloma
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.
Multiple Myeloma
Commentary on "Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents".
Multiple Myeloma
Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies.
Multiple Myeloma
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.
Multiple Myeloma
Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysis.
Multiple Myeloma
Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials.
Multiple Myeloma
Complete atrioventricular block secondary to bortezomib use in multiple myeloma.
Multiple Myeloma
Concise review - Treatment of multiple myeloma in the very elderly: How do novel agents fit in?
Multiple Myeloma
Control of Pim2 kinase stability and expression in transformed human haematopoietic cells.
Multiple Myeloma
Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma.
Multiple Myeloma
Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
Multiple Myeloma
Corrigendum: Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China.
Multiple Myeloma
Corrigendum: The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
Multiple Myeloma
Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis.
Multiple Myeloma
Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland.
Multiple Myeloma
CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma.
Multiple Myeloma
Critical role of Cav3.2 T-type calcium channels in the peripheral neuropathy induced by bortezomib, a proteasome-inhibiting chemotherapeutic agent, in mice.
Multiple Myeloma
Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma.
Multiple Myeloma
Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome.
Multiple Myeloma
Crystal structure of the Eg5 - K858 complex and implications for structure-based design of thiadiazole-containing inhibitors.
Multiple Myeloma
Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib.
Multiple Myeloma
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Multiple Myeloma
Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.
Multiple Myeloma
Current approaches to the initial treatment of symptomatic multiple myeloma.
Multiple Myeloma
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
Multiple Myeloma
Current treatment landscape for relapsed and/or refractory multiple myeloma.
Multiple Myeloma
Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Multiple Myeloma
Cyclophosphamide-Glucocorticoids versus Lenalidomide-Dexamethasone as Treatment for Multiple Myeloma at First Relapse after Autologous Stem Cell Transplantation - A Retrospective Analysis.
Multiple Myeloma
Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis.
Multiple Myeloma
DANFIN functions as an inhibitor of transcription factor NF-?B and potentiates the antitumor effect of bortezomib in multiple myeloma.
Multiple Myeloma
Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.
Multiple Myeloma
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey.
Multiple Myeloma
Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study.
Multiple Myeloma
Daratumumab induces CD38 internalization and impairs myeloma cell adhesion.
Multiple Myeloma
Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.
Multiple Myeloma
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
Multiple Myeloma
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Multiple Myeloma
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Multiple Myeloma
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Multiple Myeloma
Daratumumab provides a survival benefit in relapsed and refractory Multiple Myeloma, independent of baseline clinical characteristics: A meta-analysis.
Multiple Myeloma
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner.
Multiple Myeloma
Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin-induced apoptosis.
Multiple Myeloma
Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy.
Multiple Myeloma
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study.
Multiple Myeloma
Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.
Multiple Myeloma
Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM).
Multiple Myeloma
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
Multiple Myeloma
Design, synthesis and biological evaluation of novel non-covalent piperidine-containing peptidyl proteasome inhibitors.
Multiple Myeloma
Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from ?-amino acid as proteasome inhibitors.
Multiple Myeloma
Design, Synthesis and Biological Evaluation of Peptidyl Epoxyketone Proteasome Inhibitors Composed of ?-amino Acids.
Multiple Myeloma
Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma.
Multiple Myeloma
Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies.
Multiple Myeloma
Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.
Multiple Myeloma
Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma.
Multiple Myeloma
Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma.
Multiple Myeloma
Development of ?-Hairpin Peptides for the Measurement of SCF-Family E3 Ligase Activity in Vitro via Ornithine Ubiquitination.
Multiple Myeloma
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
Multiple Myeloma
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
Multiple Myeloma
Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
Multiple Myeloma
Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carfilzomib.
Multiple Myeloma
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
Multiple Myeloma
Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Date in China.
Multiple Myeloma
Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
Multiple Myeloma
Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells.
Multiple Myeloma
Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
Multiple Myeloma
Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
Multiple Myeloma
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
Multiple Myeloma
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.
Multiple Myeloma
Discovery of Natural Product Proteasome Inhibitors as Novel Anticancer Therapeutics: Current Status and Perspectives.
Multiple Myeloma
Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations.
Multiple Myeloma
Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
Multiple Myeloma
Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.
Multiple Myeloma
Discovery of PI-1840, a novel non-covalent and rapidly reversible proteasome inhibitor with anti-tumor activity.
Multiple Myeloma
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
Multiple Myeloma
Dissecting bortezomib: development, application, adverse effects and future direction.
Multiple Myeloma
Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients.
Multiple Myeloma
DKK1 Activates Non-canonical NF-kB Signaling via IL-6 Induced CKAP4 receptor in Multiple Myeloma.
Multiple Myeloma
Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
Multiple Myeloma
Downregulation of PA28? induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma.
Multiple Myeloma
Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma.
Multiple Myeloma
Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf.
Multiple Myeloma
Drug Release as a function of bioactivity, incubation regime, liquid, and initial load: Release of bortezomib from calcium phosphate-containing silica/collagen xerogels.
Multiple Myeloma
Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature.
Multiple Myeloma
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Multiple Myeloma
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.
Multiple Myeloma
Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.
Multiple Myeloma
Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells.
Multiple Myeloma
Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
Multiple Myeloma
Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.
Multiple Myeloma
Effect of Bortezomib Regimens and Daratumumab Monotherapy on Cellular Immunity in Multiple Myeloma Patients.
Multiple Myeloma
Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Multiple Myeloma
Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro.
Multiple Myeloma
Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
Multiple Myeloma
Effects of Hydroxy Groups in the A-Ring on the Anti-proteasome Activity of Flavone.
Multiple Myeloma
Effects on bone metabolism of new therapeutic strategies with standard chemotherapy and biologic drugs.
Multiple Myeloma
Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials.
Multiple Myeloma
Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Multiple Myeloma
Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.
Multiple Myeloma
Efficacy of Proteasome Inhibitor-Based Maintenance following Autologous Transplantation in Multiple Myeloma: a systematic review and meta-analysis.
Multiple Myeloma
Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
Multiple Myeloma
Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials.
Multiple Myeloma
Efficient brain targeting and therapeutic intracranial activity of bortezomib through intranasal co-delivery with NEO100 in rodent glioblastoma models.
Multiple Myeloma
Elevation of proteasomal substrate levels sensitizes cells to apoptosis induced by inhibition of proteasomal deubiquitinases.
Multiple Myeloma
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Multiple Myeloma
EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Multiple Myeloma
Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma.
Multiple Myeloma
Emerging drug development technologies targeting ubiquitination for cancer therapeutics.
Multiple Myeloma
Emerging role of novel combinations for induction therapy in multiple myeloma.
Multiple Myeloma
Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
Multiple Myeloma
Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma.
Multiple Myeloma
Endoplasmic reticulum stress and proteasome inhibitors in multiple myeloma: room for improvement.
Multiple Myeloma
Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma.
Multiple Myeloma
Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma.
Multiple Myeloma
Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-?B in vitro and in vivo.
Multiple Myeloma
Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.
Multiple Myeloma
Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies.
Multiple Myeloma
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells.
Multiple Myeloma
Erucylphospho-N,N,N-trimethylpropylammonium shows substantial cytotoxicity in multiple myeloma cells.
Multiple Myeloma
Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
Multiple Myeloma
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Multiple Myeloma
Exosome-Transmitted PSMA3 and PSMA3-AS1 Promote Proteasome Inhibitor Resistance in Multiple Myeloma.
Multiple Myeloma
Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.
Multiple Myeloma
Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.
Multiple Myeloma
Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy.
Multiple Myeloma
Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
Multiple Myeloma
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Multiple Myeloma
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
Multiple Myeloma
Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.
Multiple Myeloma
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Multiple Myeloma
Extracellular vesicles of multiple myeloma cells utilize the proteasome inhibitor mechanism to moderate endothelial angiogenesis.
Multiple Myeloma
FAM46C and FNDC3A are multiple myeloma tumor suppressors that act in concert to impair clearing of protein aggregates and autophagy.
Multiple Myeloma
FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.
Multiple Myeloma
FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma.
Multiple Myeloma
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Multiple Myeloma
Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
Multiple Myeloma
Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma.
Multiple Myeloma
Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation.
Multiple Myeloma
Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.
Multiple Myeloma
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
Multiple Myeloma
Frontline treatment for transplant-eligible multiple myeloma: A 6474 patients network meta-analysis.
Multiple Myeloma
Function-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropica.
Multiple Myeloma
FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.
Multiple Myeloma
Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
Multiple Myeloma
Gene networks constructed through simulated treatment learning can predict proteasome inhibitor benefit in Multiple Myeloma.
Multiple Myeloma
General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
Multiple Myeloma
Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci.
Multiple Myeloma
Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition.
Multiple Myeloma
Genome-wide approaches to systematically identify substrates of the ubiquitin-proteasome pathway.
Multiple Myeloma
Glucocorticoid and proteasome inhibitor impact on the leukemic lymphoblast: Multiple, diverse signals converging on a few key downstream regulators.
Multiple Myeloma
Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib.
Multiple Myeloma
Gold nanoparticle delivery-enhanced proteasome inhibitor effect in adenocarcinoma cells.
Multiple Myeloma
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.
Multiple Myeloma
H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth.
Multiple Myeloma
Have drug combinations supplanted stem cell transplantation in myeloma?
Multiple Myeloma
HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer.
Multiple Myeloma
Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany.
Multiple Myeloma
Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma.
Multiple Myeloma
Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.
Multiple Myeloma
High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.
Multiple Myeloma
High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.
Multiple Myeloma
High immunoproteasome concentration in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of longer OS.
Multiple Myeloma
High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.
Multiple Myeloma
Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding.
Multiple Myeloma
Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.
Multiple Myeloma
Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia.
Multiple Myeloma
Identification and Structure-Activity Relationship of HDAC6 Zinc-Finger Ubiquitin Binding Domain Inhibitors.
Multiple Myeloma
Identification of a new series of amides as non-covalent proteasome inhibitors.
Multiple Myeloma
Identification of a p53-based portable degron based on the MDM2-p53 binding region.
Multiple Myeloma
Identification of genes affecting the toxicity of anti-cancer drug bortezomib by genome-wide screening in S. pombe.
Multiple Myeloma
Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.
Multiple Myeloma
Identification of proteasome inhibitors using analysis of gene expression profiles.
Multiple Myeloma
Identification of Long Non-Coding RNAs Deregulated in Multiple Myeloma Cells Resistant to Proteasome Inhibitors.
Multiple Myeloma
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
Multiple Myeloma
IKK? inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.
Multiple Myeloma
Immunologic aspects of protein degradation by the ubiquitin-proteasome system.
Multiple Myeloma
Immunomodulators in newly diagnosed multiple myeloma: current and future concepts.
Multiple Myeloma
Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma.
Multiple Myeloma
Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review.
Multiple Myeloma
Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Multiple Myeloma
Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases.
Multiple Myeloma
Immunotherapeutic and immunoregulatory drugs in haematologic malignancies.
Multiple Myeloma
Impact of Extended Treatment Interval on the Prognosis of Multiple Myeloma Patients: A Retrospective Study.
Multiple Myeloma
Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease.
Multiple Myeloma
Impact of Pre-transplant and Post-transplant Remission Status of Patients on Survival in Newly Diagnosed Multiple Myeloma.
Multiple Myeloma
Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in Chinese patients.
Multiple Myeloma
Improved SILAC Quantification with Data-Independent Acquisition to Investigate Bortezomib-Induced Protein Degradation.
Multiple Myeloma
Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort.
Multiple Myeloma
In vitro and in vivo efficacy of the novel oral proteasome inhibitor NNU546 in multiple myeloma.
Multiple Myeloma
In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells.
Multiple Myeloma
Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis.
Multiple Myeloma
Inadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97.
Multiple Myeloma
Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
Multiple Myeloma
Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib.
Multiple Myeloma
Increased expression of the tight junction protein TJP1/ZO-1 is associated with upregulation of TAZ-TEAD activity and an adult tissue stem cell signature in carfilzomib-resistant multiple myeloma cells and high-risk multiple myeloma patients.
Multiple Myeloma
Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment.
Multiple Myeloma
Induction of apoptosis in plasma cells by B lymphocyte-induced maturation protein-1 knockdown.
Multiple Myeloma
Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.
Multiple Myeloma
Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma.
Multiple Myeloma
Inhibiting the proteasome reduces molecular and biological impacts of the natural product insecticide, spinosad.
Multiple Myeloma
Inhibition of autophagy enhances apoptosis induced by bortezomib in AML cells.
Multiple Myeloma
Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo.
Multiple Myeloma
Inhibition of chymotrypsin-like activity of the proteasome by ixazomib prevents mitochondrial dysfunction during myocardial ischemia.
Multiple Myeloma
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Multiple Myeloma
Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy.
Multiple Myeloma
Inhibition of HIF1?-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy.
Multiple Myeloma
Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma.
Multiple Myeloma
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity.
Multiple Myeloma
Inhibition of P-Glycoprotein Does Not Increase the Efficacy of Proteasome Inhibitors in Multiple Myeloma Cells.
Multiple Myeloma
Inhibition of the ?-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Multiple Myeloma
Inhibition of the FAD containing ER oxidoreductin 1 (Ero1) protein by EN-460 as a strategy for treatment of multiple myeloma.
Multiple Myeloma
Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737.
Multiple Myeloma
Inhibition of the neuronal NF?B pathway attenuates bortezomib-induced neuropathy in a mouse model.
Multiple Myeloma
Inhibition of the Proteasome ?2 Site Sensitizes Triple-Negative Breast Cancer Cells to ?5 Inhibitors and Suppresses Nrf1 Activation.
Multiple Myeloma
Inhibition of the Ubiquitin-Proteasome System by Natural Products for Cancer Therapy.
Multiple Myeloma
Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells.
Multiple Myeloma
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
Multiple Myeloma
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase 2 clinical studies.
Multiple Myeloma
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma.
Multiple Myeloma
Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.
Multiple Myeloma
Investigating Effects of Proteasome Inhibitor on Multiple Myeloma Cells Using Confocal Raman Microscopy.
Multiple Myeloma
Investigating Intestinal Permeability of Bortezomib Using a Validated HPLC-UV Method.
Multiple Myeloma
Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Multiple Myeloma
Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes.
Multiple Myeloma
Investigation of the eIF2alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells.
Multiple Myeloma
Investigational agent MLN9708/2238 targets tumor suppressor microRNA-33b in MM cells.
Multiple Myeloma
Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
Multiple Myeloma
Iron Causes Lipid Oxidation and Inhibits Proteasome Function in Multiple Myeloma Cells: A Proof of Concept for Novel Combination Therapies.
Multiple Myeloma
Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects.
Multiple Myeloma
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Multiple Myeloma
Isoginkgetin, a Natural Biflavonoid Proteasome Inhibitor, Sensitizes Cancer Cells to Apoptosis via Disruption of Lysosomal Homeostasis and Impaired Protein Clearance.
Multiple Myeloma
Isothiocyanates inhibit proteasome activity and proliferation of multiple myeloma cells.
Multiple Myeloma
Ixazomib enhances parathyroid hormone-induced ?-catenin/T-cell factor signaling by dissociating ?-catenin from the parathyroid hormone receptor.
Multiple Myeloma
Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
Multiple Myeloma
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
Multiple Myeloma
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
Multiple Myeloma
Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set.
Multiple Myeloma
Ixazomib, an oral proteasome inhibitor, exhibits potential effect in dystrophin-deficient mdx mice.
Multiple Myeloma
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.
Multiple Myeloma
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Multiple Myeloma
Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
Multiple Myeloma
Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma.
Multiple Myeloma
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
Multiple Myeloma
KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma.
Multiple Myeloma
Kinase inhibitors as potential agents in the treatment of multiple myeloma.
Multiple Myeloma
Lercanidipine Synergistically Enhances Bortezomib Cytotoxicity in Cancer Cells via Enhanced Endoplasmic Reticulum Stress and Mitochondrial Ca2+ Overload.
Multiple Myeloma
Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.
Multiple Myeloma
Limited treatment options in refractory multiple myeloma: promising therapeutic developments.
Multiple Myeloma
Linking the activity of bortezomib in multiple myeloma and autoimmune diseases.
Multiple Myeloma
Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo.
Multiple Myeloma
Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells.
Multiple Myeloma
Long term remission in a case of Plasmablastic lymphoma treated with COMP (Cyclophosphamide, Liposomal Doxorubicin, Vincristine, Prednisone) and Bortezomib.
Multiple Myeloma
Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime
Multiple Myeloma
Loperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death.
Multiple Myeloma
Low Neurotoxicity of ONX-0914 Supports the Idea of Specific Immunoproteasome Inhibition as a Side-Effect-Limiting, Therapeutic Strategy.
Multiple Myeloma
Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy.
Multiple Myeloma
Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical hematology.
Multiple Myeloma
Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens.
Multiple Myeloma
M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (?5i) Delivering Efficacy in Multiple Myeloma Models.
Multiple Myeloma
Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells.
Multiple Myeloma
MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.
Multiple Myeloma
MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.
Multiple Myeloma
Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting.
Multiple Myeloma
Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
Multiple Myeloma
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Multiple Myeloma
Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Multiple Myeloma
Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations.
Multiple Myeloma
Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
Multiple Myeloma
Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.
Multiple Myeloma
Managing Multiple Myeloma in the Face of Drug-Induced Adverse Drug Reaction.
Multiple Myeloma
MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NF?B Activation in Breast Cancer.
Multiple Myeloma
Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
Multiple Myeloma
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
Multiple Myeloma
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Multiple Myeloma
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor?+?dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
Multiple Myeloma
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Multiple Myeloma
MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy.
Multiple Myeloma
Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression.
Multiple Myeloma
Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma.
Multiple Myeloma
Measuring the Overall Rate of Protein Breakdown in Cells and the Contributions of the Ubiquitin-Proteasome and Autophagy-Lysosomal Pathways.
Multiple Myeloma
Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy.
Multiple Myeloma
Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.
Multiple Myeloma
Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence.
Multiple Myeloma
Mechanisms and Potential Treatment Options of Heart Failure in Patients With Multiple Myeloma.
Multiple Myeloma
Melphalan and its role in the management of patients with multiple myeloma.
Multiple Myeloma
Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib.
Multiple Myeloma
Methods for measuring proteasome activity: current limitations and future developments.
Multiple Myeloma
MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.
Multiple Myeloma
Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
Multiple Myeloma
Minimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: a pilot study.
Multiple Myeloma
MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
Multiple Myeloma
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells.
Multiple Myeloma
Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells.
Multiple Myeloma
Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines.
Multiple Myeloma
MLN4924, an investigational NAE inhibitor, suppresses AKT and mTOR signaling pathway through up regulating REDD1 in human myeloma cells.
Multiple Myeloma
Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs.
Multiple Myeloma
Modern Treatments and Future Directions for Relapsed/Refractory Multiple Myeloma Patients.
Multiple Myeloma
Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis.
Multiple Myeloma
Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance.
Multiple Myeloma
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
Multiple Myeloma
Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.
Multiple Myeloma
Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
Multiple Myeloma
Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.
Multiple Myeloma
Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors.
Multiple Myeloma
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
Multiple Myeloma
Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent.
Multiple Myeloma
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Multiple Myeloma
Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets.
Multiple Myeloma
Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Multiple Myeloma
Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.
Multiple Myeloma
Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis.
Multiple Myeloma
Multiple myeloma maintenance therapy: A review of the pharmacologic treatment.
Multiple Myeloma
Multiple myeloma: new uses for available agents, excitement for the future.
Multiple Myeloma
Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
Multiple Myeloma
Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
Multiple Myeloma
Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
Multiple Myeloma
Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma.
Multiple Myeloma
Nadir lymphocytopenia as a risk factor of bloodstream infection during molecular targeting pharmacotherapy in multiple myeloma.
Multiple Myeloma
Natural products inhibiting the ubiquitin-proteasome proteolytic pathway, a target for drug development.
Multiple Myeloma
Naturally occurring proteasome inhibitors from mate tea (Ilex paraguayensis) serve as models for topical proteasome inhibitors.
Multiple Myeloma
Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors.
Multiple Myeloma
Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma.
Multiple Myeloma
Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Multiple Myeloma
Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice.
Multiple Myeloma
New developments in post-transplant maintenance treatment of multiple myeloma.
Multiple Myeloma
New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
Multiple Myeloma
New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.
Multiple Myeloma
New drugs in early development for treating multiple myeloma: all that glitters is not gold.
Multiple Myeloma
New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells.
Multiple Myeloma
Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
Multiple Myeloma
NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma.
Multiple Myeloma
Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells.
Multiple Myeloma
Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects.
Multiple Myeloma
Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.
Multiple Myeloma
Non-proteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
Multiple Myeloma
Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming.
Multiple Myeloma
Noncompetitive Modulation of the Proteasome by Imidazoline Scaffolds Overcomes Bortezomib Resistance and Delays MM Tumor Growth in Vivo.
Multiple Myeloma
Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents.
Multiple Myeloma
Novel anti-myeloma immunotherapies targeting the SLAM family of receptors.
Multiple Myeloma
Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Multiple Myeloma
Novel generation of agents with proven clinical activity in multiple myeloma.
Multiple Myeloma
Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma.
Multiple Myeloma
Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells.
Multiple Myeloma
Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.
Multiple Myeloma
Novel strategies to target the ubiquitin proteasome system in multiple myeloma.
Multiple Myeloma
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Multiple Myeloma
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.
Multiple Myeloma
Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor.
Multiple Myeloma
O-GlcNAcylation Signal Mediates Proteasome Inhibitor Resistance in Cancer Cells by Stabilizing NRF1.
Multiple Myeloma
Oculomotor nerve palsy associated with bortezomib in a patient with multiple myeloma: a case report.
Multiple Myeloma
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Multiple Myeloma
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Multiple Myeloma
One-lincRNA and five-mRNA based signature for prognosis of multiple myeloma patients undergoing proteasome inhibitors therapy.
Multiple Myeloma
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
Multiple Myeloma
Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
Multiple Myeloma
Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors.
Multiple Myeloma
Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma.
Multiple Myeloma
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
Multiple Myeloma
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Multiple Myeloma
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Multiple Myeloma
Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.
Multiple Myeloma
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
Multiple Myeloma
Outcomes of primary refractory multiple myeloma and the impact of novel therapies.
Multiple Myeloma
Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone.
Multiple Myeloma
Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Multiple Myeloma
Oxidative deboronation of the Peptide boronic Acid proteasome inhibitor bortezomib: contributions from reactive oxygen species in this novel cytochrome p450 reaction.
Multiple Myeloma
Oxidative Stress Induced by the Deubiquitinase Inhibitor b-AP15 Is Associated with Mitochondrial Impairment.
Multiple Myeloma
Oxidatively modified low-density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma.
Multiple Myeloma
Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits.
Multiple Myeloma
Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.
Multiple Myeloma
Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2.
Multiple Myeloma
Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy.
Multiple Myeloma
Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
Multiple Myeloma
Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
Multiple Myeloma
PDK1 inhibitor GSK2334470 synergizes with proteasome inhibitor MG?132 in multiple myeloma cells by inhibiting full AKT activity and increasing nuclear accumulation of the PTEN protein.
Multiple Myeloma
Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma.
Multiple Myeloma
Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.
Multiple Myeloma
Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma.
Multiple Myeloma
Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma.
Multiple Myeloma
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Multiple Myeloma
Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
Multiple Myeloma
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.
Multiple Myeloma
Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution and Excretion of Carfilzomib in Rats.
Multiple Myeloma
Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
Multiple Myeloma
Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib.
Multiple Myeloma
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.
Multiple Myeloma
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
Multiple Myeloma
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma; NPI 0052 101 Part 1.
Multiple Myeloma
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Multiple Myeloma
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
Multiple Myeloma
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Multiple Myeloma
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Multiple Myeloma
Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
Multiple Myeloma
Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
Multiple Myeloma
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Multiple Myeloma
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.
Multiple Myeloma
Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma.
Multiple Myeloma
Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.
Multiple Myeloma
Phase Ib Dose-escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma.
Multiple Myeloma
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Multiple Myeloma
Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients.
Multiple Myeloma
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.
Multiple Myeloma
Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-?B signaling pathway.
Multiple Myeloma
PKC? Regulates Death Receptor 5 Expression Induced by PS-341 through ATF4- ATF3/CHOP axis in Human Lung Cancer Cells.
Multiple Myeloma
Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies.
Multiple Myeloma
Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma.
Multiple Myeloma
Pleural effusion in 11:14 translocation q1 multiple myeloma in the setting of proteasome inhibitor presents therapeutic complexity.
Multiple Myeloma
Pluronic block copolymers enhance the anti-myeloma activity of proteasome inhibitors.
Multiple Myeloma
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.
Multiple Myeloma
Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
Multiple Myeloma
Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
Multiple Myeloma
Polypropyleneimine and polyamidoamine dendrimer mediated enhanced solubilization of bortezomib: Comparison and evaluation of mechanistic aspects by thermodynamics and molecular simulations.
Multiple Myeloma
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
Multiple Myeloma
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Multiple Myeloma
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
Multiple Myeloma
Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
Multiple Myeloma
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma.
Multiple Myeloma
Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
Multiple Myeloma
Population-based meta-analysis of bortezomib exposure-response relationships in multiple myeloma patients.
Multiple Myeloma
Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System
Multiple Myeloma
Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma.
Multiple Myeloma
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Multiple Myeloma
Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting ?2 and ?5 subunits.
Multiple Myeloma
Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
Multiple Myeloma
Pre-salvage ISS and Other Important Outcome Associations in CD34 Selected Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma.
Multiple Myeloma
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.
Multiple Myeloma
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy.
Multiple Myeloma
Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response.
Multiple Myeloma
Predictive Factors for Early Relapse in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplant.
Multiple Myeloma
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.
Multiple Myeloma
Proapoptotic effects of the novel proteasome inhibitor b-AP15 on multiple myeloma cells and natural killer cells.
Multiple Myeloma
Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
Multiple Myeloma
Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis.
Multiple Myeloma
Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.
Multiple Myeloma
Progression with clinical features is associated with worse subsequent survival in multiple myeloma.
Multiple Myeloma
Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy.
Multiple Myeloma
Prolonged endoplasmic reticulum stress promotes mislocalization of immunoglobulins to the cytoplasm.
Multiple Myeloma
Prominent regression of corneal crystalline deposits in multiple myeloma after treatment with proteasome inhibitor.
Multiple Myeloma
Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma.
Multiple Myeloma
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
Multiple Myeloma
Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?
Multiple Myeloma
Proteasome 20S in multiple myeloma: comparison of concentration and chymotrypsin-like activity in plasma and serum.
Multiple Myeloma
Proteasome and heat shock protein 70 (HSP70) inhibitors as therapeutic alternative in multiple myeloma.
Multiple Myeloma
Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics.
Multiple Myeloma
Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review.
Multiple Myeloma
Proteasome inhibition as a new therapeutic principle in hematological malignancies.
Multiple Myeloma
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Multiple Myeloma
Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.
Multiple Myeloma
Proteasome inhibition blocks necroptosis by attenuating death complex aggregation.
Multiple Myeloma
Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
Multiple Myeloma
Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
Multiple Myeloma
Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
Multiple Myeloma
Proteasome inhibition in transplantation-focusing on the experience with bortezomib.
Multiple Myeloma
Proteasome inhibition increases recruitment of I?B kinase ? (IKK?), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.
Multiple Myeloma
Proteasome inhibition therapy: assessing the clinical implications in hematologic diseases.
Multiple Myeloma
Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice.
Multiple Myeloma
Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity?
Multiple Myeloma
Proteasome inhibitor holds promise for patients with refractory multiple myeloma.
Multiple Myeloma
Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Multiple Myeloma
Proteasome Inhibitor Induces Apoptosis through Induction of Endoplasmic Reticulum Stress.
Multiple Myeloma
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
Multiple Myeloma
Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells.
Multiple Myeloma
Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling.
Multiple Myeloma
Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma.
Multiple Myeloma
Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: A correlation with the proteasome status.
Multiple Myeloma
Proteasome inhibitor-induced coronary vasospasm in multiple myeloma: a case report.
Multiple Myeloma
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.
Multiple Myeloma
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
Multiple Myeloma
Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.
Multiple Myeloma
Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma.
Multiple Myeloma
Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi.
Multiple Myeloma
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.
Multiple Myeloma
Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades.
Multiple Myeloma
Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity.
Multiple Myeloma
Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem.
Multiple Myeloma
Proteasome inhibitors in first-line treatment of transplant-ineligible multiple myeloma patients.
Multiple Myeloma
Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
Multiple Myeloma
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.
Multiple Myeloma
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.
Multiple Myeloma
Proteasome inhibitors induce auditory hair cell death through peroxisome dysfunction.
Multiple Myeloma
Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion.
Multiple Myeloma
Proteasome inhibitors remarkably prevent translesion replication in cancer cells but not normal cells.
Multiple Myeloma
Proteasome inhibitors: a therapeutic strategy for haematological malignancy.
Multiple Myeloma
Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.
Multiple Myeloma
Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukemia and multiple myeloma.
Multiple Myeloma
Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma.
Multiple Myeloma
Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity.
Multiple Myeloma
Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer.
Multiple Myeloma
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
Multiple Myeloma
Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97.
Multiple Myeloma
Proteomics of apoptosis of multiple myeloma cells induced by proteasome inhibitor PS-341.
Multiple Myeloma
PS341 inhibits hepatocellular and colorectal cancer cells through the FOXO3/CTNNB1 signaling pathway.
Multiple Myeloma
Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors.
Multiple Myeloma
Quantitative analysis of bortezomib-induced IL-8 gene expression in ovarian cancer cells.
Multiple Myeloma
Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.
Multiple Myeloma
Quantitative profiling of caspase-cleaved substrates reveals different drug-induced and cell-type patterns in apoptosis.
Multiple Myeloma
Quinone methide tripterine, celastrol, induces apoptosis in human myeloma cells via NF-?B pathway.
Multiple Myeloma
Rapid induction of p62 and GABARAPL1 upon proteasome inhibition promotes survival before autophagy activation.
Multiple Myeloma
Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review.
Multiple Myeloma
RAR? activation sensitizes human myeloma cells to carfilzomib treatment through OAS-RNase L innate immune pathway.
Multiple Myeloma
Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Multiple Myeloma
Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Multiple Myeloma
Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma - Polish retrospective multicenter analysis.
Multiple Myeloma
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Multiple Myeloma
Recent Advancements of Bortezomib in Acute Lymphocytic Leukemia Treatment.
Multiple Myeloma
Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy.
Multiple Myeloma
Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
Multiple Myeloma
Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma.
Multiple Myeloma
Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib.
Multiple Myeloma
Reduced response of IRE1?/Xbp-1 signaling pathway to bortezomib contributes to drug resistance in multiple myeloma cells.
Multiple Myeloma
Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
Multiple Myeloma
Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review.
Multiple Myeloma
Relapse after allogeneic hematopoietic cell transplantation for multiple myeloma: Survival outcomes and factors influencing them.
Multiple Myeloma
Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib.
Multiple Myeloma
Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world".
Multiple Myeloma
Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma.
Multiple Myeloma
Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases.
Multiple Myeloma
Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for fas-mediated apoptosis in human leukemic cells.
Multiple Myeloma
Resistance of osteosarcoma cells to the proapoptotic effects of carfilzomib involves activation of mitogen activated protein kinase pathways.
Multiple Myeloma
Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
Multiple Myeloma
Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
Multiple Myeloma
Resveratrol Sensitizes Carfilzomib-Induced Apoptosis via Promoting Oxidative Stress in Multiple Myeloma Cells.
Multiple Myeloma
Reversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors.
Multiple Myeloma
Reversible posterior leucoencephalopathy syndrome associated with bortezomib in a patient with relapsed multiple myeloma.
Multiple Myeloma
RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma.
Multiple Myeloma
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Multiple Myeloma
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
Multiple Myeloma
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Multiple Myeloma
Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy.
Multiple Myeloma
RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
Multiple Myeloma
Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma.
Multiple Myeloma
Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells.
Multiple Myeloma
Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.
Multiple Myeloma
Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF-?B, Hypertrophic Gene Expression and Oxidative Stress.
Multiple Myeloma
Rutin inhibits carfilzomib-induced oxidative stress and inflammation via the NOS-mediated NF-?B signaling pathway.
Multiple Myeloma
S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma.
Multiple Myeloma
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Multiple Myeloma
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Multiple Myeloma
Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma.
Multiple Myeloma
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Multiple Myeloma
Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy.
Multiple Myeloma
Search for Inhibitors of the Ubiquitin-Proteasome System from Natural Sources for Cancer Therapy.
Multiple Myeloma
Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs).
Multiple Myeloma
Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study.
Multiple Myeloma
Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
Multiple Myeloma
Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I.
Multiple Myeloma
Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.
Multiple Myeloma
Sequence analysis of ?-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Multiple Myeloma
Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma.
Multiple Myeloma
Severe Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma: A Case Report and Review of the Literature.
Multiple Myeloma
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
Multiple Myeloma
Severe Right-Sided Heart Failure and Pulmonary Hypertension with Carfilzomib Treatment in Multiple Myeloma.
Multiple Myeloma
Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.
Multiple Myeloma
Silencing of SENP2 in Multiple Myeloma Induces Bortezomib Resistance by Activating NF-?B Through the Modulation of I?B? Sumoylation.
Multiple Myeloma
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Multiple Myeloma
Small molecule CP-31398 induces reactive oxygen species-dependent apoptosis in human multiple myeloma.
Multiple Myeloma
Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
Multiple Myeloma
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Multiple Myeloma
Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma.
Multiple Myeloma
Soluble and Cell-Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma.
Multiple Myeloma
Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity.
Multiple Myeloma
Specificity of protein covalent modification by the electrophilic proteasome inhibitor carfilzomib in human cells.
Multiple Myeloma
Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78.
Multiple Myeloma
Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry.
Multiple Myeloma
Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.
Multiple Myeloma
Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes.
Multiple Myeloma
Structure-based design of ?1i or ?5i specific inhibitors of human immunoproteasomes.
Multiple Myeloma
Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (?5i).
Multiple Myeloma
Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma.
Multiple Myeloma
Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysis.
Multiple Myeloma
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Multiple Myeloma
Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases.
Multiple Myeloma
Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation.
Multiple Myeloma
Synergistic action of 5Z-7-oxozeaenol and bortezomib in inducing apoptosis of Burkitt lymphoma cell line Daudi.
Multiple Myeloma
Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma.
Multiple Myeloma
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD(®) immunomodulatory drug pomalidomide.
Multiple Myeloma
Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors.
Multiple Myeloma
Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro.
Multiple Myeloma
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Multiple Myeloma
Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
Multiple Myeloma
Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
Multiple Myeloma
Synthesis and biological evaluation of the natural product komaroviquinone and related compounds aiming at a potential therapeutic lead compound for high-risk multiple myeloma.
Multiple Myeloma
Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15.
Multiple Myeloma
Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines.
Multiple Myeloma
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Multiple Myeloma
Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity And Induces Tumor Cell Death.
Multiple Myeloma
Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma.
Multiple Myeloma
Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs.
Multiple Myeloma
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
Multiple Myeloma
Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.
Multiple Myeloma
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
Multiple Myeloma
Targeting Bortezomib to Bone Increases Its Bone Anabolic Activity and Reduces Systemic Adverse Effects in Mice.
Multiple Myeloma
Targeting lipid metabolism in multiple myeloma cells: Rational development of a synergistic strategy with proteasome inhibitors.
Multiple Myeloma
Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
Multiple Myeloma
Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?
Multiple Myeloma
Targeting RFWD2 as an Effective Strategy to Inhibit Cellular Proliferation and Overcome Drug Resistance to Proteasome Inhibitor in Multiple Myeloma.
Multiple Myeloma
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple myeloma.
Multiple Myeloma
Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress?mediated cell death in multiple myeloma cells.
Multiple Myeloma
Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma.
Multiple Myeloma
Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.
Multiple Myeloma
Targeting the proteasome as a therapeutic strategy against haematological malignancies.
Multiple Myeloma
Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib.
Multiple Myeloma
Targeting the Proteasome With Bortezomib in Multiple Myeloma: Update on Therapeutic Benefit as an Upfront Single Agent, Induction Regimen for Stem-Cell Transplantation and as Maintenance Therapy.
Multiple Myeloma
Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.
Multiple Myeloma
Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy.
Multiple Myeloma
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors.
Multiple Myeloma
Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.
Multiple Myeloma
Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.
Multiple Myeloma
TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma.
Multiple Myeloma
Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.
Multiple Myeloma
The Actions and Mechanisms of P2X7R and p38 MAPK Activation in Mediating Bortezomib-Induced Neuropathic Pain.
Multiple Myeloma
The activity and safety of novel proteasome inhibitors strategies (single, doublet and triplet) for relapsed/refractory multiple myeloma.
Multiple Myeloma
The aggresome pathway as a target for therapy in hematologic malignancies.
Multiple Myeloma
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.
Multiple Myeloma
The combination of ionizing radiation and proteasomal inhibition by bortezomib enhances the expression of NKG2D ligands in multiple myeloma cells.
Multiple Myeloma
The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells.
Multiple Myeloma
The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells.
Multiple Myeloma
The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
Multiple Myeloma
The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma.
Multiple Myeloma
The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib.
Multiple Myeloma
The effects of proteasome inhibitors on bone remodeling in multiple myeloma.
Multiple Myeloma
The Effects of Proteasome Inhibitors on Telomerase Activity and Regulation in Multiple Myeloma Cells.
Multiple Myeloma
The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
Multiple Myeloma
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
Multiple Myeloma
The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group.
Multiple Myeloma
The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
Multiple Myeloma
The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma.
Multiple Myeloma
The First Autopsy Case of Fatal Acute Cardiac Failure after Administration of Carfilzomib in a Patient with Multiple Myeloma.
Multiple Myeloma
The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.
Multiple Myeloma
The future of proteasome inhibitors in relapsed/refractory multiple myeloma.
Multiple Myeloma
The G-Allele of the PSMA6 -8C>G polymorphism is associated with poor outcome in multiple myeloma independently of circulating proteasome serum levels.
Multiple Myeloma
The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.
Multiple Myeloma
The HIV-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the multiple myeloma cells proliferation in vitro and in vivo.
Multiple Myeloma
The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.
Multiple Myeloma
The immunoproteasome as a therapeutic target for hematological malignancies.
Multiple Myeloma
The immunotherapy era of myeloma: monoclonal antibodies, vaccines and adoptive T cell therapies.
Multiple Myeloma
The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.
Multiple Myeloma
The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium.
Multiple Myeloma
The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
Multiple Myeloma
The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma.
Multiple Myeloma
The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma.
Multiple Myeloma
The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma.
Multiple Myeloma
The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy.
Multiple Myeloma
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.
Multiple Myeloma
The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.
Multiple Myeloma
The next generation of novel therapies for the management of relapsed multiple myeloma.
Multiple Myeloma
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
Multiple Myeloma
The novel ?2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Multiple Myeloma
The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
Multiple Myeloma
The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
Multiple Myeloma
The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma.
Multiple Myeloma
The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells.
Multiple Myeloma
The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.
Multiple Myeloma
The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.
Multiple Myeloma
The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
Multiple Myeloma
The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib.
Multiple Myeloma
The proteasome and its inhibitors in immune regulation and immune disorders.
Multiple Myeloma
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
Multiple Myeloma
The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
Multiple Myeloma
The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
Multiple Myeloma
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.
Multiple Myeloma
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Multiple Myeloma
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.
Multiple Myeloma
The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-?1.
Multiple Myeloma
The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes.
Multiple Myeloma
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
Multiple Myeloma
The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
Multiple Myeloma
The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection.
Multiple Myeloma
The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Multiple Myeloma
The proteasome inhibitor bortezomib induces testicular toxicity by upregulation of oxidative stress, AMP-activated protein kinase (AMPK) activation and deregulation of germ cell development in adult murine testis.
Multiple Myeloma
The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.
Multiple Myeloma
The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses.
Multiple Myeloma
The proteasome inhibitor bortezomib is a potent inducer of zinc-finger AN1-type domain 2a gene expression: role of HSF1/HSF2 heterocomplexes.
Multiple Myeloma
The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells.
Multiple Myeloma
The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway.
Multiple Myeloma
The proteasome inhibitor PS-341 (Bortezomib) induces calpain-dependent I{kappa}B{alpha} degradation.
Multiple Myeloma
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Multiple Myeloma
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
Multiple Myeloma
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
Multiple Myeloma
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
Multiple Myeloma
The Proteasome Inhibitor, Bortezomib, Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.
Multiple Myeloma
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.
Multiple Myeloma
The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma.
Multiple Myeloma
The putative roles of the ubiquitin/proteasome pathway in resistance to anticancer therapy.
Multiple Myeloma
The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib.
Multiple Myeloma
The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma.
Multiple Myeloma
The Role of Hdac Inhibitors in Patients with Relapsed/Refractory Multiple Myeloma.
Multiple Myeloma
The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.
Multiple Myeloma
The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma.
Multiple Myeloma
The Role of Pre-Transplant Induction Regimens and Autologous Stem Cell Transplantation in the Era of Novel Targeted Agents.
Multiple Myeloma
The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
Multiple Myeloma
The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.
Multiple Myeloma
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.
Multiple Myeloma
The start of a new wave: developments in proteasome inhibition in multiple myeloma.
Multiple Myeloma
The ubiquitin+proteasome protein degradation pathway as a therapeutic strategy in the treatment of solid tumor malignancies.
Multiple Myeloma
The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications.
Multiple Myeloma
The ubiquitin-proteasome pathway and resistance mechanisms developed against the proteasomal inhibitors in cancer cells.
Multiple Myeloma
The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib.
Multiple Myeloma
The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib.
Multiple Myeloma
The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance.
Multiple Myeloma
The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
Multiple Myeloma
The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias.
Multiple Myeloma
The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature.
Multiple Myeloma
The use of novel agents in multiple myeloma patients with hepatic impairment.
Multiple Myeloma
The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients.
Multiple Myeloma
Therapeutic approach for relapsed/refractory multiple myeloma: the logic and practice.
Multiple Myeloma
Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
Multiple Myeloma
Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.
Multiple Myeloma
Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.
Multiple Myeloma
Thiasyrbactins Induce Cell Death via Proteasome Inhibition in Multiple Myeloma Cells.
Multiple Myeloma
Thiostrepton is an inducer of oxidative and proteotoxic stress that impairs viability of human melanoma cells but not primary melanocytes.
Multiple Myeloma
Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
Multiple Myeloma
Time-Resolved Proteomics Extends Ribosome Profiling-Based Measurements of Protein Synthesis Dynamics.
Multiple Myeloma
Toxic Effects of Bortezomib on Primary Sensory Neurons and Schwann Cells of Adult Mice.
Multiple Myeloma
TP-110, a new proteasome inhibitor, down-regulates IAPs in human multiple myeloma cells.
Multiple Myeloma
Transcriptome sequencing (RNA-seq) analysis of the effects of metal nanoparticle exposure on the transcriptome of Chlamydomonas reinhardtii.
Multiple Myeloma
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.
Multiple Myeloma
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.
Multiple Myeloma
Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group.
Multiple Myeloma
Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Multiple Myeloma
Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?
Multiple Myeloma
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model.
Multiple Myeloma
Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model.
Multiple Myeloma
Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma.
Multiple Myeloma
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
Multiple Myeloma
Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
Multiple Myeloma
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
Multiple Myeloma
Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data.
Multiple Myeloma
Trends of incidence, mortality, and survival of multiple myeloma in Switzerland between 1994 and 2013.
Multiple Myeloma
TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.
Multiple Myeloma
Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma.
Multiple Myeloma
Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect.
Multiple Myeloma
Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.
Multiple Myeloma
Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor.
Multiple Myeloma
Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.
Multiple Myeloma
Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.
Multiple Myeloma
Ubiquitin-regulated nuclear-cytoplasmic trafficking of the Nipah virus matrix protein is important for viral budding.
Multiple Myeloma
Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy.
Multiple Myeloma
UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression.
Multiple Myeloma
Updated review and perspective on 20S proteasome inhibitors in the treatment of Lung Cancer.
Multiple Myeloma
Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.
Multiple Myeloma
Upregulated expression and function of the ?4?1 integrin in multiple myeloma cells resistant to bortezomib.
Multiple Myeloma
Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors.
Multiple Myeloma
Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes.
Multiple Myeloma
Use of bortezomib to treat anti-HLA antibodies in renal transplant patients: A single-center experience.
Multiple Myeloma
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma.
Multiple Myeloma
Use of Curcumin in Multiple Myeloma patients intolerant of steroid therapy.
Multiple Myeloma
Use of systemic proteasome inhibition as an immune-modulating agent in disease.
Multiple Myeloma
Vincristine and bortezomib cause axon outgrowth and behavioral defects in larval zebrafish.
Multiple Myeloma
Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment.
Multiple Myeloma
Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.
Multiple Myeloma
VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification.
Multiple Myeloma
When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response.
Multiple Myeloma
Wnt pathway activation and ABCB1 expression account for attenuation of Proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells.
Multiple Myeloma
Wrenches in the works: drug discovery targeting the SCF ubiquitin ligase and APC/C complexes.
Multiple Myeloma
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.
Multiple Myeloma
Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma.
Multiple Myeloma
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I?B? and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Multiple Myeloma
YWHAE/14-3-3? expression impacts the protein load contributing to proteasome inhibitor sensitivity in multiple myeloma.
Multiple Myeloma
ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-?B in multiple myeloma.
Multiple Myeloma
[A new therapy with bortezomib, an oncologic medicinal product of the year 2004]
Multiple Myeloma
[Antibody therapy for multiple myeloma: novel approaches and future perspectives].
Multiple Myeloma
[Autologous peripheral blood stem cell transplantation for double-refractory myeloma with K-RAS and N-RAS mutations].
Multiple Myeloma
[Carfilzomib-induced haemolytic and uremic syndrome: Favorable outcome with eculizumab].
Multiple Myeloma
[Current status and future prospects of immunotherapy for multiple myeloma].
Multiple Myeloma
[Depletion of plasma cells - a novel strategy in the therapy of systemic lupus erythematosus in mice and man.]
Multiple Myeloma
[Drug-Resistant Mechanism of Multiple Myeloma and Its Therapy Combined with HDACi -Review].
Multiple Myeloma
[Effect of proteasome inhibitor on migration ability and hepatocyte growth factor expression of bone marrow mesenchymal stem cells in multiple myeloma patients].
Multiple Myeloma
[Effects of Proteasome Inhibitor PS-341 on the Multiple Cytokine Expressions of Mesenchymal Stem Cells from Bone Marrow in Patients with Multiple Myeloma.]
Multiple Myeloma
[Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma]
Multiple Myeloma
[Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology]
Multiple Myeloma
[Macrocalyxin A induces apoptosis of multiple Myeloma U266 cells through inhibiting the proteasome].
Multiple Myeloma
[Methods and clinical values for minimal residual disease detection in patients with multiple myeloma].
Multiple Myeloma
[Prognostic significance of sequencing-based MRD detection in multiple myeloma].
Multiple Myeloma
[Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy]
Multiple Myeloma
[Proteasome inhibition: a new therapeutic approach for the treatment of multiple myeloma]
Multiple Myeloma
[Proteasome inhibitor induces apoptosis and influences the expression of notch 1 and NF-kappaB in multiple myeloma RPMI8226 cells]
Multiple Myeloma
[Response rates to first-line treatment in eligible patients to autologous stem transplantation in Chile].
Multiple Myeloma
[Role of HDAC isoforms and development of treatment of multiple myeloma using isoform-specific HDAC inhibitors].
Multiple Myeloma
[Safety and management of adverse events of ixazomib/lenalidomide/dexamethasone therapy in Japanese patients with relapsed/refractory multiple myeloma].
Multiple Myeloma
[Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma]
Multiple Myeloma
[Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
Multiple Myeloma
[Thalidomide in the treatment of multiple myeloma: focus on combination with bortezomib].
Multiple Myeloma
[The proteasome?-?structural aspects and inhibitors: a second life for a validated drug target].
Multiple Myeloma
[Treatment of newly diagnosed multiple myeloma in transplant-eligible patients].
Multiple Myeloma
[Treatment strategy for untreated transplantation-ineligible multiple myeloma patients].
Multiple Myeloma
[Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma]
Multiple Myeloma
[Use of proteasome inhibitors in the treatment of patients with multiple myeloma]
Multiple Sclerosis
Autoantibodies to the proteasome in monosymptomatic optic neuritis may predict progression to multiple sclerosis.
Multiple Sclerosis
Decreased activity of the 20S proteasome in the brain white matter and gray matter of patients with multiple sclerosis.
Multiple Sclerosis
Deimination of the myelin basic protein decelerates its proteasome-mediated metabolism.
Multiple Sclerosis
Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.
Multiple Sclerosis
Genetic variations in the PSMA6 and PSMC6 proteasome genes are associated with multiple sclerosis and response to interferon-? therapy in Latvians.
Multiple Sclerosis
Glatiramer acetate and nanny proteins restrict access of the multiple sclerosis autoantigen myelin basic protein to the 26S proteasome.
Multiple Sclerosis
Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population.
Multiple Sclerosis
Proteasome inhibitors: a new perspective for treating autoimmune diseases.
Multiple Sclerosis
Protection against experimental autoimmune encephalomyelitis by a proteasome modulator.
Multiple Sclerosis
Untangling Extracellular Proteasome-Osteopontin Circuit Dynamics in Multiple Sclerosis.
Multiple Sclerosis, Relapsing-Remitting
Proteasome antibodies in patients with cancer or multiple sclerosis.
Multiple System Atrophy
Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human ?-synuclein under oligodendrocyte promoter: implications for multiple system atrophy.
Murine Acquired Immunodeficiency Syndrome
Activation of the ubiquitin proteolytic system in murine acquired immunodeficiency syndrome affects IkappaBalpha turnover.
Muscle Weakness
Effect of Proteasome Inhibitors on Endotoxin Induced Diaphragm Dysfunction.
Muscular Atrophy
Aggregation and proteasome: the case of elongated polyglutamine aggregation in spinal and bulbar muscular atrophy.
Muscular Atrophy
Angiotensin (1-7) Decreases Myostatin-Induced NF-?B Signaling and Skeletal Muscle Atrophy.
Muscular Atrophy
Archaeal proteasomes effectively degrade aggregation-prone proteins and reduce cellular toxicities in mammalian cells.
Muscular Atrophy
Atrogin-1/MAFbx and MuRF1 are downregulated in aging-related loss of skeletal muscle.
Muscular Atrophy
Caloric restriction optimizes the proteasome pathway with aging in rat plantaris muscle: implications for sarcopenia.
Muscular Atrophy
Calpain and capase-3 play required roles in immobilization-induced limb muscle atrophy.
Muscular Atrophy
Characterization of the Ubiquitin Specific Protease (USP) family members in the fast and slow muscle fibers from Chinese perch (Siniperca chuatsi).
Muscular Atrophy
Chemotherapy-induced muscle wasting: association with NF-?B and cancer cachexia.
Muscular Atrophy
Circulating 20S proteasome for assessing protein energy wasting syndrome in hemodialysis patients.
Muscular Atrophy
Coordinate expression of the 19S regulatory complex and evidence for ubiquitin-dependent telethonin degradation in the unloaded soleus muscle.
Muscular Atrophy
Daily variations in dietary lysine content alter the expression of genes related to proteolysis in chicken pectoralis major muscle.
Muscular Atrophy
Denervation-Induced Activation of the Standard Proteasome and Immunoproteasome.
Muscular Atrophy
Deubiquitinating enzymes in skeletal muscle atrophy-An essential role for USP19.
Muscular Atrophy
Docosahexaenoic acid-mediated protein aggregates may reduce proteasome activity and delay myotube degradation during muscle atrophy in vitro.
Muscular Atrophy
Down-regulation of Akt/mammalian target of rapamycin pathway in skeletal muscle is associated with increased REDD1 expression in response to chronic hypoxia.
Muscular Atrophy
Dynamics of autophagy and ubiquitin proteasome system coordination and interplay in skeletal muscle atrophy.
Muscular Atrophy
Effect of different dietary protein composition on skeletal muscle atrophy by suspension hypokinesia/hypodynamia in rats.
Muscular Atrophy
Effect of flywheel-based resistance exercise on processes contributing to muscle atrophy during unloading in adult rats.
Muscular Atrophy
Enhanced Clearance of Neurotoxic Misfolded Proteins by the Natural Compound Berberine and Its Derivatives.
Muscular Atrophy
High Fat Diet-Induced Skeletal Muscle Wasting Is Decreased by Mesenchymal Stem Cells Administration: Implications on Oxidative Stress, Ubiquitin Proteasome Pathway Activation, and Myonuclear Apoptosis.
Muscular Atrophy
High Fat With High Sucrose Diet Leads to Obesity and Induces Myodegeneration.
Muscular Atrophy
Histone deacetylase inhibition suppresses myogenin-dependent atrogene activation in spinal muscular atrophy mice.
Muscular Atrophy
HMGB1 release and redox regulation accompany regeneration and remodeling of skeletal muscle.
Muscular Atrophy
Implication of altered ubiquitin-proteasome system and ER stress in the muscle atrophy of diabetic rats.
Muscular Atrophy
Indoxyl sulfate induces myotube atrophy by ROS-ERK and JNK-MAFbx cascades.
Muscular Atrophy
Inducible Rpt3, a Proteasome Component, Knockout in Adult Skeletal Muscle Results in Muscle Atrophy.
Muscular Atrophy
Inhibition of the proteasome partially attenuates atrophy in botulinum neurotoxin treated skeletal muscle.
Muscular Atrophy
Insulin signaling and skeletal muscle atrophy and autophagy in transition dairy cows either overfed energy or fed a controlled energy diet prepartum.
Muscular Atrophy
Iron limitation promotes the atrophy of skeletal myocytes, whereas iron supplementation prevents this process in the hypoxic conditions.
Muscular Atrophy
Lack of ?2 -adrenoceptors aggravates heart failure-induced skeletal muscle myopathy in mice.
Muscular Atrophy
Maintenance of muscle mass and load-induced growth in Muscle RING Finger 1 null mice with age.
Muscular Atrophy
Merg1a K+ channel induces skeletal muscle atrophy by activating the ubiquitin proteasome pathway.
Muscular Atrophy
Molecular characterization of the MuRF genes in rainbow trout: Potential role in muscle degradation.
Muscular Atrophy
Myofibril breakdown during atrophy is a delayed response requiring the transcription factor PAX4 and desmin depolymerization.
Muscular Atrophy
Overexpression of the Mitochondrial T3 Receptor Induces Skeletal Muscle Atrophy during Aging.
Muscular Atrophy
Overexpression of the mitochondrial T3 receptor induces skeletal muscle atrophy during aging.
Muscular Atrophy
Paeoniflorin eliminates a mutant AR via NF-YA-dependent proteolysis in spinal and bulbar muscular atrophy.
Muscular Atrophy
PARK2/Parkin-mediated mitochondrial clearance contributes to proteasome activation during slow-twitch muscle atrophy via NFE2L1 nuclear translocation.
Muscular Atrophy
Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents.
Muscular Atrophy
Polyubiquitin in crustacean striated muscle: increased expression and conjugation during molt-induced claw muscle atrophy.
Muscular Atrophy
Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6.
Muscular Atrophy
PSMB8 encoding the ?5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome.
Muscular Atrophy
Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation.
Muscular Atrophy
The cytosolic sialidase Neu2 is degraded by autophagy during myoblast atrophy.
Muscular Atrophy
The dependency of autophagy and ubiquitin proteasome system during skeletal muscle atrophy.
Muscular Atrophy
The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy.
Muscular Atrophy
The Proteasome Inhibitor MG132 Reduces Immobilization-Induced Skeletal Muscle Atrophy in Mice.
Muscular Atrophy
The Ubr2 gene is expressed in skeletal muscle atrophying as a result of hind limb suspension, but not Merg1a expression alone.
Muscular Atrophy
The Ubr2 Gene is Expressed in Skeletal Muscle Atrophying as a Result of Hind Limb Suspension, but not Merg1a Expression Alone.
Muscular Atrophy
Tourniquet-induced ischaemia during total knee arthroplasty results in higher proteolytic activities within vastus medialis cells: a randomized clinical trial.
Muscular Atrophy
Transcriptomic analysis of the hepatic response to stress in the red cusk-eel (Genypterus chilensis): Insights into lipid metabolism, oxidative stress and liver steatosis.
Muscular Atrophy
Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction.
Muscular Atrophy
Ventilator-induced diaphragm dysfunction: the clinical relevance of animal models.
Muscular Atrophy
Vitamin D Deficiency Induced Muscle Wasting Occurs through the Ubiquitin Proteasome Pathway and Is Partially Corrected by Calcium in Male Rats.
Muscular Atrophy
Vitamin D treatment protects against and reverses oxidative stress induced muscle proteolysis.
Muscular Atrophy
[Effect of Buyang Huanwu decoction on NF-?B/MuRFl expression in rats with denervated tibial muscle atrophy].
Muscular Atrophy
[The proteasome inhibitor MG132 attenuates skeletal muscle atrophy in a rat model of chronic obstructive pulmonary disease.]
Muscular Atrophy, Spinal
CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy.
Muscular Atrophy, Spinal
Lysine-Less Variants of Spinal Muscular Atrophy SMN and SMN?7 Proteins Are Degraded by the Proteasome Pathway.
Muscular Atrophy, Spinal
The E3 ubiquitin ligase mind bomb 1 ubiquitinates and promotes the degradation of survival of motor neuron protein.
Muscular Diseases
Contribution of genetic factors to the pathogenesis of Paget's disease of bone and related disorders.
Muscular Diseases
Impaired muscle morphology in a Drosophila model of myosin storage myopathy was supressed by overexpression of an E3 ubiquitin ligase.
Muscular Diseases
Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation.
Muscular Diseases
Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents.
Muscular Diseases
Proteasome dysfunction induces muscle growth defects and protein aggregation.
Muscular Diseases
Protein recycling and limb muscle recovery after critical illness in slow- and fast-twitch limb muscle.
Muscular Diseases
Skeletal muscle alterations in chronic heart failure: differential effects on quadriceps and diaphragm.
Muscular Disorders, Atrophic
Prevention of muscle disuse atrophy by MG132 proteasome inhibitor.
Muscular Dystrophies
Bortezomib Partially Improves Laminin ?2 Chain-Deficient Muscular Dystrophy.
Muscular Dystrophies
Effect of calpain and proteasome inhibition on Ca2+-dependent proteolysis and muscle histopathology in the mdx mouse.
Muscular Dystrophies
Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.
Muscular Dystrophies
Genetic myostatin decrease in the golden retriever muscular dystrophy model does not significantly affect the ubiquitin proteasome system despite enhancing the severity of disease.
Muscular Dystrophies
Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences.
Muscular Dystrophies
Proteasome expression in the skeletal muscles of patients with muscular dystrophy.
Muscular Dystrophies
Proteasome inhibitors increase missense mutated dysferlin in patients with muscular dystrophy.
Muscular Dystrophies
Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.
Muscular Dystrophies
Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies.
Muscular Dystrophy, Duchenne
Immunoproteasome in animal models of Duchenne muscular dystrophy.
Muscular Dystrophy, Duchenne
Modulation of Protein Quality Control and Proteasome to Autophagy Switch in Immortalized Myoblasts from Duchenne Muscular Dystrophy Patients.
Muscular Dystrophy, Duchenne
Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment.
Muscular Dystrophy, Duchenne
Regulation of the calpain and ubiquitin-proteasome systems in a canine model of muscular dystrophy.
Muscular Dystrophy, Duchenne
The ubiquitin ligase tripartite-motif-protein 32 is induced in Duchenne muscular dystrophy.
Muscular Dystrophy, Oculopharyngeal
A Novel Feed-Forward Loop between ARIH2 E3-Ligase and PABPN1 Regulates Aging-Associated Muscle Degeneration.
Musculoskeletal Pain
Managing Multiple Myeloma in the Face of Drug-Induced Adverse Drug Reaction.
Myasthenia Gravis
Clinical and scientific aspects of acetylcholine receptor myasthenia gravis.
Myasthenia Gravis
Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis.
Myasthenia Gravis
Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients.
Mycoses
Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort study.
Mycosis Fungoides
miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma.
Myelodysplastic Syndromes
Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells.
Myelodysplastic Syndromes
Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study.
Myelodysplastic Syndromes
Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes.
Myelodysplastic Syndromes
Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors.
Myelodysplastic Syndromes
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Myelodysplastic Syndromes
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.
Myelodysplastic Syndromes
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Myocardial Infarction
A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese population.
Myocardial Infarction
Crosstalk between cardiomyocytes and noncardiomyocytes is essential to prevent cardiomyocyte apoptosis induced by proteasome inhibition.
Myocardial Infarction
Degradation of GRK2 and AKT is an early and detrimental event in myocardial ischemia/reperfusion.
Myocardial Infarction
Impact of proteasome inhibitor MG-132 on expression of NF-?B, IL-1? and histological remodeling after myocardial infarction.
Myocardial Infarction
Involvement of proteasome and macrophages M2 in the protection afforded by telmisartan against the acute myocardial infarction in Zucker diabetic fatty rats with metabolic syndrome.
Myocardial Infarction
Polymorphisms of LTA, LGALS2, and PSMA6 genes and coronary atherosclerosis: A pathological study of 1503 consecutive autopsy cases.
Myocardial Infarction
Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction.
Myocardial Infarction
Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction.
Myocardial Infarction
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury.
Myocardial Infarction
Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome.
Myocardial Infarction
The -8 UTR C/G polymorphism of PSMA6 gene is associated with susceptibility to myocardial infarction in type 2 diabetic patients.
Myocardial Infarction
The functional variant rs1048990 in PSMA6 is associated with susceptibility to myocardial infarction in a Chinese population.
Myocardial Infarction
The G-Allele of the PSMA6 -8C>G polymorphism is associated with poor outcome in multiple myeloma independently of circulating proteasome serum levels.
Myocardial Infarction
The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases.
Myocardial Infarction
Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction.
Myocardial Infarction
UBE2D3 contributes to myocardial ischemia-reperfusion injury by regulating autophagy in dependence of p62/SQSTM1.
Myocardial Infarction
Ubiquitin?proteasomes are the dominant mediators of the regulatory effect of microRNA?1 on cardiac remodeling after myocardial infarction.
Myocardial Infarction
Validation of the association between the gene encoding proteasome subunit alpha type 6 and myocardial infarction in a Japanese population.
Myocardial Ischemia
Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice.
Myocardial Ischemia
Inhibition of chymotrypsin-like activity of the proteasome by ixazomib prevents mitochondrial dysfunction during myocardial ischemia.
Myocardial Ischemia
Proteasome mediates removal of proteins oxidized during myocardial ischemia.
Myocardial Ischemia
Regulation of the proteasome by ATP: implications for ischemic myocardial injury and donor heart preservation.
Myocardial Ischemia
The Ubiquitin Proteasome System in Myocardial Ischemia and Preconditioning.
Myocardial Reperfusion Injury
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury.
Myocardial Reperfusion Injury
Regulation of the proteasome by ATP: implications for ischemic myocardial injury and donor heart preservation.
Myocarditis
Mitigated viral myocarditis in A/J mice by the immunoproteasome inhibitor ONX 0914 depends on inhibition of systemic inflammatory responses in CoxsackievirusB3 infection.
Myocarditis
ONX 0914 Lacks Selectivity for the Cardiac Immunoproteasome in CoxsackievirusB3 Myocarditis of NMRI Mice and Promotes Virus-Mediated Tissue Damage.
Myocarditis
PA28 modulates antigen processing and viral replication during coxsackievirus B3 infection.
Myocarditis
Proteasomal Protein Degradation: Adaptation of Cellular Proteolysis With Impact on Virus-and Cytokine-Mediated Damage of Heart Tissue During Myocarditis.
Myocarditis
Proteasome activator REGgamma enhances coxsackieviral infection by facilitating p53 degradation.
Myocarditis
Proteasome inhibition reduces coxsackievirus B3 replication in murine cardiomyocytes.
Myopathies, Structural, Congenital
Lack of myotubularin (MTM1) leads to muscle hypotrophy through unbalanced regulation of the autophagy and ubiquitin-proteasome pathways.
Myositis
AbetaPP-overexpression and proteasome inhibition increase alphaB-crystallin in cultured human muscle: relevance to inclusion-body myositis.
Myositis
Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: A potential therapeutic target.
Myositis
Autoantibodies in primary Sjögren's syndrome are directed against proteasomal subunits of the alpha and beta type.
Myositis
In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis.
Myositis
Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation.
Myositis
Inclusion-body myositis. A myodegenerative conformational disorder associated with A|gb, protein misfolding, and proteasome inhibition.
Myositis
Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition.
Myositis
Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus.
Myositis
Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers.
Myositis
Successful treatment of a novel type I interferonopathy due to a de novo PSMB9 gene mutation with a Janus kinase inhibitor.
Myositis
Upregulation of immunoproteasome subunits in myositis indicates active inflammation with involvement of antigen presenting cells, CD8 T-cells and IFN?.
Myositis, Inclusion Body
Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation.
Myxoma
Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma.
Nasal Polyps
Proteasome inhibition reduces proliferation, collagen expression, and inflammatory cytokine production in nasal mucosa and polyp fibroblasts.
Nasopharyngeal Carcinoma
Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
Nasopharyngeal Carcinoma
Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
Nasopharyngeal Carcinoma
Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer.
Nasopharyngeal Carcinoma
Proteasome inhibitors decrease paclitaxel?induced cell death in nasopharyngeal carcinoma with the accumulation of CDK1/cyclin B1.
Nasopharyngeal Neoplasms
Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer.
Nasopharyngeal Neoplasms
Novel CADD-based peptidyl vinyl ester derivatives as potential proteasome inhibitors.
Nasopharyngeal Neoplasms
Proteasome inhibitors decrease paclitaxel?induced cell death in nasopharyngeal carcinoma with the accumulation of CDK1/cyclin B1.
Nematode Infections
Cowpea-Meloidogyne incognita interaction: Root proteomic analysis during early stages of nematode infection.
Neoplasm Metastasis
A light-triggered self-reinforced nanoagent for targeted chemo-photodynamic therapy of breast cancer bone metastases via ER stress and mitochondria mediated apoptotic pathways.
Neoplasm Metastasis
Activity and subunit composition of proteasomes in head and cervical squamous cell carcinomas.
Neoplasm Metastasis
Anti-tumor activity of benzylideneacetophenone derivatives via proteasomal inhibition in prostate cancer cells.
Neoplasm Metastasis
Autophagic Inhibition of Caveolin-1 by Compound Phyllanthus urinaria L. Activates Ubiquitination and Proteasome Degradation of ?-catenin to Suppress Metastasis of Hepatitis B-Associated Hepatocellular Carcinoma.
Neoplasm Metastasis
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
Neoplasm Metastasis
Carnosol, a Natural Polyphenol, Inhibits Migration, Metastasis, and Tumor Growth of Breast Cancer via a ROS-Dependent Proteasome Degradation of STAT3.
Neoplasm Metastasis
Cell-cell dissociation upon epithelial cell scattering requires a step mediated by the proteasome.
Neoplasm Metastasis
CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer.
Neoplasm Metastasis
CHIP-mediated ubiquitination of Galectin-1 predicts colorectal cancer prognosis.
Neoplasm Metastasis
Comparative proteome analysis of three mouse lung adenocarcinoma CMT cell lines with different metastatic potential by two-dimensional gel electrophoresis and mass spectrometry.
Neoplasm Metastasis
Crystal structure of HECT domain of UBE3C E3 ligase and its ubiquitination activity.
Neoplasm Metastasis
Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer.
Neoplasm Metastasis
Depletion of the proteasome subunit PSMA7 inhibits colorectal cancer cell tumorigenicity and migration.
Neoplasm Metastasis
Deubiquitinase USP29 promotes gastric cancer cell migration by cooperating with phosphatase SCP1 to stabilize Snail protein.
Neoplasm Metastasis
Differential regulation of the REG?-proteasome pathway by p53/TGF-? signalling and mutant p53 in cancer cells.
Neoplasm Metastasis
Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases.
Neoplasm Metastasis
Functioning of Proteasomes in Lymphogenic Metastasizing of Non-Small-Cell Lung Cancer.
Neoplasm Metastasis
Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression.
Neoplasm Metastasis
Gel-based proteomics analysis of the heterogeneity of 20S proteasomes from four human pancreatic cancer cell lines.
Neoplasm Metastasis
Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer.
Neoplasm Metastasis
Green tea polyphenols as proteasome inhibitors: implication in chemoprevention.
Neoplasm Metastasis
Imaging Reporters for Proteasome Activity Identify Tumor- and Metastasis-Initiating Cells.
Neoplasm Metastasis
Immunological differences between primary and metastatic breast cancer.
Neoplasm Metastasis
Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction.
Neoplasm Metastasis
Integrating protein-protein interaction networks with gene-gene co-expression networks improves gene signatures for classifying breast cancer metastasis.
Neoplasm Metastasis
JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, HIF-independent mechanism.
Neoplasm Metastasis
Ligand independent aryl hydrocarbon receptor inhibits lung cancer cell invasion by degradation of Smad4.
Neoplasm Metastasis
Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia.
Neoplasm Metastasis
Lysosomal Degradation of CD44 Mediates Ceramide Nanoliposome-induced Anoikis and Diminshed Extravasation in Metastatic Carcinoma Cells.
Neoplasm Metastasis
Nanoparticles Coated with Neutrophil Membranes Can Effectively Treat Cancer Metastasis.
Neoplasm Metastasis
PKC?-dependent activation of the ubiquitin proteasome system is responsible for high glucose-induced human breast cancer MCF-7 cell proliferation, migration and invasion.
Neoplasm Metastasis
Proteasome inhibitor MG132 suppresses pancreatic ductal adenocarcinoma-cell migration by increasing ESE3 expression.
Neoplasm Metastasis
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.
Neoplasm Metastasis
Proteasome Subunit Alpha Type 7 Promotes Proliferation and Metastasis of Gastric Cancer Through MAPK Signaling Pathway.
Neoplasm Metastasis
Restoring E-cadherin-mediated cell-cell adhesion increases PTEN protein level and stability in human breast carcinoma cells.
Neoplasm Metastasis
Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis.
Neoplasm Metastasis
Signaling network analysis of ubiquitin-mediated proteins suggests correlations between the 26S proteasome and tumor progression.
Neoplasm Metastasis
Systems biology approach to identification of biomarkers for metastatic progression in gastric cancer.
Neoplasm Metastasis
The metastasis suppressor RARRES3 as an endogenous inhibitor of the immunoproteasome expression in breast cancer cells.
Neoplasm Metastasis
The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice.
Neoplasm Metastasis
The proteasome subunit PSMA7 located on the 20q13 amplicon is overexpressed and associated with liver metastasis in colorectal cancer.
Neoplasm Metastasis
[Association of intracellular proteinase activities with the content of locomotor proteins in tissues of primary tumors and metastasis in ovarian cancer].
Neoplasm Metastasis
[High expression of proteasome subunit PSMA7 in colorectal cancer is significantly correlated with liver metastasis]
Neoplasm, Residual
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Neoplasm, Residual
Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy.
Neoplasm, Residual
Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
Neoplasm, Residual
Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
Neoplasms
"Hidden targets of ubiquitin proteasome system: To prevent diabetic nephropathy".
Neoplasms
(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.
Neoplasms
1,10-Phenanthroline promotes copper complexes into tumor cells and induces apoptosis by inhibiting the proteasome activity.
Neoplasms
17-AAG Enhances PS-341-Induced Lung Cancer Cell Death by Blocking the NF-?B and PI3K/Akt Pathways.
Neoplasms
2-Aminoethoxydiphenylborane sensitizes anti-tumor effect of bortezomib via suppression of calcium-mediated autophagy.
Neoplasms
20S proteasome inhibitory activity of flavonoids isolated from Spatholobus suberectus.
Neoplasms
26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro.
Neoplasms
26S proteasome and insulin-like growth factor-1 in serum of dogs suffering from malignant tumors.
Neoplasms
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.
Neoplasms
3,4,5-tricaffeoylquinic acid attenuates proteasome inhibition-mediated programmed cell death in differentiated PC12 cells.
Neoplasms
3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies.
Neoplasms
5-Aza-2'-deoxycytidine reactivates gene expression via degradation of pRb pocket proteins.
Neoplasms
?-Boswellic acid, a bioactive substance used in food supplements, inhibits protein synthesis by targeting the ribosomal machinery.
Neoplasms
?-Catenin/TCF4 Complex-Mediated Induction of the NRF3 (NFE2L3) Gene in Cancer Cells.
Neoplasms
?-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation.
Neoplasms
?-Tocotrienol feeding modulates gene expression of EIF2, mTOR, protein ubiquitination through multiple-signaling pathways in chronic hepatitis C patients.
Neoplasms
?TrCP-dependent degradation of CDC25B phosphatase at the metaphase-anaphase transition is a pre-requisite for correct mitotic exit.
Neoplasms
A BAP31 intrabody induces gastric cancer cell death by inhibiting p27kip1 proteasome degradation.
Neoplasms
A binuclear complex constituted by diethyldithiocarbamate and copper(I) functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenografts.
Neoplasms
A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer.
Neoplasms
A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome.
Neoplasms
A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells.
Neoplasms
A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis.
Neoplasms
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.
Neoplasms
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.
Neoplasms
A FRET-based approach for identification of proteasome catalytic subunit composition.
Neoplasms
A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells.
Neoplasms
A High Affinity hRpn2-Derived Peptide That Displaces Human Rpn13 from Proteasome in 293T Cells.
Neoplasms
A high-throughput cellular assay to quantify the p53-degradation activity of E6 from different human papillomavirus types.
Neoplasms
A Key Role for the Ubiquitin Ligase UBR4 in Myofiber Hypertrophy in Drosophila and Mice.
Neoplasms
A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells.
Neoplasms
A mechanistic and kinetic study of the beta-lactone hydrolysis of Salinosporamide A (NPI-0052), a novel proteasome inhibitor.
Neoplasms
A microRNA-mediated decrease in eukaryotic initiation factor 2? promotes cell survival during PS-341 treatment.
Neoplasms
A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis.
Neoplasms
A natural musaceas plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells.
Neoplasms
A new class of ?-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.
Neoplasms
A new gold(I) complex-Au(PPh3)PT is a deubiquitinase inhibitor and inhibits tumor growth.
Neoplasms
A New Perspective for Osteosarcoma Therapy: Proteasome Inhibition by MLN9708/2238 Successfully Induces Apoptosis and Cell Cycle Arrest and Attenuates the Invasion Ability of Osteosarcoma Cells in Vitro.
Neoplasms
A new proteasome inhibitor, TP-110, induces apoptosis in human prostate cancer PC-3 cells.
Neoplasms
A nonsense mutant of the hepatitis B virus large S protein antagonizes multiple tumor suppressor pathways through c-Jun activation domain-binding protein1.
Neoplasms
A novel and effective inhibitor combination involving bortezomib and OTSSP167 for breast cancer cells in light of label-free proteomic analysis.
Neoplasms
A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts.
Neoplasms
A novel dithiocarbamate analogue with potentially decreased ALDH inhibition has copper-dependent proteasome-inhibitory and apoptosis-inducing activity in human breast cancer cells.
Neoplasms
A novel FoxM1-PSMB4 axis contributes to proliferation and progression of cervical cancer.
Neoplasms
A Novel Function of Molecular Chaperone HSP70: SUPPRESSION OF ONCOGENIC FOXM1 AFTER PROTEOTOXIC STRESS.
Neoplasms
A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells.
Neoplasms
A Novel Luminescence-Based High-Throughput Approach for Cellular Resolution of Protein Ubiquitination Using Tandem Ubiquitin Binding Entities (TUBEs).
Neoplasms
A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.
Neoplasms
A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent.
Neoplasms
A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.
Neoplasms
A novel role for a familiar protein in apoptosis induced by proteasome inhibition.
Neoplasms
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
Neoplasms
A para-amino substituent on the D-ring of green tea polyphenol epigallocatechin-3-gallate as a novel proteasome inhibitor and cancer cell apoptosis inducer.
Neoplasms
A Peptidomimetic Fluorescent Probe to Detect the Trypsin ?2 Subunit of the Human 20S Proteasome.
Neoplasms
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
Neoplasms
A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
Neoplasms
A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study.
Neoplasms
A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
Neoplasms
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Neoplasms
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
Neoplasms
A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Neoplasms
A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.
Neoplasms
A phase I study to assess the mass balance, excretion, and pharmacokinetics of [(14)C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors.
Neoplasms
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
Neoplasms
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
Neoplasms
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Neoplasms
A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.
Neoplasms
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.
Neoplasms
A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer.
Neoplasms
A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Biliary Tract Cancers.
Neoplasms
A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer.
Neoplasms
A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer.
Neoplasms
A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Neoplasms
A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B.
Neoplasms
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
Neoplasms
A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Neoplasms
A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cells.
Neoplasms
A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice.
Neoplasms
A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids.
Neoplasms
A systematic review of herbal medicines for the treatment of cancer cachexia in animal models.
Neoplasms
A Targeted and pH-Responsive Bortezomib Nanomedicine in the Treatment of Metastatic Bone Tumors.
Neoplasms
A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome.
Neoplasms
AACR Special Conference in cancer research: ubiquitination in normal and cancer cells.
Neoplasms
Aberrant C-terminal domain of polymerase ? targets the functional enzyme to the proteosomal degradation pathway.
Neoplasms
Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.
Neoplasms
Absence of Bax switched MG132-induced apoptosis to non-apoptotic cell death that could be suppressed by transcriptional or translational inhibition.
Neoplasms
Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3.
Neoplasms
Activated MEK/ERK Pathway Drives Widespread and Coordinated Overexpression of UHRF1 and DNMT1 in Cancer cells.
Neoplasms
Activated Rac1 regulates the degradation of I?B? and the nuclear translocation of STAT3-NF?B complexes in starved cancer cells.
Neoplasms
Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF).
Neoplasms
Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.
Neoplasms
Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-?B Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells.
Neoplasms
Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells.
Neoplasms
Activity and subunit composition of proteasomes in head and cervical squamous cell carcinomas.
Neoplasms
Activity Enhancement of the Synthetic Syrbactin Proteasome Inhibitor Hybrid and Biological Evaluation in Tumor Cells.
Neoplasms
Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.
Neoplasms
Activity-Based Near-Infrared Fluorescent Probe for LMP7: A Chemical Proteomics Tool for the Immunoproteasome in Living Cells.
Neoplasms
Acute lymphoblastic leukemia cells are sensitive to disturbances in protein homeostasis induced by proteasome deubiquitinase inhibition.
Neoplasms
Acylpeptide hydrolase inhibition as targeted strategy to induce proteasomal down-regulation.
Neoplasms
Adaptive modification and flexibility of the proteasome system in response to proteasome inhibition.
Neoplasms
Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency.
Neoplasms
Advancing the Role of Gamma-Tocotrienol as Proteasomes Inhibitor: A Quantitative Proteomic Analysis of MDA-MB-231 Human Breast Cancer Cells.
Neoplasms
Affinity Maturation of Macrocyclic Peptide Modulators of Lys48-linked Diubiquitin by a Twofold Strategy.
Neoplasms
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Neoplasms
AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.
Neoplasms
alpha-Synuclein stimulates differentiation of osteosarcoma cells: relevance to down-regulation of proteasome activity.
Neoplasms
Alterations in cytoskeletal and immune function-related proteome profiles in whole rat lung following intratracheal instillation of heparin.
Neoplasms
Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies.
Neoplasms
American Association for Cancer Research--100th Annual Meeting. HDAC inhibitors, proteasome inhibitors and vascular disrupting agents. 18-22 April 2009, Denver, CO, USA.
Neoplasms
Amino acid response by Halofuginone in Cancer cells triggers autophagy through proteasome degradation of mTOR.
Neoplasms
Amino- and chloro-8-hydroxyquinolines and their copper complexes as proteasome inhibitors and antiproliferative agents.
Neoplasms
An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability.
Neoplasms
An analysis of the safety profile of proteasome inhibitors for treating various cancers.
Neoplasms
An antibody-based amperometric biosensor for 20S proteasome activity and inhibitor screening.
Neoplasms
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib.
Neoplasms
An investigation of the mechanisms underlying the proteasome inhibitor bortezomib resistance in PC3 prostate cancer cell line.
Neoplasms
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Neoplasms
An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro.
Neoplasms
An Overview on the Histogenesis and Morphogenesis of Salivary Gland Neoplasms and Evolving Diagnostic Approaches.
Neoplasms
Analysis of changes in the proteome of HL-60 promyeloid leukemia cells induced by the proteasome inhibitor PSI.
Neoplasms
Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression.
Neoplasms
Analysis of the Processing of Seven Human Tumor Antigens by Intermediate Proteasomes.
Neoplasms
Analysis of the proteasome activity and the turnover of the serotonin receptor 2B (HTR2B) in human uveal melanoma.
Neoplasms
Analysis of UbcH10 expression represents a useful tool for the diagnosis and therapy of astrocytic tumors.
Neoplasms
Analyzing proteasomal subunit expression reveals Rpt4 as a prognostic marker in stage II colorectal cancer.
Neoplasms
Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.
Neoplasms
Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.
Neoplasms
Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
Neoplasms
Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia.
Neoplasms
Anti-tumor activity of benzylideneacetophenone derivatives via proteasomal inhibition in prostate cancer cells.
Neoplasms
Anti-tumor chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome as targets.
Neoplasms
Anticancer activity and computational modeling of ternary copper (II) complexes with 3-indolecarboxylic acid and 1,10-phenanthroline.
Neoplasms
Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
Neoplasms
Antifungal compounds with anticancer potential from Trichoderma sp. P8BDA1F1, an endophytic fungus from Begonia venosa.
Neoplasms
Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
Neoplasms
Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.
Neoplasms
Antiproliferative effects of Bortezomib in endothelial cells transformed by viral G protein-coupled receptor associated to Kaposi's sarcoma.
Neoplasms
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.
Neoplasms
Antitumor activity of novel fluoro-substituted (-)-epigallocatechin-3-gallate analogs.
Neoplasms
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
Neoplasms
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Neoplasms
Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors.
Neoplasms
Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review).
Neoplasms
APEH Inhibition Affects Osteosarcoma Cell Viability via Downregulation of the Proteasome.
Neoplasms
Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-? from degradation and induce apoptosis in prostate cancer cells.
Neoplasms
Apigenin, Chrysin, and Luteolin Selectively Inhibit Chymotrypsin-Like and Trypsin-Like Proteasome Catalytic Activities in Tumor Cells.
Neoplasms
Apoptosis and the conformational change of Bax induced by proteasomal inhibition of PC12 cells are inhibited by bcl-xL and bcl-2.
Neoplasms
Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway.
Neoplasms
Apoptosis induction of 2'-hydroxycinnamaldehyde as a proteasome inhibitor is associated with ER stress and mitochondrial perturbation in cancer cells.
Neoplasms
Apoptosis meets proteasome, an invaluable therapeutic target of anticancer drugs.
Neoplasms
Apoptosis-inducing levels of UV radiation and proteasome inhibitors produce opposite effects on p21(WAF1) in human melanoma cells.
Neoplasms
Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines.
Neoplasms
Arctigenin, an anti-tumor agent; a cutting-edge topic and up-to-the-minute approach in cancer treatment.
Neoplasms
Arene-Ru(II) Complexes of Curcumin Exert Antitumor Activity via Proteasome Inhibition and Apoptosis Induction.
Neoplasms
Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition.
Neoplasms
Aromatic monophenols from cinnamon bark act as proteasome inhibitors by upregulating ER stress, suppressing FoxM1 expression, and inducing apoptosis in prostate cancer cells.
Neoplasms
Artificial microRNAs against the viral E6 protein provoke apoptosis in HPV positive cancer cells.
Neoplasms
Assessment of Apoptosis-Inducing Effects of Docetaxel Combined with the Proteasome Inhibitor PS-341 in Human Lung Cancer Cells.
Neoplasms
Association of growth factors, HIF-1 and NF-?B expression with proteasomes in endometrial cancer.
Neoplasms
Association of Metals and Proteasome Activity in Erythrocytes of Prostate Cancer Patients and Controls.
Neoplasms
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
Neoplasms
Autophagy-independent enhancing effects of Beclin 1 on cytotoxicity of ovarian cancer cells mediated by proteasome inhibitors.
Neoplasms
Autoubiquitination of the 26S proteasome on Rpn13 regulates breakdown of ubiquitin conjugates.
Neoplasms
Baceridin, a Cyclic Hexapeptide from an Epiphytic Bacillus Strain, Inhibits the Proteasome.
Neoplasms
BAG-1 proteins protect cardiac myocytes from simulated ischemia/reperfusion-induced apoptosis via an alternate mechanism of cell survival independent of the proteasome.
Neoplasms
BAG3 down-modulation sensitizes HPV18(+) HeLa cells to PEITC-induced apoptosis and restores p53.
Neoplasms
Baicalein attenuates proteasome inhibition-induced apoptosis by suppressing the activation of the mitochondrial pathway and the caspase-8- and Bid-dependent pathways.
Neoplasms
Baicalin and Scutellarin Are Proteasome Inhibitors that Specifically Target Chymotrypsin-like Catalytic Activity.
Neoplasms
Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression.
Neoplasms
BAX/BAK-independent mitoptosis during cell death induced by proteasome inhibition?
Neoplasms
Bax?2 sensitizes colorectal cancer cells to proteasome inhibitor-induced cell death.
Neoplasms
Bcl-2 Family Proteins Contribute to Apoptotic Resistance in Lung Cancer Multicellular Spheroids.
Neoplasms
Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
Neoplasms
BET Inhibitors Synergize with Carfilzomib to Induce Cell Death in Cancer Cells via Impairing Nrf1 Transcriptional Activity and Exacerbating the Unfolded Protein Response.
Neoplasms
Betulinic Acid Exerts Cytotoxic Activity Against Multidrug-Resistant Tumor Cells via Targeting Autocrine Motility Factor Receptor (AMFR).
Neoplasms
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Neoplasms
Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-?B signaling.
Neoplasms
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.
Neoplasms
Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.
Neoplasms
Bone marrow microenvironment and the identification of new targets for myeloma therapy.
Neoplasms
Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells.
Neoplasms
Borneol and Luteolin from Chrysanthemum morifolium Regulate Ubiquitin Signal Degradation.
Neoplasms
Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.
Neoplasms
Bortezomib - First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature.
Neoplasms
Bortezomib Alone and in Combination with Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death in Vitro and in Female Nude Mice.
Neoplasms
Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure.
Neoplasms
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
Neoplasms
Bortezomib and endocannabinoid/endovanilloid system: a synergism in osteosarcoma.
Neoplasms
Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3.
Neoplasms
Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation.
Neoplasms
Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
Neoplasms
Bortezomib Causes ER Stress-related Death of Acute Promyelocytic Leukemia Cells Through Excessive Accumulation of PML-RARA.
Neoplasms
Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.
Neoplasms
Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.
Neoplasms
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
Neoplasms
Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-?B crosstalk.
Neoplasms
Bortezomib enhances radiosensitivity in oral cancer through inducing autophagy-mediated TRAF6 oncoprotein degradation.
Neoplasms
Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.
Neoplasms
Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells.
Neoplasms
Bortezomib induces apoptosis and suppresses cell growth and metastasis by inactivation of Stat3 signaling in chondrosarcoma.
Neoplasms
Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells.
Neoplasms
Bortezomib induction of C/EBP{beta} mediates Epstein-Barr virus lytic activation in Burkitt's lymphoma.
Neoplasms
Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer.
Neoplasms
Bortezomib Inhibits Nuclear Factor-{kappa}B Dependent Survival and Has Potent In vivo Activity in Mesothelioma.
Neoplasms
Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1.
Neoplasms
Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice.
Neoplasms
Bortezomib is effective to treat acute humoral rejection after liver transplantation.
Neoplasms
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
Neoplasms
Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.
Neoplasms
Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2.
Neoplasms
Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.
Neoplasms
Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
Neoplasms
Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
Neoplasms
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.
Neoplasms
Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Neoplasms
Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis.
Neoplasms
Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.
Neoplasms
Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of Both Normal and Tumor Tissues In Vivo.
Neoplasms
Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma.
Neoplasms
Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.
Neoplasms
Bortezomib treatment and regulatory T-cell depletion enhance the anti-tumor effects of adoptively infused NK cells.
Neoplasms
Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome.
Neoplasms
Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
Neoplasms
Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia.
Neoplasms
Bortezomib-Encapsulated CuS/Carbon Dot Nanocomposites for Enhanced Photothermal Therapy via Stabilization of Polyubiquitinated Substrates in the Proteasomal Degradation Pathway.
Neoplasms
Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
Neoplasms
Bortezomib-induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats.
Neoplasms
Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse.
Neoplasms
Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.
Neoplasms
Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
Neoplasms
Bortezomib-Resistant Mutant Proteasomes: Structural and Biochemical Evaluation with Carfilzomib and ONX 0914.
Neoplasms
Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells.
Neoplasms
Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1.
Neoplasms
Bowman-Birk inhibitors, proteasome peptidase activities and colorectal pre neoplasias induced by 1,2-dimethylhydrazine in Swiss mice.
Neoplasms
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.
Neoplasms
Breast cancer cell line MCF7 escapes from G1/S arrest induced by proteasome inhibition through a GSK-3? dependent mechanism.
Neoplasms
Broad Spectrum Deubiquitinase Inhibition Induces Both Apoptosis and Ferroptosis in Cancer Cells.
Neoplasms
C-Terminal HSP90 Inhibitors Block the HIF-1 Hypoxic Response by Degrading HIF-1? through the Oxygen-Dependent Degradation Pathway.
Neoplasms
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.
Neoplasms
Cadmium Induced p53-Dependent Activation of Stress Signaling, Accumulation of Ubiquitinated Proteins, and Apoptosis in Mouse Embryonic Fibroblast Cells.
Neoplasms
Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase.
Neoplasms
Caffeic acid phenethyl ester potentiates gastric cancer cell sensitivity to doxorubicin and cisplatin by decreasing proteasome function.
Neoplasms
Caffeine Abolishes the Ultraviolet-Induced REV3 Translesion Replication Pathway in Mouse Cells.
Neoplasms
Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generation.
Neoplasms
Can tumor growth be further inhibited by combining drugs such as bortezomib with image-guided interventional oncologic procedures?
Neoplasms
Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome.
Neoplasms
Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment.
Neoplasms
Cancer stem cells don't waste their time cleaning-low proteasome activity, a marker for cancer stem cell function.
Neoplasms
Cancer stem-like cell related protein CD166 degrades through E3 ubiquitin ligase CHIP in head and neck cancer.
Neoplasms
Cancer stem-like properties in colorectal cancer cells with low proteasome activity.
Neoplasms
Candidate Genes and MiRNAs Linked to the Inverse Relationship Between Cancer and Alzheimer's Disease: Insights From Data Mining and Enrichment Analysis.
Neoplasms
Capsaicin, a Component of Red Peppers, Inhibits the Growth of Androgen-Independent, p53 Mutant Prostate Cancer Cells.
Neoplasms
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.
Neoplasms
Carfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapy.
Neoplasms
Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model.
Neoplasms
Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells.
Neoplasms
Carfilzomib inhibits the growth of lung adenocarcinoma via upregulation of Gadd45a expression.
Neoplasms
Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia.
Neoplasms
Carnosol, a Natural Polyphenol, Inhibits Migration, Metastasis, and Tumor Growth of Breast Cancer via a ROS-Dependent Proteasome Degradation of STAT3.
Neoplasms
Case-only gene-environment interaction between ALAD tagSNPs and occupational lead exposure in prostate cancer.
Neoplasms
Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132.
Neoplasms
Caspase-dependent cleavage of BAG3 in proteasome inhibitors-induced apoptosis in thyroid cancer cells.
Neoplasms
CCR 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer.
Neoplasms
CDC4 Gene Expression as Potential Biomarker for Targeted Therapy in Prostate Cancer.
Neoplasms
CDK2 destabilizes tumor suppressor C/EBP? expression through ubiquitin-mediated proteasome degradation in acute myeloid leukemia.
Neoplasms
Cefepime, a fourth-generation cephalosporin, in complex with manganese, inhibits proteasome activity and induces the apoptosis of human breast cancer cells.
Neoplasms
Celastrol induce apoptosis of human multiple myeloma cells involving inhibition of proteasome activity.
Neoplasms
Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice.
Neoplasms
Cell-based bioluminescent assays for all three proteasome activities in a homogeneous format.
Neoplasms
Cell-cell dissociation upon epithelial cell scattering requires a step mediated by the proteasome.
Neoplasms
Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes.
Neoplasms
Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway.
Neoplasms
Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells.
Neoplasms
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
Neoplasms
CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice.
Neoplasms
Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.
Neoplasms
Cezanne (OTUD7B) regulates HIF-1? homeostasis in a proteasome-independent manner.
Neoplasms
Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells.
Neoplasms
Changes in immunocytochemical detectability of proteasome epitopes depending on cell growth and fixation conditions of lung cancer cell lines.
Neoplasms
Changes in proteasome chymotrypsin-like activity during the development of human mammary and thyroid carcinomas.
Neoplasms
Changes in the ratio of free NEDD8 to ubiquitin triggers NEDDylation by ubiquitin enzymes.
Neoplasms
Characterization and differential expression of a newly identified phosphorylated isoform of the human 20S proteasome beta7 subunit in tumor vs. normal cell lines.
Neoplasms
Characterization of Leiomyomatoid Angiomatous Neuroendocrine Tumour (LANT)-like Tumour in the Myometrium with Histopathological Examination.
Neoplasms
Characterization of Puma-dependent and Puma-independent neuronal cell death pathways following prolonged proteasomal inhibition.
Neoplasms
Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors.
Neoplasms
Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death.
Neoplasms
CHIP and BAP1 Act in Concert to Regulate INO80 Ubiquitination and Stability for DNA Replication.
Neoplasms
CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer.
Neoplasms
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.
Neoplasms
Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.
Neoplasms
Chlamydia trachomatis Infection Impairs MHC-I Intracellular Trafficking and Antigen Cross-Presentation by Dendritic Cells.
Neoplasms
Chromosomal instability and mTORC1 activation through PTEN loss contribute to proteotoxic stress in ovarian carcinoma.
Neoplasms
CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome.
Neoplasms
Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-?B signaling.
Neoplasms
CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
Neoplasms
Circadian modulation of proteasome activity and accumulation of oxidized protein in human embryonic kidney HEK 293 cells and primary dermal fibroblasts.
Neoplasms
Cisplatin-induced cell death in Saccharomyces cerevisiae is programmed and rescued by proteasome inhibition.
Neoplasms
CITED2 mediates the paradoxical responses of HIF-1alpha to proteasome inhibition.
Neoplasms
Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth.
Neoplasms
Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.
Neoplasms
Clioquinol promotes cancer cell toxicity through tumor necrosis factor alpha release from macrophages.
Neoplasms
Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts.
Neoplasms
Clogging the Ubiquitin-Proteasome Machinery with Marine Natural Products: Last Decade Update.
Neoplasms
Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells.
Neoplasms
cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas.
Neoplasms
Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy.
Neoplasms
Cobalt oxide nanoparticle-synergized protein degradation and phototherapy for enhanced anticancer therapeutics.
Neoplasms
Colonic Lamina Propria Inflammatory Cells from Patients with IBD Induce the Nuclear Factor-E2 Related Factor-2 Thereby Leading to Greater Proteasome Activity and Apoptosis Protection in Human Colonocytes.
Neoplasms
Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
Neoplasms
Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells.
Neoplasms
Combination of photodynamic therapy with aspirin in human-derived lung adenocarcinoma cells affects proteasome activity and induces apoptosis.
Neoplasms
Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
Neoplasms
Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment.
Neoplasms
Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.
Neoplasms
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
Neoplasms
Combination of quercetin and tannic acid in inhibiting 26S proteasome affects S5a and 20S expression, and accumulation of ubiquitin resulted in apoptosis in cancer chemoprevention.
Neoplasms
Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy.
Neoplasms
Combination therapy with proteasome inhibitors and TLR agonists enhances tumour cell death and IL-1? production.
Neoplasms
Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack.
Neoplasms
Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton.
Neoplasms
Combinations of platinums and selected phytochemicals as a means of overcoming resistance in ovarian cancer.
Neoplasms
Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Neoplasms
Combined Effect of Bortezomib and Menadione Sodium Bisulfite on Proteasomes of Tumor Cells: The Dramatic Decrease of Bortezomib Toxicity in a Preclinical Trial.
Neoplasms
Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line.
Neoplasms
Combined inhibition of autophagy and Nrf2 signaling augments bortezomib-induced apoptosis by increasing ROS production and ER stress in pancreatic cancer cells.
Neoplasms
Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer.
Neoplasms
Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
Neoplasms
Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes.
Neoplasms
Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.
Neoplasms
Comparative proteome analysis of three mouse lung adenocarcinoma CMT cell lines with different metastatic potential by two-dimensional gel electrophoresis and mass spectrometry.
Neoplasms
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.
Neoplasms
Comparative study of proteasome inhibitory, synergistic antibacterial, synergistic anticandidal, and antioxidant activities of gold nanoparticles biosynthesized using fruit waste materials.
Neoplasms
Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib.
Neoplasms
Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells.
Neoplasms
Complex formation between metabolic enzymes in tumor cells: Unfolding the MDR1-IDE paradigm.
Neoplasms
Concomitant differentiation and partial proteasome inhibition trigger apoptosis in neuroblastoma cells.
Neoplasms
Conjugated linoleic acid synthesis-related protein proteasome subunit ? 5 (PSMA5) is increased by vaccenic acid treatment in goat mammary tissue.
Neoplasms
Constitutive RelB activation in v-Src-transformed fibroblasts: requirement for IkappaB degradation.
Neoplasms
Control of death-associated protein kinase (DAPK) activity by phosphorylation and proteasomal degradation.
Neoplasms
Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression.
Neoplasms
Controlled Access of p53 to the Nucleus Regulates Its Proteasomal Degradation by MDM2.
Neoplasms
Converting redox signaling to apoptotic activities by stress-responsive regulators HSF1 and NRF2 in fenretinide treated cancer cells.
Neoplasms
Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
Neoplasms
Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin.
Neoplasms
COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas.
Neoplasms
Copper(II) ions affect the gating dynamics of the 20S proteasome: a molecular and in cell study.
Neoplasms
Copper-binding compounds as proteasome inhibitors and apoptosis inducers in human cancer.
Neoplasms
Core and specific network markers of carcinogenesis from multiple cancer samples.
Neoplasms
Correction to "The tumor proteasome is a primary target for the natural anticancer compound withaferin A isolated from 'Indian winter cherry'".
Neoplasms
Could a Common Mechanism of Protein Degradation Impairment Underlie Many Neurodegenerative Diseases?
Neoplasms
Could Dysregulation of UPS be a Common Underlying Mechanism for Cancer and Neurodegeneration? Lessons from UCHL1.
Neoplasms
Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
Neoplasms
Cross-presentation of viral antigens in dribbles leads to efficient activation of virus-specific human memory T cells.
Neoplasms
Crosstalk between autophagy and proteasome protein degradation systems: possible implications for cancer therapy.
Neoplasms
Crystal structure of HECT domain of UBE3C E3 ligase and its ubiquitination activity.
Neoplasms
Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome.
Neoplasms
CTGF associated with oncogenic activities and drug resistance in glioblastoma multiforme (GBM).
Neoplasms
Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
Neoplasms
Curcumin as an Alternative Epigenetic Modulator: Mechanism of Action and Potential Effects.
Neoplasms
Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis.
Neoplasms
Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo.
Neoplasms
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Neoplasms
Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.
Neoplasms
Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer.
Neoplasms
Current understanding on the role of standard and immunoproteasomes in inflammatory/immunological pathways of multiple sclerosis.
Neoplasms
Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
Neoplasms
Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Neoplasms
Cyclohelminthol X, a Hexa-Substituted Spirocyclopropane from Helminthosporium velutinum yone96: Structural Elucidation, Electronic Circular Dichroism Analysis, and Biological Properties.
Neoplasms
Cylindrocyclophanes with proteasome inhibitory activity from the Cyanobacterium Nostoc sp.
Neoplasms
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Neoplasms
Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib.
Neoplasms
Degradation of insulin-like growth factor-I receptor occurs via ubiquitin-proteasome pathway in human lung cancer cells.
Neoplasms
Deletion of the BH3-only protein puma protects motoneurons from ER stress-induced apoptosis and delays motoneuron loss in ALS mice.
Neoplasms
Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing.
Neoplasms
Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway.
Neoplasms
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
Neoplasms
Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors.
Neoplasms
Design, Synthesis and Evaluation of Substituted Aryl-2-Nitrovinyl Derivatives as Small Molecules Proteasome Inhibitors.
Neoplasms
Design, synthesis, and evaluation of cystargolide-based ?-lactones as potent proteasome inhibitors.
Neoplasms
Designing an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells.
Neoplasms
Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation.
Neoplasms
Detecting the genetic link between Alzheimer's disease and obesity using bioinformatics analysis of GWAS data.
Neoplasms
Determination of differentially regulated proteins upon proteasome inhibition in AML cell lines by the combination of large-scale and targeted quantitative proteomics.
Neoplasms
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
Neoplasms
Detrimental Effect of the Proteasome Inhibitor, Bortezomib in Bacterial Superantigen- and Lipopolysaccharide-induced Systemic Inflammation.
Neoplasms
Deubiquitinase inhibition of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-?B inhibition and p53 reactivation in human lung cancer cells.
Neoplasms
Deubiquitinase PSMD14 enhances hepatocellular carcinoma growth and metastasis by stabilizing GRB2.
Neoplasms
Deubiquitinase PSMD14 promotes ovarian cancer progression by decreasing enzymatic activity of PKM2.
Neoplasms
Deubiquitinating enzyme inhibitor alleviates cyclin A1-mediated proteasome inhibitor tolerance in mixed-lineage leukemia.
Neoplasms
Development and evaluation of a sandwich ELISA for quantification of the 20S proteasome in human plasma.
Neoplasms
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Neoplasms
Development of ?-Hairpin Peptides for the Measurement of SCF-Family E3 Ligase Activity in Vitro via Ornithine Ubiquitination.
Neoplasms
Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor.
Neoplasms
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
Neoplasms
Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carfilzomib.
Neoplasms
Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice.
Neoplasms
Diagnostic value and prognostic significance of plasmatic proteasome level in patients with melanoma.
Neoplasms
Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy.
Neoplasms
Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells.
Neoplasms
Different induction of GRP78 and CHOP as a predictor of sensitivity to proteasome inhibitors in thyroid cancer cells.
Neoplasms
Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
Neoplasms
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
Neoplasms
Differential effects of proteasome inhibitors on cell cycle and apoptotic pathways in human YT and Jurkat cells.
Neoplasms
Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.
Neoplasms
Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia.
Neoplasms
Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: A comparative study.
Neoplasms
Differential protein expression in honeybee (Apis mellifera L.) larvae: underlying caste differentiation.
Neoplasms
Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
Neoplasms
Differential regulation of the REG?-proteasome pathway by p53/TGF-? signalling and mutant p53 in cancer cells.
Neoplasms
Dimerized Linear Mimics of a Natural Cyclopeptide (TMC-95A) Are Potent Noncovalent Inhibitors of the Eukaryotic 20S Proteasome.
Neoplasms
Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells.
Neoplasms
Direct inhibition of the ubiquitin-proteasome pathway by ester bond-containing green tea polyphenols is associated with increased expression of sterol regulatory element-binding protein 2 and LDL receptor.
Neoplasms
Disabling the Protease DDI2 Attenuates the Transcriptional Activity of NRF1 and Potentiates Proteasome Inhibitor Cytotoxicity.
Neoplasms
Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
Neoplasms
Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
Neoplasms
Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.
Neoplasms
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
Neoplasms
Discovery of a Small Molecule Probe of Rpn-6, an Essential Subunit of the 26S Proteasome.
Neoplasms
Discovery of Natural Product Proteasome Inhibitors as Novel Anticancer Therapeutics: Current Status and Perspectives.
Neoplasms
Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations.
Neoplasms
Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
Neoplasms
Discovery of PI-1840, a novel non-covalent and rapidly reversible proteasome inhibitor with anti-tumor activity.
Neoplasms
Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
Neoplasms
Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives.
Neoplasms
Disrupted eNOS activity and expression account for vasodilator dysfunction in different stage of sepsis.
Neoplasms
Dissecting the Specificity of Adenosyl Sulfamate Inhibitors Targeting the Ubiquitin-Activating Enzyme.
Neoplasms
Disulfiram promotes the conversion of carcinogenic cadmium to a proteasome inhibitor with pro-apoptotic activity in human cancer cells.
Neoplasms
Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma in vivo.
Neoplasms
Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity.
Neoplasms
Disulfiram/copper-disulfiram Damages Multiple Protein Degradation and Turnover Pathways and Cytotoxicity is Enhanced by Metformin in Oesophageal Squamous Cell Carcinoma Cell Lines.
Neoplasms
Dithiocarbamate-Based Coordination Compounds As Potent Proteasome Inhibitors in Human Cancer Cells.
Neoplasms
Divergent effect of proteasome inhibition on interleukin-1beta and tumor necrosis factor alpha signaling in human astroglial cells.
Neoplasms
DNA damage response factors from diverse pathways, including DNA crosslink repair, mediate alternative end joining.
Neoplasms
DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies.
Neoplasms
Do VHL and HIF-1 mirror p53 and Mdm-2? Degradation-transactivation loops of oncoproteins and tumor suppressors.
Neoplasms
Donor cell-derived acute lymphocytic leukemia after allogeneic stem cell transplantation for multiple myeloma.
Neoplasms
Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1.
Neoplasms
Dorsomorphin induces cancer cell apoptosis and sensitizes cancer cells to HSP90 and proteasome inhibitors by reducing nuclear heat shock factor 1 levels.
Neoplasms
Down-regulating Proteolysis to Enhance Anticancer Activity of Peptide Nanofibers.
Neoplasms
Down-regulation of BRCA2 expression by collagen type I promotes prostate cancer cell proliferation.
Neoplasms
Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines.
Neoplasms
Down-regulation of vascular endothelial growth factor receptor 2 is a major molecular determinant of proteasome inhibitor-mediated antiangiogenic action in endothelial cells.
Neoplasms
Downregulation of 26S proteasome catalytic activity promotes epithelial-mesenchymal transition.
Neoplasms
Downregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine Osteosarcoma.
Neoplasms
Downregulation of specific FBXW7 isoforms with differential effects in T-cell lymphoblastic lymphoma.
Neoplasms
Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines.
Neoplasms
Drug Development Targeting the Ubiquitin-Proteasome System (UPS) for the Treatment of Human Cancers.
Neoplasms
Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
Neoplasms
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
Neoplasms
Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species.
Neoplasms
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Neoplasms
Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474).
Neoplasms
Dyclonine and alverine citrate enhance the cytotoxic effects of proteasome inhibitor MG132 on breast cancer cells.
Neoplasms
Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.
Neoplasms
Dynamic interplay between breast cancer cells and normal endothelium mediates the expression of matrix macromolecules, proteasome activity and functional properties of endothelial cells.
Neoplasms
Dynein function and protein clearance changes in tumor cells induced by a Kunitz-type molecule, Amblyomin-X.
Neoplasms
Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS.
Neoplasms
Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention.
Neoplasms
E-cad-Fc-Matrix Enhances Cancer Stem-Like Properties and Induces Mesenchymal Features in Colon Cancer Cells.
Neoplasms
E3 ubiquitin ligases and deubiquitinases as modulators of TRAIL-mediated extrinsic apoptotic signaling pathway.
Neoplasms
Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
Neoplasms
Effect of ajoene, a natural antitumor small molecule, on human 20S proteasome activity in vitro and in human leukemic HL60 cells.
Neoplasms
Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
Neoplasms
Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.
Neoplasms
Effect of cancer cachexia on the activity of tripeptidyl-peptidase II in skeletal muscle.
Neoplasms
Effect of Neoadjuvant Chemoradiation Therapy on Proteasome Pool in Rectal Cancer.
Neoplasms
Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines.
Neoplasms
Effect of selective proteasome inhibitors on TNF-induced activation of primary and transformed endothelial cells.
Neoplasms
Effect of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells.
Neoplasms
Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.
Neoplasms
Effects of a proteasome inhibitor on the NF-?B signalling pathway in experimental osteoarthritis.
Neoplasms
Effects of an Anticarcinogenic Bowman-Birk Protease Inhibitor on Purified 20S Proteasome and MCF-7 Breast Cancer Cells.
Neoplasms
Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity.
Neoplasms
Effects of ELF magnetic fields on protein expression profile of human breast cancer cell MCF7.
Neoplasms
Effects of Hydroxy Groups in the A-Ring on the Anti-proteasome Activity of Flavone.
Neoplasms
Effects of proteasome inhibitors MG132, ZL3VS and AdaAhx3L3VS on protein metabolism in septic rats.
Neoplasms
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Neoplasms
Effects of tethered ligands and of metal oxidation state on the interactions of cobalt complexes with the 26S proteasome.
Neoplasms
Effects of the beta2 agonist formoterol on atrophy signaling, autophagy, and muscle phenotype in respiratory and limb muscles of rats with cancer-induced cachexia.
Neoplasms
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
Neoplasms
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Neoplasms
Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases.
Neoplasms
Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts.
Neoplasms
Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants.
Neoplasms
Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo.
Neoplasms
Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Neoplasms
Effects of tumor necrosis factor-alpha on the 26S proteasome and 19S regulator in skeletal muscle of severely scalded mice.
Neoplasms
Effects on bone metabolism of new therapeutic strategies with standard chemotherapy and biologic drugs.
Neoplasms
Efficacy of bortezomib as first-line treatment for patients with multiple myeloma.
Neoplasms
EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism.
Neoplasms
Ehrlichia chaffeensis TRP32 interacts with host cell targets that influence intracellular survival.
Neoplasms
Electrostatic Map Of Proteasome ?-Rings Encodes The Design of Allosteric Porphyrin-Based Inhibitors Able To Affect 20S Conformation By Cooperative Binding.
Neoplasms
Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway.
Neoplasms
Elevated plasma 20S proteasome chymotrypsin-like activity is correlated with IL-8 levels and associated with an increased risk of death in glial brain tumor patients.
Neoplasms
Elevation of proteasomal substrate levels sensitizes cells to apoptosis induced by inhibition of proteasomal deubiquitinases.
Neoplasms
Emerging drug development technologies targeting ubiquitination for cancer therapeutics.
Neoplasms
Endogenous membrane tumor necrosis factor (TNF) is a potent amplifier of TNF receptor 1-mediated apoptosis.
Neoplasms
Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-?B in vitro and in vivo.
Neoplasms
Enhanced Efficacy against Cervical Carcinomas through Polymeric Micelles Physically Incorporating the Proteasome Inhibitor MG132.
Neoplasms
Enhanced Glioblastoma Targeting Ability of Carfilzomib Enabled by a DA7R-Modified Lipid Nanodisk.
Neoplasms
Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor.
Neoplasms
Enhanced O-GlcNAcylation Mediates Cytoprotection under Proteasome Impairment by Promoting Proteasome Turnover in Cancer Cells.
Neoplasms
Enhanced proteasomal activity is essential for long term survival and recurrence of innately radiation resistant residual glioblastoma cells.
Neoplasms
Enhanced Protein Damage Clearance Induces Broad Drug Resistance in Multitype of Cancers Revealed by an Evolution Drug-Resistant Model and Genome-Wide siRNA Screening.
Neoplasms
Enhancement of TNF-alpha-mediated cell death in vascular smooth muscle cells through cytochrome c-independent pathway by the proteasome inhibitor.
Neoplasms
Enhancing proteasomal processing improves survival for a peptide vaccine used to treat glioblastoma.
Neoplasms
Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells.
Neoplasms
Enzymatically Formed Peptide Assemblies Sequestrate Proteins and Relocate Inhibitors to Selectively Kill Cancer Cells.
Neoplasms
Enzyme inhibition by hydroamination: design and mechanism of a hybrid carmaphycin-syringolin enone proteasome inhibitor.
Neoplasms
Epidermal Growth Factor Receptor vIII Expression in U87 Glioblastoma Cells Alters Their Proteasome Composition, Function, and Response to Irradiation.
Neoplasms
Epithelial to mesenchymal transition in the pathogenesis of uterine malignant mixed Müllerian tumours: the role of ubiquitin proteasome system and therapeutic opportunities.
Neoplasms
Eponemycin exerts its antitumor effect through the inhibition of proteasome function.
Neoplasms
Essential amino acid mixtures drive cancer cells to apoptosis through proteasome inhibition and autophagy activation.
Neoplasms
Essential role of human leukocyte antigen-encoded proteasome subunits in NF-kappaB activation and prevention of tumor necrosis factor-alpha-induced apoptosis.
Neoplasms
Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo.
Neoplasms
Evaluation of copper-dependent proteasome-inhibitory and apoptosis-inducing activities of novel pyrrolidine dithiocarbamate analogues.
Neoplasms
Evaluation of curcumin acetates and amino acid conjugates as proteasome inhibitors.
Neoplasms
Evaluation of proteasome-inhibitory and apoptosis-inducing potencies of novel (-)-EGCG analogs and their prodrugs.
Neoplasms
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Neoplasms
Evaluation of Zinc-alpha-2-Glycoprotein and Proteasome Subunit beta-Type 6 Expression in Prostate Cancer Using Tissue Microarray Technology.
Neoplasms
Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis.
Neoplasms
Evidence for anti-apoptotic roles of proteasome activator 28? via inhibiting caspase activity.
Neoplasms
Evidence for the mode of action of the highly cytotoxic Streptomyces polyketide kendomycin.
Neoplasms
Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis.
Neoplasms
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies.
Neoplasms
Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Neoplasms
Exosomes mediate intercellular transfer of non-autonomous tolerance to proteasome inhibitors in mixed-lineage leukemia.
Neoplasms
Experimental and computational studies indicate specific binding of pVHL protein to Aurora-A kinase.
Neoplasms
Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.
Neoplasms
Exploration of the carmaphycins as payloads in antibody drug conjugate anticancer agents.
Neoplasms
Exploring the binding affinity of novel syringic acid analogues and critical determinants of selectivity as potent proteasome inhibitors.
Neoplasms
Exploring the proteasome system: A novel concept of proteasome inhibition and regulation.
Neoplasms
Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-?B Pathway in Preclinical Models of Pediatric High-Grade Glioma.
Neoplasms
Expression Atlas of the Deubiquitinating Enzymes in the Adult Mouse Retina, Their Evolutionary Diversification and Phenotypic Roles.
Neoplasms
Expression of immunoproteasome genes is regulated by cell-intrinsic and -extrinsic factors in human cancers.
Neoplasms
Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma.
Neoplasms
Expression of Proteasome Activator REG? in Human Laryngeal Carcinoma and Associations with Tumor Suppressor Proteins.
Neoplasms
Expression of subunits of the 19S complex and of the PA28 activator in rat skeletal muscle.
Neoplasms
FAM46C and FNDC3A are multiple myeloma tumor suppressors that act in concert to impair clearing of protein aggregates and autophagy.
Neoplasms
Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer.
Neoplasms
FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15.
Neoplasms
Feedback regulation of proteasome gene expression and its implications in cancer therapy.
Neoplasms
Fetal bovine serum requirement for pyrrolidine dithiocarbamate-induced apoptotic cell death of MCF-7 breast tumor cells.
Neoplasms
Fibroblast Growth Factor 2 lethally sensitizes cancer cells to stress-targeted therapeutic inhibitors.
Neoplasms
Fibrosis and hypoxia-inducible factor-1?-dependent tumors of the soft tissue on loss of von Hippel-Lindau in mesenchymal progenitors.
Neoplasms
Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN.
Neoplasms
Fish Oil Diet during Pre-mating, Gestation, and Lactation in Adult Offspring Rats on Cancer Cachexia Prevention.
Neoplasms
Flavanonol taxifolin attenuates proteasome inhibition-induced apoptosis in differentiated PC12 cells by suppressing cell death process.
Neoplasms
Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy.
Neoplasms
Fluorescent Probes with Unnatural Amino Acids to Monitor Proteasome Activity in Real-Time.
Neoplasms
Foe to Friend: Supramolecular Nanomedicines Consisting of Natural Polyphenols and Bortezomib.
Neoplasms
Food Shortage Causes Differential Effects on Body Composition and Tissue-Specific Gene Expression in Salmon Modified for Increased Growth Hormone Production.
Neoplasms
Formalin-fixed tumor cells effectively induce antitumor immunity both in prophylactic and therapeutic conditions.
Neoplasms
FoxM1 knockdown sensitizes human cancer cells to proteasome inhibitor-induced apoptosis but not to autophagy.
Neoplasms
Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin.
Neoplasms
Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover.
Neoplasms
Functional precision medicine identifies novel druggable targets and therapeutic options in head and neck cancer.
Neoplasms
Functioning of Proteasomes in Lymphogenic Metastasizing of Non-Small-Cell Lung Cancer.
Neoplasms
Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy.
Neoplasms
FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.
Neoplasms
G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.
Neoplasms
Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression.
Neoplasms
Gankyrin Promotes Tumor-Suppressor Protein Degradation to Drive Hepatocyte Proliferation.
Neoplasms
Gap junctions sensitize cancer cells to proteasome inhibitor MG132-induced apoptosis.
Neoplasms
Gel-based proteomics analysis of the heterogeneity of 20S proteasomes from four human pancreatic cancer cell lines.
Neoplasms
Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells.
Neoplasms
Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours.
Neoplasms
Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides.
Neoplasms
Generation and identification of a conditional knockout allele for the PSMD11 gene in mice.
Neoplasms
Genetic basis for the biosynthesis of the pharmaceutically important class of epoxyketone proteasome inhibitors.
Neoplasms
Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition.
Neoplasms
Genome-wide analysis of differentially expressed genes during the early stages of tomato infection by a potyvirus.
Neoplasms
Genome-wide identification of molecular pathways and biomarkers in response to arsenic exposure in zebrafish liver.
Neoplasms
Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis.
Neoplasms
Ghrelin induces apoptosis in colon adenocarcinoma cells via proteasome inhibition and autophagy induction.
Neoplasms
Glucose starvation and hypoxia induce nuclear accumulation of proteasome in cancer cells.
Neoplasms
Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells.
Neoplasms
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.
Neoplasms
GRP-78 secreted by tumor cells blocks the anti-angiogenic activity of bortezomib.
Neoplasms
GSK-3? signaling determines autophagy activation in the breast tumor cell line MCF7 and inclusion formation in the non-tumor cell line MCF10A in response to proteasome inhibition.
Neoplasms
Haplotype and cell proliferation analyses of candidate lung cancer susceptibility genes on chromosome 15q24-25.1.
Neoplasms
Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?
Neoplasms
HAUSP, a deubiquitinating enzyme for p53, is polyubiquitinated, polyneddylated, and dimerized.
Neoplasms
HCMV-Mediated Interference of Bortezomib-Induced Apoptosis in Colon Carcinoma Cell Line Caco-2.
Neoplasms
HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma.
Neoplasms
HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
Neoplasms
Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells.
Neoplasms
Hinokitiol copper complex inhibits proteasomal deubiquitination and induces paraptosis-like cell death in human cancer cells.
Neoplasms
Histidine kinases and histidine phosphorylated proteins in mammalian cell biology, signal transduction and cancer.
Neoplasms
Histone deacetylase inhibitor induced pVHL-independent degradation of HIF-1? and hierarchical quality control of pVHL via chaperone system.
Neoplasms
HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress.
Neoplasms
Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding.
Neoplasms
Host-Viral Interactions Revealed among Shared Transcriptomics Signatures of ARDS and Thrombosis: A Clue into COVID-19 Pathogenesis.
Neoplasms
HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells.
Neoplasms
HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation.
Neoplasms
HSP70 Inhibition by the Small-Molecule 2-Phenylethynesulfonamide Impairs Protein Clearance Pathways in Tumor Cells.
Neoplasms
Human papillomavirus-16 associated squamous cell carcinoma of the head and neck (SCCHN): a natural disease model provides insights into viral carcinogenesis.
Neoplasms
Humanized yeast genetic interaction mapping predicts synthetic lethal interactions of FBXW7 in breast cancer.
Neoplasms
Hypoxia enhances the senescence effect of bortezomib--the proteasome inhibitor--on human skin fibroblasts.
Neoplasms
Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells.
Neoplasms
Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib.
Neoplasms
Hypoxic resistance to articular chondrocyte apoptosis--a possible mechanism of maintaining homeostasis of normal articular cartilage.
Neoplasms
Identification and characterization of a membrane receptor for proteolysis-inducing factor on skeletal muscle.
Neoplasms
Identification of 4-arylidene curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase.
Neoplasms
Identification of a ?1/?2-Specific Sulfonamide Proteasome Ligand by Crystallographic Screening.
Neoplasms
Identification of a p53-based portable degron based on the MDM2-p53 binding region.
Neoplasms
Identification of an immunogenic HLA-A*0201-binding T-cell epitope of the transcription factor PAX2.
Neoplasms
Identification of chemoradiation-resistant osteosarcoma stem cells using an imaging system for proteasome activity.
Neoplasms
Identification of collaborative activities with oxidative phosphorylation in bipolar disorder.
Neoplasms
Identification of differentially expressed proteins in spontaneous thymic lymphomas from knockout mice with deletion of p53.
Neoplasms
Identification of factors that function in Drosophila salivary gland cell death during development using proteomics.
Neoplasms
Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity.
Neoplasms
Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening.
Neoplasms
Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer.
Neoplasms
Identification of proteasome inhibitors using analysis of gene expression profiles.
Neoplasms
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.
Neoplasms
Identification of substrates of SMURF1 ubiquitin ligase activity utilizing protein microarrays.
Neoplasms
IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma.
Neoplasms
IKK? inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.
Neoplasms
Imaging Reporters for Proteasome Activity Identify Tumor- and Metastasis-Initiating Cells.
Neoplasms
Immunocytochemical localization of multicatalytic protease complex (proteasome) during generation of murine IL-2-activated natural killer (A-NK) cells.
Neoplasms
Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity.
Neoplasms
Immunoproteasome Inhibitor-Doxorubicin Conjugates Target Multiple Myeloma Cells and Release Doxorubicin upon Low-Dose Photon Irradiation.
Neoplasms
Immunosensitization of Tumor Cells to Dendritic Cell-Activated Immune Responses with the Proteasome Inhibitor Bortezomib (PS-341, Velcade).
Neoplasms
Impact of gene dosage on gene expression, biological processes and survival in cervical cancer: a genome-wide follow-up study.
Neoplasms
Impaired bortezomib binding to mutant ?5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Neoplasms
Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B: cells and dendritic cells.
Neoplasms
Impairment of the Ubiquitin-Proteasome Pathway by Methyl N-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells: A NOVEL ANTIPROLIFERATIVE AGENT WITH A POTENTIAL THERAPEUTIC IMPLICATION.
Neoplasms
Implication of 14-3-3? and 14-3-3?/? in proteasome inhibition-induced apoptosis of glioma cells.
Neoplasms
Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part I: targeting p53, Mdm2, GADD153/CHOP, GRP78/BiP and heat shock proteins.
Neoplasms
Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part II: targeting cell cycle events, caspases, NF-?B and the proteasome.
Neoplasms
Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate.
Neoplasms
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
Neoplasms
In situ dynamically monitoring the proteolytic function of the ubiquitin-proteasome system in cultured cardiac myocytes.
Neoplasms
In situ photoaffinity labeling of proteasome with photoactive adriamycin analogue.
Neoplasms
In vitro and in vivo anticancer activity of copper(I) complexes with homoscorpionate tridentate tris(pyrazolyl)borate and auxiliary monodentate phosphine ligands.
Neoplasms
In Vitro and In Vivo Antitumor Activities and DNA Binding Mode of Five Coordinated Cyclometalated Organoplatinum(II) Complexes Containing Biphosphine Ligands.
Neoplasms
In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s.
Neoplasms
In vivo imaging of proteasome inhibition using a proteasome-sensitive fluorescent reporter.
Neoplasms
In Vivo Inhibition of Proteasome Activity and Tumour Growth by Murraya koenigii Leaf Extract in Breast Cancer Xenografts and by its active flavonoids in breast cancer cells.
Neoplasms
In vivo modulation of ubiquitin chains by N-methylated non-proteinogenic cyclic peptides.
Neoplasms
In-depth proteomic analysis of proteasome inhibitors bortezomib, carfilzomib and MG132 reveals that mortality factor 4-like 1 (MORF4L1) protein ubiquitylation is negatively impacted.
Neoplasms
Inactivation of the 20S proteasome in Streptomyces lividans and its influence on the production of heterologous proteins.
Neoplasms
Inactivation of USP14 Perturbs Ubiquitin Homeostasis and Delays the Cell Cycle in Mouse Embryonic Fibroblasts and in Fruit Fly Drosophila.
Neoplasms
Inactive USP14 and inactive UCHL5 cause accumulation of distinct ubiquitinated proteins in mammalian cells.
Neoplasms
Inadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97.
Neoplasms
Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
Neoplasms
Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study.
Neoplasms
Increased Expression of Atrogenes and TWEAK Family Members after Severe Burn Injury in Nonburned Human Skeletal Muscle.
Neoplasms
Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss.
Neoplasms
Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents.
Neoplasms
Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor.
Neoplasms
Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors.
Neoplasms
Increased proteasome activator 28 gamma (PA28?) levels are unspecific but correlate with disease activity in rheumatoid arthritis.
Neoplasms
Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2).
Neoplasms
Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
Neoplasms
Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment.
Neoplasms
Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-catenin-mediated transactivation.
Neoplasms
Induction of Apoptosis in U937 Cells by Using a Combination of Bortezomib and Low-Intensity Ultrasound.
Neoplasms
Induction of autophagy by proteasome inhibitor is associated with proliferative arrest in colon cancer cells.
Neoplasms
Induction of BAG2 protein during proteasome inhibitor-induced apoptosis in thyroid carcinoma cells.
Neoplasms
Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
Neoplasms
Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570.
Neoplasms
Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib.
Neoplasms
Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation.
Neoplasms
Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress.
Neoplasms
Induction of tumor cell apoptosis by taurine Schiff base copper complex is associated with the inhibition of proteasomal activity.
Neoplasms
Inflammatory macrophages induce Nrf2 transcription factor-dependent proteasome activity in colonic NCM460 cells and thereby confer anti-apoptotic protection.
Neoplasms
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.
Neoplasms
Inhibition of autophagy by autophagic inhibitors enhances apoptosis induced by bortezomib in non-small cell lung cancer cells.
Neoplasms
Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells.
Neoplasms
Inhibition of autophagy induced by proteasome inhibition increases cell death in human SHG-44 glioma cells.
Neoplasms
Inhibition of autophagy promotes cell apoptosis induced by the proteasome inhibitor MG-132 in human esophageal squamous cell carcinoma EC9706 cells.
Neoplasms
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Neoplasms
Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction.
Neoplasms
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.
Neoplasms
Inhibition of hypoxia inducible factor-1alpha by dihydroxyphenylethanol, a product from olive oil, blocks microsomal prostaglandin-E synthase-1/vascular endothelial growth factor expression and reduces tumor angiogenesis.
Neoplasms
Inhibition of metalloproteinase and proteasome activities in colon cancer cells by citrus peel extracts.
Neoplasms
Inhibition of NF-kappa B with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro.
Neoplasms
Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons.
Neoplasms
Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor.
Neoplasms
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity.
Neoplasms
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
Neoplasms
Inhibition of P-Glycoprotein Does Not Increase the Efficacy of Proteasome Inhibitors in Multiple Myeloma Cells.
Neoplasms
Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Neoplasms
Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis.
Neoplasms
Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
Neoplasms
Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts.
Neoplasms
Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts.
Neoplasms
Inhibition of proteasome activity by various fruits and vegetables is associated with cancer cell death.
Neoplasms
Inhibition of Proteasome Activity Induces Aggregation of IFIT2 in the Centrosome and Enhances IFIT2-Induced Cell Apoptosis.
Neoplasms
Inhibition of proteasome activity sensitizes human granulosa tumor cells to TRAIL-induced cell death.
Neoplasms
Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?
Neoplasms
Inhibition of proteasome, apoptosis and sensitization to tumour necrosis factor alpha: do they always go together?
Neoplasms
Inhibition of stress-inducible HSP70 impairs mitochondrial proteostasis and function.
Neoplasms
Inhibition of the JNK signalling pathway enhances proteasome inhibitor-induced apoptosis of kidney cancer cells by suppression of BAG3 expression.
Neoplasms
Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity.
Neoplasms
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Neoplasms
Inhibition of the Proteasome ?2 Site Sensitizes Triple-Negative Breast Cancer Cells to ?5 Inhibitors and Suppresses Nrf1 Activation.
Neoplasms
Inhibition of the proteasome activity by gallium(III) complexes contributes to their anti prostate tumor effects.
Neoplasms
Inhibition of the proteasome activity by graphene oxide contributes to its cytotoxicity.
Neoplasms
Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein.
Neoplasms
Inhibition of the ubiquitin-proteasome pathway activates stress kinases and induces apoptosis in renal cancer cells.
Neoplasms
Inhibition of tumor cellular proteasome activity by triptolide extracted from the Chinese medicinal plant 'thunder god vine'.
Neoplasms
Inhibition of tumor proteasome activity by gold-dithiocarbamato complexes via both redox-dependent and -independent processes.
Neoplasms
Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma.
Neoplasms
Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy.
Neoplasms
Inhibition of USP14 Deubiquitinating Activity as a Potential Therapy for Tumors with p53 Deficiency.
Neoplasms
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
Neoplasms
Inhibition on Proteasome ?1 Subunit Might Contribute to the Anti-Cancer Effects of Fangchinoline in Human Prostate Cancer Cells.
Neoplasms
Inhibitors of SCF-Skp2/Cks1 E3ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
Neoplasms
Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells.
Neoplasms
Inhibitory kappa B kinase-beta is a target for specific nuclear factor kappa B-mediated delayed cardioprotection.
Neoplasms
Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
Neoplasms
Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.
Neoplasms
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Neoplasms
Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells.
Neoplasms
Interleukin-10 activation of the interleukin-10E1 pathway and tissue inhibitor of metalloproteinase-1 expression is enhanced by proteasome inhibitors in primary prostate tumor lines.
Neoplasms
Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding.
Neoplasms
Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsins B and L, proteasome) in C2C12 myotubes.
Neoplasms
Interplay between Structure and Charge as a Key to Allosteric Modulation of Human 20S Proteasome by the Basic Fragment of HIV-1 Tat Protein.
Neoplasms
Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy.
Neoplasms
Intersection of nuclear receptors and the proteasome on the epigenetic landscape.
Neoplasms
Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model.
Neoplasms
Investigating the Effects of RBBP6 Gene Expression on Telomerase Activity in Cervical Cancer Cells.
Neoplasms
Investigation of the eIF2alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells.
Neoplasms
Involvement of ALAD-20S Proteasome Complexes in Ubiquitination and Acetylation of Proteasomal ?2 Subunits.
Neoplasms
Involvement of nuclear export in human papillomavirus type 18 E6-mediated ubiquitination and degradation of p53.
Neoplasms
Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group.
Neoplasms
Isoginkgetin, a Natural Biflavonoid Proteasome Inhibitor, Sensitizes Cancer Cells to Apoptosis via Disruption of Lysosomal Homeostasis and Impaired Protein Clearance.
Neoplasms
Isolation and structure determination of a proteasome inhibitory metabolite from a culture of Scytonema hofmanni.
Neoplasms
Isolation, Structure, and Biological Activities of Fellutamides C and D from an Undescribed Metulocladosporiella (Chaetothyriales) Using the Genome-Wide Candida albicans Fitness Test.
Neoplasms
Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells.
Neoplasms
JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
Neoplasms
JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress.
Neoplasms
JNK1 mediates degradation HIF-1alpha by a VHL-independent mechanism that involves the chaperones Hsp90/Hsp70.
Neoplasms
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.
Neoplasms
Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.
Neoplasms
Knockdown of Adhesion-Regulating Molecule 1 Inhibits Proliferation in HL60 Cells.
Neoplasms
Knockdown of human deubiquitinase PSMD14 induces cell cycle arrest and senescence.
Neoplasms
Knockdown of REG? inhibits proliferation by inducing apoptosis and cell cycle arrest in prostate cancer.
Neoplasms
KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
Neoplasms
KRIBB53 binds to OCT4 and enhances its degradation through the proteasome, causing apoptotic cell death of OCT4-positive testicular germ cell tumors.
Neoplasms
L-glutamine Schiff base copper complex as a proteasome inhibitor and an apoptosis inducer in human cancer cells.
Neoplasms
L-leucine dietary supplementation modulates muscle protein degradation and increases pro-inflammatory cytokines in tumour-bearing rats.
Neoplasms
L-Ornithine Schiff base-copper and -cadmium complexes as new proteasome inhibitors and apoptosis inducers in human cancer cells.
Neoplasms
Lactacystin, a proteasome inhibitor, potentiates the apoptotic effect of parthenolide, an inhibitor of NFkappaB activation, on drug-resistant mouse leukemia L1210 cells.
Neoplasms
Lactacystin: first-in-class proteasome inhibitor still excelling and an exemplar for future antibiotic research.
Neoplasms
LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma.
Neoplasms
Lead discovery and chemical biology approaches targeting the ubiquitin proteasome system.
Neoplasms
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
Neoplasms
Lercanidipine Synergistically Enhances Bortezomib Cytotoxicity in Cancer Cells via Enhanced Endoplasmic Reticulum Stress and Mitochondrial Ca2+ Overload.
Neoplasms
Lessons Learned from Proteasome Inhibitors, the Paradigm for Targeting Protein Homeostasis in Cancer.
Neoplasms
Ligand independent aryl hydrocarbon receptor inhibits lung cancer cell invasion by degradation of Smad4.
Neoplasms
Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability.
Neoplasms
Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo.
Neoplasms
Long non-coding RNA PSMA3-AS1 promotes glioma progression through modulating the miR-411-3p/HOXA10 pathway.
Neoplasms
Long-range allosteric regulation of the human 26S proteasome by 20S proteasome-targeting cancer drugs.
Neoplasms
Long-term incubation with proteasome inhibitors(PIs) induces I?B? degradation via the lysosomal pathway in a I?B kinase (IKK)-dependent and IKK-independent manners.
Neoplasms
Longitudinal preclinical magnetic resonance imaging of diffuse tumor burden in intramedullary myeloma following bortezomib therapy.
Neoplasms
Loperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death.
Neoplasms
Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia.
Neoplasms
Loss of lysosome-associated membrane protein 3 (LAMP3) enhances cellular vulnerability against proteasomal inhibition.
Neoplasms
Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir-bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death.
Neoplasms
Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase.
Neoplasms
Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue.
Neoplasms
Low Neurotoxicity of ONX-0914 Supports the Idea of Specific Immunoproteasome Inhibition as a Side-Effect-Limiting, Therapeutic Strategy.
Neoplasms
M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (?5i) Delivering Efficacy in Multiple Myeloma Models.
Neoplasms
Macroautophagy and ERK phosphorylation counteract the antiproliferative effect of proteasome inhibitor in gastric cancer cells.
Neoplasms
Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy.
Neoplasms
MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation.
Neoplasms
Magnetic fluid hyperthermia enhances cytotoxicity of bortezomib in sensitive and resistant cancer cell lines.
Neoplasms
Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids.
Neoplasms
Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats.
Neoplasms
MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NF?B Activation in Breast Cancer.
Neoplasms
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
Neoplasms
Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition.
Neoplasms
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Neoplasms
Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
Neoplasms
Matrix Metalloproteinase-11 Promotes Early Mouse Mammary Gland Tumor Growth through Metabolic Reprogramming and Increased IGF1/AKT/FoxO1 Signaling Pathway, Enhanced ER Stress and Alteration in Mitochondrial UPR.
Neoplasms
Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
Neoplasms
MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.
Neoplasms
MDM2-Mediated Degradation of p14ARF: A Novel Mechanism to Control ARF Levels in Cancer Cells.
Neoplasms
MdmX Is Required for p53 Interaction with and Full Induction of the Mdm2 Promoter after Cellular Stress.
Neoplasms
Measurement of active site ionization equilibria in the 670 kDa proteasome core particle using methyl-TROSY NMR.
Neoplasms
Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid.
Neoplasms
Mechanism of the attenuation of proteolysis-inducing factor stimulated protein degradation in muscle by beta-hydroxy-beta-methylbutyrate.
Neoplasms
Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation.
Neoplasms
Mechanistic and thermodynamic characterization of oxathiazolones as potent and selective covalent immunoproteasome inhibitors.
Neoplasms
Mechanistic insights into the impact of Cold Atmospheric Pressure Plasma on human epithelial cell lines.
Neoplasms
Mechanistic Rationale and Clinical Evidence for the Efficacy of Proteasome Inhibitors against Indolent and Mantle Cell Lymphomas.
Neoplasms
Mediation by NF-kappa B of cytokine induced expression of intercellular adhesion molecule 1 (ICAM-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors.
Neoplasms
Metal-based 2,3-indolinedione derivatives as proteasome inhibitors and inducers of apoptosis in human cancer cells.
Neoplasms
Methods for 20S Immunoproteasome and 20S Constitutive Proteasome Determination Based on SPRI Biosensors.
Neoplasms
Methods for the discovery of small molecules to monitor and perturb the activity of the human proteasome.
Neoplasms
Methyl-CpG-DNA binding proteins in human prostate cancer: expression of CXXC sequence containing MBD1 and repression of MBD2 and MeCP2.
Neoplasms
MG132 selectively upregulates MICB through the DNA damage response pathway in A549 cells.
Neoplasms
MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia.
Neoplasms
Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts.
Neoplasms
Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy.
Neoplasms
MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.
Neoplasms
MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.
Neoplasms
Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
Neoplasms
Mining the cinnabaramide biosynthetic pathway to generate novel proteasome inhibitors.
Neoplasms
Misfolded proteins: from little villains to little helpers in the fight against cancer.
Neoplasms
Mitochondrial dysfunction and therapeutic approaches in respiratory and limb muscles of cancer cachectic mice.
Neoplasms
Mitochondrial Malfunctioning, Proteasome Arrest and Apoptosis in Cancer Cells by Focused Intracellular Generation of Oxygen Radicals.
Neoplasms
Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines.
Neoplasms
MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Neoplasms
MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA.
Neoplasms
Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli.
Neoplasms
Modulator of apoptosis 1 (MOAP-1) is a tumor suppressor protein linked to the RASSF1A protein.
Neoplasms
Molecular aberrations in the MHC class I-restricted pathway for antigen presentation in methylcholanthrene sarcomas from nude mice: discrepancies between MHC mRNA and surface protein.
Neoplasms
Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line.
Neoplasms
Molecular and clinical aspects of proteasome inhibition in the treatment of cancer.
Neoplasms
Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells.
Neoplasms
Molecular crosstalk between the proteasome, aggresomes and autophagy: Translational potential and clinical implications.
Neoplasms
Molecular discoveries alter our view of inflammatory bowel disease. A review from scientific, clinical, and laboratory perspectives.
Neoplasms
Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors.
Neoplasms
Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors.
Neoplasms
Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent.
Neoplasms
Monitoring the Immunoproteasome in Live Cells Using an Activity-Based Peptide-Peptoid Hybrid Probe.
Neoplasms
Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation.
Neoplasms
Morphological Changes within the Rat Lateral Ventricle after the Administration of Proteasome Inhibitors.
Neoplasms
Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Neoplasms
Multi-omics analysis identifies potential mechanisms of AURKB in mediating poor outcome of lung adenocarcinoma.
Neoplasms
Multi-output model with Box-Jenkins operators of linear indices to predict multi-target inhibitors of ubiquitin-proteasome pathway.
Neoplasms
Multi-output Model with Box-Jenkins Operators of Quadratic Indices for Prediction of Malaria and Cancer Inhibitors Targeting Ubiquitin- Proteasome Pathway (UPP) Proteins.
Neoplasms
Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.
Neoplasms
Murraya koenigii leaf extract inhibits proteasome activity and induces cell death in breast cancer cells.
Neoplasms
Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: An in vitro and in vivo study.
Neoplasms
MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib.
Neoplasms
Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma.
Neoplasms
N-?-acetyltransferase 10 protein is a negative regulator of 28S proteasome through interaction with PA28?.
Neoplasms
Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.
Neoplasms
Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity.
Neoplasms
Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors.
Neoplasms
Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB.
Neoplasms
Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2.
Neoplasms
NEDDylation is essential for Kaposi's sarcoma-associated herpesvirus latency and lytic reactivation and represents a novel anti-KSHV target.
Neoplasms
Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis.
Neoplasms
Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors.
Neoplasms
Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration.
Neoplasms
Neutrophil-Derived IL-1? Impairs the Efficacy of NF-?B Inhibitors against Lung Cancer.
Neoplasms
New 26S proteasome inhibitors with high selectivity for chymotrypsin-like activity and p53-dependent cytotoxicity.
Neoplasms
New addiction to the NRF2-related factor NRF3 in cancer cells: Ubiquitin-independent proteolysis through the 20S proteasome.
Neoplasms
New aldehyde and vinylsulfone proteasome inhibitors for targeted melanoma therapy.
Neoplasms
New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective.
Neoplasms
New Difluoro Knoevenagel Condensates of Curcumin, Their Schiff Bases and Copper Complexes as Proteasome Inhibitors and Apoptosis Inducers in Cancer Cells.
Neoplasms
New Peptidomimetic Boronates for Selective Inhibition of the Chymotrypsin-like Activity of the 26S Proteasome.
Neoplasms
New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies.
Neoplasms
New therapeutic approaches for solid tumors: Histone deacetylase, methyltransferase and proteasome inhibitors.
Neoplasms
New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer.
Neoplasms
Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis.
Neoplasms
Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma.
Neoplasms
NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling.
Neoplasms
NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs.
Neoplasms
NFE2L1 and NFE2L3 Complementarily Maintain Basal Proteasome Activity in Cancer Cells through CPEB3-Mediated Translational Repression.
Neoplasms
Nigrostriatal pathway degeneration in rats after intraperitoneal administration of proteasome inhibitor MG-132.
Neoplasms
Nitric Oxide Down-Regulates Topoisomerase I and Induces Camptothecin Resistance in Human Breast MCF-7 Tumor Cells.
Neoplasms
Nitrile-Containing Fischerindoles from the Cultured Cyanobacterium Fischerella sp.
Neoplasms
NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma.
Neoplasms
Non-invasive imaging of disrupted protein homeostasis induced by proteasome inhibitor treatment using chemical exchange saturation transfer MRI.
Neoplasms
Non?covalent proteasome inhibitor PI?1840 induces apoptosis and autophagy in osteosarcoma cells.
Neoplasms
Noncompetitive Modulation of the Proteasome by Imidazoline Scaffolds Overcomes Bortezomib Resistance and Delays MM Tumor Growth in Vivo.
Neoplasms
Notching tumor: Signaling through Notch receptors improves antitumor T cell immunity.
Neoplasms
Novel 8-hydroxylquinoline analogs induce copper-dependent proteasome inhibition and cell death in human breast cancer cells.
Neoplasms
Novel CADD-based peptidyl vinyl ester derivatives as potential proteasome inhibitors.
Neoplasms
Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas.
Neoplasms
Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells.
Neoplasms
Novel copper complexes as potential proteasome inhibitors for cancer treatment (Review).
Neoplasms
Novel green synthesis of gold nanoparticles using Citrullus lanatus rind and investigation of proteasome inhibitory activity, antibacterial, and antioxidant potential.
Neoplasms
Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link.
Neoplasms
Novel multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid display improved anticancer activity independent and dependent on photoactivation.
Neoplasms
Novel N-amidinopiperidine-based proteasome inhibitor preserves dendritic cell functionality and rescues their Th1-polarizing capacity in Ramos-conditioned tumor environment.
Neoplasms
Novel organic proteasome inhibitors identified by virtual and in vitro screening.
Neoplasms
Novel phosphorylation and ubiquitination sites regulate ROS-dependent degradation of anti-apoptotic c-FLIP protein.
Neoplasms
Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway.
Neoplasms
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
Neoplasms
Novel proteasome-inhibitory syrbactin analogs inducing endoplasmic reticulum stress and apoptosis in hematological tumor cell lines.
Neoplasms
Novel proteomic strategy reveal combined alpha1 antitrypsin and cathepsin D as biomarkers for colorectal cancer early screening.
Neoplasms
Nrf1-mediated transcriptional regulation of the proteasome requires a functional TIP60 complex.
Neoplasms
Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.
Neoplasms
NRF3-POMP-20S proteasome assembly axis promotes cancer development via ubiquitin-independent proteolysis of p53 and Rb.
Neoplasms
Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor.
Neoplasms
Nuclear factor-KappaB as a common target and activator of oncogenes in head and neck squamous cell carcinoma.
Neoplasms
Nuclear proteasome activation and degradation of carboxymethylated histones in human keratinocytes following glyoxal treatment.
Neoplasms
Nuclear ubiquitin C-terminal hydrolase L5 expression associates with increased patient survival in pancreatic ductal adenocarcinoma.
Neoplasms
Nucleolar aggresomes as counterparts of cytoplasmic aggresomes in proteotoxic stress: Proteasome inhibitors induce nuclear ribonucleoprotein inclusions that accumulate several key factors of neurodegenerative diseases and cancer.
Neoplasms
Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis.
Neoplasms
O-GlcNAcylation protein disruption by Thiamet G promotes changes on the GBM U87-MG cells secretome molecular signature.
Neoplasms
O-GlcNAcylation Signal Mediates Proteasome Inhibitor Resistance in Cancer Cells by Stabilizing NRF1.
Neoplasms
Omega-3 Polyunsaturated Fatty Acids Delay the Progression of Endotoxic Shock-Induced Myocardial Dysfunction.
Neoplasms
On the involvement of calpains in the degradation of the tumor suppressor protein p53.
Neoplasms
On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants.
Neoplasms
Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy.
Neoplasms
ONX 0914 Lacks Selectivity for the Cardiac Immunoproteasome in CoxsackievirusB3 Myocarditis of NMRI Mice and Promotes Virus-Mediated Tissue Damage.
Neoplasms
Opposing effects of bortezomib-induced nuclear factor-?B inhibition on chemical lung carcinogenesis.
Neoplasms
Oppositional regulation of Noxa by JNK1 and JNK2 during apoptosis induced by proteasomal inhibitors.
Neoplasms
Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens.
Neoplasms
Optimization of in vitro measurement of proteasome activity in mammalian cells using fluorogenic substrates.
Neoplasms
Organic cadmium complexes as proteasome inhibitors and apoptosis inducers in human breast cancer cells.
Neoplasms
Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells.
Neoplasms
Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents.
Neoplasms
Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression.
Neoplasms
Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition.
Neoplasms
Overexpression of PSMC2 promotes the tumorigenesis and development of human breast cancer via regulating plasminogen activator urokinase (PLAU).
Neoplasms
Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Neoplasms
Oxidative Stress Induced by the Deubiquitinase Inhibitor b-AP15 Is Associated with Mitochondrial Impairment.
Neoplasms
Oxidative stress induces NF-kappaB nuclear translocation without degradation of IkappaBalpha.
Neoplasms
P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
Neoplasms
p28GANK overexpression is associated with chemotherapy resistance and poor prognosis in ovarian cancer.
Neoplasms
P53 facilitates degradation of human T-cell leukaemia virus type I Tax-binding protein through a proteasome-dependent pathway.
Neoplasms
p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts.
Neoplasms
p62/SQSTM1 is involved in caspase-8 associated cell death induced by proteasome inhibitor MG132 in U87MG cells.
Neoplasms
p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
Neoplasms
Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
Neoplasms
Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response.
Neoplasms
Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-?B activity in hepatocellular carcinoma.
Neoplasms
Partial proteasome inhibition in human fibroblasts triggers accelerated M1 senescence or M2 crisis depending on p53 and Rb status.
Neoplasms
Particulate cytoplasmic structures with high concentration of ubiquitin-proteasome accumulate in myeloid neoplasms.
Neoplasms
Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy.
Neoplasms
Pathway-specific differences between tumor cell lines and normal and tumor tissue cells.
Neoplasms
Pattern of MHC class I and immune proteasome expression in Walker 256 tumor during growth and regression in Brattleboro rats with the hereditary defect of arginine-vasopressin synthesis.
Neoplasms
Pattern of proteasome expression in Walker 256 tumor cells after their transplantation into the Brattleboro rats with genetic defect of vasopressin synthesis.
Neoplasms
Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells.
Neoplasms
Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.
Neoplasms
Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.
Neoplasms
Pharmacological Approaches in an Experimental Model of Non-Small Cell Lung Cancer: Effects on Tumor Biology.
Neoplasms
Pharmacological or TRIB3-Mediated Suppression of ATF4 Transcriptional Activity Promotes Hepatoma Cell Resistance to Proteasome Inhibitor Bortezomib.
Neoplasms
Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients.
Neoplasms
Pharmacological Strategies in Lung Cancer-Induced Cachexia: Effects on Muscle Proteolysis, Autophagy, Structure, and Weakness.
Neoplasms
Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases.
Neoplasms
Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice.
Neoplasms
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
Neoplasms
Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553).
Neoplasms
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
Neoplasms
Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
Neoplasms
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
Neoplasms
Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.
Neoplasms
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
Neoplasms
Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).
Neoplasms
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.
Neoplasms
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
Neoplasms
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Neoplasms
Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.
Neoplasms
Phase I Trial Using the Proteasome Inhibitor Bortezomib and Concurrent Chemoradiotherapy for Head-and-Neck Malignancies.
Neoplasms
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.
Neoplasms
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
Neoplasms
Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells.
Neoplasms
Phosphorylation of the homeotic tumor suppressor Cdx2 mediates its ubiquitin-dependent proteasome degradation.
Neoplasms
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Neoplasms
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.
Neoplasms
Pioglitazone, a PPAR-gamma ligand, exerts cytostatic/cytotoxic effects against cancer cells, that do not result from inhibition of proteasome.
Neoplasms
Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells.
Neoplasms
Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.
Neoplasms
Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors.
Neoplasms
Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization.
Neoplasms
Plasma cell myeloma positive for t(14;20) with relapse in the central nervous system.
Neoplasms
Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies.
Neoplasms
Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis.
Neoplasms
Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy.
Neoplasms
Platinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibition.
Neoplasms
Plumbagin induces paraptosis in cancer cells by disrupting the sulfhydryl homeostasis and proteasomal function.
Neoplasms
Poly C Binding Protein 1 Regulates p62/SQSTM1 mRNA Stability and Autophagic Degradation to Repress Tumor Progression.
Neoplasms
Poly-ADP ribose polymerase activates nuclear proteasome to degrade oxidatively damaged histones.
Neoplasms
Polyamine depletion reduces TNFalpha/MG132-induced apoptosis in bone marrow stromal cells.
Neoplasms
Polyamines Counteract Carbonate-Driven Proteasome Stalling in Alkaline Conditions.
Neoplasms
Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
Neoplasms
Polytherapeutic strategies with oncolytic virus-bortezomib and adjuvant NK cells in cancer treatment.
Neoplasms
Post-translational regulation of the cleaved fragment of Par-4 in ovarian and endometrial cancer cells.
Neoplasms
Post-translationally modified S12, absent in transformed breast epithelial cells, is not associated with the 26S proteasome and is induced by proteasome inhibitor.
Neoplasms
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Neoplasms
Potent antitumor agent proteasome inhibitors: a novel trigger for Bcl2 phosphorylation to induce apoptosis.
Neoplasms
Potential Marker Pathways in the Endometrium That May Cause Recurrent Implantation Failure.
Neoplasms
Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
Neoplasms
Potential use of chymotrypsin-like proteasomal activity as a biomarker for prostate cancer.
Neoplasms
Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.
Neoplasms
Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.
Neoplasms
Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer.
Neoplasms
Preclinical Evaluation of Combined Topoisomerase and Proteasome Inhibition Against Pediatric Malignancies.
Neoplasms
Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors.
Neoplasms
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Neoplasms
Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways.
Neoplasms
Preincubation with the proteasome inhibitor MG-132 enhances proteasome activity via the Nrf2 transcription factor in aging human skin fibroblasts.
Neoplasms
Preliminary studies of new proteasome inhibitors in the tumor targeting approach: synthesis and in vitro cytotoxicity.
Neoplasms
Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.
Neoplasms
Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival.
Neoplasms
Prevalence of peripheral neuropathy associated with chemotherapy in four oncology centers of Colombia.
Neoplasms
Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors.
Neoplasms
Preventive effect of a proteasome inhibitor on the formation of accelerated atherosclerosis in rabbits with uremia.
Neoplasms
Primary study on the lesions and specific proteins in BEAS-2B cells induced with the 2009 A (H1N1) influenza virus.
Neoplasms
Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells.
Neoplasms
Pro-apoptotic action of protein-carbohydrate fraction isolated from coelomic fluid of the earthworm Dendrobaena veneta against human colon adenocarcinoma cells.
Neoplasms
Pro-caspase-3 overexpression sensitises ovarian cancer cells to proteasome inhibitors.
Neoplasms
Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
Neoplasms
Procyanidin-B2 enriched fraction of cinnamon acts as a proteasome inhibitor and anti-proliferative agent in human prostate cancer cells.
Neoplasms
Prodrugs of Fluoro-Substituted Benzoates of EGC as Tumor Cellular Proteasome Inhibitors and Apoptosis Inducers.
Neoplasms
Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis.
Neoplasms
Prognostic Role of the Ubiquitin Proteasome System in Clear Cell Renal Cell Carcinoma: A Bioinformatic Perspective.
Neoplasms
Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon.
Neoplasms
Proinflammatory effect of sodium 4-phenylbutyrate in deltaF508-cystic fibrosis transmembrane conductance regulator lung epithelial cells: involvement of extracellular signal-regulated protein kinase 1/2 and c-Jun-NH2-terminal kinase signaling.
Neoplasms
Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy.
Neoplasms
Promyelocytic leukemia (PML) nuclear bodies are disorganized in colorectal tumors with total loss of major histocompatibility complex class I expression and LMP7 downregulation.
Neoplasms
Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients.
Neoplasms
Prosomes (proteasomes) changes during differentiation are related to the type of inducer.
Neoplasms
Protease Cargo in Circulating Exosomes of Breast Cancer and Ovarian Cancer Patients
Neoplasms
Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
Neoplasms
Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells.
Neoplasms
Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?
Neoplasms
Proteasomal inhibition enhances glucocorticoid receptor transactivation and alters its subnuclear trafficking.
Neoplasms
Proteasomal Protein Degradation: Adaptation of Cellular Proteolysis With Impact on Virus-and Cytokine-Mediated Damage of Heart Tissue During Myocarditis.
Neoplasms
Proteasome 20S in multiple myeloma: comparison of concentration and chymotrypsin-like activity in plasma and serum.
Neoplasms
Proteasome activator subunit 3 promotes pancreatic cancer growth via c-Myc-glycolysis signaling axis.
Neoplasms
Proteasome activity and their subunit composition in endometrial cancer tissue: correlations with clinical morphological parameters.
Neoplasms
Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells.
Neoplasms
Proteasome activity is required for the initiation of precancerous pancreatic lesions.
Neoplasms
Proteasome and heat shock protein 70 (HSP70) inhibitors as therapeutic alternative in multiple myeloma.
Neoplasms
Proteasome and NF-kappaB inhibiting phaeophytins from the green alga Cladophora fascicularis.
Neoplasms
Proteasome beta-4 subunit contributes to the development of melanoma and is regulated by miR-148b.
Neoplasms
Proteasome Complexes and Their Heterogeneity in Colorectal, Breast and Pancreatic Cancers.
Neoplasms
Proteasome Dependent Actin Remodeling Facilitates Antigen Extraction at the Immune Synapse of B Cells.
Neoplasms
Proteasome dysfunction triggers activation of SKN-1A/Nrf1 by the aspartic protease DDI-1.
Neoplasms
Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
Neoplasms
Proteasome functioning in breast cancer: connection with clinical-pathological factors.
Neoplasms
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Neoplasms
Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
Neoplasms
Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review.
Neoplasms
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Neoplasms
Proteasome inhibition as a novel mechanism of the proapoptotic activity of ?-secretase inhibitor I in cutaneous T-cell lymphoma.
Neoplasms
Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors.
Neoplasms
Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.
Neoplasms
Proteasome inhibition blocks necroptosis by attenuating death complex aggregation.
Neoplasms
Proteasome inhibition blocks NF-?B and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.
Neoplasms
Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
Neoplasms
Proteasome inhibition by quercetin triggers macroautophagy and blocks mTOR activity.
Neoplasms
Proteasome inhibition can impair caspase-8 Activation upon sub-maximal Stimulation of apoptotic tumour necrosis factor-related apoptosis inducing ligand (TRAIL) signalling.
Neoplasms
Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8.
Neoplasms
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.
Neoplasms
Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Neoplasms
Proteasome Inhibition Contributed to the Cytotoxicity of Arenobufagin after Its Binding with Na, K-ATPase in Human Cervical Carcinoma HeLa Cells.
Neoplasms
Proteasome inhibition creates a chromatin landscape favorable to RNA Pol II processivity.
Neoplasms
Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc.
Neoplasms
Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
Neoplasms
Proteasome inhibition improves fractionated radiation treatment against non-small cell lung cancer: an antioxidant connection.
Neoplasms
Proteasome inhibition in cancer is associated with enhanced tumor targeting by the adeno-associated virus/phage.
Neoplasms
Proteasome inhibition in transplantation-focusing on the experience with bortezomib.
Neoplasms
Proteasome inhibition increases recruitment of I?B kinase ? (IKK?), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.
Neoplasms
Proteasome Inhibition Induces a p38 MAPK Pathway-Dependent Antiapoptotic Program via Nrf2 in Thyroid Cancer Cells.
Neoplasms
Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity.
Neoplasms
Proteasome inhibition induces both pro- and anti-cell death pathways in prostate cancer cells.
Neoplasms
Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy.
Neoplasms
Proteasome inhibition induces macrophage apoptosis via mitochondrial dysfunction.
Neoplasms
Proteasome inhibition leads to NF-kappaB-independent IL-8 transactivation in human endothelial cells through induction of AP-1.
Neoplasms
Proteasome inhibition mediates p53 reactivation and anti-cancer activity of 6-gingerol in cervical cancer cells.
Neoplasms
Proteasome Inhibition Potentiates Antitumor Effects of Photodynamic Therapy in Mice through Induction of Endoplasmic Reticulum Stress and Unfolded Protein Response.
Neoplasms
Proteasome inhibition potentiates the cytotoxic effects of hyperthermia in HT-29 colon cancer cells through inhibition of heat shock protein 27.
Neoplasms
Proteasome inhibition prevents cell death induced by the chemotherapeutic agent cisplatin downstream of DNA damage.
Neoplasms
Proteasome inhibition reduces proliferation, collagen expression, and inflammatory cytokine production in nasal mucosa and polyp fibroblasts.
Neoplasms
Proteasome inhibition suppresses cisplatin-dependent ERCC-1 mRNA expression in human ovarian tumor cells.
Neoplasms
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
Neoplasms
Proteasome Inhibition Suppresses KIT-Independent Gastrointestinal Stromal Tumors Via Targeting Hippo/YAP/Cyclin D1 Signaling.
Neoplasms
Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors.
Neoplasms
Proteasome inhibition triggers the formation of TRAIL receptor 2 platforms for caspase-8 activation that accumulate in the cytosol.
Neoplasms
Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice.
Neoplasms
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Neoplasms
Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma.
Neoplasms
Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas.
Neoplasms
Proteasome inhibition-induced p38 MAPK/ERK signaling regulates autophagy and apoptosis through the dual phosphorylation of glycogen synthase kinase 3?.
Neoplasms
Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity?
Neoplasms
Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line.
Neoplasms
Proteasome inhibitor b-AP15 induces enhanced proteotoxicity by inhibiting cytoprotective aggresome formation.
Neoplasms
Proteasome inhibitor bortezomi-induced the apoptosis of laryngeal squamous cell carcinoma Hep-2 cell line via disrupting redox equilibrium.
Neoplasms
Proteasome inhibitor Bortezomib induces cell-cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL.
Neoplasms
Proteasome inhibitor bortezomib suppresses nuclear factor-kappa B activation and ameliorates eye inflammation in experimental autoimmune uveitis.
Neoplasms
Proteasome Inhibitor Carbobenzoxy-L-Leucyl-L-Leucyl-L-Leucinal (MG132) Enhances Therapeutic Effect of Paclitaxel on Breast Cancer by Inhibiting Nuclear Factor (NF)-?B Signaling.
Neoplasms
Proteasome inhibitor clioquinol as a candidate drug in prophylaxis and treatment of acute graft-versus-host disease.
Neoplasms
Proteasome Inhibitor Induces Apoptosis through Induction of Endoplasmic Reticulum Stress.
Neoplasms
Proteasome inhibitor inhibits proliferation and induces apoptosis in renal interstitial fibroblasts.
Neoplasms
Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma.
Neoplasms
Proteasome inhibitor lactacystin augments natural killer cell cytotoxicity of myeloma via downregulation of HLA class I.
Neoplasms
Proteasome inhibitor lactacystin enhances cisplatin cytotoxicity by increasing endoplasmic reticulum stress-associated apoptosis in HeLa cells.
Neoplasms
Proteasome inhibitor MG-132 lowers gastric adenocarcinoma TMK1 cell proliferation via bone morphogenetic protein signaling.
Neoplasms
Proteasome inhibitor MG132 enhances cisplatin-induced apoptosis in osteosarcoma cells and inhibits tumor growth.
Neoplasms
Proteasome inhibitor MG132 enhances the antigrowth and antimetastasis effects of radiation in human nonsmall cell lung cancer cells.
Neoplasms
Proteasome inhibitor MG132 enhances TRAIL-induced apoptosis and inhibits invasion of human osteosarcoma OS732 cells.
Neoplasms
Proteasome Inhibitor MG132 Induces Apoptosis and Inhibits Invasion of Human Malignant Pleural Mesothelioma Cells.
Neoplasms
Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein.
Neoplasms
Proteasome Inhibitor MG132 Inhibits Angiogenesis in Pancreatic Cancer by Blocking NF-kappaB Activity.
Neoplasms
Proteasome inhibitor MG132 inhibits the proliferation and promotes the cisplatin-induced apoptosis of human esophageal squamous cell carcinoma cells.
Neoplasms
Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway.
Neoplasms
Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp.
Neoplasms
Proteasome inhibitor MG132 suppresses pancreatic ductal adenocarcinoma-cell migration by increasing ESE3 expression.
Neoplasms
Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells.
Neoplasms
Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region.
Neoplasms
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).
Neoplasms
Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells.
Neoplasms
Proteasome Inhibitor YSY01A Abrogates Constitutive STAT3 Signaling via Down-regulation of Gp130 and JAK2 in Human A549 Lung Cancer Cells.
Neoplasms
Proteasome inhibitor-I enhances tunicamycin-induced chemosensitization of prostate cancer cells through regulation of NF-?B and CHOP expression.
Neoplasms
Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: A correlation with the proteasome status.
Neoplasms
Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells.
Neoplasms
Proteasome inhibitor-induced cleavage of HSP90 is mediated by ROS generation and caspase 10-activation in human leukemic cells.
Neoplasms
Proteasome Inhibitor-Loaded Micelles Enhance Antitumor Activity Through Macrophage Reprogramming by NF-?B Inhibition.
Neoplasms
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
Neoplasms
Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells.
Neoplasms
Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis.
Neoplasms
Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells.
Neoplasms
Proteasome inhibitors differentially affect heat shock protein response in cancer cells.
Neoplasms
Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.
Neoplasms
Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem.
Neoplasms
Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect.
Neoplasms
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
Neoplasms
Proteasome inhibitors induce AMPK activation via CaMKK? in human breast cancer cells.
Neoplasms
Proteasome inhibitors induce apoptosis in growth hormone- and prolactin-secreting rat pituitary tumor cells.
Neoplasms
Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of IkappaBalpha.
Neoplasms
Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants.
Neoplasms
Proteasome inhibitors induce inhibitory kappa B (I kappa B) kinase activation, I kappa B alpha degradation, and nuclear factor kappa B activation in HT-29 cells.
Neoplasms
Proteasome inhibitors induce nucleolar aggregation of proteasome target proteins and polyadenylated RNA by altering ubiquitin availability.
Neoplasms
Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.
Neoplasms
Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs.
Neoplasms
Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
Neoplasms
Proteasome inhibitors reduce luciferase and beta-galactosidase activity in tissue culture cells.
Neoplasms
Proteasome inhibitors remarkably prevent translesion replication in cancer cells but not normal cells.
Neoplasms
Proteasome Inhibitors Sensitize Colon Carcinoma Cells to TRAIL-Induced Apoptosis via Enhanced Release of Smac/DIABLO from the Mitochondria.
Neoplasms
Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKC?-dependent downregulation of AKT and XIAP expressions.
Neoplasms
Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
Neoplasms
Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia.
Neoplasms
Proteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent.
Neoplasms
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
Neoplasms
Proteasome inhibitors: closing the garbage can opens up new therapeutic options for patients with B-cell malignancies.
Neoplasms
Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.
Neoplasms
Proteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells.
Neoplasms
Proteasome inhibitory, antioxidant, and synergistic antibacterial and anticandidal activity of green biosynthesized magnetic Fe3O4 nanoparticles using the aqueous extract of corn (Zea mays L.) ear leaves.
Neoplasms
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.
Neoplasms
Proteasome modulators: essential chemical genetic tools for understanding human diseases.
Neoplasms
Proteasome particle-rich structures are widely present in human epithelial neoplasms: correlative light, confocal and electron microscopy study.
Neoplasms
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis.
Neoplasms
Proteasome Structure, Function, and Lessons Learned from Beta-Lactone Inhibitors.
Neoplasms
Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity.
Neoplasms
Proteasome Subunit Alpha Type 7 Promotes Proliferation and Metastasis of Gastric Cancer Through MAPK Signaling Pathway.
Neoplasms
Proteasome Ubiquitin Receptor hRpn13 and its Interacting Deubiquitinating Enzyme Uch37 are Required for Proper Cell Cycle Progression.
Neoplasms
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
Neoplasms
Proteasome-dependent degradation of Smad7 is critical for lung cancer metastasis.
Neoplasms
Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein.
Neoplasms
Proteasome-mediated regulation of CpG DNA- and peptidoglycan-induced cytokines, inflammatory genes, and mitogen-activated protein kinase activation.
Neoplasms
Proteasomes in Patient Rectal Cancer and Different Intestine Locations: Where Does Proteasome Pool Change?
Neoplasms
Protection Against Titanium Particle-Induced Inflammatory Osteolysis by the Proteasome Inhibitor Bortezomib In Vivo.
Neoplasms
Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment.
Neoplasms
Protein profile changes in the human breast cancer cell line MCF-7 in response to SEL1L gene induction.
Neoplasms
Proteome-transcriptome alignment of molecular portraits achieved by self-contained gene set analysis: Consensus colon cancer subtypes case study.
Neoplasms
Proteomic analysis of affinity-purified extracellular proteasomes reveals exclusively 20S complexes.
Neoplasms
Proteomic analysis of canine oral tumor tissues using MALDI-TOF mass spectrometry and in-gel digestion coupled with mass spectrometry (GeLC MS/MS) approaches.
Neoplasms
Proteomic Analysis of the E3 Ubiquitin-Ligase Hakai Highlights a Role in Plasticity of the Cytoskeleton Dynamics and in the Proteasome System.
Neoplasms
Proteomic analysis of tumor tissue in CT-26 implanted BALB/C mouse after treatment with ascorbic acid.
Neoplasms
Proteomic analysis uncovers common effects of IFN-? and IL-27 on the HLA class I antigen presentation machinery in human cancer cells.
Neoplasms
Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.
Neoplasms
Proteomic characterization of Withaferin A-targeted protein networks for the treatment of monoclonal myeloma gammopathies.
Neoplasms
Proteomic exploration of the impacts of pomegranate fruit juice on the global gene expression of prostate cancer cell.
Neoplasms
Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
Neoplasms
Proteomic identification of down-regulation of oncoprotein DJ-1 and proteasome activator subunit 1 in hepatitis B virus-infected well-differentiated hepatocellular carcinoma.
Neoplasms
Proteomic profiling of differential display analysis for human oral squamous cell carcinoma: 14-3-3 ? Protein is upregulated in human oral squamous cell carcinoma and dependent on the differentiation level.
Neoplasms
Proteomics identifies neddylation as a potential therapy target in small intestinal neuroendocrine tumors.
Neoplasms
Proteomics to study the diversity and dynamics of proteasome complexes: from fundamentals to the clinic.
Neoplasms
PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells.
Neoplasms
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
Neoplasms
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
Neoplasms
PSMA5 promotes the tumorigenic process of prostate cancer and is related to bortezomib resistance.
Neoplasms
PSMB4 overexpression enhances the cell growth and viability of breast cancer cells leading to a poor prognosis.
Neoplasms
PSMC2 Regulates Cell Cycle Progression Through the p21/Cyclin D1 Pathway and Predicts a Poor Prognosis in Human Hepatocellular Carcinoma.
Neoplasms
PSMD5 Inactivation Promotes 26S Proteasome Assembly during Colorectal Tumor Progression.
Neoplasms
PSME3 Promotes TGFB1 Secretion by Pancreatic Cancer Cells to Induce Pancreatic Stellate Cell Proliferation.
Neoplasms
PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer.
Neoplasms
PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma.
Neoplasms
PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma.
Neoplasms
Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib.
Neoplasms
Punaglandins, chlorinated prostaglandins, function as potent Michael receptors to inhibit ubiquitin isopeptidase activity.
Neoplasms
Pyrrolidine Dithiocarbamate Facilitates Arsenic Trioxide Against Pancreatic Cancer via Perturbing Ubiquitin-Proteasome Pathway.
Neoplasms
Pyrrolidine dithiocarbamate-zinc(II) and -copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity.
Neoplasms
Quantitative analysis of a ubiquitin-dependent substrate using capillary electrophoresis with dual laser-induced fluorescence.
Neoplasms
Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.
Neoplasms
Quercetin suppresses the chymotrypsin-like activity of proteasome via inhibition of MEK1/ERK1/2 signaling pathway in hepatocellular carcinoma HepG2 cells.
Neoplasms
Quiescent fibroblasts are protected from proteasome inhibition-mediated toxicity.
Neoplasms
Radioimmunotherapy with antibody to HPV16 E6 oncoprotein is effective in experimental cervical tumor expressing low levels of E6.
Neoplasms
Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species.
Neoplasms
Radix Tetrastigma Hemsleyani Flavone Suppresses Cutaneous Squamous Cell Carcinoma A431 Cells via Proteasome Inhibition.
Neoplasms
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Neoplasms
Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers: effects on replication, transcription, translation, and the cellular stress response.
Neoplasms
Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.
Neoplasms
Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of Paclitaxel and bortezomib using an adaptive dose-finding approach.
Neoplasms
Reactive nucleolar and Cajal body responses to proteasome inhibition in sensory ganglion neurons.
Neoplasms
Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Neoplasms
Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Neoplasms
Recent Advances in the Discovery of Novel Peptide Inhibitors Targeting 26S Proteasome.
Neoplasms
Recent advances in the identification and development of 20S proteasome inhibitors.
Neoplasms
Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy.
Neoplasms
Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
Neoplasms
Reciprocal REG?-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma.
Neoplasms
RedOx status, proteasome and APEH: insights into anticancer mechanisms of t10,c12-conjugated linoleic acid isomer on A375 melanoma cells.
Neoplasms
REG? accelerates melanoma formation by regulating Wnt/?-catenin signalling pathway.
Neoplasms
REG? deficiency suppresses tumor progression via stabilizing CK1? in renal cell carcinoma.
Neoplasms
Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
Neoplasms
Regulation of cell signaling pathways by dietary agents for cancer prevention and treatment.
Neoplasms
Regulation of Fas in response to bortezomib and epirubicin in colorectal cancer cells.
Neoplasms
Regulation of FOXO protein stability via ubiquitination and proteasome degradation.
Neoplasms
Regulation of NRF1, a master transcription factor of proteasome genes: implications for cancer and neurodegeneration.
Neoplasms
Regulation of p53 and Rb links the alternative NF-?B pathway to EZH2 expression and cell senescence.
Neoplasms
Regulation of PSMB5 and ?-Subunits of Mammalian Proteasome by Constitutively Activated STAT3: Potential Role in Bortezomib Mediated Anticancer Therapy.
Neoplasms
Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway.
Neoplasms
Regulation of the Proteasome: Evaluating the Lung Proteasome as a New Therapeutic Target.
Neoplasms
Remodeling of the epitope repertoire of a candidate idiotype vaccine by targeting to lysosomal degradation in dendritic cells.
Neoplasms
Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition.
Neoplasms
Reporter PET Images Bortezomib Treatment-Mediated Suppression of Cancer Cell Proteasome Activity.
Neoplasms
Repression of breast cancer cell growth by proteasome inhibitors in vitro: impact of mitogen-activated protein kinase phosphatase 1.
Neoplasms
Repression of protein translation and mTOR signaling by proteasome inhibitor in colon cancer cells.
Neoplasms
Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases.
Neoplasms
Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug.
Neoplasms
Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.
Neoplasms
Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
Neoplasms
REST-dependent expression of TRF2 renders non-neuronal cancer cells resistant to DNA damage during oxidative stress.
Neoplasms
Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors.
Neoplasms
Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
Neoplasms
Retinoblastoma protein co-purifies with proteasomal insulin-degrading enzyme: implications for cell proliferation control.
Neoplasms
Retroviruses have differing requirements for proteasome function in the budding process.
Neoplasms
Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3?/hypoxia-inducible factor-1?.
Neoplasms
Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways.
Neoplasms
Revisiting the role of the immunoproteasome in the activation of the canonical NF-?B pathway.
Neoplasms
Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy.
Neoplasms
Ritonavir Interacts With Bortezomib to Enhance Protein Ubiquitination and Histone Acetylation Synergistically in Renal Cancer Cells.
Neoplasms
RNA-Seq Reveals Spliceosome and Proteasome Genes as Most Consistent Transcripts in Human Cancer Cells.
Neoplasms
Role of a 19S Proteasome Subunit- PSMD10Gankyrin in Neurogenesis of Human Neuronal Progenitor Cells.
Neoplasms
Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Neoplasms
Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells.
Neoplasms
Role of the proteasome in the downregulation of transcription factors NFkappaB and C/EBP in macrophages from tumor hosts.
Neoplasms
Roles of estrogen receptor and p21WAF1 in bortezomib-induced growth inhibition in human breast cancer cells.
Neoplasms
Roles of heat shock factor 1 and 2 in response to proteasome inhibition: consequence on p53 stability.
Neoplasms
Roles of NRF3 in the Hallmarks of Cancer: Proteasomal Inactivation of Tumor Suppressors.
Neoplasms
RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.
Neoplasms
Ruthenium(ii) and palladium(ii) homo- and heterobimetallic complexes: synthesis, crystal structures, theoretical calculations and biological studies.
Neoplasms
Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells.
Neoplasms
Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products.
Neoplasms
Salinosporamide Natural Products: Potent 20?S Proteasome Inhibitors as Promising Cancer Chemotherapeutics.
Neoplasms
Salinosporamides D-J from the marine actinomycete Salinispora tropica, bromosalinosporamide, and thioester derivatives are potent inhibitors of the 20S proteasome.
Neoplasms
Salmon spawning migration and muscle protein metabolism: the August Krogh principle at work.
Neoplasms
Sanggenon C decreases tumor cell viability associated with proteasome inhibition.
Neoplasms
SC68896, a Novel Small Molecule Proteasome Inhibitor, Exerts Antiglioma Activity In vitro and In vivo.
Neoplasms
Scaled-down purification protocol to access proteomic analysis of 20S proteasome from human tissue samples: comparison of normal and tumor colorectal cells.
Neoplasms
Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
Neoplasms
Screening of tissue microarrays for ubiquitin proteasome system components in tumors.
Neoplasms
Search for Inhibitors of the Ubiquitin-Proteasome System from Natural Sources for Cancer Therapy.
Neoplasms
Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs).
Neoplasms
Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Neoplasms
Secretome analysis of multiple pancreatic cancer cell lines reveals perturbations of key functional networks.
Neoplasms
Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
Neoplasms
Selective induction of the tumor marker glutathione S-transferase P1 by proteasome inhibitors.
Neoplasms
Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia.
Neoplasms
Selective inhibition of the immunoproteasome by ligand-induced crosslinking of the active site.
Neoplasms
Selective intracellular delivery of proteasome inhibitors through pH-sensitive polymeric micelles directed to efficient antitumor therapy.
Neoplasms
Selective Substrates and Activity-Based Probes for Imaging of the Human Constitutive 20S Proteasome in Cells and Blood Samples.
Neoplasms
Selectively enhanced radiation sensitivity in prostate cancer cells associated with proteasome inhibition.
Neoplasms
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
Neoplasms
Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-?B deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Neoplasms
Sem1 is a functional component of the nuclear pore complex-associated messenger RNA export machinery.
Neoplasms
Sensitivity of proteasome to its inhibitors increases during cAMP-induced differentiation of neuroblastoma cells in culture and causes decreased viability.
Neoplasms
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits.
Neoplasms
Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.
Neoplasms
Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.
Neoplasms
Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.
Neoplasms
Separation, identification and characterization of stress degradation products of bortezomib using HPLC and LC-MS.
Neoplasms
Sequence analysis of ?-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Neoplasms
Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines.
Neoplasms
SerpinB2 protection of retinoblastoma protein from calpain enhances tumor cell survival.
Neoplasms
Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance.
Neoplasms
Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest.
Neoplasms
Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6.
Neoplasms
Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo.
Neoplasms
Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition.
Neoplasms
Signaling network analysis of ubiquitin-mediated proteins suggests correlations between the 26S proteasome and tumor progression.
Neoplasms
Silencing Hsp25/Hsp27 gene expression augments proteasome activity and increases CD8+ T-cell-mediated tumor killing and memory responses.
Neoplasms
Silencing of Proteasome 26S Subunit ATPase 2 Regulates Colorectal Cancer Cell Proliferation, Apoptosis, and Migration.
Neoplasms
Simplified synthetic TMC-95A/B analogues retain the potency of proteasome inhibitory activity.
Neoplasms
Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells.
Neoplasms
Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci.
Neoplasms
Single-cell imaging of the heat-shock response in colon cancer cells suggests that magnitude and length rather than time of onset determines resistance to apoptosis.
Neoplasms
Single-cell Transcriptome Analyses Reveal Molecular Signals to Intrinsic and Acquired Paclitaxel Resistance in Esophageal Squamous Cancer Cells.
Neoplasms
Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy.
Neoplasms
Small heat shock proteins and the ubiquitin-proteasome system in malignant tumors.
Neoplasms
Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors.
Neoplasms
SNIPER(TACC3) induces cytoplasmic vacuolization and sensitizes cancer cells to Bortezomib.
Neoplasms
Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
Neoplasms
Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells.
Neoplasms
Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.
Neoplasms
Specific inhibition of hypoxia-inducible factor (HIF)-1 alpha activation and of vascular endothelial growth factor (VEGF) production by flavonoids.
Neoplasms
Specific role of cytoplasmic dynein in the mechanism of action of an antitumor molecule, Amblyomin-X.
Neoplasms
Stability of the HTLV-1 Antisense-Derived Protein, HBZ, Is Regulated by the E3 Ubiquitin-Protein Ligase, UBR5.
Neoplasms
STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
Neoplasms
STD and TRNOESY NMR studies for the epitope mapping of the phosphorylation motif of the oncogenic protein beta-catenin recognized by a selective monoclonal antibody.
Neoplasms
sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.
Neoplasms
Structural characterization of functionalized gold nanoparticles for drug delivery in cancer therapy: a NMR based approach.
Neoplasms
Structure of the oncoprotein gankyrin in complex with S6 ATPase of the 26S proteasome.
Neoplasms
Structure-Activity Relationship Analyses of Glycyrrhetinic Acid Derivatives as Anticancer Agents.
Neoplasms
Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor.
Neoplasms
Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties.
Neoplasms
Structure-proteasome-inhibitory activity relationships of dietary flavonoids in human cancer cells.
Neoplasms
Studies of phosphoproteomic changes induced by NPM-ALK highlight deregulation of TNF/Fas/TRAIL signaling pathway in ALK-positive anaplastic large cell lymphoma.
Neoplasms
Studies of the synthesis of all stereoisomers of MG-132 proteasome inhibitors in the tumor targeting approach.
Neoplasms
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma.
Neoplasms
Sulforaphane activates heat shock response and enhances proteasome activity through upregulation of HSP27.
Neoplasms
Superior antimitogenic and chemosensitization activities of the combination treatment of the histone deacetylase inhibitor apicidin and proteasome inhibitors on human colorectal cancer cells.
Neoplasms
Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers.
Neoplasms
Suppression of FOXM1 Sensitizes Human Cancer Cells to Cell Death Induced by DNA-Damage.
Neoplasms
Suppression of MG132-mediated cell death by peroxiredoxin 1 through influence on ASK1 activation in human thyroid cancer cells.
Neoplasms
Suppression of NF-kappaB-dependent proinflammatory gene expression in human RPE cells by a proteasome inhibitor.
Neoplasms
Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
Neoplasms
Suppression of the Oncogenic Transcription Factor FOXM1 by Proteasome Inhibitors.
Neoplasms
Synchrotron X-ray imaging reveals a correlation of tumor copper speciation with Clioquinol's anticancer activity.
Neoplasms
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
Neoplasms
Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma.
Neoplasms
Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis.
Neoplasms
Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors.
Neoplasms
Synergistic induction of apoptosis of rheumatoid arthritis synovial cells by H(2)O(2) and N-acetyl-leucyl-leucyl-norleucinal.
Neoplasms
Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.
Neoplasms
Syntheses of C-13 and C-14-labeled versions of the investigational proteasome inhibitor MLN9708.
Neoplasms
Synthesis and activity of isoxazoline vinyl ester pseudopeptides as proteasome inhibitors.
Neoplasms
Synthesis and biological activity of peptide proline-boronic acids as proteasome inhibitors.
Neoplasms
Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors.
Neoplasms
Synthesis and biological properties of C-terminal vinyl ketone pseudotripeptides.
Neoplasms
Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines.
Neoplasms
Synthesis of Salinosporamide A and Its Analogs as 20S Proteasome Inhibitors and SAR Summarization.
Neoplasms
Synthesis, Bioactivity, Docking and Molecular Dynamics Studies of Furan-Based Peptides as 20S Proteasome Inhibitors.
Neoplasms
Synthesis, Computational Docking Study, and Biological Evaluation of a Library of Heterocyclic Curcuminoids with Remarkable Antitumor Activity.
Neoplasms
Synthesis, radiosynthesis, and biological evaluation of new proteasome inhibitors in a tumor targeting approach.
Neoplasms
Synthetic Lethal Drug Combinations Targeting Proteasome and Histone Deacetylase Inhibitors in TP53-Mutated Cancers.
Neoplasms
Synthetic peracetate tea polyphenols as potent proteasome inhibitors and apoptosis inducers in human cancer cells.
Neoplasms
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Neoplasms
Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity And Induces Tumor Cell Death.
Neoplasms
Systematic Analyses of Substrate Preferences of 20S Proteasomes Using Peptidic Epoxyketone Inhibitors.
Neoplasms
Systemic deficits in transporter for antigen presentation (TAP)-1 or proteasome subunit LMP2 have little or no effect on tumor incidence.
Neoplasms
Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia.
Neoplasms
Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Neoplasms
Systems biology approach to identification of biomarkers for metastatic progression in gastric cancer.
Neoplasms
Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
Neoplasms
Tannic acid potently inhibits tumor cell proteasome activity, increases p27 and Bax expression, and induces G1 arrest and apoptosis.
Neoplasms
Targeted Delivery of Proteasome Inhibitors to Somatostatin-Receptor-Expressing Cancer Cells by Octreotide Conjugation.
Neoplasms
Targeted elimination of breast cancer cells with low proteasome activity is sufficient for tumor regression.
Neoplasms
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
Neoplasms
Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode.
Neoplasms
Targeted Tumor Therapy Remixed-An Update on the Use of Small-Molecule Drugs in Combination Therapies.
Neoplasms
Targeting apoptosis pathway with natural terpenoids: implications for treatment of breast and prostate cancer.
Neoplasms
Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
Neoplasms
Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
Neoplasms
Targeting malignancies with disulfiram (antabuse): multidrug resistance, angiogenesis, and proteasome.
Neoplasms
Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
Neoplasms
Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?
Neoplasms
Targeting poor proteasomal function with radioiodine eliminates CT26 colon cancer stem cells resistant to bortezomib therapy.
Neoplasms
Targeting the proteasome as a therapeutic strategy against haematological malignancies.
Neoplasms
Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.
Neoplasms
Targeting the tumor proteasome as a mechanism to control the synthesis and bioactivity of matrix macromolecules.
Neoplasms
Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.
Neoplasms
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
Neoplasms
Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy.
Neoplasms
Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.
Neoplasms
Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies.
Neoplasms
Targeting Tumor Ubiquitin-Proteasome Pathway with Polyphenols for Chemosensitization.
Neoplasms
Temporal Quantitative Proteomics Reveals Proteomic and Phosphoproteomic Alterations Associated with Adaptive Response to Hypoxia in Melanoma Cells.
Neoplasms
Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib.
Neoplasms
Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity.
Neoplasms
TFF3 modulates NF-{kappa}B and a novel negative regulatory molecule of NF-{kappa}B in intestinal epithelial cells via a mechanism distinct from TNF-{alpha}.
Neoplasms
The 20S immunoproteasome and constitutive proteasome bind with the same affinity to PA28?? and equally degrade FAT10.
Neoplasms
The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI.
Neoplasms
The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells.
Neoplasms
The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction.
Neoplasms
The bad seed gardener: Deubiquitinases in the cancer stem-cell signaling network and therapeutic resistance.
Neoplasms
The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance.
Neoplasms
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
Neoplasms
The biological mechanisms of cancer-related skeletal muscle wasting: the role of progressive resistance exercise.
Neoplasms
The CCAAT box-binding transcription factor NF-Y regulates basal expression of human proteasome genes.
Neoplasms
The cellular response to ectopic overexpression of the tuberous sclerosis genes, TSC1 and TSC2: a proteomic approach.
Neoplasms
The cilia-regulated proteasome and its role in the development of ciliopathies and cancer.
Neoplasms
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
Neoplasms
The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo.
Neoplasms
The COP9 signalosome mediates beta-catenin degradation by deneddylation and blocks adenomatous polyposis coli destruction via USP15.
Neoplasms
The cytotoxic concentration of rosmarinic acid increases MG132-induced cytotoxicity, proteasome inhibition, autophagy, cellular stresses, and apoptosis in HepG2 cells.
Neoplasms
The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells.
Neoplasms
The deubiquitinase USP11 regulates cell proliferation and ferroptotic cell death via stabilization of NRF2 USP11 deubiquitinates and stabilizes NRF2.
Neoplasms
The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
Neoplasms
The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients with Advanced Solid Tumors or Lymphoma.
Neoplasms
The effect of proteasome inhibition on the generation of the human leukocyte antigen peptidome.
Neoplasms
The emergence of drug resistance to targeted cancer therapies: Clinical evidence.
Neoplasms
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
Neoplasms
The ERG1a potassium channel increases basal intracellular calcium concentration and calpain activity in skeletal muscle cells.
Neoplasms
The essential 26S proteasome subunit Rpn11 confers multidrug resistance to mammalian cells.
Neoplasms
The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
Neoplasms
The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer.
Neoplasms
The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.
Neoplasms
The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.
Neoplasms
The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.
Neoplasms
The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders.
Neoplasms
The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of (188)re-labeled anti-E6 C1P5 antibody in cervical cancer in mice.
Neoplasms
The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
Neoplasms
The Keap1-Nrf2-antioxidant response element pathway: a review of its regulation by melatonin and the proteasome.
Neoplasms
The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells.
Neoplasms
The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma.
Neoplasms
The Molecular Motor F-ATP Synthase Is Targeted by the Tumoricidal Protein HAMLET.
Neoplasms
The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.
Neoplasms
The nanoparticulate Quillaja saponin KGI exerts anti-proliferative effects by down-regulation of cell cycle molecules in U937 and HL-60 human leukemia cells.
Neoplasms
The novel ?2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Neoplasms
The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma.
Neoplasms
The oncogenic role of REG ? is exerted by activating the Wnt/?-catenin signaling pathway in osteosarcoma.
Neoplasms
The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma.
Neoplasms
The p97 inhibitor CB-5083 is a unique disrupter of protein homeostasis in models of Multiple Myeloma.
Neoplasms
The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase.
Neoplasms
The proteasome activator PA200 regulates tumor cell responsiveness to glutamine and resistance to ionizing radiation.
Neoplasms
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
Neoplasms
The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
Neoplasms
The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5.
Neoplasms
The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-?/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer.
Neoplasms
The Proteasome Inhibitor Bortezomib (Velcade) Sensitizes Some Human Tumor Cells to Apo2L/TRAIL-Mediated Apoptosis.
Neoplasms
The Proteasome Inhibitor Bortezomib Affects Chondrosarcoma Cells via the Mitochondria-Caspase Dependent Pathway and Enhances Death Receptor Expression and Autophagy.
Neoplasms
The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
Neoplasms
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.
Neoplasms
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Neoplasms
The proteasome inhibitor bortezomib induces an inhibitory chromatin environment at a distal enhancer of the estrogen receptor-? gene.
Neoplasms
The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Neoplasms
The Proteasome Inhibitor Bortezomib Inhibits Inflammatory Response of Periodontal Ligament Cells and Ameliorates Experimental Periodontitis in Rats.
Neoplasms
The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients.
Neoplasms
The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis.
Neoplasms
The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
Neoplasms
The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack.
Neoplasms
The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells.
Neoplasms
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.
Neoplasms
The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice.
Neoplasms
The proteasome inhibitor lactacystin enhances GSH synthesis capacity by increased expression of antioxidant components in an Nrf2-independent, but p38 MAPK-dependent manner in rat colorectal carcinoma cells.
Neoplasms
The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis.
Neoplasms
The Proteasome Inhibitor MG-132 Induces AIF Nuclear Translocation Through Down-Regulation of ERK and Akt/mTOR Pathway.
Neoplasms
The proteasome inhibitor MG-132 protects hypoxic SiHa cervical carcinoma cells after cyclic hypoxia/reoxygenation from ionizing radiation.
Neoplasms
The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism.
Neoplasms
The proteasome inhibitor MG132 induces apoptosis in human pancreatic cancer cells.
Neoplasms
The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
Neoplasms
The proteasome inhibitor PS-341 (Bortezomib) induces calpain-dependent I{kappa}B{alpha} degradation.
Neoplasms
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Neoplasms
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
Neoplasms
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
Neoplasms
The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.
Neoplasms
The proteasome is involved in determining differential utilization of double-strand break repair pathways.
Neoplasms
The proteasome regulates collagen-induced platelet aggregation via nuclear-factor-kappa-B (NF?B) activation.
Neoplasms
The proteostasis guardian HSF1 directs the transcription of its paralog and interactor HSF2 during proteasome dysfunction.
Neoplasms
The putative roles of the ubiquitin/proteasome pathway in resistance to anticancer therapy.
Neoplasms
The regulation of combined treatment-induced cell death with recombinant TRAIL and bortezomib through TRAIL signaling in TRAIL-resistant cells.
Neoplasms
The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models.
Neoplasms
The RNA polymerase III repressor MAF1 is regulated by ubiquitin-dependent proteasome degradation and modulates cancer drug resistance and apoptosis.
Neoplasms
The RNA-binding protein Musashi-1 regulates proteasome subunit expression in breast cancer- and glioma-initiating cells.
Neoplasms
The role of compartmentalized signaling pathways in the control of mitochondrial activities in cancer cells.
Neoplasms
The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
Neoplasms
The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
Neoplasms
The role of the ubiquitin proteasome system in cerebellar development and medulloblastoma.
Neoplasms
The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design.
Neoplasms
The role of ubiquitination in tumorigenesis and targeted drug discovery.
Neoplasms
The stress-inducible transcription factor ATF4 accumulates at specific rRNA-processing nucleolar regions after proteasome inhibition.
Neoplasms
The transcription levels and prognostic values of seven proteasome alpha subunits in human cancers.
Neoplasms
The triterpenoid pristimerin induces U87 glioma cell apoptosis through reactive oxygen species-mediated mitochondrial dysfunction.
Neoplasms
The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy.
Neoplasms
The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry".
Neoplasms
The Tumor Suppressor SCRIB is a Negative Modulator of the Wnt/?-Catenin Signaling Pathway.
Neoplasms
The ubiquitin ligase Itch mediates the antiapoptotic activity of epidermal growth factor by promoting the ubiquitylation and degradation of the truncated C-terminal portion of Bid.
Neoplasms
The Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis.
Neoplasms
The ubiquitin proteasome system - Implications for cell cycle control and the targeted treatment of cancer.
Neoplasms
The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases.
Neoplasms
The Ubiquitin Proteasome System in Hematological Malignancies: New Insight into Its Functional Role and Therapeutic Options.
Neoplasms
The ubiquitin+proteasome protein degradation pathway as a therapeutic strategy in the treatment of solid tumor malignancies.
Neoplasms
The ubiquitin-proteasome pathway and resistance mechanisms developed against the proteasomal inhibitors in cancer cells.
Neoplasms
The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities.
Neoplasms
The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment.
Neoplasms
The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases.
Neoplasms
The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib.
Neoplasms
The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention.
Neoplasms
The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance.
Neoplasms
The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
Neoplasms
The up-regulation of proteasome subunits and lysosomal proteases in hepatocellular carcinomas of the HBx gene knockin transgenic mice.
Neoplasms
The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy.
Neoplasms
The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
Neoplasms
The X-Linked Tumor Suppressor TSPX Interacts and Promotes Degradation of the Hepatitis B Viral Protein HBx via the Proteasome Pathway.
Neoplasms
Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors.
Neoplasms
Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.
Neoplasms
Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells.
Neoplasms
Thiostrepton, a natural compound that triggers heat shock response and apoptosis in human cancer cells: a proteomics investigation.
Neoplasms
Thymoquinone: An edible redox-active quinone for the pharmacotherapy of neurodegenerative conditions and glial brain tumors. A short review.
Neoplasms
Tight Junction Protein 1: New Insights into Proteasome Inhibitor Resistance and Myeloma Pathophysiology.
Neoplasms
Tissue specific increase of the catalytic subunits of the 26S proteasome by indirect antioxidant dithiolethione in mice: enhanced activity for degradation of abnormal protein.
Neoplasms
Titania-Coated Gold Nano-Bipyramids for Blocking Autophagy Flux and Sensitizing Cancer Cells to Proteasome Inhibitor-Induced Death.
Neoplasms
Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells.
Neoplasms
TP-110, a new proteasome inhibitor, down-regulates IAPs in human multiple myeloma cells.
Neoplasms
Tradeoff between metabolic i-proteasome addiction and immune evasion in triple-negative breast cancer.
Neoplasms
Transcription factor AP-2alpha is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor alpha-induced apoptosis in breast cancer cells.
Neoplasms
Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells.
Neoplasms
Transforming growth factor-beta suppresses the ability of Ski to inhibit tumor metastasis by inducing its degradation.
Neoplasms
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.
Neoplasms
Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes.
Neoplasms
Treating MCF7 breast cancer cell with proteasome inhibitor Bortezomib restores apoptotic factors and sensitizes cell to Docetaxel.
Neoplasms
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
Neoplasms
Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination.
Neoplasms
TRIB3 destabilizes tumor suppressor PPAR? expression through ubiquitin-mediated proteasome degradation in acute myeloid leukemia.
Neoplasms
TRIM11 activates the proteasome and promotes overall protein degradation by regulating USP14.
Neoplasms
TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.
Neoplasms
Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression.
Neoplasms
tRNA Fragments Show Intertwining with mRNAs of Specific Repeat Content and Have Links to Disparities.
Neoplasms
Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells.
Neoplasms
Tumor cell lines expressing the proteasome subunit isoform LMP7E1 exhibit immunoproteasome deficiency.
Neoplasms
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
Neoplasms
Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients.
Neoplasms
Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells.
Neoplasms
Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor.
Neoplasms
Tumor necrosis factor alpha induces expression of genes for matrix degradation in human chondrocyte-like HCS-2/8 cells through activation of NF-kappaB: abrogation of the tumor necrosis factor alpha effect by proteasome inhibitors.
Neoplasms
Tumor necrosis factor alpha stimulates p62 accumulation and enhances proteasome activity independently of ROS.
Neoplasms
Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses Against Short-Lived Proteins Through a P62-Dependent Mechanism.
Neoplasms
Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis.
Neoplasms
Tumors acquire inhibitor of apoptosis protein (IAP)-mediated apoptosis resistance through altered specificity of cytosolic proteolysis.
Neoplasms
Tumors escape immunosurveillance by overexpressing the proteasome activator PSME3.
Neoplasms
Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress.
Neoplasms
Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistry.
Neoplasms
Ubiquitin ligases and medulloblastoma: genetic markers of the four consensus subgroups identified through transcriptome datasets.
Neoplasms
Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells.
Neoplasms
Ubiquitin-Proteasome System Regulation of an Evolutionarily Conserved RNA Polymerase II-Associated Factor 1 Involved in Pancreatic Oncogenesis.
Neoplasms
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
Neoplasms
Ubiquitin-proteasome system-targeted therapy for uveal melanoma: what is the evidence?
Neoplasms
Ubiquitin/proteasome-rich particulate cytoplasmic structures (PaCSs) in the platelets and megakaryocytes of ANKRD26-related thrombo-cytopenia.
Neoplasms
Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation.
Neoplasms
Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18.
Neoplasms
Ubiquitination and the ubiquitin - proteasome system in the pathogenesis and treatment of squamous head and neck carcinoma.
Neoplasms
Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies.
Neoplasms
Up-regulation of miR-146b and down-regulation of miR-200b contribute to the cytotoxic effect of Histone deacetylase inhibitors on ras-transformed thyroid cells.
Neoplasms
Up-regulation of PSMB4 is associated with neuronal apoptosis after neuroinflammation induced by lipopolysaccharide.
Neoplasms
Up-regulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation.
Neoplasms
Up-regulation of the DR5 Expression by Proteasome Inhibitor MG132 Augments TRAIL-Induced Apoptosis in Soft Tissue Sarcoma Cell Lines.
Neoplasms
Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities.
Neoplasms
Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.
Neoplasms
Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors.
Neoplasms
Upregulation of PSMB4 is Associated with the Necroptosis after Spinal Cord Injury.
Neoplasms
Upregulation of Rpn10 promotes tumor progression via activation of the NF-?B pathway in clear cell renal cell carcinoma.
Neoplasms
Uraemic serum induces dysfunction of vascular endothelial cells: role of ubiquitin-proteasome pathway.
Neoplasms
Utilization of Lipid-Based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib.
Neoplasms
Utilization of [11C]phosgene for radiosynthesis of N-(2-{3-[3,5-bis(trifluoromethyl)]phenyl[11C]ureido}ethyl)glycyrrhetinamide, an inhibitory agent for proteasome and kinase in tumors.
Neoplasms
Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription.
Neoplasms
Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues.
Neoplasms
Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis.
Neoplasms
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Neoplasms
Vincristine and bortezomib cause axon outgrowth and behavioral defects in larval zebrafish.
Neoplasms
Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation.
Neoplasms
Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment.
Neoplasms
VLX1570 induces apoptosis through the generation of ROS and induction of ER stress on leukemia cell lines.
Neoplasms
VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification.
Neoplasms
Wheat sprout extract-induced apoptosis in human cancer cells by proteasomes modulation.
Neoplasms
When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response.
Neoplasms
When hypoxia signalling meets the ubiquitin-proteasomal pathway, new targets for cancer therapy.
Neoplasms
Withaferin a inhibits the proteasome activity in mesothelioma in vitro and in vivo.
Neoplasms
Wnt pathway activation and ABCB1 expression account for attenuation of Proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells.
Neoplasms
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.
Neoplasms
Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma.
Neoplasms
ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-?B in multiple myeloma.
Neoplasms
Zinc Protoporphyrin Suppresses ?-Catenin Protein Expression in Human Cancer Cells: The Potential Involvement of Lysosome-Mediated Degradation.
Neoplasms
[Association of intracellular proteinase activities with the content of locomotor proteins in tissues of primary tumors and metastasis in ovarian cancer].
Neoplasms
[Biosensors as a tool to use in the experiments on blood and selected blood proteins].
Neoplasms
[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].
Neoplasms
[Detection for therapeutic targets specifically expressed in myeloma side population cells].
Neoplasms
[Diagnostics of thyroid cancer: limitations of the existing methods and perspectives for future developments].
Neoplasms
[Features of the immune proteasome expression in ascite Zajdela hepatoma after implantation into Brattleboro rats with the hereditary defect of arginine-vasopressin synthesis].
Neoplasms
[Mechanism of G2/M cell cycle arrest before apoptosis in leukemia cell line HL-60 induced by proteasome inhibitor MG132]
Neoplasms
[P28GANK is a novel marker for prognosis and therapeutic target in gastric cancer].
Neoplasms
[Proteasome and calpain activities in colon cancer: the relation with metastasis and prognosis].
Neoplasms
[Proteasome inhibitors sensitize ovarian cancer cells to paclitaxel induced apoptosis]
Neoplasms
[Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer]
Neoplasms
[Regulation of insulin-like growth factors and NF-kappaB by proteasome system in endometrial cancer].
Neoplasms
[The ubiquitin system for intracellular protein degradation--involvement in human pathologies and therapeutic implications]
Neoplasms, Germ Cell and Embryonal
KRIBB53 binds to OCT4 and enhances its degradation through the proteasome, causing apoptotic cell death of OCT4-positive testicular germ cell tumors.
Neoplasms, Glandular and Epithelial
Proteasome particle-rich structures are widely present in human epithelial neoplasms: correlative light, confocal and electron microscopy study.
Neoplasms, Plasma Cell
Effects on bone metabolism of new therapeutic strategies with standard chemotherapy and biologic drugs.
Neoplasms, Plasma Cell
FAM46C and FNDC3A are multiple myeloma tumor suppressors that act in concert to impair clearing of protein aggregates and autophagy.
Neoplasms, Plasma Cell
Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
Neoplasms, Plasma Cell
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.
Neoplasms, Squamous Cell
Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer.
Nephritis
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
Nephritis
Ubiquitin C-Terminal Hydrolase L1 is required for regulated protein degradation through the ubiquitin proteasome system in kidney.
Nephrotic Syndrome
A case of nephrotic syndrome, showing evidence of response to saquinavir.
Nephrotic Syndrome
Use of Bortezomib in Heavy-Chain Deposition Disease: A Report of 3 Cases.
Nervous System Diseases
Downregulation of UBE2Q1 is associated with neuronal apoptosis in rat brain cortex following traumatic brain injury.
Nervous System Diseases
Multicatalytic proteinase is associated with characteristic oval structures in cortical Lewy bodies: an immunocytochemical study with light and electron microscopy.
Nervous System Diseases
Promiscuous Roles of Autophagy and Proteasome in Neurodegenerative Proteinopathies.
Nervous System Diseases
Retinoic acid protects against proteasome inhibition associated cell death in SH-SY5Y cells via the AKT pathway.
Nervous System Diseases
The CCAAT box-binding transcription factor NF-Y regulates basal expression of human proteasome genes.
Nervous System Diseases
The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases.
Nervous System Diseases
The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.
Nervous System Diseases
Ubiquitination and E3 Ubiquitin Ligases in Rare Neurological Diseases with Comorbid Epilepsy.
Neuralgia
Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients.
Neuralgia
Interplay between the Endogenous Opioid System and Proteasome Complex: Beyond Signaling.
Neurilemmoma
Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy.
Neurilemmoma
Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.
Neuroblastoma
6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation.
Neuroblastoma
?-secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets.
Neuroblastoma
A Central Role for Phosphorylated p38? in Linking Proteasome Inhibition-Induced Apoptosis and Autophagy.
Neuroblastoma
A Proteomics Approach to Investigate miR-153-3p and miR-205-5p Targets in Neuroblastoma Cells.
Neuroblastoma
Aggresome-forming TTRAP mediates pro-apoptotic properties of Parkinson's disease-associated DJ-1 missense mutations.
Neuroblastoma
Agouti Related Peptide Secreted Via Human Mesenchymal Stem Cells Upregulates Proteasome Activity in an Alzheimer's Disease Model.
Neuroblastoma
Amyloid peptides in different assembly states and related effects on isolated and cellular proteasomes.
Neuroblastoma
Amyloid-? Secretion, Generation, and Lysosomal Sequestration in Response to Proteasome Inhibition: Involvement of Autophagy.
Neuroblastoma
Apigenin Reduces Proteasome Inhibition-Induced Neuronal Apoptosis by Suppressing the Cell Death Process.
Neuroblastoma
Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway.
Neuroblastoma
Assessment of proteasome impairment and accumulation/aggregation of ubiquitinated proteins in neuronal cultures.
Neuroblastoma
Assessment of the direct and indirect effects of MPP+ and dopamine on the human proteasome: implications for Parkinson's disease aetiology.
Neuroblastoma
Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
Neuroblastoma
Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation.
Neuroblastoma
Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway.
Neuroblastoma
Carfilzomib enhances cisplatin-induced apoptosis in SK-N-BE(2)-M17 human neuroblastoma cells.
Neuroblastoma
Cereblon inhibits proteasome activity by binding to the 20S core proteasome subunit beta type 4.
Neuroblastoma
Characterization of the protein ubiquitination response induced by Doxorubicin.
Neuroblastoma
Cobalt chloride affects the death of SH-SY5Y cells induced by inhibition of ubiquitin proteasome system. Role of heat shock protein 70 and caspase 3.
Neuroblastoma
Cocaine and ethanol target 26S proteasome activity and gene expression in neuroblastoma cells.
Neuroblastoma
Concomitant differentiation and partial proteasome inhibition trigger apoptosis in neuroblastoma cells.
Neuroblastoma
Deletion of the BH3-only protein puma protects motoneurons from ER stress-induced apoptosis and delays motoneuron loss in ALS mice.
Neuroblastoma
Development and Validation of a Screening Assay for the Evaluation of Putative Neuroprotective Agents in the Treatment of Parkinson's Disease.
Neuroblastoma
Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.
Neuroblastoma
FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma.
Neuroblastoma
gp130 cytokines stimulate proteasomal degradation of tyrosine hydroxylase via extracellular signal regulated kinases 1 and 2.
Neuroblastoma
Heparan sulfate degradation products can associate with oxidized proteins and proteasomes.
Neuroblastoma
HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib.
Neuroblastoma
Identification of the protein disulfide isomerase family member PDIp in experimental Parkinson's disease and Lewy body pathology.
Neuroblastoma
Identifying altered gene expression in neuroblastoma cells preceding apoptosis.
Neuroblastoma
In vivo degradation of N-myc in neuroblastoma cells is mediated by the 26S proteasome.
Neuroblastoma
Induction of 26S proteasome subunit PSMB5 by the bifunctional inducer 3-methylcholanthrene through the Nrf2-ARE, but not the AhR/Arnt-XRE, pathway.
Neuroblastoma
Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma.
Neuroblastoma
Inhibitory effects of pesticides on proteasome activity: implication in Parkinson's disease.
Neuroblastoma
Lactacystin requires reactive oxygen species and Bax redistribution to induce mitochondria-mediated cell death.
Neuroblastoma
Lig-8, a bioactive lignophenol derivative from bamboo lignin, protects against neuronal damage in vitro and in vivo.
Neuroblastoma
Mevastatin induces degeneration and decreases viability of cAMP-induced differentiated neuroblastoma cells in culture by inhibiting proteasome activity, and mevalonic acid lactone prevents these effects.
Neuroblastoma
N-Acetyl Cysteine Blunts Proteotoxicity in a Heat Shock Protein-Dependent Manner.
Neuroblastoma
Neuroprotective Effects of Protein Tyrosine Phosphatase 1B Inhibition against ER Stress-Induced Toxicity.
Neuroblastoma
Novel covalent modifications of alpha-synuclein during the recovery from proteasomal dysfunction.
Neuroblastoma
Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment.
Neuroblastoma
p53-mediated mitochondrial dysfunction by proteasome inhibition in dopaminergic SH-SY5Y cells.
Neuroblastoma
PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma.
Neuroblastoma
Prostaglandin J2 alters pro-survival and pro-death gene expression patterns and 26 S proteasome assembly in human neuroblastoma cells.
Neuroblastoma
Proteasome activation and nNOS down-regulation in neuroblastoma cells expressing a Cu,Zn superoxide dismutase mutant involved in familial ALS.
Neuroblastoma
Proteasome activity is critical for the cAMP-induced differentiation of neuroblastoma cells.
Neuroblastoma
Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors.
Neuroblastoma
Proteasome inhibitor differentially regulates expression of the major immediate early genes of human cytomegalovirus in human central nervous system-derived cell lines.
Neuroblastoma
Proteasome or calpain inhibition does not alter cellular tau levels in neuroblastoma cells or primary neurons.
Neuroblastoma
Proteasome Stress Triggers Death of SH-SY5Y and T98G Cells via Different Cellular Mechanisms.
Neuroblastoma
Proteasome subunit and opioid receptor gene expression down-regulation induced by paraquat and maneb in human neuroblastoma SH-SY5Y cells.
Neuroblastoma
Proteasome-mediated effects on amyloid precursor protein processing at the gamma-secretase site.
Neuroblastoma
Protein repertoire impact of Ubiquitin-Proteasome System impairment: insight into the protective role of beta-estradiol.
Neuroblastoma
Proteomic characterization of aggregating proteins after the inhibition of the ubiquitin proteasome system.
Neuroblastoma
Proteomic signature of neuroblastoma cells UKF-NB-4 reveals key role of lysosomal sequestration and the proteasome complex in acquiring chemoresistance to cisplatin.
Neuroblastoma
Proteomics identify nuclear export as a targetable pathway in neuroblastoma: Comment on "XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of I?B".
Neuroblastoma
Reciprocal Effects of alpha-Synuclein Overexpression and Proteasome Inhibition in Neuronal Cells and Tissue.
Neuroblastoma
Retinoic acid protects against proteasome inhibition associated cell death in SH-SY5Y cells via the AKT pathway.
Neuroblastoma
Role of increased expression of the proteasome in the protective effects of sulforaphane against hydrogen peroxide-mediated cytotoxicity in murine neuroblastoma cells.
Neuroblastoma
Sarco(endo)plasmic reticulum ATPase is a molecular partner of Wolfram syndrome 1 protein, which negatively regulates its expression.
Neuroblastoma
Screening for genetic abnormalities involved in ovarian carcinogenesis using retroviral expression libraries.
Neuroblastoma
Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Neuroblastoma
Sensitivity of proteasome to its inhibitors increases during cAMP-induced differentiation of neuroblastoma cells in culture and causes decreased viability.
Neuroblastoma
Sepiapterin attenuates 1-methyl-4-phenylpyridinium-induced apoptosis in neuroblastoma cells transfected with neuronal NOS: role of tetrahydrobiopterin, nitric oxide, and proteasome activation.
Neuroblastoma
Short Chemical Ischemia Triggers Phosphorylation of eIF2? and Death of SH-SY5Y Cells but not Proteasome Stress and Heat Shock Protein Response in both SH-SY5Y and T98G Cells.
Neuroblastoma
SIRT2 interferes with autophagy-mediated degradation of protein aggregates in neuronal cells under proteasome inhibition.
Neuroblastoma
Specific inhibition of the chymotrypsin-like activity of the proteasome induces a bipolar morphology in neuroblastoma cells.
Neuroblastoma
Structural and functional evidence for citicoline binding and modulation of 20S proteasome activity: Novel insights into its pro-proteostatic effect.
Neuroblastoma
Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt/PKB activation in neuroblastoma.
Neuroblastoma
Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity And Induces Tumor Cell Death.
Neuroblastoma
Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma.
Neuroblastoma
Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.
Neuroblastoma
Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitor.
Neuroblastoma
TCF11/Nrf1-mediated induction of proteasome expression prevents cytotoxicity by Rotenone.
Neuroblastoma
The accumulation of neurotoxic proteins, induced by proteasome inhibition, is reverted by trehalose, an enhancer of autophagy, in human neuroblastoma cells.
Neuroblastoma
The bipyridyl herbicide paraquat induces proteasome dysfunction in human neuroblastoma SH-SY5Y cells.
Neuroblastoma
The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
Neuroblastoma
The Extent of Neurodegeneration and Neuroprotection in Two Chemical In Vitro Models Related to Parkinson's Disease is Critically Dependent on Cell Culture Conditions.
Neuroblastoma
The proteasome activator PA200 regulates expression of genes involved in cell survival upon selective mitochondrial inhibition in neuroblastoma cells.
Neuroblastoma
The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
Neuroblastoma
The Role of Autophagy in Chemical Proteasome Inhibition Model of Retinal Degeneration.
Neuroblastoma
XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB.
Neurodegenerative Diseases
20S proteasome mediated degradation of DHFR: implications in neurodegenerative disorders.
Neurodegenerative Diseases
A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers.
Neurodegenerative Diseases
A Novel Luminescence-Based High-Throughput Approach for Cellular Resolution of Protein Ubiquitination Using Tandem Ubiquitin Binding Entities (TUBEs).
Neurodegenerative Diseases
A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system.
Neurodegenerative Diseases
Accumulation of phosphorylated neurofilaments and increase in apoptosis-specific protein and phosphorylated c-Jun induced by proteasome inhibitors.
Neurodegenerative Diseases
Affinity Purification of Mammalian 26S Proteasomes Using an Ubiquitin-Like Domain.
Neurodegenerative Diseases
Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA.
Neurodegenerative Diseases
Aged monkey brains reveal the role of ubiquitin-conjugating enzyme UBE2N in the synaptosomal accumulation of mutant huntingtin.
Neurodegenerative Diseases
Agouti Related Peptide Secreted Via Human Mesenchymal Stem Cells Upregulates Proteasome Activity in an Alzheimer's Disease Model.
Neurodegenerative Diseases
An antibody-based amperometric biosensor for 20S proteasome activity and inhibitor screening.
Neurodegenerative Diseases
Annexin A3 is associated with cell death in lactacystin-mediated neuronal injury.
Neurodegenerative Diseases
Antagonism of proteasome inhibitor-induced heme oxygenase-1 expression by PINK1 mutation.
Neurodegenerative Diseases
Archaeal proteasomes effectively degrade aggregation-prone proteins and reduce cellular toxicities in mammalian cells.
Neurodegenerative Diseases
Archaeal Unfoldase Counteracts Protein Misfolding Retinopathy in Mice.
Neurodegenerative Diseases
Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?
Neurodegenerative Diseases
Assessment of proteasome impairment and accumulation/aggregation of ubiquitinated proteins in neuronal cultures.
Neurodegenerative Diseases
Association Analysis of Proteasome Subunits and Transporter Associated with Antigen Processing on Chinese Patients with Parkinson's Disease.
Neurodegenerative Diseases
Brain aging in acquired immunodeficiency syndrome: increased ubiquitin-protein conjugate is correlated with decreased synaptic protein but not amyloid plaque accumulation.
Neurodegenerative Diseases
c-Jun N-terminal kinase pathway mediates Lactacystin-induced cell death in a neuronal differentiated Neuro2a cell line.
Neurodegenerative Diseases
Celastrol causes apoptosis and cell cycle arrest in rat glioma cells.
Neurodegenerative Diseases
Cell-Clearing Systems Bridging Repeat Expansion Proteotoxicity and Neuromuscular Junction Alterations in ALS and SBMA.
Neurodegenerative Diseases
Chaperone-mediated 26S Proteasome Remodeling Facilitates Free K63 Ubiquitin Chain Production and Aggresome Clearance.
Neurodegenerative Diseases
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation.
Neurodegenerative Diseases
Comprehensive Analysis of Proteasomal Complexes in Mouse Brain Regions Detects ENO2 as a Potential Partner of the Proteasome in the Striatum.
Neurodegenerative Diseases
Comprehensive Profiling of Protein Ubiquitination for Drug Discovery.
Neurodegenerative Diseases
Continued 26S proteasome dysfunction in mouse brain cortical neurons impairs autophagy and the Keap1-Nrf2 oxidative defence pathway.
Neurodegenerative Diseases
Cross-functional E3 ligases Parkin and C-terminus Hsp70-interacting protein in neurodegenerative disorders.
Neurodegenerative Diseases
Crystal structure of a low molecular weight activator Blm-pep with yeast 20S proteasome - insights into the enzyme activation mechanism.
Neurodegenerative Diseases
Cyclin-dependent kinase activity is required for apoptotic death but not inclusion formation in cortical neurons after proteasomal inhibition.
Neurodegenerative Diseases
D: -Serine exposure resulted in gene expression changes implicated in neurodegenerative disorders and neuronal dysfunction in male Fischer 344 rats.
Neurodegenerative Diseases
Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies.
Neurodegenerative Diseases
Different action mechanisms of low- and high-level quercetin in the brains of adult zebrafish (Danio rerio).
Neurodegenerative Diseases
Differential effect of calmodulin antagonists on MG132-induced mitochondrial dysfunction and cell death in PC12 cells.
Neurodegenerative Diseases
Differential effects of Usp14 and Uch-L1 on the ubiquitin proteasome system and synaptic activity.
Neurodegenerative Diseases
Differential recruitment of UBQLN2 to nuclear inclusions in the polyglutamine diseases HD and SCA3.
Neurodegenerative Diseases
Direct and/or Indirect Roles for SUMO in Modulating Alpha-Synuclein Toxicity.
Neurodegenerative Diseases
Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
Neurodegenerative Diseases
Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives.
Neurodegenerative Diseases
Dissecting a role of a charge and conformation of Tat2 peptide in allosteric regulation of 20S proteasome.
Neurodegenerative Diseases
Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition.
Neurodegenerative Diseases
Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease.
Neurodegenerative Diseases
Dynamic Expression Changes in the Transcriptome of the Prefrontal Cortex after Repeated Exposure to Cocaine in Mice.
Neurodegenerative Diseases
Dysfunction of the unfolded protein response increases neurodegeneration in aged rat hippocampus following proteasome inhibition.
Neurodegenerative Diseases
Effect of geranylgeranylaceton on cellular damage induced by proteasome inhibition in cultured spinal neurons.
Neurodegenerative Diseases
Effects of reactive gamma-ketoaldehydes formed by the isoprostane pathway (isoketals) and cyclooxygenase pathway (levuglandins) on proteasome function.
Neurodegenerative Diseases
Elevated proteasome capacity extends replicative lifespan in Saccharomyces cerevisiae.
Neurodegenerative Diseases
Enhanced proteasome degradation extends Caenorhabditis elegans lifespan and alleviates aggregation-related pathologies.
Neurodegenerative Diseases
Enhancement of proteasome activity by a small-molecule inhibitor of USP14.
Neurodegenerative Diseases
Evaluating age-associated phenotypes in a mouse model of protein dyshomeostasis.
Neurodegenerative Diseases
Facilitated Tau Degradation by USP14 Aptamers via Enhanced Proteasome Activity.
Neurodegenerative Diseases
Failure of ubiquitin proteasome system: risk for neurodegenerative diseases.
Neurodegenerative Diseases
Fast axonal transport of the proteasome complex depends on membrane interaction and molecular motor function.
Neurodegenerative Diseases
Fluspirilene Analogs Activate the 20S Proteasome and Overcome Proteasome Impairment by Intrinsically Disordered Protein Oligomers.
Neurodegenerative Diseases
FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington's disease and their derived neural cells.
Neurodegenerative Diseases
Genetic evidence linking age-dependent attenuation of the 26S proteasome with the aging process.
Neurodegenerative Diseases
Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition.
Neurodegenerative Diseases
HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer.
Neurodegenerative Diseases
HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS.
Neurodegenerative Diseases
Hypothesis: proteasomal dysfunction: a primary event in neurogeneration that leads to nitrative and oxidative stress and subsequent cell death.
Neurodegenerative Diseases
Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly.
Neurodegenerative Diseases
Immunologic aspects of protein degradation by the ubiquitin-proteasome system.
Neurodegenerative Diseases
Impairment of protein degradation and proteasome function in hereditary neuropathies.
Neurodegenerative Diseases
Implications of Valosin-containing Protein in Promoting Autophagy to Prevent Tau Aggregation.
Neurodegenerative Diseases
In vitro treatments with ceftriaxone promote elimination of mutant glial fibrillary acidic protein and transcription down-regulation.
Neurodegenerative Diseases
Inactive USP14 and inactive UCHL5 cause accumulation of distinct ubiquitinated proteins in mammalian cells.
Neurodegenerative Diseases
Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease.
Neurodegenerative Diseases
Indirect inhibition of 26S proteasome activity in a cellular model of Huntington's disease.
Neurodegenerative Diseases
Inhibition of proteasome activity by anthocyanins and anthocyanidins.
Neurodegenerative Diseases
Interaction of amyotrophic lateral sclerosis/frontotemporal lobar degeneration-associated fused-in-sarcoma with proteins involved in metabolic and protein degradation pathways.
Neurodegenerative Diseases
Lactacystin Stimulates Stellation of Cultured Rat Cortical Astrocytes.
Neurodegenerative Diseases
Life and death in the trash heap: The ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral Ischemia.
Neurodegenerative Diseases
Linkage between the proteasome pathway and neurodegenerative diseases and aging.
Neurodegenerative Diseases
Loss of TDP-43 Inhibits Amyotrophic Lateral Sclerosis-Linked Mutant SOD1 Aggresome Formation in an HDAC6-Dependent Manner.
Neurodegenerative Diseases
Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system.
Neurodegenerative Diseases
Mechanistic and thermodynamic characterization of oxathiazolones as potent and selective covalent immunoproteasome inhibitors.
Neurodegenerative Diseases
Melatonin synergistically increases resveratrol-induced heme oxygenase-1 expression through the inhibition of ubiquitin-dependent proteasome pathway: a possible role in neuroprotection.
Neurodegenerative Diseases
Methods for the discovery of small molecules to monitor and perturb the activity of the human proteasome.
Neurodegenerative Diseases
Methylmercury can induce Parkinson's-like neurotoxicity similar to 1-methyl-4- phenylpyridinium: a genomic and proteomic analysis on MN9D dopaminergic neuron cells.
Neurodegenerative Diseases
Minimal length requirement for proteasomal degradation of ubiquitin-dependent substrates.
Neurodegenerative Diseases
Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry.
Neurodegenerative Diseases
Modulation of proteasome activity by curcumin and didemethylcurcumin.
Neurodegenerative Diseases
Monitoring the Immunoproteasome in Live Cells Using an Activity-Based Peptide-Peptoid Hybrid Probe.
Neurodegenerative Diseases
Mutant ubiquitin UBB+1 induces mitochondrial fusion by destabilizing mitochondrial fission-specific proteins and confers resistance to oxidative stress-induced cell death in astrocytic cells.
Neurodegenerative Diseases
N-Acyldopamine induces aggresome formation without proteasome inhibition and enhances protein aggregation via p62/SQSTM1 expression.
Neurodegenerative Diseases
Natural alkaloid harmine promotes degradation of alpha-synuclein via PKA-mediated ubiquitin-proteasome system activation.
Neurodegenerative Diseases
Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors.
Neurodegenerative Diseases
Neuroprotective effects of MAPK/ERK1/2 and calpain inhibitors on lactacystin-induced cell damage in primary cortical neurons.
Neurodegenerative Diseases
New suggestive genetic loci and biological pathways for attention function in adult attention-deficit/hyperactivity disorder.
Neurodegenerative Diseases
Nucleolar aggresomes as counterparts of cytoplasmic aggresomes in proteotoxic stress: Proteasome inhibitors induce nuclear ribonucleoprotein inclusions that accumulate several key factors of neurodegenerative diseases and cancer.
Neurodegenerative Diseases
Oxidative stress-induced ubiquitination of RCAN1 mediated by SCFbeta-TrCP ubiquitin ligase.
Neurodegenerative Diseases
Partial Failure of Proteostasis Systems Counteracting TDP-43 Aggregates in Neurodegenerative Diseases.
Neurodegenerative Diseases
Patented small molecule inhibitors in the ubiquitin proteasome system.
Neurodegenerative Diseases
Peptidase activities of the 20/26S proteasome and a novel protease in human brain.
Neurodegenerative Diseases
Pharmacological intervention in a transgenic mouse model improves Alzheimer's-associated pathological phenotype: Involvement of proteasome activation.
Neurodegenerative Diseases
Polyphenolic flavonoid (Myricetin) upregulated proteasomal degradation mechanisms: Eliminates neurodegenerative proteins aggregation.
Neurodegenerative Diseases
Positive correlation between proteasome activity and polyphenols in the telencephalon of adult female mice.
Neurodegenerative Diseases
Postnatal proteasome inhibition induces neurodegeneration and cognitive deficiencies in adult mice: a new model of neurodevelopment syndrome.
Neurodegenerative Diseases
Precise assembly and regulation of 26S proteasome and correlation between proteasome dysfunction and neurodegenerative diseases.
Neurodegenerative Diseases
Procyanidin-B2 enriched fraction of cinnamon acts as a proteasome inhibitor and anti-proliferative agent in human prostate cancer cells.
Neurodegenerative Diseases
Prostaglandin J2 alters pro-survival and pro-death gene expression patterns and 26 S proteasome assembly in human neuroblastoma cells.
Neurodegenerative Diseases
Proteasome Activation as a New Therapeutic Approach To Target Proteotoxic Disorders.
Neurodegenerative Diseases
Proteasome activation delays aging and protects against proteotoxicity in neurodegenerative disease.
Neurodegenerative Diseases
Proteasome and oxidative phoshorylation changes may explain why aging is a risk factor for neurodegenerative disorders.
Neurodegenerative Diseases
Proteasome Inhibition Alleviates SNARE-Dependent Neurodegeneration.
Neurodegenerative Diseases
Proteasome inhibition arrests neurite outgrowth and causes "dying-back" degeneration in primary culture.
Neurodegenerative Diseases
Proteasome inhibition by lactacystin in primary neuronal cells induces both potentially neuroprotective and pro-apoptotic transcriptional responses: a microarray analysis.
Neurodegenerative Diseases
Proteasome inhibition induces stress kinase dependent transport deficits--implications for Alzheimer's disease.
Neurodegenerative Diseases
Proteasome inhibition stabilizes tau inclusions in oligodendroglial cells that occur after treatment with okadaic acid.
Neurodegenerative Diseases
Proteasome inhibitors prevent oxidative stress-induced nerve cell death by a novel mechanism.
Neurodegenerative Diseases
Proteasome inhibitors promote the sequestration of PrPSc into aggresomes within the cytosol of prion-infected CAD neuronal cells.
Neurodegenerative Diseases
Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia.
Neurodegenerative Diseases
Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer.
Neurodegenerative Diseases
Protein misfolding in neurodegenerative diseases: implications and strategies.
Neurodegenerative Diseases
Protein oxidative modification in the aging organism and the role of the ubiquitin proteasomal system.
Neurodegenerative Diseases
Protein repertoire impact of Ubiquitin-Proteasome System impairment: insight into the protective role of beta-estradiol.
Neurodegenerative Diseases
Proteolytic stress causes heat shock protein induction, tau ubiquitination, and the recruitment of ubiquitin to tau-positive aggregates in oligodendrocytes in culture.
Neurodegenerative Diseases
Proteomic characterization of aggregating proteins after the inhibition of the ubiquitin proteasome system.
Neurodegenerative Diseases
Raloxifene is a Female-specific Proteostasis Therapeutic in the Spinal Cord.
Neurodegenerative Diseases
Rapid induction of p62 and GABARAPL1 upon proteasome inhibition promotes survival before autophagy activation.
Neurodegenerative Diseases
Reactive nucleolar and Cajal body responses to proteasome inhibition in sensory ganglion neurons.
Neurodegenerative Diseases
Regulatory Role of Ubiquitin Specific Protease-13 (USP13) in Misfolded Protein Clearance in Neurodegenerative Diseases.
Neurodegenerative Diseases
Removing protein aggregates: the role of proteolysis in neurodegeneration.
Neurodegenerative Diseases
Restructured endoplasmic reticulum generated by mutant amyotrophic lateral sclerosis-linked VAPB is cleared by the proteasome.
Neurodegenerative Diseases
Resveratrol attenuates oxidative stress and improves behaviour in 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) challenged mice.
Neurodegenerative Diseases
Retinoic acid protects against proteasome inhibition associated cell death in SH-SY5Y cells via the AKT pathway.
Neurodegenerative Diseases
Roles of the proteasome in neurodegenerative disease: refining the hypothesis.
Neurodegenerative Diseases
Selective Substrates and Activity-Based Probes for Imaging of the Human Constitutive 20S Proteasome in Cells and Blood Samples.
Neurodegenerative Diseases
Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington's disease.
Neurodegenerative Diseases
Synthesis and activity of isoxazoline vinyl ester pseudopeptides as proteasome inhibitors.
Neurodegenerative Diseases
Synthesis and proteasome inhibition of N-allyl vinyl ester-based peptides.
Neurodegenerative Diseases
Targeting the 26S Proteasome To Protect Against Proteotoxic Diseases.
Neurodegenerative Diseases
Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.
Neurodegenerative Diseases
The 20S proteasome isolated from Alzheimer's disease brain shows post-translational modifications but unchanged proteolytic activity.
Neurodegenerative Diseases
The accumulation of neurotoxic proteins, induced by proteasome inhibition, is reverted by trehalose, an enhancer of autophagy, in human neuroblastoma cells.
Neurodegenerative Diseases
The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration.
Neurodegenerative Diseases
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
Neurodegenerative Diseases
The proteasome: a central regulator of inflammation and macrophage function.
Neurodegenerative Diseases
The Role of HSP70 and Its Co-chaperones in Protein Misfolding, Aggregation and Disease.
Neurodegenerative Diseases
The role of the ubiquitin proteasome system in synapse remodeling and neurodegenerative diseases.
Neurodegenerative Diseases
The roles of the proteasome pathway in signal transduction and neurodegenerative diseases.
Neurodegenerative Diseases
The Ubiquitin Proteasome System as a Potential Target for the Treatment of Neurodegenerative Diseases.
Neurodegenerative Diseases
The ubiquitin proteasome system as a potential therapeutic target for treatment of neurodegenerative diseases.
Neurodegenerative Diseases
The ubiquitin proteasome system in glia and its role in neurodegenerative diseases.
Neurodegenerative Diseases
The ubiquitin proteasome system in neurodegenerative diseases: Culprit, accomplice or victim?
Neurodegenerative Diseases
The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg.
Neurodegenerative Diseases
The ubiquitin proteasome system in synaptic and axonal degeneration: a new twist to an old cycle.
Neurodegenerative Diseases
The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases.
Neurodegenerative Diseases
The Underlying Role of Oxidative Stress in Neurodegeneration: A Mechanistic Review.
Neurodegenerative Diseases
Transcriptional regulation of human USP24 gene expression by NF-kappa B.
Neurodegenerative Diseases
Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
Neurodegenerative Diseases
Ubiquitin signaling in neurodegenerative diseases: an autophagy and proteasome perspective.
Neurodegenerative Diseases
Ubiquitin-proteasome pathway components as therapeutic targets for CNS maladies.
Neurodegenerative Diseases
Ubiquitin-specific protease 14 is a new therapeutic target for the treatment of diseases.
Neurodegenerative Diseases
Ubiquitin-Synaptobrevin Fusion Protein Causes Degeneration of Presynaptic Motor Terminals in Mice.
Neurodegenerative Diseases
Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3.
Neurodegenerative Diseases
Up-regulation of endoplasmic reticulum stress-related genes during the early phase of treatment of cultured cortical neurons by the proteasomal inhibitor lactacystin.
Neurodegenerative Diseases
Up-regulation of the clusterin gene after proteotoxic stress: implication of HSF1-HSF2 heterocomplexes.
Neurodegenerative Diseases
[Regulation of the protein degradation pathway by the ubiquitin family: its implication in neurodegenerative diseases]
Neuroendocrine Tumors
Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours.
Neuroendocrine Tumors
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
Neurofibrosarcoma
Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.
Neurofibrosarcoma
Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors.
Neuroinflammatory Diseases
Bassoon proteinopathy drives neurodegeneration in multiple sclerosis.
Neuroinflammatory Diseases
BV-2 stimulation by lactacystin results in a strong inflammatory reaction and apoptotic neuronal death in SH-SY5Y cells.
Neuroinflammatory Diseases
Diagnosis, Pathogenesis and Therapeutic Targets in Amyotrophic Lateral Sclerosis.
Neuroinflammatory Diseases
Dysregulated microRNAs in neural system: Implication in pathogenesis and biomarker development in Parkinson's disease.
Neuroinflammatory Diseases
Investigations into the Role of 26S Proteasome Non-ATPase Regulatory Subunit 13 in Neuroinflammation.
Neuroinflammatory Diseases
Lipopolysaccharide-induced neuroinflammation leads to the accumulation of ubiquitinated proteins and increases susceptibility to neurodegeneration induced by proteasome inhibition in rat hippocampus.
Neuroinflammatory Diseases
Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs.
Neuroinflammatory Diseases
LPS-induced down-regulation of NO-sensitive guanylyl cyclase in astrocytes occurs by proteasomal degradation in clastosomes.
Neuroinflammatory Diseases
Neuroinflammation alters cellular proteostasis by producing endoplasmic reticulum stress, autophagy activation and disrupting ERAD activation.
Neuroinflammatory Diseases
Over-Activated Proteasome Mediates Neuroinflammation on Acute Intracerebral Hemorrhage in Rats.
Neuroinflammatory Diseases
Protein kinase inhibitors for amyotrophic lateral sclerosis therapy.
Neuroinflammatory Diseases
Reactive glia show increased immunoproteasome activity in Alzheimer's disease.
Neuroinflammatory Diseases
REG? controls Th17 cell differentiation and autoimmune inflammation by regulating dendritic cells.
Neuroinflammatory Diseases
Systemic LPS-induced neuroinflammation increases the susceptibility for proteasome inhibition-induced degeneration of the nigrostriatal pathway.
Neuroinflammatory Diseases
Upregulation of PSMB4 is Associated with the Necroptosis after Spinal Cord Injury.
Neuromuscular Diseases
Preferential degradation of oxidized proteins by the 20S proteasome may be inhibited in aging and in inflammatory neuromuscular diseases.
Neuronal Ceroid-Lipofuscinoses
Cln6 mutants associated with neuronal ceroid lipofuscinosis are degraded in a proteasome dependent manner.
Neutropenia
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Neutropenia
Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Neutropenia
Ubiquitin/proteasome-rich particulate cytoplasmic structures (PaCSs) in the platelets and megakaryocytes of ANKRD26-related thrombo-cytopenia.
Nevus
Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression.
Nocardia Infections
Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors.
Non-alcoholic Fatty Liver Disease
Moderate chronic ethanol consumption exerts beneficial effects on nonalcoholic fatty liver in mice fed a high-fat diet: possible role of higher formation of triglycerides enriched in monounsaturated fatty acids.
Non-alcoholic Fatty Liver Disease
Nutrigenomics of high fat diet induced obesity in mice suggests relationships between susceptibility to fatty liver disease and the proteasome.
Non-alcoholic Fatty Liver Disease
Proteasome dysfunction under compromised redox metabolism dictates liver injury in NASH through ASK1/PPAR? binodal complementary modules.
Non-alcoholic Fatty Liver Disease
Serum ubiquitin levels in patients with nonalcoholic steatohepatitis.
non-chaperonin molecular chaperone atpase deficiency
[Mechanism of heat shock protein 90 for regulating 26S proteasome in hyperthermia].
Obesity
Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity.
Obesity
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).
Obesity
Defective regulation of the ubiquitin/proteasome system in the hypothalamus of obese male mice.
Obesity
Detecting the genetic link between Alzheimer's disease and obesity using bioinformatics analysis of GWAS data.
Obesity
Nutrigenomics of high fat diet induced obesity in mice suggests relationships between susceptibility to fatty liver disease and the proteasome.
Obesity
Proteasome activity correlates with male BMI and contributes to the differentiation of adipocyte in hADSC.
Obesity
PROTEASOME DYSFUNCTION ASSOCIATED TO OXIDATIVE STRESS AND PROTEOTOXICITY IN ADIPOCYTES COMPROMISE INSULIN SENSITIVITY IN HUMAN OBESITY.
Obesity
Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver.
Obesity
Proteasome dysfunction under compromised redox metabolism dictates liver injury in NASH through ASK1/PPAR? binodal complementary modules.
Obesity
Proteasome Subunits mRNA Expressions Correlate With Male BMI: Implications for a Role in Obesity.
Obesity
Skeletal muscle myotubes in severe obesity exhibit altered ubiquitin-proteasome and autophagic/lysosomal proteolytic flux.
Obesity, Morbid
The GID ubiquitin ligase complex is a regulator of AMPK activity and organismal lifespan.
Opportunistic Infections
HSCT corrects primary immunodeficiency and immune dysregulation in patients with POMP-related auto-inflammatory disease.
Opportunistic Infections
Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors.
Optic Atrophy, Autosomal Dominant
Recombinant High-Mobility Group Box 1 (rHMGB1) Promotes NRF2-Independent Mitochondrial Fusion through CXCR4/PSMB5-Mediated Drp1 Degradation in Endothelial Cells.
Optic Neuritis
Autoantibodies to the proteasome in monosymptomatic optic neuritis may predict progression to multiple sclerosis.
Osteitis Deformans
Genetics of bone diseases: Paget's disease, fibrous dysplasia, osteopetrosis, and osteogenesis imperfecta.
Osteoarthritis
Effects of a proteasome inhibitor on the NF-?B signalling pathway in experimental osteoarthritis.
Osteoarthritis
Hypoxic resistance to articular chondrocyte apoptosis--a possible mechanism of maintaining homeostasis of normal articular cartilage.
Osteoarthritis
Local induction of heat shock protein 70 (Hsp70) by proteasome inhibition confers chondroprotection during surgically induced osteoarthritis in the rat knee.
Osteoarthritis
Protection against murine osteoarthritis by inhibition of the 26S proteasome and lysine-48 linked ubiquitination.
Osteoarthritis
Suppression of pain and joint destruction by inhibition of the proteasome system in experimental osteoarthritis.
Osteolysis
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
Osteolysis
Effects of proteasome inhibitors on cytokines, metalloproteinases and their inhibitors and collagen type-I expression in periprosthetic tissues and fibroblasts from loose arthroplasty endoprostheses.
Osteolysis
Extracellular matrix degradation and tissue remodeling in periprosthetic loosening and osteolysis: focus on matrix metalloproteinases, their endogenous tissue inhibitors, and the proteasome.
Osteolysis
Nanosized Alumina Particle and Proteasome Inhibitor Bortezomib Prevented inflammation and Osteolysis Induced by Titanium Particle via Autophagy and NF-?B Signaling.
Osteolysis
Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades.
Osteolysis
Protection Against Titanium Particle-Induced Inflammatory Osteolysis by the Proteasome Inhibitor Bortezomib In Vivo.
Osteonecrosis
Bioinformatics analysis of microRNA linked to ubiquitin proteasome system in traumatic osteonecrosis of the femoral head.
Osteoporosis
Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation-induced osteoporosis.
Osteoporosis, Postmenopausal
Silencing Proteasome 26S Subunit ATPase 2 (PSMC2) Protects the Osteogenic Differentiation In Vitro and Osteogenesis In Vivo.
Osteosarcoma
A Comparative Oncology Drug Discovery Pipeline to Identify and Validate New Treatments for Osteosarcoma.
Osteosarcoma
A New Perspective for Osteosarcoma Therapy: Proteasome Inhibition by MLN9708/2238 Successfully Induces Apoptosis and Cell Cycle Arrest and Attenuates the Invasion Ability of Osteosarcoma Cells in Vitro.
Osteosarcoma
Adenylate cyclase regulation via proteasome-mediated modulation of Galphas levels.
Osteosarcoma
alpha-Synuclein stimulates differentiation of osteosarcoma cells: relevance to down-regulation of proteasome activity.
Osteosarcoma
Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation.
Osteosarcoma
APEH Inhibition Affects Osteosarcoma Cell Viability via Downregulation of the Proteasome.
Osteosarcoma
Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells.
Osteosarcoma
ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma.
Osteosarcoma
Bortezomib and endocannabinoid/endovanilloid system: a synergism in osteosarcoma.
Osteosarcoma
Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2?/ATF4/CHOP axis.
Osteosarcoma
Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132.
Osteosarcoma
Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations.
Osteosarcoma
Identification of cellular proteins interacting with equine infectious anemia virus S2 protein.
Osteosarcoma
Identification of chemoradiation-resistant osteosarcoma stem cells using an imaging system for proteasome activity.
Osteosarcoma
Impaired cell cycle regulation of the osteoblast-related heterodimeric transcription factor Runx2-Cbfbeta in osteosarcoma cells.
Osteosarcoma
Induction of apoptosis in human osteosarcoma Saos-2 cells by the proteasome inhibitor MG132 and the protective effect of pRb.
Osteosarcoma
Molecular mechanisms of Polyphyllin I-induced apoptosis and reversal of the epithelial-mesenchymal transition in human osteosarcoma cells.
Osteosarcoma
Non?covalent proteasome inhibitor PI?1840 induces apoptosis and autophagy in osteosarcoma cells.
Osteosarcoma
Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
Osteosarcoma
Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma.
Osteosarcoma
Proteasome inhibitor MG132 enhances cisplatin-induced apoptosis in osteosarcoma cells and inhibits tumor growth.
Osteosarcoma
Proteasome inhibitor MG132 enhances TRAIL-induced apoptosis and inhibits invasion of human osteosarcoma OS732 cells.
Osteosarcoma
Proteasome inhibitor MG132 induces apoptosis in human osteosarcoma U2OS cells.
Osteosarcoma
Proteasome-mediated degradation of the vitamin D receptor (VDR) and a putative role for SUG1 interaction with the AF-2 domain of VDR.
Osteosarcoma
Resistance of osteosarcoma cells to the proapoptotic effects of carfilzomib involves activation of mitogen activated protein kinase pathways.
Osteosarcoma
Significance of NF-kappaB signaling and PARP1 activity in the TNF-induced inhibition of PHEX gene expression in human osteoblasts.
Osteosarcoma
The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid-induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RAR?.
Osteosarcoma
The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice.
Osteosarcoma
Transcriptional repression of E2F gene by proteasome inhibitors in human osteosarcoma cells.
Osteosarcoma
[Cytotoxic effect of cisplatin with proteasome inhibitor on osteosarcoma cells]
Osteosclerosis
Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.
Ovarian Cysts
Proteasome Activity and C-Reactive Protein Concentration in the Course of Inflammatory Reaction in Relation to the Type of Abdominal Operation and the Surgical Technique Used.
Ovarian Neoplasms
Autophagy-independent enhancing effects of Beclin 1 on cytotoxicity of ovarian cancer cells mediated by proteasome inhibitors.
Ovarian Neoplasms
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Ovarian Neoplasms
Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.
Ovarian Neoplasms
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.
Ovarian Neoplasms
Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.
Ovarian Neoplasms
Chromosomal instability and mTORC1 activation through PTEN loss contribute to proteotoxic stress in ovarian carcinoma.
Ovarian Neoplasms
Deubiquitinase PSMD14 promotes ovarian cancer progression by decreasing enzymatic activity of PKM2.
Ovarian Neoplasms
Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.
Ovarian Neoplasms
Evaluating cytoplasmic and nuclear levels of inflammatory cytokines in cancer cells by western blotting.
Ovarian Neoplasms
Expression profiles and prognostic values of BolA family members in ovarian cancer.
Ovarian Neoplasms
Glucose starvation and hypoxia induce nuclear accumulation of proteasome in cancer cells.
Ovarian Neoplasms
Histone deacetylase inhibitor induced pVHL-independent degradation of HIF-1? and hierarchical quality control of pVHL via chaperone system.
Ovarian Neoplasms
Hybrid sequencing-based personal full-length transcriptomic analysis implicates proteostatic stress in metastatic ovarian cancer.
Ovarian Neoplasms
Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors.
Ovarian Neoplasms
Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.
Ovarian Neoplasms
Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors.
Ovarian Neoplasms
Pro-caspase-3 overexpression sensitises ovarian cancer cells to proteasome inhibitors.
Ovarian Neoplasms
Protease Cargo in Circulating Exosomes of Breast Cancer and Ovarian Cancer Patients
Ovarian Neoplasms
Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Ovarian Neoplasms
Proteasome inhibition increases recruitment of I?B kinase ? (IKK?), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.
Ovarian Neoplasms
Proteasome inhibition leads to altered signaling in the proteome of cisplatin-resistant human ovarian carcinoma cell line.
Ovarian Neoplasms
Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.
Ovarian Neoplasms
Proteasome inhibition suppresses cisplatin-dependent ERCC-1 mRNA expression in human ovarian tumor cells.
Ovarian Neoplasms
Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells.
Ovarian Neoplasms
Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
Ovarian Neoplasms
Proteomic analysis of degradation ubiquitin signaling by ubiquitin occupancy changes responding to 26S proteasome inhibition.
Ovarian Neoplasms
PSMC2/CCND1 axis promotes development of ovarian cancer through regulating cell growth, apoptosis and migration.
Ovarian Neoplasms
RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.
Ovarian Neoplasms
Specific MALDI Imaging and Profiling for Biomarker Hunting and Validation: Fragment of the 11S Proteasome Activator Complex, Reg Alpha Fragment, Is a New Potential Ovary Cancer Biomarker.
Ovarian Neoplasms
STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
Ovarian Neoplasms
Synergistic activity of the histone deacetylase inhibitor trichostatin A and the proteasome inhibitor PS-341 against taxane-resistant ovarian cancer cell lines.
Ovarian Neoplasms
Synergistic Efficacy in Human Ovarian Cancer Cells by Histone Deacetylase Inhibitor TSA and Proteasome Inhibitor PS-341.
Ovarian Neoplasms
The C-terminal fragment of the immunoproteasome PA28S (Reg alpha) as an early diagnosis and tumor-relapse biomarker: evidence from mass spectrometry profiling.
Ovarian Neoplasms
The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-?/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer.
Ovarian Neoplasms
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.
Ovarian Neoplasms
Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor.
Ovarian Neoplasms
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
Ovarian Neoplasms
VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal.
Ovarian Neoplasms
[Association of intracellular proteinase activities with the content of locomotor proteins in tissues of primary tumors and metastasis in ovarian cancer].
Ovarian Neoplasms
[Proteasome inhibitors sensitize ovarian cancer cells to paclitaxel induced apoptosis]
Pancreatic Neoplasms
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.
Pancreatic Neoplasms
A binuclear complex constituted by diethyldithiocarbamate and copper(I) functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenografts.
Pancreatic Neoplasms
Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cells.
Pancreatic Neoplasms
Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production.
Pancreatic Neoplasms
Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine.
Pancreatic Neoplasms
Characterization of GPR56 protein and its suppressed expression in human pancreatic cancer cells.
Pancreatic Neoplasms
Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.
Pancreatic Neoplasms
Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
Pancreatic Neoplasms
Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts.
Pancreatic Neoplasms
Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1.
Pancreatic Neoplasms
Gel-based proteomics analysis of the heterogeneity of 20S proteasomes from four human pancreatic cancer cell lines.
Pancreatic Neoplasms
Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells.
Pancreatic Neoplasms
Homoharringtonine could induce quick protein synthesis of PSMD11 through activating MEK1/ERK1/2 signaling pathway in pancreatic cancer cells.
Pancreatic Neoplasms
Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells.
Pancreatic Neoplasms
Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity.
Pancreatic Neoplasms
Lysosomal Degradation of CD44 Mediates Ceramide Nanoliposome-induced Anoikis and Diminshed Extravasation in Metastatic Carcinoma Cells.
Pancreatic Neoplasms
Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Pancreatic Neoplasms
New Difluoro Knoevenagel Condensates of Curcumin, Their Schiff Bases and Copper Complexes as Proteasome Inhibitors and Apoptosis Inducers in Cancer Cells.
Pancreatic Neoplasms
Noxa/Mcl-1 balance influences the effect of the proteasome inhibitor MG-132 in combination with anticancer agents in pancreatic cancer cell lines.
Pancreatic Neoplasms
Proteasome activator subunit 3 promotes pancreatic cancer growth via c-Myc-glycolysis signaling axis.
Pancreatic Neoplasms
Proteasome Complexes and Their Heterogeneity in Colorectal, Breast and Pancreatic Cancers.
Pancreatic Neoplasms
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Pancreatic Neoplasms
Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer.
Pancreatic Neoplasms
Proteasome Inhibitor MG132 Inhibits Angiogenesis in Pancreatic Cancer by Blocking NF-kappaB Activity.
Pancreatic Neoplasms
Proteasome inhibitor MG132 suppresses pancreatic ductal adenocarcinoma-cell migration by increasing ESE3 expression.
Pancreatic Neoplasms
Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer.
Pancreatic Neoplasms
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
Pancreatic Neoplasms
Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
Pancreatic Neoplasms
Synergistic antitumor effects of radiation and proteasome inhibitor treatment in pancreatic cancer through the induction of autophagy and the downregulation of TRAF6.
Pancreatic Neoplasms
Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines.
Pancreatic Neoplasms
Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia.
Pancreatic Neoplasms
The proteasome inhibitor MG132 induces apoptosis in human pancreatic cancer cells.
Pancreatic Neoplasms
The ubiquitin-proteasome pathway mediates gelsolin protein downregulation in pancreatic cancer.
Pancreatic Neoplasms
Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells.
Pancreatitis
Bortezomib-induced acute pancreatitis: Case report and review of the literature.
Pancreatitis
CaMKII/proteasome/cytosolic calcium/cathepsin B axis was present in tryspin activation induced by nicardipine.
Pancreatitis
Dynamic changes of proteasome and protective effect of bortezomib, a proteasome inhibitor, in mice with acute pancreatitis.
Pancreatitis
Proteasome inhibitor ameliorates severe acute pancreatitis and associated lung injury of rats.
Pancreatitis
The Potential Effect of Proteasome Inhibitor PS-341 on Severe Acute Pancreatitis Detected by Positron Emission Tomography in ICR Mice.
Pancreatitis
[Effect of MG-132 upon the expression of intercellular adhesion molecule-1 in cerulein-induced acute pancreatitis in mice]
Pancreatitis
[Protective effect of proteasome inhibitor MG-132 in rats with severe acute pancreatitis and lung injury]
Papilloma
COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system.
Papilloma
Enhanced Efficacy against Cervical Carcinomas through Polymeric Micelles Physically Incorporating the Proteasome Inhibitor MG132.
Papilloma
Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
Papilloma
Molecular mechanism of curcumin action in signaling pathways: Review of the latest research.
Papilloma
REG? is critical for skin carcinogenesis by modulating the Wnt/?-catenin pathway.
Papilloma
Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.
Papilloma
[Transcriptional inhibition of human papilloma virus in cervical carcinoma cells reactivates functions of the tumor suppressor p53]
Paralysis
18?-Glycyrrhetinic Acid Proteasome Activator Decelerates Aging and Alzheimer's Disease Progression in Caenorhabditis elegans and Neuronal Cultures.
Paralysis
Diaphragm muscle fiber function and structure in humans with hemidiaphragm paralysis.
Paralysis
The A? Containing Brain Extracts Having Different Effects in Alzheimer's Disease Transgenic Caenorhabditis elegans and Mice.
Paraneoplastic Cerebellar Degeneration
Proteasome antibodies in paraneoplastic cerebellar degeneration.
Paraproteinemias
Chemotherapy-induced peripheral neuropathies in hematological malignancies.
Paraproteinemias
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma.
Parasitic Diseases
Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors.
Parasitic Diseases
The Proteasome as a Drug Target in the Metazoan Pathogen, Schistosoma mansoni.
Parkinson Disease
A Mechanistic Study of Proteasome Inhibition-Induced Iron Misregulation in Dopamine Neuron Degeneration.
Parkinson Disease
A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease.
Parkinson Disease
A short overview on the role of alpha-synuclein and proteasome in experimental models of Parkinson's disease.
Parkinson Disease
Alpha-synuclein aggregation, Ubiquitin proteasome system impairment, and L-Dopa response in zinc-induced Parkinsonism: resemblance to sporadic Parkinson's disease.
Parkinson Disease
alpha-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis.
Parkinson Disease
Alterations in cytoskeletal and immune function-related proteome profiles in whole rat lung following intratracheal instillation of heparin.
Parkinson Disease
Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Parkinson Disease
Analysis of gene expression in neural cells subject to chronic proteasome inhibition.
Parkinson Disease
Archaeal proteasomes effectively degrade aggregation-prone proteins and reduce cellular toxicities in mammalian cells.
Parkinson Disease
Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates.
Parkinson Disease
Assessment of the direct and indirect effects of MPP+ and dopamine on the human proteasome: implications for Parkinson's disease aetiology.
Parkinson Disease
Association Analysis of Proteasome Subunits and Transporter Associated with Antigen Processing on Chinese Patients with Parkinson's Disease.
Parkinson Disease
Brain proteasomal function in sporadic Parkinson's disease and related disorders.
Parkinson Disease
c-Jun N-terminal kinase mediates lactacystin-induced dopamine neuron degeneration.
Parkinson Disease
Caveolin-1 interacts with alpha-synuclein and mediates toxic actions of cellular alpha-synuclein overexpression.
Parkinson Disease
Characterization of chronic low-level proteasome inhibition on neural homeostasis.
Parkinson Disease
Chronic systemic treatment with a high-dose proteasome inhibitor in mice produces akinesia unrelated to nigrostriatal degeneration.
Parkinson Disease
Co-expression network-based analysis of hippocampal expression data associated with Alzheimer's disease using a novel algorithm.
Parkinson Disease
Compensatory role of the Nrf2-ARE pathway against paraquat toxicity: Relevance of 26S proteasome activity.
Parkinson Disease
Computational identification of key genes that may regulate gene expression reprogramming in Alzheimer's patients.
Parkinson Disease
Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis.
Parkinson Disease
Cysteine cathepsins are essential in lysosomal degradation of ?-synuclein.
Parkinson Disease
Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies.
Parkinson Disease
Development and Validation of a Screening Assay for the Evaluation of Putative Neuroprotective Agents in the Treatment of Parkinson's Disease.
Parkinson Disease
Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats.
Parkinson Disease
Direct and/or Indirect Roles for SUMO in Modulating Alpha-Synuclein Toxicity.
Parkinson Disease
Direct binding with histone deacetylase 6 mediates the reversible recruitment of parkin to the centrosome.
Parkinson Disease
Direct intranigral administration of an ubiquitin proteasome system inhibitor in rat: Behavior, positron emission tomography, immunohistochemistry.
Parkinson Disease
Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition.
Parkinson Disease
Dopaminergic Neuroprotection via Nrf2-ARE Pathway Activation: Identification of an Activator from Green Perilla Leaves.
Parkinson Disease
Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease.
Parkinson Disease
Effects of systemic PSI administration on catecholaminergic cells in the brain, adrenal medulla and carotid body in Wistar rats.
Parkinson Disease
Elevation of heme oxygenase-1 by proteasome inhibition affords dopaminergic neuroprotection.
Parkinson Disease
Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease.
Parkinson Disease
Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease.
Parkinson Disease
Expanding the role of proteasome homeostasis in Parkinson's disease: beyond protein breakdown.
Parkinson Disease
Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice.
Parkinson Disease
Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys.
Parkinson Disease
Failures in Protein Clearance Partly Underlie Late Onset Neurodegenerative Diseases and Link Pathology to Genetic Risk.
Parkinson Disease
Functional Pathway Identification With CRISPR/Cas9 Genome-wide Gene Disruption in Human Dopaminergic Neuronal Cells Following Chronic Treatment With Dieldrin.
Parkinson Disease
GDNF Overexpression from the Native Locus Reveals its Role in the Nigrostriatal Dopaminergic System Function.
Parkinson Disease
Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM.
Parkinson Disease
Glial cell-derived neurotrophic factor protects against proteasome inhibition-induced dopamine neuron degeneration by suppression of endoplasmic reticulum stress and caspase-3 activation.
Parkinson Disease
Global transcriptional profiling of the postmortem brain of a patient with G114V genetic Creutzfeldt-Jakob disease.
Parkinson Disease
Impaired transcriptional upregulation of Parkin promoter variant under oxidative stress and proteasomal inhibition: clinical association.
Parkinson Disease
Impairment of non-associative learning in a rat experimental model of preclinical stage of Parkinson's disease.
Parkinson Disease
Impairment of proteasome and anti-oxidative pathways in the induced pluripotent stem cell model for sporadic Parkinson's disease.
Parkinson Disease
Inhibitory effects of pesticides on proteasome activity: implication in Parkinson's disease.
Parkinson Disease
Insights into the effects of alpha-synuclein expression and proteasome inhibition on glutathione metabolism through a dynamic in silico model of Parkinson's disease: validation by cell culture data.
Parkinson Disease
Involvement of ubiquitin proteasome system in protective mechanisms of Puerarin to MPP(+)-elicited apoptosis.
Parkinson Disease
Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease.
Parkinson Disease
Lactacystin requires reactive oxygen species and Bax redistribution to induce mitochondria-mediated cell death.
Parkinson Disease
Long-term heat shock proteins (HSPs) induction by carbenoxolone improves hallmark features of Parkinson's disease in a rotenone-based model.
Parkinson Disease
Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs.
Parkinson Disease
Loss of TDP-43 Inhibits Amyotrophic Lateral Sclerosis-Linked Mutant SOD1 Aggresome Formation in an HDAC6-Dependent Manner.
Parkinson Disease
Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinson's disease.
Parkinson Disease
Mitochondrial accumulation of polyubiquitinated proteins and differential regulation of apoptosis by polyubiquitination sites Lys-48 and -63.
Parkinson Disease
Mitochondrial Dysfunction Precedes Other Sub-Cellular Abnormalities in an In Vitro Model Linked with Cell Death in Parkinson's Disease.
Parkinson Disease
Morphological and Metabolic Changes in the Nigro-Striatal Pathway of Synthetic Proteasome Inhibitor (PSI)-Treated Rats: A MRI and MRS Study.
Parkinson Disease
N-Acetyl-L-Methionyl-L-Dopa-Methyl Ester as a dual acting drug that relieves L-Dopa-induced oxidative toxicity.
Parkinson Disease
N-Acetylcysteine in Combination with IGF-1 Enhances Neuroprotection against Proteasome Dysfunction-Induced Neurotoxicity in SH-SY5Y Cells.
Parkinson Disease
Neuronal inclusions in degenerative disorders Do they represent static features or a key to understand the dynamics of the disease?
Parkinson Disease
Neuroprotective and neurogenic effects of novel tetramethylpyrazine derivative T-006 in Parkinson's disease models through activating the MEF2-PGC1? and BDNF/CREB pathways.
Parkinson Disease
Neurotoxin-induced selective ubiquitination and regulation of MEF2A isoform in neuronal stress response.
Parkinson Disease
Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated ?-synuclein.
Parkinson Disease
Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.
Parkinson Disease
Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinson's disease.
Parkinson Disease
Nuclear localization of the 20S proteasome subunit in Parkinson's disease.
Parkinson Disease
Oxidation and interaction of DJ-1 with 20S proteasome in the erythrocytes of early stage Parkinson's disease patients.
Parkinson Disease
Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease.
Parkinson Disease
p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition.
Parkinson Disease
p53-mediated mitochondrial dysfunction by proteasome inhibition in dopaminergic SH-SY5Y cells.
Parkinson Disease
Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease.
Parkinson Disease
Plasma ubiquitin C-terminal hydrolase L1 levels reflect disease stage and motor severity in Parkinson's disease.
Parkinson Disease
Posttranslational Modifications and Clearing of ?-Synuclein Aggregates in Yeast.
Parkinson Disease
Proteasome function and pathological proteins in the pathogenesis of Parkinson's disease.
Parkinson Disease
Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover.
Parkinson Disease
Proteasome inhibition and aggregation in Parkinson's disease: a comparative study in untransfected and transfected cells.
Parkinson Disease
Proteasome inhibition in medaka brain induces the features of Parkinson's disease.
Parkinson Disease
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
Parkinson Disease
Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
Parkinson Disease
Proteasome inhibitor lactacystin disturbs the intracellular calcium homeostasis of dopamine neurons in ventral mesencephalic cultures.
Parkinson Disease
Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models.
Parkinson Disease
Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle.
Parkinson Disease
Proteasome inhibitor-induced apoptosis is mediated by positive feedback amplification of PKCdelta proteolytic activation and mitochondrial translocation.
Parkinson Disease
Proteomic Study of a Parkinson's Disease Model of Undifferentiated SH-SY5Y Cells Induced by a Proteasome Inhibitor.
Parkinson Disease
Reciprocal Upshot of Nitric Oxide, Endoplasmic Reticulum Stress, and Ubiquitin Proteasome System in Parkinson's Disease Pathology.
Parkinson Disease
Reduced protein stability of human DJ-1/PARK7 L166P, linked to autosomal recessive Parkinson disease, is due to direct endoproteolytic cleavage by the proteasome.
Parkinson Disease
Reductions of the components of the calreticulin/calnexin quality-control system by proteasome inhibitors and their relevance in a rodent model of Parkinson's disease.
Parkinson Disease
Resveratrol attenuates oxidative stress and improves behaviour in 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) challenged mice.
Parkinson Disease
Retraction. Proteasome inhibitor-induced model of Parkinson's disease (Ann Neurol 2006;60:243-247).
Parkinson Disease
Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders.
Parkinson Disease
Rpt2 proteasome subunit reduction causes Parkinson's disease like symptoms in Drosophila.
Parkinson Disease
Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease.
Parkinson Disease
Selective susceptibility of human dopaminergic neural stem cells to dopamine-induced apoptosis.
Parkinson Disease
Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease.
Parkinson Disease
Systemic LPS-induced neuroinflammation increases the susceptibility for proteasome inhibition-induced degeneration of the nigrostriatal pathway.
Parkinson Disease
TCF11/Nrf1-mediated induction of proteasome expression prevents cytotoxicity by Rotenone.
Parkinson Disease
Tetramethylpyrazine Analogue T-006 Promotes the Clearance of Alpha-synuclein by Enhancing Proteasome Activity in Parkinson's Disease Models.
Parkinson Disease
The central regulator p62 between ubiquitin proteasome system and autophagy and its role in the mitophagy and Parkinson's disease.
Parkinson Disease
The Extent of Neurodegeneration and Neuroprotection in Two Chemical In Vitro Models Related to Parkinson's Disease is Critically Dependent on Cell Culture Conditions.
Parkinson Disease
The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity.
Parkinson Disease
The parkinsonism-associated protein FBXO7 cooperates with the BAG6 complex in proteasome function and controls the subcellular localization of the complex.
Parkinson Disease
The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease.
Parkinson Disease
The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1.
Parkinson Disease
The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson's Disease (PD).
Parkinson Disease
Thyroarytenoid Muscle Gene Expression in a Rat Model of Early-Onset Parkinson's Disease.
Parkinson Disease
Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease.
Parkinson Disease
Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition: implications for Parkinson's disease.
Parkinson Disease
Ubiquitin enzymes, ubiquitin and proteasome activity in blood mononuclear cells of MCI, Alzheimer and Parkinson patients.
Parkinson Disease
Ubiquitin proteasome system in Parkinson's disease: A keeper or a witness?
Parkinson Disease
UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
Parkinson Disease
Up-regulation of endoplasmic reticulum stress-related genes during the early phase of treatment of cultured cortical neurons by the proteasomal inhibitor lactacystin.
Parkinson Disease
Using the attract method to identify core pathways in juvenile idiopathic arthritis.
Parkinson Disease
Ziram causes dopaminergic cell damage by inhibiting E1 ligase of the proteasome.
Parkinson Disease
[Effect of Electroacupuncture on 26 S Proteasome and Nuclear Factor kappa B in Substantia Nigra of Rats with Rotenone-induced Parkinson's Disease].
Parkinson Disease
[Proteasomal inhibitor lactacystin induces cell apoptosis and caspase 3 activation in PC12 cells]
Parkinson Disease
[Regulation of dopaminergic neuronal death by endogenous dopamine and proteasome activity].
Parkinson Disease
[Sleep changes during degeneration of neurons in the substantia nigra induced by inhibitor of proteasomes lactacystin in rats].
Parkinsonian Disorders
Alpha-synuclein aggregation, Ubiquitin proteasome system impairment, and L-Dopa response in zinc-induced Parkinsonism: resemblance to sporadic Parkinson's disease.
Parkinsonian Disorders
Clinicopathological correlations in behavioural variant frontotemporal dementia.
Parkinsonian Disorders
D1 dopamine receptor stimulation impairs striatal proteasome activity in Parkinsonism through 26S proteasome disassembly.
Parkinsonian Disorders
Guanosine improves motor behavior, reduces apoptosis, and stimulates neurogenesis in rats with parkinsonism.
Parkinsonian Disorders
L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor.
Parkinsonian Disorders
L-dopa impairs proteasome activity in Parkinsonism through D1 dopamine receptor.
Parkinsonian Disorders
Nocardia asteroides strain GUH-2 induces proteasome inhibition and apoptotic death of cultured cells.
Parkinsonian Disorders
Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration.
Parkinsonian Disorders
The parkinsonism-associated protein FBXO7 cooperates with the BAG6 complex in proteasome function and controls the subcellular localization of the complex.
Parkinsonian Disorders
[Impairment of the ubiquitin-proteasome system and neurodegeneration]
peptide-n4-(n-acetyl-beta-glucosaminyl)asparagine amidase deficiency
Defects in the Neuroendocrine Axis Contribute to Global Development Delay in a Drosophila Model of NGLY1 Deficiency.
peptide-n4-(n-acetyl-beta-glucosaminyl)asparagine amidase deficiency
Drug screens of NGLY1 deficiency in worm and fly models reveal catecholamine, NRF2 and anti-inflammatory-pathway activation as potential clinical approaches.
peptide-n4-(n-acetyl-beta-glucosaminyl)asparagine amidase deficiency
Loss of peptide:N-glycanase causes proteasome dysfunction mediated by a sugar-recognizing ubiquitin ligase.
Peri-Implantitis
Identification of key genes and pathways for peri-implantitis through the analysis of gene expression data.
Periodontitis
The Proteasome Inhibitor Bortezomib Inhibits Inflammatory Response of Periodontal Ligament Cells and Ameliorates Experimental Periodontitis in Rats.
Peripheral Nervous System Diseases
?-Keto phenylamides as P1'-extended proteasome inhibitors.
Peripheral Nervous System Diseases
A Targeted and pH-Responsive Bortezomib Nanomedicine in the Treatment of Metastatic Bone Tumors.
Peripheral Nervous System Diseases
Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathy.
Peripheral Nervous System Diseases
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib.
Peripheral Nervous System Diseases
BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibition.
Peripheral Nervous System Diseases
Bortezomib Induces the Formation of Nuclear poly(A) RNA Granules Enriched in Sam68 and PABPN1 in Sensory Ganglia Neurons.
Peripheral Nervous System Diseases
Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma.
Peripheral Nervous System Diseases
Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients.
Peripheral Nervous System Diseases
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
Peripheral Nervous System Diseases
Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.
Peripheral Nervous System Diseases
Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature.
Peripheral Nervous System Diseases
Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma.
Peripheral Nervous System Diseases
Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis.
Peripheral Nervous System Diseases
Effect of an experimental proteasome inhibitor on the cytoskeleton, cytosolic protein turnover, and induction in the neuronal cells in vitro.
Peripheral Nervous System Diseases
Effect of proteasome inhibitors with different chemical structures on the ubiquitin-proteasome system in vitro.
Peripheral Nervous System Diseases
Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy.
Peripheral Nervous System Diseases
Genetic advances uncover mechanisms of chemotherapy-induced peripheral neuropathy.
Peripheral Nervous System Diseases
Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib.
Peripheral Nervous System Diseases
Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Peripheral Nervous System Diseases
Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.
Peripheral Nervous System Diseases
Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat.
Peripheral Nervous System Diseases
Mitochondrial dysfunction in the pathogenesis of chemotherapy-induced peripheral neuropathy.
Peripheral Nervous System Diseases
Mutations associated with Charcot-Marie-Tooth disease cause SIMPLE protein mislocalization and degradation by the proteasome and aggresome-autophagy pathways.
Peripheral Nervous System Diseases
Neurotoxicity induced by antineoplastic proteasome inhibitors.
Peripheral Nervous System Diseases
Non-proteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
Peripheral Nervous System Diseases
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Peripheral Nervous System Diseases
Pain Management in Patients with Multiple Myeloma: An Update.
Peripheral Nervous System Diseases
Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy.
Peripheral Nervous System Diseases
Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
Peripheral Nervous System Diseases
PMP22 accumulation in aggresomes: implications for CMT1A pathology.
Peripheral Nervous System Diseases
Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System
Peripheral Nervous System Diseases
Prevalence of peripheral neuropathy associated with chemotherapy in four oncology centers of Colombia.
Peripheral Nervous System Diseases
Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi.
Peripheral Nervous System Diseases
Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect.
Peripheral Nervous System Diseases
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.
Peripheral Nervous System Diseases
Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib.
Peripheral Nervous System Diseases
Reactive nucleolar and Cajal body responses to proteasome inhibition in sensory ganglion neurons.
Peripheral Nervous System Diseases
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.
Peripheral Nervous System Diseases
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Peripheral Nervous System Diseases
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Peripheral Nervous System Diseases
Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy.
Peripheral Nervous System Diseases
Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Peripheral Nervous System Diseases
Synergistic action of 5Z-7-oxozeaenol and bortezomib in inducing apoptosis of Burkitt lymphoma cell line Daudi.
Peripheral Nervous System Diseases
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD(®) immunomodulatory drug pomalidomide.
Peripheral Nervous System Diseases
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Peripheral Nervous System Diseases
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
Peripheral Nervous System Diseases
The Actions and Mechanisms of P2X7R and p38 MAPK Activation in Mediating Bortezomib-Induced Neuropathic Pain.
Peripheral Nervous System Diseases
The association of neuronal stress with activating transcription factor 3 in dorsal root ganglion of in vivo and in vitro models of bortezomib-induced neuropathy.
Peripheral Nervous System Diseases
The start of a new wave: developments in proteasome inhibition in multiple myeloma.
Peripheral Nervous System Diseases
Ubiquitin-based anticancer therapy: Carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors.
Peripheral Nervous System Diseases
Utilization of iPSC-derived human neurons for high-throughput drug-induced peripheral neuropathy screening.
Peripheral Nervous System Diseases
[POEMS syndrome: Diagnosis, stratification, treatments].
Peritonitis
The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle.
Persistent Infection
Hepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activity.
Persistent Infection
Roles of the two distinct proteasome pathways in hepatitis C virus infection.
Persistent Infection
The ubiquitin proteasome system plays a role in venezuelan equine encephalitis virus infection.
Pestivirus Infections
The structure of classical swine fever virus N(pro): a novel cysteine Autoprotease and zinc-binding protein involved in subversion of type I interferon induction.
Pheochromocytoma
Bortezomib Alone and in Combination with Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death in Vitro and in Female Nude Mice.
Pheochromocytoma
Lig-8, a highly bioactive lignophenol derivative from bamboo lignin, exhibits multifaceted neuroprotective activity.
Pheochromocytoma
Proteasome Inhibitors: A Potential Medical Therapy for Malignant Pheochromocytoma.
Pheochromocytoma
Role of autophagy and proteasome degradation pathways in apoptosis of PC12 cells overexpressing human alpha-synuclein.
Pick Disease of the Brain
Clinicopathological correlations in behavioural variant frontotemporal dementia.
Pituitary Neoplasms
Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
Pituitary Neoplasms
Proteasome inhibitors induce apoptosis in growth hormone- and prolactin-secreting rat pituitary tumor cells.
Plant Diseases
The Chinese wild grapevine (Vitis pseudoreticulata) E3 ubiquitin ligase Erysiphe necator-induced RING finger protein 1 (EIRP1) activates plant defense responses by inducing proteolysis of the VpWRKY11 transcription factor.
Plasmacytoma
(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.
Plasmacytoma
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Plasmacytoma
Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapy.
Plasmacytoma
Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.
Plasmacytoma
Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
Plasmacytoma
Wheat sprout extract-induced apoptosis in human cancer cells by proteasomes modulation.
Pleural Effusion
Pleural effusion in 11:14 translocation q1 multiple myeloma in the setting of proteasome inhibitor presents therapeutic complexity.
Pneumonia
Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome.
Pneumonia, Pneumococcal
Proteasome ?5i Subunit Deficiency Affects Opsonin Synthesis and Aggravates Pneumococcal Pneumonia.
Pneumonia, Ventilator-Associated
Proteasomes in Human Bronchoalveolar Lavage Fluid After Burn and Inhalation Injury.
Polycystic Kidney, Autosomal Dominant
MicroRNA501-5p induces p53 proteasome degradation through the activation of the mTOR/MDM2 pathway in ADPKD cells.
Polyneuropathies
A randomized exploratory phase 2 study in patients with chemotherapy-related peripheral neuropathy evaluating whole-body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises.
Polyneuropathies
Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Severe refractory CIDP: a case series of 10 patients treated with bortezomib.
Porcine Reproductive and Respiratory Syndrome
The ubiquitin proteasome system is necessary for efficient proliferation of porcine reproductive and respiratory syndrome virus.
Porphyria, Erythropoietic
Missense UROS mutations causing congenital erythropoietic porphyria reduce UROS homeostasis that can be rescued by proteasome inhibition.
Porphyria, Erythropoietic
Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria.
Poxviridae Infections
Orthopoxviruses require a functional ubiquitin-proteasome system for productive replication.
Pre-Eclampsia
Altered expression of p97/Valosin containing protein and impaired autophagy in preeclamptic human placenta.
Pre-Eclampsia
Differential proteomic analysis of highly purified placental cytotrophoblasts in preeclampsia demonstrates a state of increased oxidative stress and reduced cytotrophoblast antioxidant defense.
Pre-Eclampsia
Genome-wide hypermethylation coupled with promoter hypomethylation in the chorioamniotic membranes of early onset pre-eclampsia.
Pre-Eclampsia
Increased oxidative stress in pre-eclamptic placenta is associated with altered proteasome activity and protein patterns.
Pre-Eclampsia
Proteasome Levels and Activity in Pregnancies Complicated by Severe Preeclampsia and Hemolysis, Elevated Liver Enzymes, and Thrombocytopenia (HELLP) Syndrome.
Pre-Eclampsia
[Microarray analysis of differentially expressed genes in peripheral leucocytes derived from severe preeclampsia and normotensive pregnancies]
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
The mTOR inhibitor RAD001 (Everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B ALL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute lymphoblastic leukemia cells are sensitive to disturbances in protein homeostasis induced by proteasome deubiquitinase inhibition.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Efficacy of chemotherapy combined with bortezomib for two cases of relapsed/refractory acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Higher ratio immune vs. constitutive proteasome level as novelindicator of sensitivity of pediatric acute leukemia cells to proteasomeinhibitors.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Proteasome chymotrypsin-like activity in plasma as a useful marker for children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Proteasome Inhibition by Carfilzomib Induced Apotosis and Autophagy in a T-cell Acute Lymphoblastic Leukemia Cell Line.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Proteasome inhibitors remarkably prevent translesion replication in cancer cells but not normal cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-?B activity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-?B.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Defective expression of the T-cell receptor-CD3 zeta chain in T-cell acute lymphoblastic leukaemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
Premature Birth
Amniotic Fluid Proteasome and Immunoproteasome in the Setting of Intra-Amniotic Infection, Inflammation, and Preterm Birth.
Premature Birth
Effect of proteasome pathway on initiation of mouse labor induced by antiprogesterone.
Primary Graft Dysfunction
A novel mechanism for immune regulation after human lung transplantation.
Primary Graft Dysfunction
Caspase-cleaved cytokeratin 18 and 20 S proteasome in liver degeneration.
Primary Immunodeficiency Diseases
Heterozygous Truncating Variants in POMP Escape Nonsense-Mediated Decay and Cause a Unique Immune Dysregulatory Syndrome.
Primary Myelofibrosis
Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.
Primary Myelofibrosis
Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.
Primary Myelofibrosis
The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.
Primary Myelofibrosis
Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.
Prion Diseases
Cytosolic prion protein (PrP) is not toxic in N2a cells and primary neurons expressing pathogenic PrP mutations.
Prion Diseases
Disease-related prion protein forms aggresomes in neuronal cells leading to caspase activation and apoptosis.
Prion Diseases
Expression of mutant or cytosolic PrP in transgenic mice and cells is not associated with endoplasmic reticulum stress or proteasome dysfunction.
Prion Diseases
Global transcriptional profiling of the postmortem brain of a patient with G114V genetic Creutzfeldt-Jakob disease.
Prion Diseases
Interaction between misfolded PrP and the ubiquitin-proteasome system in prion-mediated neurodegeneration.
Prion Diseases
Mechanistic insights into the cure of prion disease by novel antiprion compounds.
Prion Diseases
Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation.
Prion Diseases
Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie-infected mice.
Prion Diseases
Prion-Associated Neurodegeneration Causes Both Endoplasmic Reticulum Stress and Proteasome Impairment in a Murine Model of Spontaneous Disease.
Prion Diseases
Proteasome inhibitors promote the sequestration of PrPSc into aggresomes within the cytosol of prion-infected CAD neuronal cells.
Prion Diseases
Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation.
Prostatic Neoplasms
1,10-Phenanthroline promotes copper complexes into tumor cells and induces apoptosis by inhibiting the proteasome activity.
Prostatic Neoplasms
15,16-Dihydrotanshinone I, a Compound of Salvia miltiorrhiza Bunge, Induces Apoptosis through Inducing Endoplasmic Reticular Stress in Human Prostate Carcinoma Cells.
Prostatic Neoplasms
A differential expression network method identifies ankylosing spondylitis-related genes.
Prostatic Neoplasms
A natural musaceas plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells.
Prostatic Neoplasms
A new proteasome inhibitor, TP-110, induces apoptosis in human prostate cancer PC-3 cells.
Prostatic Neoplasms
AKR1C3 promotes AR-V7 protein stabilization and confers resistance to AR-targeted therapies in advanced prostate cancer.
Prostatic Neoplasms
An investigation of the mechanisms underlying the proteasome inhibitor bortezomib resistance in PC3 prostate cancer cell line.
Prostatic Neoplasms
Anti-tumor activity of benzylideneacetophenone derivatives via proteasomal inhibition in prostate cancer cells.
Prostatic Neoplasms
Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-? from degradation and induce apoptosis in prostate cancer cells.
Prostatic Neoplasms
Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines.
Prostatic Neoplasms
Aromatic monophenols from cinnamon bark act as proteasome inhibitors by upregulating ER stress, suppressing FoxM1 expression, and inducing apoptosis in prostate cancer cells.
Prostatic Neoplasms
Association of Metals and Proteasome Activity in Erythrocytes of Prostate Cancer Patients and Controls.
Prostatic Neoplasms
Bisbibenzyls, novel proteasome inhibitors, suppress androgen receptor transcriptional activity and expression accompanied by activation of autophagy in prostate cancer LNCaP cells.
Prostatic Neoplasms
Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Prostatic Neoplasms
Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3.
Prostatic Neoplasms
Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.
Prostatic Neoplasms
Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells.
Prostatic Neoplasms
Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2.
Prostatic Neoplasms
Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
Prostatic Neoplasms
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt.
Prostatic Neoplasms
Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells.
Prostatic Neoplasms
CDC4 Gene Expression as Potential Biomarker for Targeted Therapy in Prostate Cancer.
Prostatic Neoplasms
Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice.
Prostatic Neoplasms
Cell cycle-dependent effects of 3,3'-diindolylmethane on proliferation and apoptosis of prostate cancer cells.
Prostatic Neoplasms
Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts.
Prostatic Neoplasms
Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells.
Prostatic Neoplasms
Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade.
Prostatic Neoplasms
Cotargeting stress-activated hsp27 and autophagy as a combinatorial strategy to amplify endoplasmic reticular stress in prostate cancer.
Prostatic Neoplasms
Diltiazem Enhances the Apoptotic Effects of Proteasome Inhibitors to Induce Prostate Cancer Cell Death.
Prostatic Neoplasms
Disulfiram promotes the conversion of carcinogenic cadmium to a proteasome inhibitor with pro-apoptotic activity in human cancer cells.
Prostatic Neoplasms
Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
Prostatic Neoplasms
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Prostatic Neoplasms
Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases.
Prostatic Neoplasms
EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism.
Prostatic Neoplasms
Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors.
Prostatic Neoplasms
Enzalutamide-induced Proteolytic Degradation of the Androgen Receptor in Prostate Cancer Cells Is Mediated Only to a Limited Extent by the Proteasome System.
Prostatic Neoplasms
Evaluation of Zinc-alpha-2-Glycoprotein and Proteasome Subunit beta-Type 6 Expression in Prostate Cancer Using Tissue Microarray Technology.
Prostatic Neoplasms
Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation.
Prostatic Neoplasms
Glucosamine induces cell death via proteasome inhibition in human ALVA41 prostate cancer cell.
Prostatic Neoplasms
Hyperthermia-induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells.
Prostatic Neoplasms
Inhibition of bcl-x(l) phosphorylation by tea polyphenols or epigallocatechin-3-gallate is associated with prostate cancer cell apoptosis.
Prostatic Neoplasms
Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction.
Prostatic Neoplasms
Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis.
Prostatic Neoplasms
Inhibition of the proteasome activity by gallium(III) complexes contributes to their anti prostate tumor effects.
Prostatic Neoplasms
Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein.
Prostatic Neoplasms
Inhibition on Proteasome ?1 Subunit Might Contribute to the Anti-Cancer Effects of Fangchinoline in Human Prostate Cancer Cells.
Prostatic Neoplasms
L-Ornithine Schiff base-copper and -cadmium complexes as new proteasome inhibitors and apoptosis inducers in human cancer cells.
Prostatic Neoplasms
Long non-coding RNA FAM66C is associated with clinical progression and promotes cell proliferation by inhibiting proteasome pathway in prostate cancer.
Prostatic Neoplasms
Marchantin M: a novel inhibitor of proteasome induces autophagic cell death in prostate cancer cells.
Prostatic Neoplasms
Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells.
Prostatic Neoplasms
Matrine inhibits prostate cancer via activation of the unfolded protein response/endoplasmic reticulum stress signaling and reversal of epithelial to mesenchymal transition.
Prostatic Neoplasms
Metals in anticancer therapy: copper(II) complexes as inhibitors of the 20S proteasome.
Prostatic Neoplasms
MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L).
Prostatic Neoplasms
MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA.
Prostatic Neoplasms
Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli.
Prostatic Neoplasms
Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line.
Prostatic Neoplasms
Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB.
Prostatic Neoplasms
Neuropeptide-inducible upregulation of proteasome activity precedes nuclear factor kappa B activation in androgen-independent prostate cancer cells.
Prostatic Neoplasms
New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.
Prostatic Neoplasms
Novel phosphorylation and ubiquitination sites regulate ROS-dependent degradation of anti-apoptotic c-FLIP protein.
Prostatic Neoplasms
Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells.
Prostatic Neoplasms
Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells.
Prostatic Neoplasms
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Prostatic Neoplasms
Potent In Vitro and In Vivo Anticancer Activity of New Bipyridine and Bipyrimidine Gold (III) Dithiocarbamate Derivatives.
Prostatic Neoplasms
Potential use of chymotrypsin-like proteasomal activity as a biomarker for prostate cancer.
Prostatic Neoplasms
Predictive value of PAK6 and PSMB4 expression in patients with localized prostate cancer treated with dose-escalation radiation therapy and androgen deprivation therapy.
Prostatic Neoplasms
Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells.
Prostatic Neoplasms
Procyanidin-B2 enriched fraction of cinnamon acts as a proteasome inhibitor and anti-proliferative agent in human prostate cancer cells.
Prostatic Neoplasms
Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies.
Prostatic Neoplasms
Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells.
Prostatic Neoplasms
Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.
Prostatic Neoplasms
Proteasome Inhibition by Bortezomib Increases IL-8 Expression in Androgen-Independent Prostate Cancer Cells: The Role of IKK?.
Prostatic Neoplasms
Proteasome inhibition induces both pro- and anti-cell death pathways in prostate cancer cells.
Prostatic Neoplasms
Proteasome Inhibitor Bortezomib Increases Radiation Sensitivity in Androgen Independent Human Prostate Cancer Cells.
Prostatic Neoplasms
Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region.
Prostatic Neoplasms
Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells.
Prostatic Neoplasms
Proteasome inhibitor-I enhances tunicamycin-induced chemosensitization of prostate cancer cells through regulation of NF-?B and CHOP expression.
Prostatic Neoplasms
Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells.
Prostatic Neoplasms
Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells.
Prostatic Neoplasms
Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of IkappaBalpha.
Prostatic Neoplasms
Proteasome mediated degradation of Id-1 is associated with TNFalpha-induced apoptosis in prostate cancer cells.
Prostatic Neoplasms
Proteomics analyses of prostate cancer cells reveal cellular pathways associated with androgen resistance.
Prostatic Neoplasms
PSMA5 promotes the tumorigenic process of prostate cancer and is related to bortezomib resistance.
Prostatic Neoplasms
Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells.
Prostatic Neoplasms
Selectively enhanced radiation sensitivity in prostate cancer cells associated with proteasome inhibition.
Prostatic Neoplasms
Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo.
Prostatic Neoplasms
Silencing of PSMC2 inhibits development and metastasis of prostate cancer through regulating proliferation, apoptosis and migration.
Prostatic Neoplasms
Specific positive and negative effects of FLIP on cell survival in human prostate cancer.
Prostatic Neoplasms
Structure-activity relationships of synthetic analogs of (-)-epigallocatechin-3-gallate as proteasome inhibitors.
Prostatic Neoplasms
Suppression of TRPM7 Inhibited Hypoxia-Induced Migration and Invasion of Androgen-Independent Prostate Cancer Cells by Enhancing RACK1-Mediated Degradation of HIF-1?.
Prostatic Neoplasms
The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.
Prostatic Neoplasms
The NF-?B subunit RelB regulates the migration and invasion abilities and the radio-sensitivity of prostate cancer cells.
Prostatic Neoplasms
The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-?/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer.
Prostatic Neoplasms
The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells.
Prostatic Neoplasms
The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism.
Prostatic Neoplasms
The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor.
Prostatic Neoplasms
The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry".
Prostatic Neoplasms
Transcription-independent and -dependent p53-mediated apoptosis in response to genotoxic and non-genotoxic stress.
Prostatic Neoplasms
Velcade sensitizes prostate cancer cells to TRAIL induced apoptosis and suppresses tumor growth in vivo.
Prostatic Neoplasms
Versatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery.
Prostatic Neoplasms
Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.
Prostatic Neoplasms
Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
Prostatic Neoplasms
[Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer]
proteasome endopeptidase complex deficiency
A ubiquitin stress response induces altered proteasome composition.
proteasome endopeptidase complex deficiency
Analysis of the spontaneous mutator phenotype associated with 20S proteasome deficiency in S. cerevisiae.
proteasome endopeptidase complex deficiency
Genetic and proteomic analyses of a proteasome-activating nucleotidase A mutant of the haloarchaeon Haloferax volcanii.
proteasome endopeptidase complex deficiency
HSCT corrects primary immunodeficiency and immune dysregulation in patients with POMP-related auto-inflammatory disease.
proteasome endopeptidase complex deficiency
Polyubiquitin linkage profiles in three models of proteolytic stress suggest the etiology of Alzheimer disease.
proteasome endopeptidase complex deficiency
Proteasome nuclear import mediated by Arc3 can influence efficient DNA damage repair and mitosis in Schizosaccharomyces pombe.
proteasome endopeptidase complex deficiency
Protein recycling and limb muscle recovery after critical illness in slow- and fast-twitch limb muscle.
Protein C Deficiency
[Biosensors as a tool to use in the experiments on blood and selected blood proteins].
Protein Deficiency
The interaction of superoxide with nitric oxide destabilizes hypoxia-inducible factor-1alpha.
Protein Deficiency
[Proteasome degradation of protein C and plasmin inhibitor mutants: molecular mechanism of congenital protein deficiency]
Pseudomonas Infections
Pulmonary Pseudomonas aeruginosa infection induces autophagy and proteasome proteolytic pathways in skeletal muscles: effects of a pressurized whey protein-based diet in mice.
Psoriasis
An ensemble of the iCluster method to analyze longitudinal lncRNA expression data for psoriasis patients.
Psoriasis
Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis.
Psoriasis
High plasma proteasome levels are detected in patients with metastatic malignant melanoma.
Psoriasis
Localized delivery of a lipophilic proteasome inhibitor into human skin for treatment of psoriasis.
Psoriasis
Naturally occurring proteasome inhibitors from mate tea (Ilex paraguayensis) serve as models for topical proteasome inhibitors.
Psoriasis
Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model.
Psoriasis
Proteolytic activity and expression of the 20S proteasome are increased in psoriasis lesional skin.
Psoriasis
Reduced Proteasome Activity and Enhanced Autophagy in Blood Cells of Psoriatic Patients.
Psoriasis
The proteasome maturation protein POMP increases proteasome assembly and activity in psoriatic lesional skin.
Pterygium
The inhibitive effects of proteasome inhibitor MG-132 on pterygium fibroblasts in vitro and the potential key regulators involved.
Pterygium
UVB-mediated down-regulation of proteasome in cultured human primary pterygium fibroblasts.
Pulmonary Arterial Hypertension
Forkhead box M1 transcription factor: a novel target for pulmonary arterial hypertension therapy.
Pulmonary Arterial Hypertension
Inhibition of ubiquitin proteasome function prevents monocrotaline-induced pulmonary arterial remodeling.
Pulmonary Arterial Hypertension
Proteasome inhibitor PS-341 attenuates flow-induced pulmonary arterial hypertension.
Pulmonary Disease, Chronic Obstructive
Activation of the ubiquitin-proteasome pathway in the diaphragm in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Decreased proteasomal function accelerates cigarette smoke-induced pulmonary emphysema in mice.
Pulmonary Disease, Chronic Obstructive
Diaphragm muscle fiber dysfunction in chronic obstructive pulmonary disease: toward a pathophysiological concept.
Pulmonary Disease, Chronic Obstructive
Dissecting the molecular effects of cigarette smoke on proteasome function.
Pulmonary Disease, Chronic Obstructive
Does oxidative stress modulate limb muscle atrophy in severe copd patients?
Pulmonary Disease, Chronic Obstructive
Effects of exercise training on quadriceps muscle gene expression in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Enhancing tristetraprolin activity reduces the severity of cigarette smoke-induced experimental chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Heightened Endoplasmic Reticulum Stress in COPD Lungs: The Role of Nrf2-Regulated Proteasomal Activity.
Pulmonary Disease, Chronic Obstructive
Histone 3.3 participates in a self-sustaining cascade of apoptosis that contributes to the progression of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Involvement of the FoxO1/MuRF1/Atrogin-1 Signaling Pathway in the Oxidative Stress-Induced Atrophy of Cultured Chronic Obstructive Pulmonary Disease Myotubes.
Pulmonary Disease, Chronic Obstructive
Proteasome activity related with the daily physical activity of COPD patients.
Pulmonary Disease, Chronic Obstructive
Proteasome function is not impaired in healthy aging of the lung.
Pulmonary Disease, Chronic Obstructive
Proteasome inhibition improves diaphragm function in an animal model for COPD.
Pulmonary Disease, Chronic Obstructive
Proteasomes in lungs from organ donors and patients with end-stage pulmonary diseases.
Pulmonary Disease, Chronic Obstructive
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.
Pulmonary Disease, Chronic Obstructive
Role of autophagy in COPD skeletal muscle dysfunction.
Pulmonary Disease, Chronic Obstructive
Skeletal muscle molecular responses to resistance training and dietary supplementation in COPD.
Pulmonary Disease, Chronic Obstructive
Systemic inflammation in chronic obstructive pulmonary disease and lung cancer: common driver of pulmonary cachexia?
Pulmonary Disease, Chronic Obstructive
What shall we do with the damaged proteins in lung disease? Ask the proteasome!
Pulmonary Disease, Chronic Obstructive
[The proteasome inhibitor MG132 attenuates skeletal muscle atrophy in a rat model of chronic obstructive pulmonary disease.]
Pulmonary Emphysema
Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences.
Pulmonary Fibrosis
Bortezomib Inhibits Lung Fibrosis and Fibroblast Activation Without Proteasome Inhibition.
Pulmonary Fibrosis
Proteasome dysfunction in alveolar type 2 epithelial cells is associated with acute respiratory distress syndrome.
Pulmonary Fibrosis
Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis.
Pulmonary Fibrosis
What shall we do with the damaged proteins in lung disease? Ask the proteasome!
Purpura, Thrombocytopenic, Idiopathic
T cell immune abnormalities in immune thrombocytopenia.
Pyoderma Gangrenosum
Monogenic autoinflammatory diseases: concept and clinical manifestations.
Rabies
[A DNA Construct That Encodes the Rabies Virus Consensus Glycoprotein with a Proteasome Degradation Signal Induces Antibody Production with IgG2A Subtype Predominance].
Rectal Neoplasms
Effect of Neoadjuvant Chemoradiation Therapy on Proteasome Pool in Rectal Cancer.
Rectal Neoplasms
Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors.
Rectal Neoplasms
Proteasomes in Patient Rectal Cancer and Different Intestine Locations: Where Does Proteasome Pool Change?
Renal Insufficiency
Emerging roles of proteasomes in ischemia-reperfusion injury of organs.
Renal Insufficiency
Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world".
Renal Insufficiency, Chronic
Caspase-3 cleaves specific 19S proteasome subunits in skeletal muscle stimulating proteasome activity.
Renal Insufficiency, Chronic
Circulating 20S proteasome for assessing protein energy wasting syndrome in hemodialysis patients.
Renal Insufficiency, Chronic
Differential expression of proteins from cultured endothelial cells exposed to uremic versus normal serum.
Renal Insufficiency, Chronic
Muscle wasting in chronic kidney disease: the role of the ubiquitin proteasome system and its clinical impact.
Renal Insufficiency, Chronic
Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486.
Reperfusion Injury
Adrenaline in pro-oxidant conditions elicits intracellular survival pathways in isolated rat cardiomyocytes.
Reperfusion Injury
Back to your heart: Ubiquitin proteasome system-regulated signal transduction.
Reperfusion Injury
Bicarbonate Increases Ischemia-Reperfusion Damage by Inhibiting Mitophagy.
Reperfusion Injury
Effect of a low dose of proteasome inhibitor on cell death and gene expression in neonatal rat cardiomyocyte cultures exposed to anoxia-reoxygenation.
Reperfusion Injury
Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice.
Reperfusion Injury
Inhibition of the proteasome preserves Mitofusin-2 and mitochondrial integrity, protecting cardiomyocytes during ischemia-reperfusion injury.
Reperfusion Injury
Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors.
Reperfusion Injury
Oxidative stress-associated impairment of proteasome activity during ischemia-reperfusion injury.
Reperfusion Injury
Possible involvement of ubiquitin proteasome system and other proteases in acute and delayed aspects of ischemic preconditioning of brain in mice.
Reperfusion Injury
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury.
Reperfusion Injury
Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury.
Reperfusion Injury
Proteasome inhibition promotes functional recovery after peripheral nerve reperfusion injury.
Reperfusion Injury
Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation.
Reperfusion Injury
Proteasome inhibitors protect the steatotic and non-steatotic liver graft against cold ischemia reperfusion injury.
Reperfusion Injury
Proteasome inhibitors: possible novel therapeutic strategy for ischemia-reperfusion injury?
Reperfusion Injury
Proteasome peptidase activities parallel histomorphological and functional consequences of ischemia-reperfusion injury in the lung.
Reperfusion Injury
The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury.
Reperfusion Injury
The protective effects of the proteasome inhibitor bortezomib (velcade) on ischemia-reperfusion injury in the rat retina.
Respiratory Distress Syndrome
Alveolar Extracellular 20S Proteasome in Patients with Acute Respiratory Distress Syndrome.
Respiratory Distress Syndrome
Distinct Proteasome Subpopulations in the Alveolar Space of Patients with the Acute Respiratory Distress Syndrome.
Respiratory Distress Syndrome
Proteasome dysfunction in alveolar type 2 epithelial cells is associated with acute respiratory distress syndrome.
Respiratory Distress Syndrome
Race to arsenal COVID-19 therapeutics: Current alarming status and future directions.
Respiratory Insufficiency
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
Retinal Degeneration
Chemical proteasome inhibition as a novel animal model of inner retinal degeneration in rats.
Retinal Degeneration
Inactivation of VCP/ter94 suppresses retinal pathology caused by misfolded rhodopsin in Drosophila.
Retinal Degeneration
Proteasome overload is a common stress factor in multiple forms of inherited retinal degeneration.
Retinal Degeneration
The Role of Autophagy in Chemical Proteasome Inhibition Model of Retinal Degeneration.
Retinitis Pigmentosa
A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system.
Retinoblastoma
APC/C and retinoblastoma interaction: cross-talk of retinoblastoma protein with the ubiquitin proteasome pathway.
Retinoblastoma
Complex formation between metabolic enzymes in tumor cells: Unfolding the MDR1-IDE paradigm.
Retinoblastoma
Expression of p28GANK and its correlation with RB in human hepatocellular carcinoma.
Retinoblastoma
Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression.
Retinoblastoma
Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein.
Retinoblastoma
Proteolytic degradation of the retinoblastoma family protein p107: A putative cooperative role of calpain and proteasome.
Retinoblastoma
Roles of NRF3 in the Hallmarks of Cancer: Proteasomal Inactivation of Tumor Suppressors.
Retinoblastoma
Synergistic cytotoxic interactions between sodium butyrate, MG132 and camptothecin in human retinoblastoma Y79 cells.
Retinoblastoma
The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells.
Retinoblastoma
The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53.
Retinoblastoma
The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Rett Syndrome
Defective proteasome biogenesis into skin fibroblasts isolated from Rett syndrome subjects with MeCP2 non-sense mutations.
Rhabdomyosarcoma
Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.
Rhabdomyosarcoma
Effect of inhibition of the Ubiquitin-Proteasome System and Hsp90 on growth and survival of Rhabdomyosarcoma cells in vitro.
Rhabdomyosarcoma
The effect of the NF-kappa B inhibitors curcumin and lactacystin on myogenic differentiation of rhabdomyosarcoma cells.
Rhabdomyosarcoma
The involvement of proteasome in myogenic differentiation of murine myocytes and human rhabdomyosarcoma cells.
ring-type e3 ubiquitin transferase deficiency
Parkin deficiency increases the resistance of midbrain neurons and glia to mild proteasome inhibition: the role of autophagy and glutathione homeostasis.
Rosacea
Evaluation of a First-in-Class Proteasome Inhibitor in Patients With Moderate to Severe Rosacea.
Sarcoidosis
Alveolar Extracellular 20S Proteasome in Patients with Acute Respiratory Distress Syndrome.
Sarcoidosis
mRNA expression profile of bronchoalveolar lavage fluid cells from patients with idiopathic pulmonary fibrosis and sarcoidosis.
Sarcoidosis
Proteasomes in lungs from organ donors and patients with end-stage pulmonary diseases.
Sarcoidosis
Sarcoidosis activates diverse transcriptional programs in bronchoalveolar lavage cells.
Sarcoma
Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells.
Sarcoma
High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas.
Sarcoma
New 26S proteasome inhibitors with high selectivity for chymotrypsin-like activity and p53-dependent cytotoxicity.
Sarcoma
Selinexor (KPT-330) induces tumor suppression through nuclear sequestration of IkappaB and down-regulation of survivin.
Sarcoma
Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Sarcoma
The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA.
Sarcoma
Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses Against Short-Lived Proteins Through a P62-Dependent Mechanism.
Sarcoma
Up-regulation of the DR5 Expression by Proteasome Inhibitor MG132 Augments TRAIL-Induced Apoptosis in Soft Tissue Sarcoma Cell Lines.
Sarcoma
Wnt pathway activation and ABCB1 expression account for attenuation of Proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells.
Sarcoma, Avian
Distinct protease pathways control cell shape and apoptosis in v-src-transformed quail neuroretina cells.
Sarcoma, Avian
Enhanced levels of multicatalytic proteinase mRNAs in Rous sarcoma virus transformed cells.
Sarcoma, Avian
Retroviruses have differing requirements for proteasome function in the budding process.
Sarcoma, Avian
The role of Src protein in the process formation of PC12 cells induced by the proteasome inhibitor MG-132.
Sarcoma, Ewing
Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
Sarcoma, Ewing
Preclinical Evaluation of Combined Topoisomerase and Proteasome Inhibition Against Pediatric Malignancies.
Sarcoma, Ewing
Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors.
Sarcoma, Ewing
Proteasome inhibitor Bortezomib induces cell-cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL.
Sarcoma, Kaposi
Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma.
Sarcoma, Synovial
HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma.
Sarcopenia
Caloric restriction optimizes the proteasome pathway with aging in rat plantaris muscle: implications for sarcopenia.
Sarcopenia
Effect of Dietary Silk Peptide on Obesity, Hyperglycemia, and Skeletal Muscle Regeneration in High-Fat Diet-Fed Mice.
Sarcopenia
Meeting Report: American Aging Association 40(th) Annual Meeting, Raleigh, North Carolina, June 3-6, 2011.
Schistosomiasis
Effects of proteasome inhibitor MG-132 on the parasite Schistosoma mansoni.
Schistosomiasis
Inhibition of 19S proteasome deubiquitinating activity in Schistosoma mansoni affects viability, oviposition, and structural changes.
Schistosomiasis
Schistosoma mansoni: functional proteasomes are required for development in the vertebrate host.
Scleroderma, Systemic
The ubiquitin proteasome system as a potential therapeutic target for systemic sclerosis.
Scrapie
Cellular prion protein (PrPC) protects neuronal cells from the effect of huntingtin aggregation.
Seizures
Spatiotemporal progression of ubiquitin-proteasome system inhibition after status epilepticus suggests protective adaptation against hippocampal injury.
Sepsis
Activity and expression of the 20S proteasome are increased in skeletal muscle during sepsis.
Sepsis
Amino acids, independent of insulin, attenuate skeletal muscle autophagy in neonatal pigs during endotoxemia.
Sepsis
Differential Regulation of the Autophagy and Proteasome Pathways in Skeletal Muscles in Sepsis.
Sepsis
Endotoxin reduces CD95-induced neutrophil apoptosis by cIAP-2-mediated caspase-3 degradation.
Sepsis
Glucocorticoids do not regulate the expression of proteolytic genes in skeletal muscle from Cushing's syndrome patients.
Sepsis
Inability to replete white adipose tissue during recovery phase of sepsis is associated with increased autophagy, apoptosis, and proteasome activity.
Sepsis
INHIBITION OF GSK-3? ACTIVITY WITH LITHIUM IN VITRO ATTENUATES SEPSIS-INDUCED CHANGES IN MUSCLE PROTEIN TURNOVER.
Sepsis
Marginal dietary zinc deprivation augments sepsis-induced alterations in skeletal muscle TNF-? but not protein synthesis.
Sepsis
Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis.
Sepsis
Protein kinases, TNF-{alpha}, and proteasome contribute in the inhibition of fructose intestinal transport by sepsis in vivo.
Sepsis
Resveratrol Downregulates Biomarkers of Sepsis via Inhibition of Proteasome's Proteases.
Sepsis
Roles of Toll-Like Receptor 4, I?B Kinase, and the Proteasome in the Intestinal Alterations Caused by Sepsis.
Sepsis
Serum amyloid A-luciferase transgenic mice: response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition.
Sepsis
Temporally Distinct Regulation of Pathways Contributing to Cardiac Proteostasis During the Acute and Recovery Phases of Sepsis.
Sepsis
The proteasome as a lipopolysaccharide-binding protein in macrophages: differential effects of proteasome inhibition on lipopolysaccharide-induced signaling events.
Sepsis
The value of correlation of serum 20S proteasome concentration and percentage of lymphocytic apoptosis in critically ill patients: a prospective observational study.
Sepsis
Tripeptidyl-peptidase II expression and activity are increased in skeletal muscle during sepsis.
Sepsis
[Effect of ubiquitin-proteasome pathway on inflammatory reaction in intestine and its barrier function in rats with postburn sepsis]
Sepsis
[Gene expression of C2 subunit of proteasome in cardiac muscle in burned rats with sepsis]
Sertoli Cell-Only Syndrome
Quantitative proteomic analysis of human testis reveals system-wide molecular and cellular pathways associated with non-obstructive azoospermia.
Severe Acute Respiratory Syndrome
Expression, post-translational modification and biochemical characterization of proteins encoded by subgenomic mRNA8 of the severe acute respiratory syndrome coronavirus.
Severe Acute Respiratory Syndrome
Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome.
Severe Acute Respiratory Syndrome
The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle.
Severe Fever with Thrombocytopenia Syndrome
Proteasome Inhibitor PS-341 Effectively Blocks Infection by the Severe Fever with Thrombocytopenia Syndrome Virus.
Shock, Septic
A combination of proteasome inhibitors and antibiotics prevents lethality in a septic shock model.
Shock, Septic
Lipopolysaccharides Promote S-Nitrosylation and Proteasomal Degradation of Liver Kinase B1 (LKB1) in Macrophages in Vivo.
Shock, Septic
Proteasome inhibition decreases inflammation in human endothelial cells exposed to lipopolysaccharide.
Shock, Septic
Targeting the ubiquitin proteasome pathway for the treatment of septic shock in patients.
Sjogren's Syndrome
Expression of Proteasomal Immunosubunit {beta}1i Is Dysregulated in Inflammatory Infiltrates of Minor Salivary Glands in Sjogren's Syndrome.
Sjogren's Syndrome
Expression of proteasome immunosubunit in labial glands of patients with primary Sjogren's syndrome.
Sjogren's Syndrome
Gene Expression of Catalytic Proteasome Subunits and Resistance Toward Proteasome Inhibition of B Lymphocytes from Patients with Primary Sjogren Syndrome.
Skin Diseases
Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production.
Skin Diseases
Heterozygous Truncating Variants in POMP Escape Nonsense-Mediated Decay and Cause a Unique Immune Dysregulatory Syndrome.
Skin Diseases
HSCT corrects primary immunodeficiency and immune dysregulation in patients with POMP-related auto-inflammatory disease.
Skin Diseases
Mutations in proteasome subunit ? type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity.
Skin Diseases
Skin-Associated B Cells in the Pathogenesis of Cutaneous Autoimmune Diseases-Implications for Therapeutic Approaches.
Sleep Initiation and Maintenance Disorders
T2D and Depression Risk Gene Proteasome Modulator 9 is Linked to Insomnia.
Small Cell Lung Carcinoma
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
Small Cell Lung Carcinoma
Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
Small Cell Lung Carcinoma
Changes in immunocytochemical detectability of proteasome epitopes depending on cell growth and fixation conditions of lung cancer cell lines.
Small Cell Lung Carcinoma
Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Small Cell Lung Carcinoma
Identification of differentially expressed genes and pathways crosstalk analysis in Rheumatoid and Osteoarthritis using next-generation sequencing and protein-protein networks.
Small Cell Lung Carcinoma
Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer.
Small Cell Lung Carcinoma
Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.
Spasm
Vascular Spasm: A Newly Unraveled Cause for Cardiovascular Adversity of Proteasome Inhibition.
Spinal Cord Injuries
cAMP stimulates the ubiquitin/proteasome pathway in rat spinal cord neurons.
Spinal Cord Injuries
Nanoparticles Exacerbate Both Ubiquitin and Heat Shock Protein Expressions in Spinal Cord Injury: Neuroprotective Effects of the Proteasome Inhibitor Carfilzomib and the Antioxidant Compound H-290/51.
Spinocerebellar Ataxias
Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases.
Spinocerebellar Ataxias
Allosteric regulation of deubiquitylase activity through ubiquitination.
Spinocerebellar Ataxias
Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1.
Spinocerebellar Ataxias
Delayed spinocerebellar ataxia in transgenic mice expressing mutant ubiquitin.
Spinocerebellar Ataxias
Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice.
Spinocerebellar Ataxias
Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation.
Spinocerebellar Ataxias
Proteasome function is inhibited by polyglutamine-expanded ataxin-1, the SCA1 gene product.
Spinocerebellar Ataxias
Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions.
Spinocerebellar Ataxias
Targeting Ubiquitin Proteasome Pathway with Traditional Chinese Medicine for Treatment of Spinocerebellar Ataxia Type 3.
Spinocerebellar Ataxias
The proteasome-associated deubiquitinating enzyme Usp14 is essential for the maintenance of synaptic ubiquitin levels and the development of neuromuscular junctions.
Spinocerebellar Ataxias
The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias.
Spinocerebellar Ataxias
Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3.
Spondylitis, Ankylosing
Ankylosing spondylitis monocytes show upregulation of proteins involved in inflammation and the Ubiquitin Proteasome pathway.
Spondylitis, Ankylosing
Association of large molecular weight proteasome 7 gene polymorphism with ankylosing spondylitis.
Spondylitis, Ankylosing
Association to HLA-DRB1*08, HLA-DPB1*0301 and homozygosity for an HLA-linked proteasome gene in juvenile ankylosing spondylitis.
Squamous Cell Carcinoma of Head and Neck
Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation.
Squamous Cell Carcinoma of Head and Neck
Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
Squamous Cell Carcinoma of Head and Neck
Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.
Squamous Cell Carcinoma of Head and Neck
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Squamous Cell Carcinoma of Head and Neck
Circulating Proteasomes in the Pathogenesis of Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.
Squamous Cell Carcinoma of Head and Neck
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
Squamous Cell Carcinoma of Head and Neck
Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines.
Squamous Cell Carcinoma of Head and Neck
In HPV-Positive HNSCC Cells, Functional Restoration of the p53/p21 Pathway by Proteasome Inhibitor Bortezomib Does Not Affect Radio- or Chemosensitivity.
Squamous Cell Carcinoma of Head and Neck
Inhibition of HDAC6 Protein Enhances Bortezomib-induced Apoptosis in Head and Neck Squamous Cell Carcinoma (HNSCC) by Reducing Autophagy.
Squamous Cell Carcinoma of Head and Neck
Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
Squamous Cell Carcinoma of Head and Neck
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Squamous Cell Carcinoma of Head and Neck
p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Proteasome inhibitor bortezomi-induced the apoptosis of laryngeal squamous cell carcinoma Hep-2 cell line via disrupting redox equilibrium.
Squamous Cell Carcinoma of Head and Neck
Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis.
Squamous Cell Carcinoma of Head and Neck
RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage.
Squamous Cell Carcinoma of Head and Neck
SEC61G identified as a prognostic biomarker of head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
The molecular mechanisms of XBP-1 gene silencing on IRE1?-TRAF2-ASK1-JNK pathways in oral squamous cell carcinoma under endoplasmic reticulum stress.
Squamous Cell Carcinoma of Head and Neck
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
Squamous Cell Carcinoma of Head and Neck
The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients.
Squamous Cell Carcinoma of Head and Neck
[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].
Squamous Cell Carcinoma of Head and Neck
[Proteasome inhibitor bortezomib sensitizes Hep-2 human laryngeal squamous cell carcinoma cells to ionizing radiation in vitro and in vivo]
Starvation
AMPK regulates ESCRT-dependent microautophagy of proteasomes concomitant with proteasome storage granule assembly during glucose starvation.
Starvation
Arabidopsis SINAT Proteins Control Autophagy by Mediating Ubiquitylation and Degradation of ATG13.
Starvation
Autophagic Degradation of the 26S Proteasome Is Mediated by the Dual ATG8/Ubiquitin Receptor RPN10 in Arabidopsis.
Starvation
Both negative and positive G1 cell cycle regulators undergo proteasome-dependent degradation during sucrose starvation in Arabidopsis.
Starvation
Changes in the expression and the enzymic properties of the 20S proteasome in sugar-starved maize roots. evidence for an in vivo oxidation of the proteasome.
Starvation
Decreased heat shock protein 27 expression and altered autophagy in human cells harboring A8344G mitochondrial DNA mutation.
Starvation
Deficient autophagy in epithelial stem cells drives aging in the freshwater cnidarian Hydra.
Starvation
Downregulation of ubiquitin-dependent proteolysis by eicosapentaenoic acid in acute starvation.
Starvation
Effect of starvation on global gene expression and proteolysis in rainbow trout (Oncorhynchus mykiss).
Starvation
Genome-wide RNAi Screen for Fat Regulatory Genes in C. elegans Identifies a Proteostasis-AMPK Axis Critical for Starvation Survival.
Starvation
Glucose starvation and hypoxia induce nuclear accumulation of proteasome in cancer cells.
Starvation
GOLPH3 silencing inhibits adhesion of glioma U251 cells by regulating ITGB1 degradation under serum starvation.
Starvation
Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy.
Starvation
Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells.
Starvation
Isoginkgetin, a Natural Biflavonoid Proteasome Inhibitor, Sensitizes Cancer Cells to Apoptosis via Disruption of Lysosomal Homeostasis and Impaired Protein Clearance.
Starvation
Mechanism of endocytic regulation of intestinal tight junction remodeling during nutrient starvation in jejunal IPEC-J2 cells.
Starvation
Mechanisms of deregulation of IFN regulatory factor-1 in ras-transformed fibroblasts.
Starvation
Modulation of the cell cycle regulating transcription factor E2F1 pathway by the proteasome following amino acid starvation.
Starvation
NMDA antagonists exacerbate neuronal death caused by proteasome inhibition in cultured cortical and striatal neurons.
Starvation
Nuclear localization of proteasomes participates in stress-inducible resistance of solid tumor cells to topoisomerase II-directed drugs.
Starvation
p62- and ubiquitin-dependent stress-induced autophagy of the mammalian 26S proteasome.
Starvation
Proteasomal degradation of Sfp1 contributes to the repression of ribosome biogenesis during starvation and is mediated by the proteasome activator Blm10.
Starvation
Proteasome 19S RP and translation preinitiation complexes are secreted within exosomes upon serum starvation.
Starvation
Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Starvation
Proteasome storage granules protect proteasomes from autophagic degradation upon carbon starvation.
Starvation
Proteomics identifies ubiquitin-proteasome targets and new roles for chromatin-remodeling in the Arabidopsis response to phosphate starvation.
Starvation
Responses of Saccharomyces cerevisiae to nitrogen starvation in wine alcoholic fermentation.
Starvation
Salmon spawning migration and muscle protein metabolism: the August Krogh principle at work.
Starvation
Serum starvation raises turnover of phosphorylated p62/SQSTM1 (Serine 349), reveals expression of proteasome and N-glycanase1 interactive protein RAD23B and sensitizes human synovial fibroblasts to BAY 11-7085-induced cell death.
Starvation
Spatial Organization of Proteasome Aggregates in the Regulation of Proteasome Homeostasis.
Starvation
Starvation Induces Proteasome Autophagy with Different Pathways for Core and Regulatory Particles.
Starvation
Stress induced nuclear granules form in response to accumulation of misfolded proteins in Caenorhabditis elegans.
Starvation
Stress-induced polyubiquitination of proteasomal ubiquitin receptors targets the proteolytic complex for autophagic degradation.
Starvation
Synergistic effects of TOR and proteasome pathways on the yeast transcriptome and cell growth.
Starvation
The GST-BHMT assay reveals a distinct mechanism underlying proteasome inhibition-induced macroautophagy in mammalian cells.
Starvation
The Mycobacterium tuberculosis proteasome active site threonine is essential for persistence yet dispensable for replication and resistance to nitric oxide.
Starvation
VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD.
Starvation
WRKY42 Modulates Phosphate Homeostasis through Regulating Phosphate Translocation and Acquisition in Arabidopsis.
Starvation
Yeast Dun1 kinase regulates ribonucleotide reductase inhibitor Sml1 in response to iron deficiency.
Status Epilepticus
Spatiotemporal progression of ubiquitin-proteasome system inhibition after status epilepticus suggests protective adaptation against hippocampal injury.
Stevens-Johnson Syndrome
ABC transporters and the proteasome complex are implicated in susceptibility to Stevens-Johnson syndrome and toxic epidermal necrolysis across multiple drugs.
Stomach Neoplasms
A BAP31 intrabody induces gastric cancer cell death by inhibiting p27kip1 proteasome degradation.
Stomach Neoplasms
Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
Stomach Neoplasms
Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
Stomach Neoplasms
ANXA1?derived peptides suppress gastric and colon cancer cell growth by targeting EphA2 degradation.
Stomach Neoplasms
Benzoquinones from Cyperus spp. trigger IRE1?-independent and PERK-dependent ER stress in human stomach cancer cells and are novel proteasome inhibitors.
Stomach Neoplasms
Caffeic acid phenethyl ester potentiates gastric cancer cell sensitivity to doxorubicin and cisplatin by decreasing proteasome function.
Stomach Neoplasms
Cbl-b regulates the sensitivity of cetuximab through ubiquitin-proteasome system in human gastric cancer cells.
Stomach Neoplasms
Characterization of the immune escape phenotype of human gastric cancers with and without high-frequency microsatellite instability.
Stomach Neoplasms
Degradation of retinoid X receptor alpha by TPA through proteasome pathway in gastric cancer cells.
Stomach Neoplasms
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
Stomach Neoplasms
Increased muscle proteasome activity correlates with disease severity in gastric cancer patients.
Stomach Neoplasms
Investigation the mechanism of the apoptosis induced by lactacystin in gastric cancer cells.
Stomach Neoplasms
Macroautophagy and ERK phosphorylation counteract the antiproliferative effect of proteasome inhibitor in gastric cancer cells.
Stomach Neoplasms
Menadione induces G2/M arrest in gastric cancer cells by down-regulation of CDC25C and proteasome mediated degradation of CDK1 and cyclin B1.
Stomach Neoplasms
Novel CADD-based peptidyl vinyl ester derivatives as potential proteasome inhibitors.
Stomach Neoplasms
Proteasome inhibitor MG-132 lowers gastric adenocarcinoma TMK1 cell proliferation via bone morphogenetic protein signaling.
Stomach Neoplasms
Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp.
Stomach Neoplasms
Proteasome particle-rich structures are widely present in human epithelial neoplasms: correlative light, confocal and electron microscopy study.
Stomach Neoplasms
Proteasome Subunit Alpha Type 7 Promotes Proliferation and Metastasis of Gastric Cancer Through MAPK Signaling Pathway.
Stomach Neoplasms
The autophagic-lysosomal and ubiquitin proteasome systems are simultaneously activated in the skeletal muscle of gastric cancer patients with cachexia.
Stomach Neoplasms
The differential proteome profile of stomach cancer: identification of the biomarker candidates.
Stomach Neoplasms
The host defense peptide LL-37 activates the tumor-suppressing bone morphogenetic protein signaling via inhibition of proteasome in gastric cancer cells.
Stomach Neoplasms
Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells.
Stomach Neoplasms
[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].
Stomach Neoplasms
[Screening and analysis of associated genes in the carcinogenesis and progression of gastric cancer]
Stroke
Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia.
Stroke
Systemic Proteasome Inhibition Induces Sustained Post-stroke Neurological Recovery and Neuroprotection via Mechanisms Involving Reversal of Peripheral Immunosuppression and Preservation of Blood-Brain-Barrier Integrity.
Stroke
The novel proteasome inhibitor BSc2118 protects against cerebral ischaemia through HIF1A accumulation and enhanced angioneurogenesis.
Stroke
The proteasome system and proteasome inhibitors in stroke: controlling the inflammatory response.
Stroke
Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy.
Supranuclear Palsy, Progressive
Clinicopathological correlations in behavioural variant frontotemporal dementia.
Synucleinopathies
Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells.
Synucleinopathies
Is malfunction of the ubiquitin proteasome system the primary cause of alpha-synucleinopathies and other chronic human neurodegenerative disease?
Synucleinopathies
Proteasome subunit proteins and neuropathology in tauopathies and synucleinopathies: Consequences for proteomic analyses.
Synucleinopathies
The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation.
Tachycardia
Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction.
Tachycardia, Ventricular
Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction.
Tachycardia, Ventricular
Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction.
Tauopathies
Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases.
Tauopathies
Cilostazol, a phosphodiesterase 3 inhibitor, activates proteasome-mediated proteolysis and attenuates tauopathy and cognitive decline.
Tauopathies
Clinicopathological correlations in behavioural variant frontotemporal dementia.
Tauopathies
Failure in heat-shock protein expression in response to UBB+1 protein in progressive supranuclear palsy in humans.
Tauopathies
Failures in Protein Clearance Partly Underlie Late Onset Neurodegenerative Diseases and Link Pathology to Genetic Risk.
Tauopathies
Proteasome subunit proteins and neuropathology in tauopathies and synucleinopathies: Consequences for proteomic analyses.
Tauopathies
Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.
TDP-43 Proteinopathies
Disease-Associated Mutations of TDP-43 Promote Turnover of the Protein Through the Proteasomal Pathway.
Telangiectasis
Human T-lymphotropic virus type 1 p30 interacts with REGgamma and modulates ATM (ataxia telangiectasia mutated) to promote cell survival.
Teratozoospermia
Identification of candidate causal genes and their associated pathogenic mechanisms underlying teratozoospermia based on the spermatozoa transcript profiles.
Testicular Neoplasms
Ubiquitin proteasome system and autophagy associated proteins in human testicular tumors.
Tetanus
[Relationship between hippocampal long term potentiation induction and activity of 26S proteasome]
Thrombocytopenia
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Thrombocytopenia
Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Thrombocytopenia
Proteasome Inhibitor PS-341 Effectively Blocks Infection by the Severe Fever with Thrombocytopenia Syndrome Virus.
Thrombocytopenia
Proteasome Levels and Activity in Pregnancies Complicated by Severe Preeclampsia and Hemolysis, Elevated Liver Enzymes, and Thrombocytopenia (HELLP) Syndrome.
Thrombocytopenia
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Thrombocytopenia
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
Thrombocytopenia
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Thrombocytopenia
Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.
Thrombosis
Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro.
Thrombosis
Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats.
Thrombosis
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Thrombotic Microangiopathies
Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature.
Thrombotic Microangiopathies
Proteasome inhibitor-associated thrombotic microangiopathy: A review of cases reported to the FDA adverse event reporting system and published in the literature.
Thrombotic Microangiopathies
Thrombotic microangiopathy associated with proteasome inhibitors.
Thrombotic Microangiopathies
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Thrombotic Microangiopathies
Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.
Thyroid Carcinoma, Anaplastic
Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Thyroid Carcinoma, Anaplastic
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Thyroid Carcinoma, Anaplastic
Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin.
Thyroid Carcinoma, Anaplastic
Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
Thyroid Diseases
Large multifunctional proteasome 2 gene Arg60His variant in autoimmune thyroid disease in Shanghai Chinese.
Thyroid Diseases
Proteasome subunits, low-molecular-mass polypeptides 2 and 7 are hyperexpressed by target cells in autoimmune thyroid disease but not in insulin-dependent diabetes mellitus: implications for autoimmunity.
Thyroid Neoplasms
A systematic analysis of heart transcriptome highlights divergent cardiovascular disease pathways between animal models and humans.
Thyroid Neoplasms
Abnormally high expression of proteasome activator-gamma in thyroid neoplasm.
Thyroid Neoplasms
Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
Thyroid Neoplasms
Beclin 1 enhances proteasome inhibition-mediated cytotoxicity of thyroid cancer cells in macroautophagy-independent manner.
Thyroid Neoplasms
Caspase-dependent cleavage of BAG3 in proteasome inhibitors-induced apoptosis in thyroid cancer cells.
Thyroid Neoplasms
Changes in proteasome chymotrypsin-like activity during the development of human mammary and thyroid carcinomas.
Thyroid Neoplasms
Different induction of GRP78 and CHOP as a predictor of sensitivity to proteasome inhibitors in thyroid cancer cells.
Thyroid Neoplasms
First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib.
Thyroid Neoplasms
Implication of Nrf2 and ATF4 in differential induction of CHOP by proteasome inhibition in thyroid cancer cells.
Thyroid Neoplasms
Implication of Oxygen-Regulated Protein 150 (ORP150) in Apoptosis Induced by Proteasome Inhibitors in Human Thyroid Cancer Cells.
Thyroid Neoplasms
Induction of BAG2 protein during proteasome inhibitor-induced apoptosis in thyroid carcinoma cells.
Thyroid Neoplasms
Involvement of Nrf2 in proteasome inhibition-mediated induction of ORP150 in thyroid cancer cells.
Thyroid Neoplasms
miR-451a inhibits cancer growth, epithelial-mesenchymal transition and induces apoptosis in papillary thyroid cancer by targeting PSMB8.
Thyroid Neoplasms
Nrf2 is commonly activated in papillary thyroid carcinoma, and it controls antioxidant transcriptional responses and viability of cancer cells.
Thyroid Neoplasms
Proteasome Inhibition Induces a p38 MAPK Pathway-Dependent Antiapoptotic Program via Nrf2 in Thyroid Cancer Cells.
Thyroid Neoplasms
Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a.
Thyroid Neoplasms
Quercetin-Induced Cell Death in Human Papillary Thyroid Cancer (B-CPAP) Cells.
Thyroid Neoplasms
REG? potentiates TGF-?/Smad signal dependent epithelial-mesenchymal transition in thyroid cancer cells.
Thyroid Neoplasms
Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells.
Thyroid Neoplasms
Suppression of MG132-mediated cell death by peroxiredoxin 1 through influence on ASK1 activation in human thyroid cancer cells.
Thyroid Neoplasms
Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.
Thyroid Neoplasms
Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms.
Thyroiditis
Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto's thyroiditis, but not for Graves' hyperthyroidism, in mice.
Thyroiditis, Autoimmune
Prevalence of 20S proteasome, anti-nuclear and thyroid antibodies in young patients at onset of type 1 diabetes mellitus and the risk of autoimmune thyroiditis.
Tics
Identification of chemoradiation-resistant osteosarcoma stem cells using an imaging system for proteasome activity.
Tics
z-Leucinyl-Leucinyl-Norleucinal Induces Apoptosis of Human Glioblastoma Tumor-Initiating Cells by Proteasome Inhibition and Mitotic Arrest Response.
Tinnitus
Proteasome Activity in the Plasma as a Novel Biomarker in Mild Cognitive Impairment with Chronic Tinnitus.
Tonsillitis
Standard and immunoproteasomes expression in paediatric tonsillectomy patients.
Toxoplasmosis
Toxoplasma gondii infection of activated J774-A1 macrophages causes inducible nitric oxide synthase degradation by the proteasome pathway.
Tremor
RAN translation at CGG repeats induces ubiquitin proteasome system impairment in models of fragile X-associated tremor ataxia syndrome.
Tremor
Resveratrol Protects from Toxin-Induced Parkinsonism: Plethora of Proofs Hitherto Petty Translational Value.
Triple Negative Breast Neoplasms
A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells.
Triple Negative Breast Neoplasms
Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis.
Triple Negative Breast Neoplasms
Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
Triple Negative Breast Neoplasms
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Triple Negative Breast Neoplasms
Inhibition of the Proteasome ?2 Site Sensitizes Triple-Negative Breast Cancer Cells to ?5 Inhibitors and Suppresses Nrf1 Activation.
Triple Negative Breast Neoplasms
Interleukin-8-Induced Invasion Assay in Triple-Negative Breast Cancer Cells.
Triple Negative Breast Neoplasms
Lapatinib--induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
Triple Negative Breast Neoplasms
Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition.
Triple Negative Breast Neoplasms
Mutant p53-Nrf2 axis regulates the proteasome machinery in cancer.
Triple Negative Breast Neoplasms
Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells.
Triple Negative Breast Neoplasms
Novel Copper Complexes That Inhibit the Proteasome and Trigger Apoptosis in Triple-Negative Breast Cancer Cells.
Triple Negative Breast Neoplasms
P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
Triple Negative Breast Neoplasms
Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy.
Triple Negative Breast Neoplasms
Proteasome inhibitors induce AMPK activation via CaMKK? in human breast cancer cells.
Triple Negative Breast Neoplasms
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.
Triple Negative Breast Neoplasms
Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer.
Triple Negative Breast Neoplasms
Tradeoff between metabolic i-proteasome addiction and immune evasion in triple-negative breast cancer.
Trypanosomiasis, African
Anti-Trypanosomal Proteasome Inhibitors Cure Hemolymphatic and Meningoencephalic Murine Infection Models of African Trypanosomiasis.
Trypanosomiasis, African
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.
Trypanosomiasis, African
Inhibition of proteasome activity blocks cell cycle progression at specific phase boundaries in African trypanosomes.
Trypanosomiasis, African
Trypanocidal activities of trileucine methyl vinyl sulfone proteasome inhibitors.
Trypanosomiasis, African
Trypanocidal effect of alpha',beta'-epoxyketones indicates that trypanosomes are particularly sensitive to inhibitors of proteasome trypsin-like activity.
Tuberculosis
"Depupylation" of prokaryotic ubiquitin-like protein from mycobacterial proteasome substrates.
Tuberculosis
A luminescence assay for natural product inhibitors of the Mycobacterium tuberculosis proteasome.
Tuberculosis
An adenosine triphosphate-independent proteasome activator contributes to the virulence of Mycobacterium tuberculosis.
Tuberculosis
Assembling proteomics data as a prerequisite for the analysis of large scale experiments.
Tuberculosis
Bacterial proteasome activator bpa (rv3780) is a novel ring-shaped interactor of the mycobacterial proteasome.
Tuberculosis
Binding-induced folding of prokaryotic ubiquitin-like protein on the Mycobacterium proteasomal ATPase targets substrates for degradation.
Tuberculosis
Characterization of the proteasome accessory factor (paf) operon in Mycobacterium tuberculosis.
Tuberculosis
Correction for Bai et al., Structural analysis of the dodecameric proteasome activator PafE in Mycobacterium tuberculosis.
Tuberculosis
Development of potential proteasome inhibitors against Mycobacterium tuberculosis.
Tuberculosis
Development of Tyrphostin Analogues to Study Inhibition of the Mycobacterium tuberculosis Pup Proteasome System*.
Tuberculosis
Discovery of new [Formula: see text] proteasome inhibitors using a knowledge-based computational screening approach.
Tuberculosis
Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates.
Tuberculosis
Erratum to: Discovery of new Mycobacterium tuberculosis proteasome inhibitors using a knowledge-based computational screening approach.
Tuberculosis
Fellutamide B is a potent inhibitor of the Mycobacterium tuberculosis proteasome.
Tuberculosis
Game of 'Somes: Protein Destruction for Mycobacterium tuberculosis Pathogenesis.
Tuberculosis
Identification of New Mycobacterium tuberculosis Proteasome Inhibitors Using a Knowledge-Based Computational Screening Approach.
Tuberculosis
Identification of plant-derived natural products as potential inhibitors of the Mycobacterium tuberculosis proteasome.
Tuberculosis
In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice.
Tuberculosis
Induced Folding Under Membrane Mimetic and Acidic Conditions Implies Undiscovered Biological Roles of Prokaryotic Ubiquitin-Like Protein Pup.
Tuberculosis
Loss-of-Function Mutations in HspR Rescue the Growth Defect of a Mycobacterium tuberculosis Proteasome Accessory Factor E (pafE) Mutant.
Tuberculosis
Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome.
Tuberculosis
Mycobacterium tuberculosis prcBA genes encode a gated proteasome with broad oligopeptide specificity.
Tuberculosis
Mycobacterium tuberculosis proteasomal ATPase Mpa has a ?-grasp domain that hinders docking with the proteasome core protease.
Tuberculosis
Mycobacterium tuberculosis Proteasome Accessory Factor A (PafA) Can Transfer Prokaryotic Ubiquitin-Like Protein (Pup) between Substrates.
Tuberculosis
N,C-Capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets.
Tuberculosis
Optimization and Evaluation of 5-Styryl-Oxathiazol-2-one Mycobacterium tuberculosis Proteasome Inhibitors as Potential Antitubercular Agents.
Tuberculosis
Prokayrotic ubiquitin-like protein (Pup) proteome of Mycobacterium tuberculosis.
Tuberculosis
Proteasomal Control of Cytokinin Synthesis Protects Mycobacterium tuberculosis against Nitric Oxide.
Tuberculosis
Pup, a prokaryotic ubiquitin-like protein, is an intrinsically disordered protein.
Tuberculosis
PUPylation provides the punch as Mycobacterium tuberculosis battles the host macrophage.
Tuberculosis
Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.
Tuberculosis
Selective Phenylimidazole-Based Inhibitors of the Mycobacterium tuberculosis Proteasome.
Tuberculosis
Structural analysis of Mycobacterium tuberculosis homologues of the eukaryotic proteasome assembly chaperone 2 (PAC2).
Tuberculosis
Structural analysis of the dodecameric proteasome activator PafE in Mycobacterium tuberculosis.
Tuberculosis
Structural basis for the assembly and gate closure mechanisms of the Mycobacterium tuberculosis 20S proteasome.
Tuberculosis
Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome.
Tuberculosis
Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate.
Tuberculosis
Survival in Hostile Conditions: Pupylation and the Proteasome in Actinobacterial Stress Response Pathways.
Tuberculosis
The mycobacterial proteasomal ATPase Mpa forms a gapped ring to engage the 20S proteasome.
Tuberculosis
The Mycobacterium tuberculosis proteasome active site threonine is essential for persistence yet dispensable for replication and resistance to nitric oxide.
Tuberculosis
The Mycobacterium tuberculosis proteasome: more than just a barrel-shaped protease.
Tuberculosis
The Mycobacterium tuberculosis Pup-proteasome system regulates nitrate metabolism through an essential protein quality control pathway.
Tuberculosis
The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide.
Tuberculosis
Ubiquitin-like protein involved in the proteasome pathway of Mycobacterium tuberculosis.
Tuberculosis
[Establishment of a Mycobacterium tuberculosis proteasome inhibitor model in vitro].
Tuberous Sclerosis
The GID ubiquitin ligase complex is a regulator of AMPK activity and organismal lifespan.
ubiquitinyl hydrolase 1 deficiency
Differential effects of Usp14 and Uch-L1 on the ubiquitin proteasome system and synaptic activity.
Uremia
Preventive effect of a proteasome inhibitor on the formation of accelerated atherosclerosis in rabbits with uremia.
Uremia
Renal cytoplasmic proteasome proteinase activities are altered in chronic renal failure.
Uremia
Salmon spawning migration and muscle protein metabolism: the August Krogh principle at work.
Uremia
The balance between glucocorticoids and insulin regulates muscle proteolysis via the ubiquitin-proteasome pathway.
Ureteral Obstruction
Effects of proteasome inhibitors on rat renal fibrosis in vitro and in vivo.
Urinary Bladder Neoplasms
Bladder cancer detection using a peptide substrate of the 20S proteasome.
Urinary Bladder Neoplasms
Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer.
Urinary Bladder Neoplasms
Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells.
Urinary Bladder Neoplasms
Core and specific network markers of carcinogenesis from multiple cancer samples.
Urinary Bladder Neoplasms
Curcumin promotes KLF5 proteasome degradation through downregulating YAP/TAZ in bladder cancer cells.
Urinary Bladder Neoplasms
Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells.
Urinary Bladder Neoplasms
Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.
Urinary Bladder Neoplasms
Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation.
Urinary Bladder Neoplasms
Synergistic effects of cisplatin and proteasome inhibitor bortezomib on human bladder cancer cells.
Urinary Bladder Neoplasms
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.
Urinary Bladder Neoplasms
The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells.
Urinary Bladder Neoplasms
[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].
uroporphyrinogen-iii synthase deficiency
Missense UROS mutations causing congenital erythropoietic porphyria reduce UROS homeostasis that can be rescued by proteasome inhibition.
Urticaria
High plasma proteasome levels are detected in patients with metastatic malignant melanoma.
Uterine Cervical Neoplasms
?,?-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells.
Uterine Cervical Neoplasms
A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants.
Uterine Cervical Neoplasms
Bortezomib Targets the Caspase-Like Proteasome Activity in Cervical Cancer Cells, Triggering Apoptosis That Can be Enhanced by Nelfinavir.
Uterine Cervical Neoplasms
Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells.
Uterine Cervical Neoplasms
Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance.
Uterine Cervical Neoplasms
Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8 + T cell immune response and antitumor effects in a preclinical cervical cancer model.
Uterine Cervical Neoplasms
Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment.
Uterine Cervical Neoplasms
Detection of Protein Ubiquitination Sites by Peptide Enrichment and Mass Spectrometry.
Uterine Cervical Neoplasms
Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
Uterine Cervical Neoplasms
Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression.
Uterine Cervical Neoplasms
Enhanced Efficacy against Cervical Carcinomas through Polymeric Micelles Physically Incorporating the Proteasome Inhibitor MG132.
Uterine Cervical Neoplasms
Genetic polymorphisms of proteasome subunit genes of the MHC-I antigen-presenting system are associated with cervical cancer in a Chinese Han population.
Uterine Cervical Neoplasms
High-Risk Human Papillomavirus E7 Proteins Target PTPN14 for Degradation.
Uterine Cervical Neoplasms
Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study.
Uterine Cervical Neoplasms
Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway.
Uterine Cervical Neoplasms
PI3K/AKT pathway-mediated regulation of p27(Kip1) is associated with cell cycle arrest and apoptosis in cervical cancer.
Uterine Cervical Neoplasms
Proteasome inhibition can impair caspase-8 Activation upon sub-maximal Stimulation of apoptotic tumour necrosis factor-related apoptosis inducing ligand (TRAIL) signalling.
Uterine Cervical Neoplasms
Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8.
Uterine Cervical Neoplasms
Proteasome inhibition mediates p53 reactivation and anti-cancer activity of 6-gingerol in cervical cancer cells.
Uterine Cervical Neoplasms
Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis.
Uterine Cervical Neoplasms
Proteasome inhibitors induce AMPK activation via CaMKK? in human breast cancer cells.
Uterine Cervical Neoplasms
PSMD9 expression correlates with recurrence after radiotherapy in patients with cervical cancer.
Uterine Cervical Neoplasms
Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines.
Uterine Cervical Neoplasms
Suppression of HIF-1? accumulation by betulinic acid through proteasome activation in hypoxic cervical cancer.
Uterine Cervical Neoplasms
The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of (188)re-labeled anti-E6 C1P5 antibody in cervical cancer in mice.
Uterine Cervical Neoplasms
The new-generation proteasome inhibitor oprozomib increases the sensitivity of cervical cancer cells to cisplatin-induced apoptosis.
Uterine Cervical Neoplasms
[Transcriptional inhibition of human papilloma virus in cervical carcinoma cells reactivates functions of the tumor suppressor p53]
Uveitis
Anti-inflammatory effect of the proteasome inhibitor bortezomib on endotoxin-induced uveitis in rats.
Uveitis
Proteasome inhibitor bortezomib suppresses nuclear factor-kappa B activation and ameliorates eye inflammation in experimental autoimmune uveitis.
Uveitis, Anterior
Polymorphism in the LMP2 gene influences the relative risk for acute anterior uveitis in unselected patients with ankylosing spondylitis.
Vaccinia
Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides.
Vaccinia
Identification of Poxvirus Genome Uncoating and DNA Replication Factors with Mutually Redundant Roles.
Vaccinia
Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes.
Vaccinia
Post-translational regulation of rotavirus protein NSP1 expression in mammalian cells.
Vaccinia
Selective involvement of proteasomes and cysteine proteases in MHC class I antigen presentation.
Varicocele
Functional Analysis of Differentially Expressed Acetylated Spermatozoal Proteins in Infertile Men with Unilateral and Bilateral Varicocele.
Vascular Diseases
Crosstalk between Nrf2 and the proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging.
Vascular Diseases
Proteasome inhibition represses unfolded protein response and Nox4, sensitizing vascular cells to endoplasmic reticulum stress-induced death.
Vascular System Injuries
Caspase-3-dependent apoptosis in vascular smooth muscle cell by proteasome inhibition.
Vascular System Injuries
The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection.
Vascular System Injuries
The proteasome as a target for prevention of restenosis following vascular injury.
Vasculitis
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
Vasculitis
Serum 20S proteasome levels are associated with disease activity in MPO-ANCA-associated microscopic polyangiitis.
Vasculitis
Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review.
Venous Thrombosis
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Vesicular Stomatitis
Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication.
Vesicular Stomatitis
Generation of the vesicular stomatitis virus nucleoprotein cytotoxic T lymphocyte epitope requires proteasome-dependent and -independent proteolytic activities.
Vesicular Stomatitis
Selective restriction of Nef-defective human immunodeficiency virus type 1 by a proteasome-dependent mechanism.
Vesicular Stomatitis
The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state.
Vesicular Stomatitis
The ubiquitin-vacuolar protein sorting system is selectively required during entry of influenza virus into host cells.
Virus Diseases
A new class of ?-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.
Virus Diseases
Activity-based profiling of the proteasome pathway during hepatitis C virus infection.
Virus Diseases
Cell Clearing Systems as Targets of Polyphenols in Viral Infections: Potential Implications for COVID-19 Pathogenesis.
Virus Diseases
Constitutive and interferon-gamma-induced expression of the human proteasome subunit multicatalytic endopeptidase complex-like 1.
Virus Diseases
Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication.
Virus Diseases
Dynamic interactions between Bombyx mori nucleopolyhedrovirus and its host cells revealed by transcriptome analysis.
Virus Diseases
Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
Virus Diseases
Escape mutations alter proteasome processing of major histocompatibility complex class I-restricted epitopes in persistent hepatitis C virus infection.
Virus Diseases
Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study.
Virus Diseases
Grass carp reovirus capsid protein interacts with cellular proteasome subunit beta-type 7: Evidence for the involvement of host proteasome during aquareovirus infection.
Virus Diseases
Hepatic expression of proteasome subunit alpha type-6 is upregulated during viral hepatitis and putatively regulates the expression of ISG15 ubiquitin-like modifier, a proviral host gene in hepatitis C virus infection.
Virus Diseases
Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro.
Virus Diseases
Identification of substrates of SMURF1 ubiquitin ligase activity utilizing protein microarrays.
Virus Diseases
Immunoproteasome Upregulation Is Not Required to Control Protein Homeostasis during Viral Infection.
Virus Diseases
Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus.
Virus Diseases
Inhibition of hepatitis E virus replication by proteasome inhibitor is nonspecific.
Virus Diseases
Inhibition of the host proteasome facilitates papaya ringspot virus accumulation and proteosomal catalytic activity is modulated by viral factor HcPro.
Virus Diseases
Interaction of the Tobacco mosaic virus replicase protein with a NAC domain transcription factor is associated with the suppression of systemic host defenses.
Virus Diseases
Mitochondrial cell death suppressors carried by human and murine cytomegalovirus confer resistance to proteasome inhibitor-induced apoptosis.
Virus Diseases
Modification of cytoskeleton and prosome networks in relation to protein synthesis in influenza A virus-infected LLC-MK2 cells.
Virus Diseases
Plant Virus Infection and the Ubiquitin Proteasome Machinery: Arms Race along the Endoplasmic Reticulum.
Virus Diseases
Potential roles of microRNAs and their target genes in human multiple myeloma.
Virus Diseases
Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization.
Virus Diseases
Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins.
Virus Diseases
Proteasome subunit beta type-8 from sevenband grouper negatively regulates cytokine responses by interfering NF-?B signaling upon nervous necrosis viral infection.
Virus Diseases
Proteasome-dependent dispersal of PML nuclear bodies in response to alkylating DNA damage.
Virus Diseases
PSMB1 Negatively Regulates the Innate Antiviral Immunity by Facilitating Degradation of IKK-?.
Virus Diseases
Respiratory viral infection in lung transplantation induces exosomes that trigger chronic rejection.
Virus Diseases
Rice stripe Tenuivirus nonstructural protein 3 hijacks the 26S proteasome of the small brown planthopper, via direct interaction with regulatory-particle non-ATPase subunit 3.
Virus Diseases
Roles of the two distinct proteasome pathways in hepatitis C virus infection.
Virus Diseases
Rotavirus replication requires a functional proteasome for effective assembly of viroplasms.
Virus Diseases
The ER quality control and ER associated degradation machineries are vital for viral pathogenesis.
Virus Diseases
The immunoproteasome and viral infection: a complex regulator of inflammation.
Virus Diseases
The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection.
Virus Diseases
The ubiquitin proteasome system plays a role in venezuelan equine encephalitis virus infection.
Virus Diseases
The ubiquitin-proteasome system regulates the accumulation of Turnip yellow mosaic virus RNA-dependent RNA polymerase during viral infection.
Virus Diseases
TRIM5? Degradation via Autophagy Is Not Required for Retroviral Restriction.
Virus Diseases
Tripeptidyl peptidase II serves as an alternative to impaired proteasome to maintain viral growth in the host cells.
Virus Diseases
Ubiquitin-specific protease 14 is a new therapeutic target for the treatment of diseases.
Virus Diseases
Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection.
Vitamin D Deficiency
Vitamin D Deficiency Induced Muscle Wasting Occurs through the Ubiquitin Proteasome Pathway and Is Partially Corrected by Calcium in Male Rats.
Vitiligo
A case-control study on association of proteasome subunit beta 8 (PSMB8) and transporter associated with antigen processing 1 (TAP1) polymorphisms and their transcript levels in vitiligo from Gujarat.
Waldenstrom Macroglobulinemia
Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
Waldenstrom Macroglobulinemia
Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia.
Waldenstrom Macroglobulinemia
Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia.
Waldenstrom Macroglobulinemia
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
Waldenstrom Macroglobulinemia
Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.
Waldenstrom Macroglobulinemia
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Waldenstrom Macroglobulinemia
CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors.
Waldenstrom Macroglobulinemia
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.
Waldenstrom Macroglobulinemia
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.
Waldenstrom Macroglobulinemia
Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
Waldenstrom Macroglobulinemia
Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
Waldenstrom Macroglobulinemia
Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia.
Waldenstrom Macroglobulinemia
Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia.
Waldenstrom Macroglobulinemia
Proteasome inhibitor therapy for Waldenström's macroglobulinemia.
Waldenstrom Macroglobulinemia
Role of proteasome inhibition in Waldenström's macroglobulinemia.
Waldenstrom Macroglobulinemia
Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia.
Waldenstrom Macroglobulinemia
Severe Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma: A Case Report and Review of the Literature.
Wasting Syndrome
Circulating 20S proteasome for assessing protein energy wasting syndrome in hemodialysis patients.
Wasting Syndrome
Insulin suppresses the increased activities of lysosomal cathepsins and ubiquitin conjugation system in burn-injured rats.
West Nile Fever
West Nile virus genome amplification requires the functional activities of the proteasome.
Whooping Cough
Evading the proteasome: absence of lysine residues contributes to pertussis toxin activity by evasion of proteasome degradation.
Whooping Cough
The pertussis toxin S1 subunit is a thermally unstable protein susceptible to degradation by the 20S proteasome.
Wound Infection
Pseudomonas syringae pv. syringae uses proteasome inhibitor syringolin A to colonize from wound infection sites.
Xeroderma Pigmentosum
Caffeine Abolishes the Ultraviolet-Induced REV3 Translesion Replication Pathway in Mouse Cells.
Xeroderma Pigmentosum
Erythropoietic Defect Associated with Reduced Cell Proliferation in Mice Lacking the 26S Proteasome Shuttling Factor Rad23b.
Xeroderma Pigmentosum
Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-?B and AP-1 signalling.
Yersinia Infections
Yersinia enterocolitica impairs activation of transcription factor NF-kappaB: involvement in the induction of programmed cell death and in the suppression of the macrophage tumor necrosis factor alpha production.
Zika Virus Infection
An Integrated Systems Biology Approach Identifies the Proteasome as A Critical Host Machinery for ZIKV and DENV Replication.
Zika Virus Infection
NS5-independent Ablation of STAT2 by Zika virus to antagonize interferon signalling.
Zika Virus Infection
Quantitative Proteomic Analysis of Mosquito C6/36 Cells Reveals Host Proteins Involved in Zika Virus Infection.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Wang, C.C.; Bozdech, Z.; Liu, C.l.; Shipway, A.; Backes, B.J.; Harris, J.L.; Bogyo, M.
Biochemical analysis of the 20 S proteasome of Trypanosoma brucei
J. Biol. Chem.
278
15800-15808
2003
Homo sapiens, Trypanosoma brucei (O96780), Trypanosoma brucei (O96787), Trypanosoma brucei (O96788), Trypanosoma brucei (Q9BMX8), Trypanosoma brucei (Q9GU36), Trypanosoma brucei (Q9GU37), Trypanosoma brucei (Q9NDA1), Trypanosoma brucei (Q9NDA2), Trypanosoma brucei (Q9NDA3), Trypanosoma brucei (Q9NHC5), Trypanosoma brucei (Q9NHC6), Trypanosoma brucei (Q9U793), Trypanosoma brucei (Q9U794), Trypanosoma brucei (Q9XZG5), Trypanosoma brucei
brenda
EXTERNAL LINKS (specific for EC-Number 3.4.25.1)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
